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wt%  Drug loading in weight percent  
aa  Amino acid 
Ab Antibody  
ACN Acetonitrile  
AD Alzheimer’s disease  
AGM Aminoglutethimide  
AIDS  Acquired immunodeficiency syndrome  
Ala  Alanine 
ALL  Acute lymphoblastic leukemia  
ALN  Alendronate 
AML  Acute myeloid leukemia 
Amph B  Amphotericin B 
Anh  Anhydrous 
APAF-1  Apoptotic protease activating factor-1  
APP  Amyloid precursor protein 
Ar  Argon 
Asp Aspartate 
ATP  Adenosine triphosphate 
AUC  Area under the curve  
BBB Blood brain barrier 
BCS Breast conservative surgery 
BDMC Bisdemethoxycurcumi 
Boc Tertiary-butyloxycarbonyl  
BSA Bovine serum albumin 
BTB   Blood tumor barrier  




CAA Cancer Associated Adipocyte 
CAC  Critical aggregation concentration  
CD  Circular dichroism 
CD Cyclodextrin 
CDCl3 Deuterated chloroform  
CHO Chinese hamster ovary 
CMC  Critical micelle concentration  
CNS  Central nervous system  
COSY  Correlated spectroscopy  
CPT  Camptothecin 
CsA Cyclosporine A 
CTC Circulating tumor cell 
Cys  Cysteine 
DCC  N,N ́-dicyclohexylcarbodiimide  
ddH2O  Deionized water 
DDS  Drug delivery system  
DIC  N,N’-Diisopropyl carbodiimide  
DIEA  N,N-Diisopropylethylamine 
DLS  Dynamic light scattering 
DMEM  Dulbecco’s modified eagle’s medium  
DMF  N,N'-Dimethyl formamide  
DMSO   Dimethyl sulphoxide  
DMTMM  4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4- methylmorpholinium  
DNA  Deoxyribonucleic acid  
DOSY  Diffusion-ordered spectroscopy  
DOTA  1,4,7-tetrazacyclododecane-1,4,7-10-tetraacetic acid  
Dox Doxorubicin 




DTT  1,4-dithiothreitol 
EC  European commission  
ECM Extracellular matrix 
EDC  1-Ethyl-3-(-3-dimethylaminopropyl) carbodiimide  
EDTA  Ethylenediaminetetraacetic acid  
EG  Ethylene glycol 
EGFR Epidermal growth factor receptor 
EMT Epithelial-mesenchymal transition 
EPI   Epirubicin 
ER Estrogen receptor 
EPR Enhanced permeability and retention  
eq  Equivalents 
ESF  European science foundation 
FACS  Fluorescence activated cell sorting  
FBS  Fetal bovine serum 
FCS  Fluorescence correlation spectroscopy  
FDA  Food and drug administration  
FDC  Free drug content 
FITC Fluorescein Isothiocyanate 
FT-IR  Fourier transform infrared spectroscopy  
G-CSF Granulocyte colony stimulating factor 
GAU  Glutamic acid units 
GFLG  Gly-Phe-Leu-Gly  
Gly   Glycine 
GO Gene ontologies 
GPC  Gel permeation chromatography  
GSH  Glutathione 




HDL High Density Lipoprotein 
HER2 Human epidermal growth factor receptor-2 
HES  Hydroxyethylstarch 
HEWL  Hen egg white lysozyme 
HGH  Human growth hormone  
HOBt  Hydroxybenzotriazole 
HPLC  High pressure liquid chromatography  
HPMA  N-(2’-Hydroxypropyl)methacrylamide  
hrGCSF  Human recombinant granulocyte-colony stimulating factor  
i.m.  Intramuscular 
i.p.  Intraperitoneal 
i.v.  Intravenous 
ID  Injected dose 
IGF1R Insulin-like growth factor-1 receptor 
IHC  Immunohistochemistry 
IL  Interleukin 
KDa  Kilodalton 
Leu  Leucine 
Lys Lysine 
LSGS  Low serum growth supplement  
m/z  Mass/charge 
mAb  Monoclonal antibody  
MBq  Mega Becquerel 
MCR  Mean count rate  
MDR  Multidrug resistance 
ME  Macrophage elastase 
MMP  Matrix metalloproteinase 




MS  Mass spectrometry 
MTT  3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium   
MTX Methotrexate 
MWCO  Molecular weight cut off  
N2  Nitrogen  
NaOH Sodium hydroxide  
nBu N-Butylamine  
NCA N-Carboxyanhydride  
NCE New chemical entity  
NGF Nerve growth factor 
NHS N-Hydroxysuccinimide  
NIR Near infra red 
NMR Nuclear Magnetic Resonance  
NOESY Nuclear Overhauser Effect Spectroscopy  
NPs Nanoparticles  
OG  Oregon green cadaverine  
PAA Poly amino acid 
PAMAM  Poly(amido amine)  
PB  Phosphate buffer  
PBS Phosphate buffer saline  
PBLG  Phosphate buffer saline  
pCR Pathologic complete remission rate 
PD Pharmacodynamics 
PDC  Polymer drug conjugate 
PDI  Polydispersity index  
PEG  Poly(ethylene glycol)  
PEI  Poly(ethylene imine)  




PET  Positron emission tomography  
PGA  Poly(L-glutamic acid)  
PGG Poly(L-γ-glutamyl-glutamine) 
Phe Phenylalanine 
PK  Pharmacokinetics 
PLA  Polylactic acid 
PMMA  Poly(methyl methacrylate) 
PNS  Peripheral nervous system 
PPC  Polymer protein conjugate 
PR Progesterone receptor 
PT  Polymer therapeutics 
PTX  Paclitaxel 
RES Reticulum endothelium system 
RFU Relative fluorescence units 
Rg Gyration radius  
RGD Arginylglycylaspartic 
Rh Hydrodynamic radius  
RI Refractive index 
ROCK Rho associated kinase 
ROP Ring opening polymerization 
ROS Reactive oxygen species 
RT Radiation treatment 
r.t. Room temperature 
RTKs Receptor tyrosine kinases 
RM Radical mastectomy 
SANS Small angle neutron scattering 
SAS Small angle scattering 




SEC Size exclusion chromatography 
SEM Standard error of the mean 
SGLT1 Sodium-glucose linked transporter 
SPECT Single photon emission computed tomography 
STAT Signal transducer and activator of transcription 
TDC Total drug content 
Tf Transferrin 
TKI Tyrosine-kinase inhibitor 
TI Topoisomerase inhibitor 
TNBC Triple-negative breast cancer 
TFA Trifluoroacetic acid 
TJ Tight junction  
TNF Tumor necrosis factor 
UV Ultraviolet   
v/v Volume/volume 






































































Among breast cancer subtypes, triple negative breast cancer (TNBC) represents 
around 15-20% of newly diagnosed cancer cases. Together with heterogeneous behavior 
among single patients, TNBC presents with a complex molecular landscape, low 
detection rate, and an aggressive and highly proliferative profile and these characteristics 
provide for the poor prognosis of TNBC patients. The lack of hormonal receptor (ER, PR, 
and HER2) expression impedes the administration of targeted therapies, and for this 
reason, the development of novel therapies for TNBC represents a primary clinical need. 
Research into the development of polymer conjugates for the treatment of TNBC 
falls into four main areas: 
i) The detailed study and comprehension of relevant preclinical mouse models 
that faithfully mimic the clinical scenario as a nanomedicine evaluation 
platform. 
ii) The development of new polymer-drug combination conjugates with 
optimized drug ratio and stimuli-responsive polymer-drug linker(s) in order to 
achieve adequate drug(s) pharmacokinetics at the site of action.  
iii) The exhaustive physicochemical characterization that allowed the 
establishment of structure-activity relationships (SAR). Additionally, the 
integration of -omics in order to identify pharmacological biomarkers to better 
design and monitor the activity of selected nanoconjugates. 
 
We now address these main points in this Thesis, which aimed to design polymer-
drug combination conjugates for the treatment of TNBC. Drug combination therapies 
have emerged as a valid option for the treatment of breast cancer, as this approach permits 
synergistic drug targeting of multiple pathways. 
Studies employing animal models of disease allow for the understanding of 
disease development and progression, the search for therapeutic targets, and the 
validation of therapeutic strategies; however, the lack of accurately characterized research 
models that faithfully mimic the pathological features of human TNBC frequently 
hampers research aims. We now present the broad and detailed characterization of 




reproduce the human clinical scenario. Our comparisons have uncovered important 
descriptors (some coming from –omics analysis) regarding the interconnected 
tissular/molecular processes driving disease progression towards metastasis. These 
descriptors include metastatic spread via the lymphatic route, immune system 
remodeling, cancer-associated adipocytes, and crucial metabolomic alterations. 
As part of the development of a polymer-based therapy for TNBC, we present a 
versatile and straightforward methodology for the preparation of well-defined 
polyglutamate-based drug combination conjugates based on the well-established 
properties of the poly-glutamic acid (PGA) as a multivalent and biodegradable polymer 
carrier. We synthesized and characterized a family of conjugates containing amino acid-
based proteolytic drug linkers including Gly, Gly-Gly, Gly-Phe-Leu-Gly as key drivers 
in the final macromolecule solution conformation (which drives the biological fate). 
These new drug delivery systems incorporate both chemotherapy (doxorubicin) and 
endocrine therapy (the aromatase inhibitor aminoglutethimide) as a synergistic 
combination. Overall, we demonstrate how the presence of a small flexible Gly linker can 
drastically modify the spatial conformation of the entire polymer–drug macromolecule, 
promoting the synergistic release of both drugs and significantly improving the biological 
activity. 
The release of drug combinations conjugated to the polymer backbone via 
protease-cleavable drug linkers, such as those noted above, relies on the heterogeneous 
expression levels (at both the patient and tumor level) of various proteolytic enzymes 
some of them not found within the tumor microenvironment, target we wish to reach to 
be able to modulate metastatic processes. To improve drug release intracellularly but also 
at the tumor microenvironment, we developed a new family of conjugates incorporating 
the pH-sensitive hydrazone linker. These conjugates provided improved antitumor and 
antimetastatic activity (supported by histology and transcriptomic analysis); however, we 
noted that the pH-sensitive drug-linker length significantly influences the cell death 
mechanism involved. 
Finally, we applied the knowledge acquired from the development of the previous 
polymer-drug combination conjugates, together with the selection of a more powerful 
combination of synergistic drugs for TNBC treatment (including a tyrosine-kinase 




effective family of polymer-drug conjugates. This novel system demonstrated enhanced 
antitumor activity in a human TNBC mice model, leading to a 50% primary tumor growth 
reduction and the almost complete remission of lung metastasis. 
Overall, the findings exhibited throughout this Thesis highlight the need for a 
deeper understanding of polymer-drug conjugates at supramolecular level, including the 
need for a complete physicochemical characterization to allow the design of more 
effective polymer-drug conjugates. Additionally, we highlight the importance of the full 
characterization of the animal models employed and the parameters driving primary 
















































































OBJECTIVES OF THE RESEARCH 
The main objective of this Thesis is the design and development of biocompatible 
and biodegradable polypeptide-based-drug combination conjugates for the treatment of 
advanced stage / metastatic triple-negative breast cancer (TNBC). Strategy to be always 
performed by using well-controlled synthetic approaches, validated by exhaustive 
characterization techniques and tested in relevant preclinical models in order to accelerate 
bench to bedside process. 
This global aim frames the following specific objectives: 
1. The development and full characterization of two spontaneously metastatic and 
preclinically relevant orthotopic triple negative breast cancer animal models as 
platforms for advanced therapeutics validation.  
 
2. Synthesis, full physico-chemical characterization and biological evaluation of 
poly-L-glutamic acid(PGA)-drug combination conjugates that incorporate drugs at 
an adequate ratio as well as bioresponsive polymer-drug(s) linkers to achieve 
synergism in TNBC models. 
The rational designed of the combination conjugates will involve: 
i) Exploring linkers of different bioresponsive nature (protease vs. pH responsive). 
ii) Structure-activity relationship studies in biologically relevant media. 
iii) In vitro and in vivo studies (safety, pharmacokinetics and anticancer activity) in 
preclinically relevant models (Objective 1). 
 
3. Implementation of –omics techniques (metabolomics and transcriptomics) in the 
development of polymer combination conjugates in order to understand not only 
molecular mechanism of action but also identify relevant biomarker and 





















































I.1. Breast Cancer  
Breast cancer is a group of systemic diseases involving abnormal cell growth 
within breast tissue, with the potential to invade or spread to other parts of the body [1]. 
The most frequent clinical signs of breast cancer include the appearance of different sized-
lumps in the breast, a sudden change in breast size, form, or aspect, dimpling of the skin, 
fluid exudate from the nipple, and red or scaly patches of skin [2]. As breast cancer 
develops, metastasis can occur, leading to clinical symptoms such as bone pain, 
swollen lymph nodes, shortness of breath, and yellow skin [3]. 
 
I.1.1. Characteristics, Prevalence, Staging, and Molecular Subtypes 
 Breast cancer represents the most common invasive cancer in women and the 
leading cause of cancer-related deaths among women in the world [4]. Breast cancer 
development is staged into five phases (Table 1) according to the tumor size, location, 
involvement of lymph node, and spread. Breast cancer and clinical outcome directly 
correlates with the stage (Figure 1A) at diagnosis and with patient age (Figure 1B). 
While recent advances in screening and treatment have improved survival rates, data from 
2008 still demonstrates a 20% increase in breast cancer incidence (Figure 2) and an 
associated 14% increase in cancer-related mortality [5].  
 
 





Figure 1. A) Five-year survival rates for women by breast cancer stage (after initial diagnosis), US, 2014. 
B) Estimated new female breast cancer cases and deaths by age, USA, 2017. 
 
Breast cancer has been historically classified according to tumor size, 
morphology, and nodal involvement, with the immunohistochemical expression of three 
membrane proteins (progesterone receptor (PR), estrogen receptor (ER) and epidermal 
growth factor (EGFR) receptor 2 (HER2)) in biopsies employed as means to assess patient 
prognosis and manage treatment approaches.  
 
 
Figure 2.  Trends in incidence rates of invasive and in situ female breast cancer by age, 1975-2014, USA 
[6]. 
However, the recent development of new expression-profiling tools, including 
protein microarrays, has uncovered additional heterogeneity within breast cancer patients, 
with classifications now expanded past PR/ER/HER2 expression status [7]. This 
conceptual shift has led to advances in patient treatment stratification due to increased 





Figure 3: Patient outcome based on breast tumor intrinsic subtypes. Adapted from [7]. 
Studies now highlight six major molecular/transcriptional subtypes (Figure 3) of 
breast cancer: basal-like, luminal A, luminal B, HER2-enriched, normal-like, Claudin-
low and triple negative [7]. Each subtype correlates with differential histopathological 
features, tumor evolution, therapeutic response, overall patient management, and clinical 
outcome (Table 2). Namely: 
Luminal A represents a relatively common subtype of breast cancer, defined by 
high expression of ER and PR and low expression of the Ki67 proliferation marker 
and the HER2 oncoprotein. Luminal A tumors tend to be low grade, slow growing, 
and less aggressive and normally associate with the best prognosis, particularly in 
the short term, due to elevated responsiveness to anti-hormone therapy [9, 10]. 
Luminal B tumors also exhibit ER and/or PR expression, but with higher levels 
of Ki67 (indicative of a large proportion of actively dividing cells) or HER2 with 
high histologic grade [11]. Luminal B tumors tend to exhibit an aggressive clinical 
behavior with prognosis similar to non-luminal cancers (including basal-like 
subtype) [12] and an associated poorer survival rate than luminal A cancers [10]. 
Patients with luminal B tumors are often diagnosed at a younger age, exhibit 
slightly quicker growing tumors, and tend to display factors (including poorer 
tumor grade, larger tumor sizes, and frequent lymph node involvement) that lead 
to a poorer prognosis when compared to patients with luminal A tumors. 
HER2-enriched tumors exhibit heterogeneous biology and clinic behaviors and 




an associated poorer short-term prognosis compared to hormone receptor (HR)-
positive breast cancers. Although the majority of HER2-positive tumors are HR-
negative by immunohistochemistry, ∼30% are typically HR-positive [13]. Within 
HR-positive tumors, 40-50% are HER2-positive with Luminal A and B tumors 
representing the bulk of the remainder. Within the HR-negative disease, 80-90% 
are HER2+ and 10-20% are Basal-like [13]. Thus, HR status does not fully 
describe these molecular subtypes. 
Normal-like tumors present with similarities to normal breast tissue. The 
significance of this subtype has yet to be determined, and some argue that it may 
represent contamination of samples with normal breast tissue [14]. Studies have 
discovered some similarities to luminal A disease (HR-positive, HER2-negative, 
and low Ki-67 expression). While normal-like tumors suffer from a prognosis 
slightly worse than luminal A, the classification of this infrequent subtype remains 
unclear due to high molecular heterogeneity. 
Claudin-low represents the latest subtype identified by gene expression profiling 
studies [15], mainly characterized by the lack of expression of claudin proteins 
(components of tight junctions between adjacent epithelial cells) and epithelial 
cell adhesion molecules. Claudin-low tumors are typically triple negative (61–
71%), while 25 to 39% of triple negative breast cancers are considered claudin-
low. Claudin-low tumors differ from basal-like tumors by the inconsistent 
expression of basal keratins and significantly lower expression of proliferation-
associated genes [15]. Accordingly, claudin-low tumors have a lower pathologic 
complete remission rate (pCR) with neoadjuvant chemotherapy than basal-like 
tumors, but higher than luminal tumors. The identification of the claudin-low 
subtype provides further evidence of the broad underlying biology of TNBC and 
the need for a better understanding of the different subtypes of breast cancer and 
the associated therapeutic implications. 
Triple-Negative tumors lack the expression of ER, PR, and HER2 and represent 
around 15-20% of the new diagnosed cancer cases [16]. The following section 





Table 2: Summary of breast tumor molecular subtypes. *Subtypes with detailed expression patterns and 
clinical implications discussed in the text, which represent the majority of the breast tumor cases. ΔThe 
prevalence of each subtype derives from [17]. 
 
I.1.2. Triple-Negative Breast Cancer: Molecular Landscape and Clinical 
Characteristics 
Together with a highly aggressive nature and heterogeneous behavior in patients, 
the characteristics of TNBC include a complex molecular landscape, low detection rate, 
and an aggressive/highly proliferative profile, which combine to give the worse prognosis 
of all subtypes. Additionally, TNBC patients suffer from significantly reduced survival 
rates when compared to non-TNBC (nTNBC) patients (Figure 4). Pathologically, TNBC 
displays rapid growth rates with prominent lymphoplasmacytic inflammatory infiltrate 
with visceral metastasis expected at late stages (mainly in lungs, liver, and brain). 
Furthermore, frequent lymphatic system compromise impedes focused treatment and 
favors tumor recurrence [18]. Rapid tumor evolution leads to the development of an inner 
hypoxic and/or necrotic core [19] associated with multiple drug resistance (MDR) and 
overall worse prognostic [20]. 
 
 
Intrinsic subtype IHC status Grade Outcome PrevalenceΔ 
Luminal A* [ER+, PR+] HER2-,KI67- 1|2 Good 23.7% 
Luminal B* [ER+, PR+] HER2-,KI67+ 2|3 Intermediate 38.8% 
HER2 over-expression* [ER-,PR-] HER2+ 2|3 Poor 11.2% 
TNBC/Basal-like* 
[ER-,PR-] HER2-, basal 
marker+ 
3 Poor 18.3% 
Normal-like* [ER+, PR+] HER2-,KI67- 1|2|3 Intermediate 7.8% 




Unfortunately, TNBC currently lacks targeted therapeutics [21-23], patients 
usually respond to treatment heterogeneously [24], and the lack of standardized treatment 
for TNBC in the metastatic scenario makes TNBC treatment an unmet clinical need [25]. 
Nevertheless, TNBC does display sensitivity to chemotherapeutic agents, such as 
anthracyclines and taxanes [26], leading to reduced recurrence in some cases [27]. 
However, the role of chemotherapeutic agents in TNBC treatment remains unclear, with 
more advances required to improve drug delivery and reduce unwanted side effects.  
 
Figure 4: TNBC survival compared to nTNBC survival [28] 
 
I.1.3. Classification and Subtypes of Triple-Negative Breast Cancer 
TNBC encompasses a wide spectrum of entities with different biological 
characteristics and clinical behavior [29]. The American College of Pathology [30], 
American Society of Clinical Oncology [31], and St. Gallen guidelines [11] define TNBC 
as breast cancer with less than 1% of tumor cells expressing ER and PR via 
immunohistochemistry (IHC). However, the high prevalence of uncommon 
histopathological subtypes, such as metaplastic (90%), medullary (95%), adenoid cystic 
(90-100%), and apocrine (40-60%) carcinomas [24] typifies the heterogeneous nature of 
TNBC. While molecular assessments also demonstrate a wide range of heterogeneity, 
breast cancer characterization applies the detection of common markers such as basal 
cytokeratin (CK) 5/6 and EGFR [32]. 
Attempts to distinguish TNBC subtypes at the molecular levels have employed a 




hybridization [34], histopathological quantification, laser-capture microdissection [35], 
and reverse phase protein arrays [36]. Transcriptional analyses employing these tools has 
now highlighted the existence of up to six distinct TNBC subtypes. 
Basal-Like (BL1 and BL2) Subtypes 
The enrichment for genes from cell cycle, cell division, and DNA damage 
response (ATR/BRCA) pathways characterizes the BL1 subtype. High Ki67 
mRNA expression and nuclear Ki67 staining by ICH (> 70%) further supports the 
proliferative nature of this subtype. The BL2 subtype also involves growth factor 
signaling (EGF, NGF, MET, Wnt/β-catenin, and IGF1R), glycolysis, and 
gluconeogenesis pathways [37]. 
Immunomodulatory (IM) Subtype 
The high expression of factors involved in immune cell processes, 
including immune cell signaling, characterizes the immunomodulatory (IM) 
subtype. Immune signaling genes within the IM subtype substantially overlap with 
the gene signature for medullary breast cancer: a rare, histologically distinct 
TNBC form that, despite its high-grade histology, is associated with a favorable 
prognosis. This subtype also exhibits activation of signal transducer and activator 
of transcription (STAT) transcription factor-mediated pathways and has the best 
prognosis of TNBC subtypes. 
Mesenchymal (M) and Mesenchymal Stem-Like (MSL) Subtypes 
The mesenchymal (M) subtype expressed components and pathways 
involved in cell motility, extracellular receptor interaction, and cell differentiation 
pathways. The mesenchymal stem-like (MSL) subtype shares many 
characteristics of the M subtype; however, the MSL subtype also expresses genes 
related to growth factor signaling pathways.  
Luminal Androgen Receptor (LAR) Subtype 
The luminal androgen receptor (LAR) subtype represents the most 
differential TNBC subtype; while this subtype is ER-negative, highly expressed 




pathways (steroid synthesis, porphyrin metabolism, and androgen/estrogen 
metabolism) [38]. Tumors exhibit AR, ER, prolactin, and ErbB4 signaling, but 
ERα-negative IHC staining; however, gene expression profiling demonstrates the 
expression of ESR1 (the gene encoding ERα) and other estrogen-regulated genes 
(PGR, FOXA, XBP1, GATA3). Thus, these ‘ER-negative' tumors demonstrate 
molecular evidence of ER activation. Tumors within the LAR group also express 
numerous downstream AR targets and coactivators, with AR expression by IHC 
more than 10-fold higher compared to other TNBC subtypes.  
 
I.1.4. Metastasis in Breast Cancer and Triple Negative Breast Cancer 
The metastatic process comprises the spread of malignant cells from a primary 
tumor to distant sites through the blood or lymphatic system (Figure 5) [39]. Metastasis 
is considered the major breast cancer complication and represents the main cause of death 
in breast cancer patients. Primary tumor crosstalk with other organs via systemic factors 
(cytokines, chemokines, soluble proteins, exosomes, etc.) to promote primary tumor 
growth and metastasis and may promote systemic inflammation and a variety of other 
non-metastatic systemic complications such as cachexia, osteoporosis, osteopetrosis, and 
paraneoplastic syndromes. The most recent studies have shown that gene expression 
profile of breast tumors can predict the expected site of distant metastasis [40, 41]. 
 




While the rate of bone metastases is similar between TNBC and other breast 
cancer subtypes, TNBC patients are four times more likely to develop visceral metastases 
than patients with non-TNBC subtypes [43]. Once a patient develops a primary tumor 
with distant metastasis, variables other than the number of affected organs and the 
locations involved have no bearing on outcome and patients with visceral metastasis 
generally have a poor outcome.  
The analysis of survival in patients suffering from TNBC metastasis revealed that 
the route of first metastasis correlates significantly with survival of TNBC patients: 
distant metastases to the brain being the poorest survival indicator, followed by liver, 
pleura, bone, and lung [44]. 
Metastasis occurs in a series of discrete steps known as the “metastatic cascade” 
(Figure 6). If the tumor cell completes the metastatic cascade, the process can repeat, 
with the metastatic secondary tumor the origin for a secondary metastatic cascade [45]. 
STAGE 1: Tumor Cell Dissemination and Epithelial-Mesenchymal 
Transition 
Epithelial tissues, representing the origins of most solid tumors, usually form 
relatively rigid sheets of epithelial cells. The separation from the tumor stroma by the 
basement membrane organizes the structure by lateral belts of cell–cell adhesion 
complexes, building the extracellular matrix (ECM). Invasive tumor cells must first alter 
cell-to-cell adhesion and cell adhesion to the ECM, considered as a first barrier to 
invasion. 
During the evolution of an in situ tumor into an invasive carcinoma, epithelial 
tumor cells release from their neighbors within the tumor stroma and breach the basement 
membrane barrier. To overcome this and other impediments to invasion, carcinoma cells 
trigger an epithelial-mesenchymal transition (EMT), a critical process for diverse aspects 
of normal embryonic development. The EMT program, which involves dissolution of 
adherents and tight junctions and a loss of cell polarity, dissociates the cells within 
epithelial cell sheets into individual cells that exhibit multiple mesenchymal attributes, 
including enhanced motility and invasiveness [46, 47]. Multiple signaling pathways and 
molecules, including Receptor Tyrosine Kinases (RTKs), the transforming growth factor 
β (TGFB) superfamily, WNT, and NFκB [48], orchestrate the EMT. Cells undergoing 




[49] to aid invasion of surrounding tissues and vessels and many tumor overexpress such 
MMPs. Of note, TNBCs display a higher tendency for early distant metastasis and cancer 
recurrence due to enhanced EMT when compared to other breast cancer subtypes [50].  
STAGE 2: Tumor Cell Passage through Lymph Node or Blood Vessel Walls 
To invade tissues and vessels, cells must acquire the ability to migrate. Cell 
migration starts with the extension of cell membrane protrusions, driven by a continuous 
cycle of actin polymerization. Invasive tumor cells migrate either as single cells or 
collectively in the form of files, clusters, or sheets. Studies have observed collective 
invasion of tumor cells in tumors with incomplete or no EMT. Single cell migration 
occurs slowly, through “mesenchymal” migration or more rapidly, via an “amoeboid” 
form that does not require ECM remodeling [51]. 
Structural features of tumor-associated blood and lymphatic vessels drive the 
mechanics of cancer cell intravasation. Through a variety of ECM-remodeling 
mechanisms, tumor cells stimulate the generation and development of new blood vessels 
within their local microenvironment (neoangiogenesis) to provide themselves with 
nutrients and an oxygen supply. However, tumor-derived neovasculature tends to be 
weak, incomplete, tortuous, prone to leakiness, and under a continuous state of 
reconfiguration [52] when compared to blood vessels present in normal tissues. The weak 
nature of the tumor-associated microvasculature and the absence of adequate pericyte 
coverage combine to facilitate cancer cell intravasation. Again, a wide variety of signaling 
pathways and molecules control intravasation, including cyclooxygenase-2 (COX-2), 
epiregulin (EREG), MMP-1, and MMP-2. The presence of these factors synergistically 
promotes breast carcinoma intravasation and stimulates neoangiogenesis and the 
formation of weak and leaky blood vessels.  
STAGE 3: Survival and Travel through the Lymphatic System and 
Bloodstream to Distant Sites 
After cancer cell intravasate into the blood vessel lumen, they can propagate 
widely through the venous/arterial and lymphatic vessel circulation. Circulating tumor 
cells (CTC) detected [53] within the bloodstream of carcinoma patients provide crucial 
information regarding metastatic stage. However, CTCs in blood circulation must survive 
multiple stresses (anoikis processes, capillaries entrapment, the hemodynamic shear 




difference between metastatic and non-metastatic cells in breast cancer lies not with 
migration capacity, but rather migration direction: non-metastatic mammary tumor cells 
move randomly and appear unpolarized, while metastatic cells polarize towards blood 
vessels and migrate directionally [54, 55]. 
STAGE 4: Arrival in Distant Small Blood Vessels, Invasion of Blood Vessel 
Walls, and Movement into the Surrounding Tissue/the Role of Exosomes in 
Metastatic Dissemination 
Generally, individual tumor cell types preferentially form metastases in specific 
target organs [56, 57]. Tissue specific tropism may be a product of vasculature layout and 
size restrictions (passive targeting), homing via ligand-receptor recognition (active 
targeting), or via the production of pre-metastatic niches for CTCs. In addition to 
mediating migration and invasion [58, 59], spherical nanovesicles of 40-100 nm in 
diameter known as exosomes play an important role in the modulation of pre-metastatic 
niche [60]. Exosomes, found in most body fluids, contribute to cell−cell communication 
and may represent diagnostic/prognostic markers for cancer intensive investigation. 
Advanced imaging techniques in orthotopic breast cancer models demonstrated 
the movement of breast cancer cell exosomes to metastatic sites [61-63] and tumor cell-
derived exosome driven increases in vascular permeability in vitro and in vivo [64]. 
Furthermore, breast cancer cell-derived exosomes induce proinflammatory cytokines in 
distant macrophages [65] and promote metastasis via immunosuppressive activities [66]. 
STAGE 5. Extravasation through Blood/Lymphatic Vessels 
Once lodged in the microvasculature of distant organs, CTCs invade the vascular 
basement membrane and ECM initiating intraluminal growth and forming discrete groups 
of cells that eventually ruptures the walls of surrounding vessels, thereby placing tumor 
cells in direct contact with the tissue parenchyma [67]. To overcome physical barriers to 
extravasation in tissues with low intrinsic microvessel permeability, primary tumors 
secrete factors (e.g. EREG, COX-2, MMP-1, and MMP-2 [68]) that perturb distant 
microenvironments and induce vascular hyperpermeability. Ultimately, these tumor cells 





STAGE 6. Micrometastasis Formation 
Extravasated carcinoma cells must survive in the new microenvironment of the 
invaded parenchyma of distant tissues in order to form micrometastasis. The 
microenvironment at the metastatic locus usually differs widely from the original TME. 
These microenvironmental differences may include the type and amount of stromal cells, 
ECM constituents, available growth factors and cytokines, nutrients/oxygen supply and 
even the microarchitecture of the tissue itself.  
Cancer cells may solve the problem of a discordant microenvironment at the 
invaded site via the establishment of a “pre-metastatic niche”. Thanks to the release 
systemic signals including lysyl oxidase (LOX), [69] or MMP-9 [70] the mobilization of 
VEGF receptor 1-positive (VEGFR1+) hematopoietic stem cells is induced from the bone 
marrow to these future sites of metastasis.  Additional mechanisms may include the 
stimulation of various integrins as well as liberation of molecules that have been 
sequestered in the ECM, such as the carcinoma cell chemoattractant stromal cell-derived 
factor 1 (SDF-1) [71]. Once more, the secretion of cancer cell-derived exosomes may be 
crucial to the generation of a pre-metastatic niche [72] by converting distant 
microenvironments into more hospitable sites for disseminated tumor cells. 
STAGE 7. Blood Vessel Growth Creates a Blood Supply that Allows 
Continuing Tumor Growth. Metastasis Colonization. 
Once disseminated cancer cells have survived the initial interaction with the 
microenvironment of a foreign tissue, how the cancer cell then proliferates and forms 
large macroscopic metastases remains unclear. In fact, these occult micrometastases may 
persist in one of two ways. The spread tumor cells may hold largely quiescent, with their 
proliferation at metastatic sites greatly impaired due to incompatibilities with the foreign 
microenvironments that surround them [73]. Alternatively, the cancer cells in occult 
micrometastases may proliferate continuously; however, a net increase in their overall 






Figure 6: Metastatic cascade representation. Adapted from Ref [75]. 
 
I.1.5. Current Therapeutic Approaches for Triple Negative Breast Cancer 
Due to the intrinsic lack of expression of target receptors in tumor cells, TNBC 
patients do not benefit from hormonal-based therapy. Current treatment options for 
TNBC include breast conservative surgery (BCS) followed by radiation treatment (RT) 
and systemic chemotherapy. 
Despite the fact that TNBC tends to be more aggressive, surgical decision making 
often depends on traditional clinico-pathological variables and ultimately on patient 
preference [25]. Freedman et al [76] concluded that local recurrence rate after BCS in 
TNBC patients were lower than in other aggressive subtypes of breast cancer, so they 
remain appropriate candidates for breast conservation. However, the risk of local and 




TNBC patients receive conventional adjuvant radiotherapy following radical 
mastectomy (RM) or breast conserving surgery (BCS), as for other breast cancer 
subtypes; however, there still exists controversy regarding this issue among oncologists 
[78]. Given the rapid growth rates and aggressiveness of TNBC, BCS followed by 
radiotherapy could not lead to equivalent outcome than RM as in other types of breast 
cancer. Although radiotherapy decreases local recurrence after mastectomy in TNBC, 
overall patient survival failed to improve [79]. 
Chemotherapeutic drugs represent the only systemic treatment currently available 
for TNBC, even though this approach is only curative in a subset of patients with 
chemotherapy-sensitive disease (indicated by the 30% to 35% rates of pathologic 
complete response (pCR) [80]). While some reports suggest that TNBC responds to 
chemotherapy better than other types of breast cancer, prognosis remains poor [81]. 
Chemotherapeutic strategies for the management of TNBC include targeting DNA repair 
(platinum compounds and taxanes), p53 (taxanes), or cell proliferation (anthracyclines), 
and targeted therapies [82]. Platinum-derived anticancer treatments have demonstrated 
promising activity, but up to 70–80% of patients still suffer from residual disease 
following neoadjuvant cisplatin-based treatment strategies [83]. Besides, taxanes display 
certain activity in TNBC in most cases, they have not shown particular benefit over non-
TNBC [84]. The chemosensitivity of TNBC tumors displaying p53 mutations remains a 
controversial point, given the reported resistance of p53-mutated breast cancers to 
anthracycline chemotherapy [85]. Currently, taxane/anthracycline sequential 
chemotherapy regimens provide the highest pCR rates (~40% to 45%). However, the 
inclusion or substitution of other chemotherapeutic drugs (capecitabine, gemcitabine, 
vinorelbine, or ixabepilone) resulted in little or no improvement in pCR rates [86]. 
As mentioned before, TNBC patients with high rates of visceral metastases suffer 
from a relatively short median survival (7-13 months) and a limited duration of response 
to successive chemotherapeutic regimens. TNBC is typically associated with an initially 
higher response rate to chemotherapeutics, but lacks of proper response following 
treatment with existing chemotherapy agents, resulting a shorter overall survival [87]. 
The underlying molecular mechanisms for this inconsistency are yet to be elucidated, 
although the inherent genomic instability of TNBC could support the possibility of 




I.1.6. Potential Therapeutic Approaches for Triple Negative Breast Cancer 
While several clinical trials have tested small molecule inhibitors and monoclonal 
antibodies against crucial cellular pathways in TNBC patients, none have entered clinical 
practice due to limited efficacy. A better understanding of the underlying biology of 
TNBC may identify new therapeutic targets and allow TNBC patient stratification. 
Classification of tumors at the molecular level via microarray and DNA sequencing 
analysis may facilitate drug development.  
SRC Proto-oncogene Tyrosine-protein Kinase Inhibitors 
The SRC proto-oncogene tyrosine-protein kinase plays roles in cell adhesion and 
motility [88], both of which represent crucial mechanisms for cancer progression and 
invasiveness. In preclinical studies, TNBC cell lines displayed high sensitivity to 
Dasatinib, a small molecule kinase inhibitor of the Src, Abl, and KIT protein kinases [89]. 
Additional studies indicated heightened sensitivity of mesenchymal-like TNBC subtypes 
to Src inhibitors [90], which may be explained by the overexpression of genes related to 
cell motility in mesenchymal-like TNBC subtypes and the crucial role of Src in cell 
migration. 
Poly ADP-ribose Polymerase (PARP) Inhibitors 
TNBC generally displays a high prevalence of mutations in the breast cancer-1 
(BRCA1) gene [90], which codes for an enzyme that mediates DNA damage repair such 
as that caused by chemotherapy. The poly (ADP-ribose) polymerase (PARP) family of 
proteins regulate DNA repair, genomic stability, and programmed cell death. Therefore, 
PARP therapy alone or in combination with chemotherapy/radiotherapy may enhance 
DNA damage levels and promote cancer cell death [91]. Of note, the US Food and Drug 
Administration (FDA) approved the first PARP inhibitor, olaparib (Formerly, Lynparza), 
for the treatment of metastatic, HER2-negative breast cancer in patients with 
BRCA1or BRCA2 mutation that had previously undergone chemotherapy [92]. 
Androgen Receptor (AR) Inhibitors 
While normal breast development requires androgen receptor (AR) signaling, 




expression studies have identified TNBC subsets (particularly the LAR subfamily) 
enriched for AR signaling-related factors. Furthermore, preclinical and proof-of-concept 
clinical studies have demonstrated potential for AR-signaling inhibition as a treatment 
option for TNBC [93]. To this end, recent studies discovered that a combination of AR 
inhibition with the antiandrogen drugs enzalutamide and bicalutamide significantly 
reduced proliferation, anchorage-independent growth, migration, and invasion, and 
increased apoptosis in LAR and three non-LAR TNBC molecular subtypes 
(mesenchymal-like, mesenchymal stem-like, and basal-like 2) [94, 95]. 
Epigenetic Targets 
There exists evidence of gene silencing in patients suffering from TNBC by DNA 
methylation and/or histone deacetylation [96, 97], and so, epigenetic silencing may be 
involved in the lack of hormone receptor expression in TNBCs. Treatment with DNA 
methyltransferase (DNMT) inhibitors or histone deacetylase (HDAC) inhibitors may 
reactivate genes involved in the endocrine pathway and subsequently restore sensitivity 
to endocrine therapy. Treatment with the 5-aza-2'-deoxycytidine (decitabine) DNMT 
inhibitor has proven effective in treating hematological neoplasms [98]. 
 Vascular Endothelial Growth Factor (VEGF) Inhibitors 
As stated above, BL-2 and MSL subtypes of TNBC express higher levels of VEGF 
pathway genes [99], which aid tumor cells in the development of new blood vessels 
(angiogenesis) to acquire the oxygen and nutrient supply required for growth and spread.  
Bevacizumab (formerly Avastin) interferes with VEGF activity by preventing VEGF 
from interacting with receptors on blood vessel walls [21], thereby, inhibiting VEGF-
mediated angiogenesis. 
Epidermal Growth Factor Receptor (EGFR)-targeted therapies 
While the overexpression of EGFR in TNBC can promote cancer cell growth, 
Cetuximab (Formerly, Erbitux) inhibits both EGFR signaling and cancer cell growth. Of 





Figure 7: Classification of TNBC and candidate therapeutic targets. Adapted from Ref [22]  
 
Figure 8. Potential therapeutic strategies and agent examples for TNBC. Adapted from Ref [14] 
 
I.1.7. Nuclear Magnetic Resonance-Metabolomics and Transcriptomics as 
Tools for Biomarker Identification in Triple Negative Breast Cancer 
NMR-Metabolomics 
Nuclear magnetic resonance (NMR)-mediated metabolomic analysis permits the 




regarding their metabolic networks and interactions, with a high potential for precisely 
describing the physiological state of a tissue or entire organism [101]. Metabolomic 
analysis of metastasized organs and/or tissues, and tumor biopsies provides information 
in two different areas: 
Firstly, given the wide range of applications, metabolomics permits the 
identification of metabolic alterations in different tissues as a consequence of cancer 
development. Thus, metabolomics enables the understanding of disease progression and 
describes the complex pathways driving the disease. Additionally, “metabolomics 
signatures” of ongoing disease can be considered as a prognostic/diagnostic tool and may 
promote the discovery of potential biomarkers for cancer development or metastasis (see 
Chapter II). Recent studies have identified “metabolic vulnerabilities” in TNBC, which 
represent new and potentially exciting therapeutic targets for TNBC [102]. 
Secondly, metabolomics can aid our understanding of the molecular mechanisms 
involved in the response to new drugs/drug-delivery systems (DDS) [103]. The 
applicability of this experimental approach to cell cultures and animal models makes 
metabolomics a useful tool for establishing direct connections between in vitro and in 
vivo data, thus providing a reliable platform for the characterization of the biological 
output of anticancer agents. 
Transcriptomics through mRNA sequencing 
Transcriptomics has become an essential instrument for both basic and clinical 
research, and the incorporation of transcriptomic mRNA analysis as a characterization 
tool for TNBC subtypes has identified several new modulators of TNBC, as genes 
driving TNBC development and aggressivity [104]. Similarly to NMR-metabolomics, 
transcriptomics also aids the comprehension of the pathways involved in spontaneous 
cancer-related processes, such as invasion and metastasis. The elucidation of differential 
gene expression in metastatic tumors is a key step to understand the complex mechanisms 
controlling tumor adaptability [105]. 
Remarkably, transcriptomics has allowed to unveil distinctive features of the 
transcriptional regulation program in breast cancer, including the discovery of inter-




the profile of immune cells in primary breast cancers [107] and the analysis of breast 
cancer recurrence risk from a wide set of patients [108]. 
Transcriptomic analysis provides an opportunity to simultaneously analyze a large 
number of genes/targets and identify the mechanisms of action of different antitumor 
drugs after treatments [109]. Additionally, the differentially expressed genes after 
anticancer DDS administration can reflect the differential 
pharmacokinetics/pharmacodynamics thus helping in the better design of this advanced 
therapeutics (see Chapter IV). The main efforts in this field are focused on the integrative 
understanding of transcriptional regulation in the establishment and modification of the 
cancer cellular landscape, particularly how the regulatory program of a “healthy” cell 
drifts towards a “cancerous” phenotype [110]. In this context, high-throughput omic 
technologies have provided us unprecedented tools to study the alterations found in 
cancer at a deeper level. 
 
I.2. Nanomedicine-based Approaches for Breast Cancer Treatment 
The goal of chemotherapy, the only systemic treatment available for TNBC, is to 
deliver high-efficacy drugs to a specified location at a required concentration for a set 
period. Pharmacokinetic control is difficult to achieve due to the different transient states 
of drugs in adhesion, distribution, metabolism, and excretion. Additionally, cancer cells 
tend to develop drug resistance (e.g., MDR [111]) during the course of treatment, 
eventually leading to failure of chemotherapy.  
Nanomedicine advances hope to overcome many of the limitations of current 
chemotherapeutic formulations, including low efficacy, unwanted side-effects, and low 
bioavailability [112, 113]. Nanocarriers with controlled surface charge and surface 
modifications (e.g., polyethylene glycol (PEG)) and fixed sizes (e.g., 100–200 nm in 
diameter), may serve as efficient vehicles for anticancer agents with higher selectivity for 
primary tumor and metastases, and reduced drug resistance and side effects. More than 
40 nanomedicines including nanocristals, polymer therapeutics, liposomes, inorganic or 
viral nanoparticles are already used in routine clinical cancer care with more than 70 




In particular, nanomedicines as treatment options for TNBC may provide early 
diagnosis, accurate cancer imaging, and controlled drug delivery [115]. The combination 
of drugs and nanocarriers permits high drug loading, high transportation efficiency across 
the cell membrane and tunable pharmacokinetics [116], allowing controlled drug release 
with minimal side effects. Furthermore, such formulations aid escape clearance by the 
reticuloendothelial system (RES), thereby promoting longer blood half-life, and help to 
overcome resistance mechanisms [117].  
Finally, the multivalency offered by many nanomedicine approaches also permits 
the design of efficient combination therapy by ensuring the concomitant delivery of two 
or more anticancer agents with synergistic effects. This is a very promising strategy 
towards advanced therapeutics with already one combination liposomal formulation, 
Combiplex® approved by FDA [118-120] (See Section 3.4). 
 





Also to note that, systemic administration of nanomedicines usually relies on 
passive accumulation (EPR effect), exclusively due to their intrinsic size within the blood 
pool on arrival the tumor stroma [122] (See Section 3.2). However, the rapid development 
of solid tumors often leads to hypoxic and necrotic regions, which represent difficult 
targets for systemic treatments [123]. Active targeting has been not a very successful 
strategy so far but it is believe with omics and molecular technics novel targets to be use 
as adequate vectors would be identify in the near future that could push active targeting 
approaches forward [124]. 
 
I.2.1. Currently used Nanomedicines for Breast Cancer Treatment 
A limited number of FDA-approved nanomedicines exist for breast cancer 
treatment [125], the most well-known include paclitaxel (PTX) protein-bound 
nanoparticles (Abraxane or nab-paclitaxel) and liposome-encapsulated doxorubicin 
(Doxil). 
 Abraxane comprises paclitaxel non-covalently bound to a 130 nm nanoparticle 
processed from human serum albumin (Figure 10) and permits safer patient 
administration due to the absence of the excipient cremophor®, as well as a rapid 
accumulation of paclitaxel at the tumor site [126, 127]. Compared to the parental “free” 
drug, Abraxane permits a 9-fold greater permeation of paclitaxel into tissues via 
transporter-mediated pathways, a 33% higher intratumoral drug concentration, a 10-fold 
higher mean maximal concentration of free paclitaxel, and a 4-fold lower elimination 
ratio [128]. In clinical trials, Abraxane demonstrated comparable or better efficacy over 
paclitaxel for locally advanced breast cancer or inflammatory breast cancer [129] and can 
be safely combined with ordinary chemotherapy or targeted therapies. 
                       




Doxil represents the first FDA-approved anticancer nanodrug (1995) and consists 
of a PEGylated liposomal formulation of around 85 nm in diameter of the anthracycline 
drug doxorubicin (Figure 11) [130]. Three unconnected principles drove Doxil 
development; (i) long circulation time and evasion of RES via the PEGylated liposomes; 
(ii) high doxorubicin loading determined by a transmembrane gradient, which also 
permits specific drug release at the tumor; and (iii) the liposome lipidic bilayer that 
exhibits a dynamic phase composed of phosphatidylcholine and cholesterol.   
Doxil permits doxorubicin tumor accumulation via EPR-mediated passive 
targeting [131], leading to improved tumor growth suppression rates and overall 
survival. Although the maximum tolerated dose (MTD) for Doxil is similar to free 
doxorubicin (Dox), due to the appearace of foot and hand disease as side effect, Doxil led 
to a major (~3-fold) reduction in anthracycline-associated cardiotoxicity when compared 
to free Dox [132]. Generally, Doxil studies provide the precedents for the safe and 
effective application of nanomedicines in combination with standard drug therapy [125]. 
 
Figure 11. Schematic representation of Doxil 
 
I.3. Polymer Therapeutics  
The term “Polymer Therapeutics” (PT) describes a wide family of nano-sized 
medicines (5-100 nm in diameter) considered the first polymeric nanomedicines [133]. 
Of note, the polymeric drug glatiramer acetate for the treatment of multiple sclerosis 
(Copaxone®, Teva Pharm), and the polymer conjugate polyethylene glycol (PEG)-
filgrastim for the treatment of neutropenia (Neulasta®, Amgen) have appeared in the top 




Polymer therapeutics are comprised of a wide-range of nano-sized constructs 
whose common feature is the incorporation of a rationally designed covalent chemical 
bond between a water-soluble polymeric carrier (with or without inherent activity) and 
the bioactive molecule(s). Although only these three characteristics define PT, the 
incorporation of site-specific targeting moieties or/and imaging molecules and even its 
capability of self-assembled in larger nanoconstructs has extended the initial term [134]. 
 
I.3.1. Classification of Polymer Therapeutics 
PTs comprise polymeric drugs [135], polymer-drug conjugates (PDCs) [136-138], 
polymer-protein conjugates [139, 140], polymeric micelles, in which the drug is attached 
by covalent bonding [141, 142], and multicomponent polyplexes (polyelectrolyte 
complexes) which are being developed as non-viral vectors [143, 144]. The development 
of polymer-drug conjugates represents one of the aims of the present Thesis, and will be 
described in detail (Section 4). 
PTs allow for tailored drug loading, the incorporation of drug combinations, and 
intelligent bio-responsive linkers that release drugs under specific biological conditions, 
such as those found at tumor sites [145]. 
      
Figure 12. Schematic representation of polymer therapeutics families, their main characteristics, and the 




All the described PT subtypes use specific water-soluble polymers, either as the 
bioactive agent itself or as an inert functional part of a multifaceted construct for 
improved drug, protein, or gene delivery. The versatility of synthetic chemistry in PT and 
the incorporation of bioresponsive moieties and biomimetic features enhances the scope 
for PT in comparison with other nanomedicines [145]. 
The therapeutic approach in which PT are based is built on two relevant 
foundations. Firstly, controlled and sustained drug release within a suitable therapeutic 
window, and secondly, targeting drug release at the desired site of action. Intravenous 
administration (i.v.) is the preferred route of administration for most of the polymer-drug 
conjugates in the clinics, with the purpose of faster bioavailability within the bloodstream 
in comparison with other administration routes and the avoidance of tissue-specific 
biological barriers [146, 147]. 
PT offers many advantages over other nanomedicines, such as (i) greater water 
solubility (appropriate for very hydrophobic drugs such as Dox or paclitaxel PTX); (ii) 
improved plasma half-life by means of a higher hydrodynamic volume, which decreases 
kidney clearance; (iii) protection against proteolytic enzymes, or unspecific cellular 
uptake; (iv) reduction or prevention of aggregation, immunogenicity and antigenicity; and 
(v) improved pharmacokinetics (PK) at the whole body, cellular, and subcellular level. 
More than 30 years of PT development has led to 24 products entering the market 
(Table 3), with a growing number entering clinical development (Tables 4 and 5). The 
improved understanding of biodistribution, clearance, mechanism of action, and stability 
of the first generation of PTs, as well as improved physicochemical characterization, has 
prompted a second generation of better quality PTs with promising characteristics. 
 
I.3.2. Passive Targeting of PT by the Enhanced Permeability and Retention 
Effect 
The advantages of nanomedicines, in particular PT, relate to their controllable 
sizes and their size-dependent macromolecular properties. Following i.v. administration, 
a given nanomedicine can passively extravasate more selectively at tumor tissues due to 




drainage. This selective effect, first described by Maeda and Matsumura [148], is known 
as the “enhanced permeability and retention (EPR) effect”. EPR-mediated targeting also 
function within inflamed areas, thereby justifying the development and use of this class 
of macromolecular carriers in infectious and inflammatory conditions [149]. 
EPR-mediated targeting is finally determined by circulating plasma concentration, 
stability, and plasma half-life of the PT [150]. However, the EPR effect is also influenced 
by tumor type, tumor region, presence of intratumoral necrotic or inflamed area, and 
tumor vascularization. Therefore, poorly-vascularized damaged tissues are less suitable 
for nanomedicine-based treatments [151], demonstrating for a requirement for new PT-
based therapeutic approaches incorporating targeting moieties. 
The EPR effect also suffers from several additional limitations that promote the 
application of active targeting strategies [152]. These include (i) the inability of the 
nanomedicine to interact with blood components or blood vessels; (ii) the requirement 
for weakly negative to near neutral total surface charges; (iii) a requirement for systemic 
circulation times of several hours/days; and (iv) interactions of the nanomedicine with 
serum proteins and the subsequent alteration in size profiles. 
 
Figure 13. Enhanced permeability and retention (EPR) effect and passive targeting representation. Adapted 
from Ref [156] 
The EPR effect in human patients also presents with patient-to-patient variability, 
depending on a patient's pathological and physiological characteristics and clinical 




EPR effect. Some studies support EPR-mediated accumulation of nanomedicines within 
tumors, while others show that the EPR effect depends on the tumor model, suggesting 
that the EPR effect alone may not provide the entire solution. Maeda himself recognizes 
this heterogeneity and has developed methods to enhance the EPR effect in order to 
overcome the heterogeneity and improve drug delivery to tumors [155][34]. 
 
I.3.3. Cellular Internalization Pathways of Polymer Therapeutics 
Following tumor accumulation by the EPR effect, endocytic mechanisms control 
uptake of PTs into the tumor cell. Of note, water-soluble polymer-drug conjugates (PDCs) 
limit cellular uptake to the endocytic pathway looking for a lysosomotropic delivery, 
[145] and this fact has allowed to bypass drug resistance mechanisms. Following capture 
of nanomedicines at the cell membranes and the formation of intracellular vesicles called 
endosomes, a complex sequence of fusion events leads to the formation of the lysosome, 
which displays low pH (5.5) and high concentration of proteolytic enzymes [157]. The 
vast majority of PDCs rely on this pathway to finally release the conjugated drug from 
the polymer, though polymer backbone or polymer-drug linker degradation by low pH or 
proteolytic enzyme activity. A detailed analysis of enzyme- and pH-responsive PDCs can 
be found in Section 5. 
 
Figure 14. Lysosomotropic intracellular drug delivery process followed by Polymer-Drug conjugates. 




I.3.4. Polymer-based Combination Therapy 
The multivalent nature of many polymeric carriers allows the incorporation of 
more than one active moieties to promote synergistic combinatorial effects. Four types of 
polymer-based combination therapy have been proposed (Figure 15), encompassing the 
administration of: 
I. Polymer-drug conjugate + free drug(s) (Type I) 
II. Polymer-drug conjugate + polymer-drug conjugate (Type II) 
III. Single polymeric carrier bearing the combination of drugs (Type III) 
IV. Polymer-directed enzyme prodrug therapy (PDEPT) or polymer-enzyme 
liposome therapy (PELT) 
 
Figure 15. Polymer-based combination therapy strategies. 
During this thesis, we synthesized, characterized, and biologically evaluated three 
different Type III polymer-based combination therapies for the treatment of TNBC 
(Chapters 3, 4 and 5).  
Type III polymer-based combination therapy offers several benefits in comparison 
with single polymer-drug conjugates:  
I. Guaranteed simultaneous (controlled) delivery of both drugs to the same site of 
action. 
II. The presence of rationally designed linker allow us to tune the relative 
pharmacokinetics that allow to achieve synergism. 
III. Allows administration as a single dose, which translates into benefits in patience 




However, the enhanced complexity of the systems brings new challenges, 
including: 
I. The previous identification of appropriate drug combinations and ratios to achieve 
synergistic effects. 
II. The requirement for more controlled drug release kinetics. 
III. The possibility of reduced loading capacity due to steric impediments at the 
molecular level. 
IV. The requirement for a more detailed physico-chemical characterization as the 
incorporation of two active agents significantly enhances the complexity of the 
nanosystem [120]. 
 
I.4. Polymer Conjugates as Therapeutics 
Polymer-drug conjugates have long been considered the backbone of the drug 
delivery field, and the successful translation of several of these conjugates into clinical 
practice has demonstrated the potential of this approach to improve patient outcomes. The 
most recent advances in this field include DDS with ultra-high drug loadings, 
biodegradable polymeric backbones, and new drug conjugation chemistries, as well as 
the use of polymeric carriers as “platforms” that enable the incorporation of different 
therapeutic and imaging agents for applications in multifunctional therapies. 
 
I.4.1. Polymer-protein Conjugates  
The first polymer-protein conjugates (PPC), pioneered by Abuchowski et al. in 
1977, demonstrated how polyethylene glycol (PEG) conjugation (or PEGylation) could 
ameliorate protein immunogenicity, improve solubility, and extend plasma half-life [159, 
160]. PEG is a highly water-soluble, flexible, uncharged, and biocompatible polymer that 
has been widely used as an excipient and starting product in the pharmaceutical industry. 
When bound to a therapeutic protein, PEG shields antigenic epitopes via steric repulsion, 
thus reducing immunogenicity [161]. Furthermore, steric repulsion prevents degradation 




phagocyte system (MPS). The increase in molecular weight and hydrodynamic radius 
conferred by PEG conjugation further reduces plasma clearance by renal filtration. 
Accordingly, the improvements in protein stability, plasma half-life, and immunogenicity 
reduce the required frequency of dosing and improve the overall safety profile of the 
therapeutic agent. The clinical impact of PEGylation has been established by several 
clinically approved PEG-protein conjugates as therapies for hepatitis C, acute lymphatic 
leukemia, and rheumatoid arthritis (Table 3) [162]. Furthermore, nucleic acids can also 
be PEGylated to reduce renal clearance and extend the circulation half-life of, for 
example, aptamer therapeutics, including the approved drug Macugen for macular 
degeneration [163-165]. These successes have encouraged the clinical evaluation of 
various PEGylated proteins, including enzymes, cytokines, growth factors, and antibodies 
(Table 3, 4 and 5). 
However, the non-biodegradable nature of PEG represents an important limitation 
to clinical application. Currently approved PEGylated protein therapeutics employ PEGs 
of ≤40 kDa molecular weight, close to the glomerular filtration threshold of 
approximately 50 kDa [165]. While increased molecular weight generally affords 
extended circulation time, concerns regarding the accumulation of non-biodegradable 
PEG limit the optimization of polymer molecular weight and resultant pharmacokinetics. 
However, new biodegradable alternatives to PEG such as polyoxazolidines or 
polypept(o)ides can enhance protein pharmacokinetics, and present an exciting 
opportunity in the development of the next generation of polymer-protein conjugates 
[166-168]. 
Additionally, conflicting reports on the immunogenicity and antigenicity of PEG 
have further provoked interest in the development of non-fouling and biocompatible PEG 
replacements [169]. Notably, a heparin-mimicking polymer affords stabilization to a 
heparin-binding protein-basic fibroblast growth factor, which is otherwise unstable even 
after PEGylation [170]. In addition to the traditional advantages of polymer conjugation, 
the ligation of responsive polymers affords “smart” conjugates in which protein activity 
and release can be modulated [171]. Additionally, amphiphilic polymer-protein 
conjugates can be incorporated into sophisticated superstructures to alter their 
pharmacokinetic profile and to increase functionality via the entrapment and co-delivery 




I.4.2. Polymer-drug Conjugates 
PDCs represent one of the most successful and oldest polymeric DDS. The first 
attempts to enhance the therapeutic output of drugs by conjugation to macromolecules 
were performed in the 50s-60s, when Jatzkewitz focused on a variety of soluble polymers, 
in particular poly(vinylpyrrolidone) [173]. Mathé et al. conjugated drugs to 
immunoglobulins for the first time in 1958, establishing the first platform for PDCs [174]. 
The field of PDCs underwent a paradigm shift in 1975, when Ringsdorf conceptualized 
the application of biocompatible polymers as efficient drug carriers and thus encouraged 
the rational design of PT candidates that would entered in clinical testing years later 
(Kopecek, Duncan, Ulbrich and Rihova) [175, 176].  
Rational design, a key requisite for the successful development of PDCs, 
encompasses three components: a water-soluble polymeric carrier, a bioresponsive linker, 
and a bioactive agent [175]. However, due to the multivalency of polymers applied in 
PDC development, more than one compound can be conjugated to the polymeric 
backbone, allowing the introduction of targeting residues (in order to trigger active 
targeting-receptor-mediated endocytosis) [177] or more than one drug (polymer-based 
combination therapy, see Section 3.4) [119]. Furthermore, the conjugation of imaging 
agents for theranostic purposes[178] could enhance the therapeutic value of a given PDC. 
Within the first generation of PDCs only a few polymeric carriers have shown success in 
clinical trials, including: 
 Poly(N-hydroxypropyl methacrylamide) (polyHPMA)-Dox Developed and 
described for the first time by Kopeček, Ulbrich and Duncan, with (PK2) and 
without (PK1) galactosamine as active residue  [177, 179-181]. 
 Poly(glutamic acid) conjugates of paclitaxel (XyotaxTM or OpaxioTM) or 
camptothecin (CT-2106) – First synthesized by Li and Wallace [182-184]. 
 PEG-cyclodextrin-camptothecin nanoparticulated conjugate of 30 nm (CRLX101 
or IT-101) - Developed by Davis [185, 186]. 
 PEG-polypeptide block copolymer conjugated with SN-38 (NK-012), 



































The first polymer- drug conjugates to reach clinical trials employed copolymers 
of HPMA, poly-L-glutamic acid (PGA), or PEG as carriers of cytotoxic chemotherapeutic 
agents. PK1, the first clinically investigated water-soluble polymer-small molecule drug 
conjugate, comprises Dox bound to an HPMA copolymer via a lysosomally cleavable 
peptidyl linker [145]. Given the non-biodegradability of the HPMA copolymer, the 
authors chose a size of 30 kDa to ensure renal elimination. In preclinical animal models, 
PK1 demonstrated a 15-fold improvement in plasma half-life, an enhanced safety profile, 
and greater anti-tumor efficacy compared to unconjugated doxorubicin [190]. Notably, 
PK1 displayed 17-77x greater tumor accumulation of drug relative to free doxorubicin in 
these models. Furthermore, a 45-250x higher drug concentrations in tumor relative to 
healthy tissues suggested the relative importance of passive tumor targeting [190]. 
However, PK1 testing in clinical trials in the late 1990s found marginal efficacy and 
tumor accumulation of the conjugate in only a small subset of patients and efficacy was 
marginal. While PK1 displayed extended circulation time and an overall improved safety 
profile[191], its development was abandoned. 
Given their lack of biodegradability and subsequent limitations on molecular 
weight, first generation conjugates of PEG and HPMA exhibit suboptimal 
pharmacokinetics. Hence, current research efforts focus on the evaluation of conjugates 
employing new biodegradable and backbone-degradable water-soluble polymers. New 
water-soluble, biocompatible, and biodegradable polymers, such as polycarbonates or 
polypeptides, are likewise being synthesized and evaluated, expanding the repertoire of 
polymers available for drug conjugation [192, 193]. Additionally, biologically active 
polymers, such as peptide molecular transporters, are being employed as drug carriers 
due to the added biological functionality they afford. 
Molecular architecture is also emerging as an important modulator of PDC in vivo 
fate and subsequent therapeutic efficacy, with circular and branched structures generally 
exhibiting extended plasma half-lives and greater efficacy than their linear counterparts 
[194-197]. Importantly, polymer branching affords an alternative approach to the 
synthesis of high molecular weight conjugates without compromising the drug loading 
efficiency of di-end-functional polymers such as PEG. In addition to polymer molecular 
weight and architecture, linker chemistry modulation can achieve optimized drug release 
profiles and enhanced therapeutic efficacy. For example, the incorporation of hydrazone 




dexamethasone constructs, respectively [198]. In an in vivo rat model of arthritis, the slow 
releasing conjugate exhibited sustained anti-inflammatory activity, leading to an 
improved therapeutic outcome compared to the fast releasing formulation. 
The vast majority of PDCs synthesized, characterized, and evaluated throughout 
this Thesis have been based on polypeptides, in particular polyglutamates (PGA). We 
present a deep review on the rational design, key design features, physico-chemical 
properties, and controlled drug release in polypeptide conjugates in Section 5. 
 
I.5. Polypeptide-Based Conjugates as Therapeutics 
Polyamino acids (PAA or polypeptide)-based materials have gained much 
attention in the field of biomedicine over recent decades. [199-201] PAAs mimic natural 
proteins and demonstrate remarkable biocompatibility and biodegradability due to the 
endogenous nature of the building monomers. Development of polymerization techniques 
(mainly N-carboxyanhydride ring-opening polymerization (NCA-ROP)) [20] and 
synthetic chemistry have permitted the production of polypeptides with narrow 
polydispersity, minimal side product formation, high reproducibility, and precise 
functionalization of the polypeptide backbone. [202] 
The suitability of polypeptide-based materials for drug delivery applications is 
also confirmed through the steady increase in the number of polypeptide-based 
compounds reaching preclinical studies and clinical trials. [200] In this section, we will 
mainly focus on polypeptide drug-conjugates and their key design features; further 
reading on polypeptide-based materials can be found in the literature. [200, 203, 204] 
Applicability of synthetic polypeptide-based conjugate development has reached 
multiple areas of medicine, including the elaboration of anti-microbial, [205-207] anti-
virus, [208, 209] anti-cancer, [209-215] anti-diabetic, [216] anti-apoptotic, [217] and anti-
tuberculosis drugs,[218] magnetic resonance imaging (MRI) agents, [219] and 
theranostic agents. [36] The great advantage of polypeptides is their structural versatility 
which allows the generation of a myriad of architectures with differential physico-
chemical features, allowing high loading rates and the possibility to conjugate drugs of 




has been used for the delivery of highly lipophilic drugs (PTX, [213] 4-(N-
hydroxyphenyl)retinamide, [220] camptothecin (CPT), [221] N,N-dimethylsphingosine), 
[222] hydrophilic drugs (dopamine), [223] peptoids, [224] metal complexes (Gd(III)-
DO3A, [225] VO, [226] and Cu [227]), and nucleic acids. [228] Structural versatility of 
polypeptide conjugates is also exemplified by the wide range of delivery systems in which 
P(L-Asp), P(L-Glu), or P(L-Lys), for example, are present. [208, 229, 230] 
Engineering polypeptide complexity is an accepted approach in order to mimic 
nature and cross many biological barriers in a target pathology. This has led to the 
identification of interconnected systems selected from a rather wide, complex, and 
diverse toolbox. Advanced polypeptide conjugates are complex systems with several 
structural levels and diverse architectures. Even though each conjugate is a unique 
system, its final physico-chemical properties comply with strictly explicit and determined 
trends. 
Existing key design features can be described at three distinct levels: primary, 
selection of structural elements before the synthesis of the polymer (e.g., polymer matrix 
nature and architecture, linker design and responsiveness, active molecule nature); 
secondary, optimization of the physico-chemical properties of the synthesized conjugates 
(e.g., size, charge, conformation, geometry, topology); and tertiary, modulating the 
biological properties through fine tuning of the previous two levels in reiterative design 
cycles. 
However, precise design of advanced polypeptide-based conjugates toward the 
pursued biological output remains a serious challenge due to several related points:  
1. Multiple different parameters involved in the design can significantly alter the 
final properties of the conjugate. 
2. Lack of scientific data devoted to the strategic and logical design of 
sophisticated polypeptide systems. 
3. Lack of appropriate characterization tools and techniques to disclose the 
interaction of the nanocarriers with biological interfaces. [231] 
4. Structural complexity and molecular mass inhomogeneity have made 
computer simulations of such systems highly challenging and so, only a few 




revealed some correlations between structure of the conjugate and its properties. 
[114] 
Herein, we will focus on the role of structural elements (especially stimuli 
responsive polymer-drug linkers) and the physico-chemical parameters that determine a 
given system biological performance and, therefore, their successful applicability and 
transferability. Throughout the following sections, we will endeavor to illustrate the role 
of different parameters affecting the final physico-chemical properties, the responsive 
nature, and the biological performance of the conjugate. 
 
I.5.1. Rational Design of Polypeptide-Based Conjugates 
The rational design of polypeptide-based therapeutics for the treatment of a given 
pathology must be holistically driven using a step-wise design following the pathway 
taken by the therapeutic through the body. [233] Therefore, the administration route, the 
biological barriers to be crossed, and the target site of action all require scrutiny for the 
successful selection and design of the conjugate with selected properties. The physico-
chemical parameters of the drug delivery systems determine their inherent ability to cross 
the required biological barriers. [234] Another important aspect to be considered for 
appropriate biological activity is the specific response to the different physiological 
environments encountered in the body. This knowledge would ensure an adequate overall 
stability, optimal response, and thus, delivery of the cargo in the target site of action at 
the desired timing. Furthermore, the administration route and the dose schedule in the 
target patient population are key issues for the successful translation of a drug delivery 
system. [235, 236] 
 
I.5.1.1. Biological Barriers and Administration Routes 
“Biological barriers” is a generalized term for a group of specific protective 
mechanisms present throughout the body. All the known biological barriers can be 




Level 1 (absorption: reaching the bloodstream). Independent of the administration 
route, the first obstacle for most conjugates is the bloodstream to allow adequate body 
distribution and to reach the selected molecular target. Design of effective conjugates 
must ensure their chemical stability and integrity during blood circulation at physiological 
conditions (ionic strength, redox potential, pH, presence of proteases, etc.) until arrival at 
the desired site of action. The easiest administration strategy for a given drug conjugate 
is intravenous injection, which represents the most widely used route due to rapid onset 
and high bioavailability. For polypeptide-based therapeutics, alternative routes of 
administration include topical, [237, 238] oral, [239] and pulmonary, [240] delivery 
through different mucus barriers (buccal, nasal, vaginal, ocular, etc.), [36, 219, 240] and 
through direct injection to the site of disease (intraocular, intraperitoneal etc.). However, 
in this context, these administration routes have not yet been fully exploited.  
Level 2 (circulatory barriers). In the bloodstream, the immune, reticuloendothelial 
(RES), and hepatic systems are the main obstacles for adequate delivery. Recognition of 
foreign entities is implemented by a family of proteins known as opsonins which absorb 
to the surface of the nanosystem and promote phagocytosis. While the exact mechanisms 
behind opsonization have yet to be fully delineated, certain physico-chemical and surface 
properties which affect the level of opsonization have been ascertained. [241, 242] 
Furthermore, as macromolecules, some conjugates will trigger the activation of the 
complement system, the innate immune response, limiting the effectiveness of the 
treatment besides the subsequent development of hypersensitivity reactions or allergies. 
[243] 
Level 3 (tissue-specific barriers and tumor stroma). Some organs are provided 
with highly specific blood tissue barriers (blood-brain, blood-ocular, blood-retinal, blood-
testis, blood-thymus and blood-air). Crossing the blood-brain barrier (BBB) using 
polypeptide conjugates has only recently gained much attention following the publication 
of the so-called “Trojan Horse” strategy. [244, 245] However, to the best of our 
knowledge, there is currently no reported evidence for polypeptide conjugates crossing 
any other of the above-mentioned barriers apart from our own recently patented work on 
the BBB. [245] However, solid tumors develop a deficient lymphatic drainage and an 
abnormal architecture of neovasculature with wide fenestration within the stroma, 
allowing permeation of macromolecules. In this scenario, passive targeting by the so-




development of anti-cancer polypeptide conjugate therapies. [215, 247, 248] However, 
for future developments, it is important to take into account that the EPR effect is a rapidly 
evolving concept. [249] 
Level 4 (cellular barriers). The passive diffusion of molecules with a molecular 
mass above 1 kDa is efficiently blocked by the cell membrane. Conjugates can enter the 
cell through endocytosis (including clathrin-mediated, caveolin-mediated and clathrin-
and-caveolin-independent), phagocytosis, or macropinocytosis. [250, 251] To enhance 
endocytic cell internalization, different ligands can be conjugated to the surface of the 
polypeptides (e.g., folic acid, cholesterol, or Arginylglycylaspartic acid (RGD) based 
peptides). [252, 253] 
Level 5 (subcellular barriers). Targeting of specific organelles (e.g., the nucleus 
or mitochondrion) represents the least researched area within drug delivery. Endocytic 
processes define the trafficking of a given agent to different subcellular vesicles or 
organelles. Most polypeptide-drug conjugates are designed to enter the cell by clathrin-
mediated endocytosis to be actively transported to lysosomes for further degradation, a 
process which is advantageous for bioresponsive-drug release. [251, 254] In clathrin-
mediated endocytosis, endosomal escape is the only way to ensure access of the carrier 
to targeted organelle. In this case, the incorporation of bioresponsive elements in the 
conjugate backbone or specific targeting sequences are required. 
 





I.5.2. Key Design Features of Polypeptide Conjugates 
In general, polypeptide conjugates used in drug delivery consists of four parts: the 
biodegradable polymer matrix, the active agent (e.g., small molecules), the linker, and 
targeting (and/or imaging) moieties. However, the linking and targeting moieties are not 
always essential conjugate design features Figure 17. 
Conjugation of active agents to the polypeptidic carrier can have a prominent 
effect on the final physico-chemical properties. However, conjugates do tend to replicate 
the biodistribution and pharmacokinetic behavior of the original polymer matrix if no 
major conformational changes are induced by the conjugated drug(s) (importance of 
drug(s) nature and loading). [256] This topic is thoroughly discussed in section 5.3. 
Conversely, the polypeptide matrix itself can affect the activity of the conjugated agent, 
especially when functional groups determining activity are blocked or utilized for 
conjugation. The chemotherapeutic agent paclitaxel (PTX), for example, is connected to 
the polypeptide through the 2′-hydroxyl position which is essential for tubulin binding. 
[257] Thus, PTX conjugated to P(L-Glu) is inactive and needs to be degraded within the 
cell to provide its therapeutic effect. [258] Polymer conjugates of Dox, also require in-
cell degradation, as the anti-tumorigenic effect requires Dox interaction with the DNA 
and the polymer conjugate cannot penetrate the nuclear membrane. [36] However, 
polymer conjugation prevents Dox-related cardiotoxic effects. [259] Nevertheless, 
polymer conjugation does not always alter the activity of the conjugated agent and, in 
some cases (e.g., phloridzin (Prz), [260] doxycycline [261]), drug activity is increased. 
The versatility of PAAs is demonstrated by the diversity of developed systems to 
date; ranging from linear or branched homopolypeptides to block (and random) 
copolypeptides capable of generating hierarchically assembled nanostructures from 
synthesized polypeptide conjugates (e.g., micelles and core cross-linked micelles, 
vesicles, cross-linked networks and hydrogels). [200, 262, 263] In each case amino acid 
building block choice is driven by the required functionality. Additionally, ROP of NCAs 
renders polypeptides with conserved N-terminal ends and can be used to introduce 
functionalities at the C-terminal site for latter conjugation strategies. Synthetic aspects of 
polypeptide production are outside of the scope of this Chapter and can be found 
elsewhere. [202, 220, 264, 265] In the context of Polypeptide Therapeutics, amino acids 




(1) Functional classification: According to the chemical reactivity of the 
associated side chains, amino acids can be classified as functional (where side chains 
contain functional groups suitable for active molecule conjugation) and non-functional 
(where side chain modification is unpractical or inaccessible). (2) Structural 
classification: According to the structural or architectural properties brought to the 
scaffold, amino acids can be grouped as hydrophobic (e.g., Ala, Val, Leu, Ile, Phe, Tyr, 
Trp), α-helix forming (e.g., Leu, Phe), β-sheet forming (e.g., Ala, Val), random coil 
promoters (mainly ionizable side chains in their charged state), or polar (or ionizable). 
[266] 
Although the conjugation of active agents to the polypeptide backbone does not 
necessarily need to occur through side-chain functionalities, most of the examples in the 
literature operate within this strategy. This fact is attributed to the multivalency of PAA 
backbones and high cargo loading attainable. There are a number of amino acids with 
functional side groups that have yet to be thoroughly explored for polypeptide therapeutic 
design, including methionine, serine, threonine, and cysteine. [267] In practice, glutamic 
acid, aspartic acid, and lysine are the most exploited amino acids in polypeptide conjugate 
synthesis. 
 
Figure 17. Schematic representation of the key design features related to structural levels and physico-





I.5.3. Physico-Chemical Properties Driving the Bio-Nano Interface 
Interaction of a polypeptide conjugate with the bio-nano interface is driven by a 
complex system of simultaneous interactions which requires the step-wise design of 
experimental conditions in relevant physiological environments to completely reveal the 
material’s performance in a biological milieu. [231] Polypeptide conjugates are discussed 
in the following section in relation to the influence of active agent incorporation on the 
final physico-chemical properties and the impact on their biological output. 
 
I.5.3.1. Effect of Size 
The size of the conjugate is an important parameter that determines its fate in the 
bloodstream, its targeting ability, and mechanisms of cellular uptake. In the bloodstream, 
nanosystems smaller than 5 nm rapidly penetrate capillary fenestrae, equilibrate with the 
extracellular matrix, and become rapidly cleared by renal glomerular capillaries. Larger 
particles exhibit prolonged circulation (except in cases when clearance is guided by 
factors other than size), although the RES eliminates nanosystems larger than 200 nm 
from the circulation. Thus, the diameter of the nanosized therapeutics suitable for in vivo 
application should lie in the range from 5 to 200 nm. It is important to note that even in 
this size range, nanomedicines display non-uniform size-behavior, unique for each 
material. [268] This fact is often disregarded and few studies have investigated size 
optimization for the nanosystems.  
A serious problem with passive size-dependent accumulation of nanoconstructs is 
similar capillary porosity in different tissues. Studies into the anti-cancer efficiency of 
amphiphilic block copolymer PEG-P(L-Asp)-Dox found that micelles demonstrated 
tissue cytotoxicity that was probably related to accumulation specificity and retention 
time in the specific tissue. [269, 270] As shown in Figure 18, the conjugate concentrated 
in the spleen, liver, and tumor because of the corresponding size of fenestrae (approx. 
100–200 nm). Thus, highly selective tissue targeting with polypeptide conjugates (and 





Figure 18. Tissue-to-blood concentration ratio (Kb = Ctissue/Cblood) of PEG-PAsp-Dox. Adapted from Ref 
[270] 
Self-assembly of nanoconstructs is highly dependent on the nature of the 
assembling polymers and conjugated drug(s) and many different driving forces specific 
for each system are involved in its regulation. Self-assembly is regulated by the 
minimization of the interfacial energy directed by hydrophobic/hydrophilic balance, –
 stacking, dipole interactions, and hydrogen bonding among different domains. The 
balanced forces determine the compactness, conformation, and size of the conjugate. 
Of note, many hydrophilic polypeptides and related copolymers do not aggregate 
in water and self-assembly of such systems is often induced by simple conjugation with 
a hydrophobic drug. For example, both PEG-P(L-Asp) and PEG-P(L-Glu) form 
nanosized systems after conjugation with Dox, while non-conjugated polymers do not 
aggregate in aqueous solution. [271] 
When highly hydrophobic drugs are conjugated to self-assembled PAA 
(co)polymers, or when the content of the hydrophobic drug increases, the size of the 
resulting polymer-drug conjugate usually rises significantly. The size increase is in direct 
non-linear proportion to the drug conjugation ratio. The assessment of a series of CPT 
conjugated PEG5000-P(L-Glu) graft-copolymers demonstrated that an increased CPT 
content led to an increase in final nanosystem size from 30 nm (15.2 wt% of CPT) to 65 
nm (25.1 wt% of CPT). [272] Zhou et al. obtained similar results for a synthesized series 
of PEG45-P(L-Lys)25-SS-CPTx (x=3, 6, and 8), where all of the conjugates formed 
spherical particles with diameters of 85, 118, and 152 nm, respectively. [273] Analogous 
trends were observed for other hydrophobic drugs such as Dox. For PEG-P(L-Asp) 




conjugation with Pyrazinamide (86% conjugation) resulted in the formation of micelles 
with an average diameter of 78.2 nm [218] while Isoniazid conjugation (65% 
modification) led to the formation of significantly larger micelles (266 ±27 nm). [274]  
Post-synthetic modification with hydrophobic moieties through coordination 
bonds leads to nanosystem compaction, as was shown for many metal-containing drugs. 
For example, spherical nanoconjugates of γ-P(LGlu)-(citric acid)-Cisplatin (CDDP) 
displayed an average size of 107±6.3 nm while free γ-P(L-Glu) was larger, at 212±8.6 
nm. [274] The same trend is typical for physical encapsulation of hydrophobic drugs. 
Some drugs have changeable effects on the size of the conjugate. Assessment of γ-P(L-
Glu) series with different anti-diabetes drug Prz content, demonstrated that all conjugates 
formed spherical nanoconstructs with average sizes of 149±23 (P(L-Glu)-Prz-7%), 
187±4.0 (P(L-Glu)-Prz-15%), and 170±19 (P(L-Glu)-Prz-25%) nm. [260] However, 
some drugs have a less pronounced effect on size. This includes P(L-Glu)-Dox conjugates 
with 15% and 30% loading, which demonstrated even less pronounced size dependence 
with nanosystem sizes of 6.2±1.3 nm and 7.5±0.7 nm, respectively. [261]  
Molecules for active targeting are conjugated either at the polymer side-chains 
[241] or at the terminal ends of the polymer and only a few targeting molecules per chain 
are present. Nevertheless, the effect of even a low conjugation level on conjugate size can 
be pronounced depending on residue nature. Targeting moieties are usually hydrophilic 
and, in most cases, conjugation results in an increase in nanosystem size independently 
of the polymer matrix nature, mainly if terminal conjugation is used. For terminal end 
modification of PEG-poly(γ-benzyl-L-Glutamate) (PEG-P(L-Glu-Bz)) with 
glycyrrhetinic acid (GA), the size of the modified micelles was higher than for the non-
modified copolymer (181.1 and 175.4 nm, respectively). [241] An increase in size also 
occurred for dendrimeric P(L-Lys) nanosystems modified with folic acid [275] or 
galactose [276] and for PEG-P(L-Asp) nanosystems modified with biotin. [277] In 
general, terminal modification resulted in a size increase from 3% to 70%.  
The effect of conjugation on size when more than one drug or a drug and a 
targeting moiety are used is often more significant than that observed for single 
component conjugation, possibly due to both intra- and inter-molecular interactions. P(L-
Glu) dendrimers with oligomeric silsesquioxane core with a size of 3 nm grew to 135 nm 




unusual morphology, as each nanoassembly was an aggregate of smaller nanoobjects of 
2–3 nm (the size of single dendrimers). This suggests that hydrophobic interactions within 
the conjugates, due to the presence of Dox molecules on the periphery of the nanosystem, 
drove the self-assembly process.[278] Dox and Wortmannin conjugation to PEG-P(L-
Asp-hydrazide) block copolymers generated nanosystems of less than 70 nm in diameter, 
although when the amount of Wortmannin increased, nanoassembly size also increased 
gradually. The only exception was observed for micelles with a 50:50 ratio which 
displayed a size of 91 nm. [279] In some reports, molecular weight (Mw), is used to 
explain biological performance and can affect biodistribution in a similar way to size. For 
tumor targeting, the EPR effect is most pronounced for agents with an Mw above 50 kDa 
(either single molecule or self-assembled nanosystem). [280] For P(L-Glu)-CPT 
conjugates, an increase in Mw from 33 to 50 kDa enhanced anti-tumor efficacy against 
B16 melanoma cancer cells without significant changes in the maximal tolerated dose. 
[221] Similar results were also obtained for P(L-Glu)-CDDP conjugates with different 
Mw. [281] 
The Mw of the matrix is a crucial parameter for polypeptide conjugates suitable 
for MRI as it affects T1 relaxivity, water exchange rate, accumulation in target tissues, 
and rotational correlation lifetime of Gd(III) species (so far only Gd-containing 
polypeptide conjugates have been investigated). [282] Polymeric P(L-Glu)-
diethylenetriaminepentaacetic acid (DTPA)-Gd conjugates displayed sustained signal 
enhancement from necrotic tissues, while oligomeric P(L-Glu)-DTPA-Gd and low Mw 
conjugates showed a much shorter signal. [283] The Mw of each conjugate also affected 
the speed of signal disappearance -the quicker clearance of lower Mw conjugates resulted 
in quicker signal disappearance-. The 50 and 87 kDa conjugates demonstrated prolonged 
signal increase duration in the tumor periphery and interstitium with no significant 
difference when compared to each other. [284] 
 
I.5.3.2. Effect of Charge 
Nanosystem surface charge has a prominent effect on the in vivo fate of 
conjugates, determining the recognition in and clearance from the circulation, interactions 
with cell membranes, cellular uptake, and toxicity. Surface charge also determines the 




media. [285] In the blood, zeta (ξ) potential determines the pharmacokinetic properties of 
the conjugate and the possibility of phagocytosis.  
Conjugates with a positive zeta potential such as (P(L-Glu-hydrazide)-b-
poly(N,N-dimethylaminopropylmethacrylamide))3-g-PEG-Dox (ξ=+46.3 mV) are not 
directly applicable in vivo, because of charge-associated toxicity, but can be transformed 
to negatively charged nanoconstructs by conjugation or complexation with anionic 
molecules (e.g., siRNA). It is generally accepted that polypeptide conjugates suitable for 
in vivo application should carry a small negative or neutral charge in order to inhibit 
opsonization and RES elimination. 
 
Figure 19. Effect of the terminal group of p(X-Alam-Lys) on the cellular uptake. Adapted from Ref [286] 
 
Effect of Zeta Potential on Cellular Uptake 
Nanosystem binding to the lipid cell membrane is the first step in cellular uptake 
and is greatly affected by nanosystem surface charge. Variations in zeta potential can be 
used to control binding to the cell both in vitro and in vivo. Cellular surface charge is 
usually negative due to sulfated proteoglycans (core proteins anchored in the lipid bilayer 
and glycosaminoglycan side chains of dermatan, keratin, or chondroitin sulfate). [287] 
Nanosystems with higher surface charges tend to bind strongly to the membrane, and this 
increases cellular uptake. However, moderate cationic polymers have shown high 
insertion efficiency in negatively charged films, whereas highly cationic and anionic 
polymer displayed reduced interaction with such monolayer films. [288] Even though 
cellular uptake is higher for polycations, negatively charged conjugates can also penetrate 




For anionic polypeptides, uptake is also dependent on the absolute value of the zeta 
potential. For a p(X-Alam-Lys) series, where X is either free, acetylated, succinylated, or 
maleilated Glu, polypeptides (Figure 19) with a larger negative charge density (Suc-Glu) 
displayed greater uptake by murine macrophages when compared to the less negatively 
charged acetylated and malariated conjugates since the C=C double bond in maleic acid 
residue is conjugated with C=O, and this influences the state of the terminal carboxylic 
group. [288] 
 
Zeta Potential in Polymer Conjugate Design 
During conjugation, the zeta potential value of the system changes according to 
the charge of the modifying moiety. For example, CDDP conjugates of PEG114-b-P(L-
Glu)12 block copolymer (10% CDDP) displayed a relatively low zeta potential of 
−3.93±0.5 mV due to the conjugation of the carboxylate anion with platinum. [287] The 
drug loading influences the charge density of the nanosystem in direct non-linear 
proportion. For example, zeta potentials for two samples of P(L-Glu)160-PEG5000 with 
10% and 20% loadings of CDDP was of −17.7±1.0 mV and −8.5±1.3 mV, respectively. 
[281] This trend seems logical from an electrostatic point of view, although its 
mathematical expression is often complicated and rarely reported. In some cases, zeta 
potential behavior does not follow expected trends. Tsai et al. demonstrated unusual 
changes in zeta potential for γ-P(L-Glu) conjugated with Dox and galactose. When 
conjugated with Dox, the zeta potential of the system increased from −37 to −27 mV and 
after conjugation with galactose, zeta-potential slightly decreased (−32 mV). This was 
expected because Dox bears a slightly positive charge while the hydroxyl groups of 
galactose are slightly negative. However, conjugation of Dox and galactose significantly 
decreased the zeta potential to −75 mV with no obvious reason. [289] Thus, prediction of 
synergistic effect on zeta potential remains a serious challenge in the preliminary design 
of polypeptide conjugates. Zeta potential can also be controlled by changing the ratio of 
monomers of opposite charge. For a series of random P(L-Glu)-P(L-Lys) polymers by 
varying lysine/glutamate content it was possible to change the value of zeta potential from 
−30.3 to +4.9 mV. [290] Further CDDP loading increased the zeta potential of all 
nanosystems. For example, a study found that the zeta potentials of aggregates for three 
compounds (Glutamate/Lysine molar ratio of 4/1, 1.5/1, and 1/1) to be −30.3, −21.8, and 




However, each conjugate displayed different zeta potential changes at different pH. By 
careful manipulation of drug loading and monomer ratio, the authors managed to tune 
pH-dependent surface charge reversion at high level of precision. [290] 
 
I.5.3.3. Effect of Conformation 
The conformation of the polymer chain is not usually considered as a key 
parameter determining applicability of a conjugate as a drug delivery system. Compared 
to size and charge, chain conformation has minimal influence on recognition and 
elimination from the bloodstream. However, conformation strongly affects nanosystem 
stability, interaction with cellular membranes, and biological activity. [291] For example, 
PEG-b-P(L-Glu)-CDDP and PEG-b-P(D-Glu)-CDDP, which adopt helical 
conformations with different handedness, displayed no differences in biodistribution or 
anti-cancer activity. However, micelles with a random P(D,L-Glu) copolymer matrix, 
which are unable to form helical conformation, were less active and cleared faster, even 
though the nanosystem size was similar. The authors concluded that an α-helical structure 
additionally stabilized micelles and extended their bioavailability. [292] Additionally, 
polypeptides containing amino acids that stimulate α-helical conformation (Ala, Phe, 
Leu) are generally much stronger membrane disrupting agents than amino acids 
stimulating β-sheet conformation (Ile, Val). The conformation of polypeptides and 
polypeptide based conjugates is very sensitive to pH of the solution and to conjugation 
or, more generally, to the electrostatically equilibrated structure of the nanosystem. Upon 
pH change, functional groups in the amino acid residues become ionized/neutralized and 





Figure 20. A, B) Effect of the terminal amino acid sequence on the helicity of the PLys adapted from Refs 
[125, 126]; C) effect of terminal group on helicity of γ-4-((2-(piperidin-1-yl)ethyl)aminomethyl)benzyl-
PGA. Adapted from Ref [294] and Ref [295] 
In some cases, conformation is concentration dependent. For example, PEG-P(L-
Glu) complexes with polylysines at concentrations of 0.02, 0.05, and higher than 0.1 mg 
mL−1, micelles existed as random coil, mixed, and β-sheet conformation, respectively. 
Most probably, PEG chains suppress the collapse of the nanosystems into a random coil 
due to increased surface area/volume ratio. [296] 
 
Effect of Conjugation on Conformation 
Conjugation has a complex effect on conformation because, in addition to utilizing 
the functional groups of the polypeptide, conjugated moieties introduce new spatial and 
charged elements that change the electrostatic equilibrium. Conjugated molecules can be 
thus classified as stabilizing or destabilizing. Serine, for example, has a tendency to 
stabilize ordered structures (either α-helix or β-sheet) as was shown for a series of 
branched P(L-Lys). The incorporation of terminal Ser and Leu in the side-chains of 
branched P(L-Lys) led to the acquisition of a more ordered (α-helical) conformation in 
comparison with Ala (Figure 20). [297] Glutamate replacement of leucine in P[L-
Lys(Leu1.0-Ser0.9-DLAla7.0)] changed the tendency to form helical structure, with a 




acidic conditions glutamate-containing polymers tended to stabilize or destabilize helical 
structures depending on the surroundings. 
Under appropriate conditions, polymers with both serine and glutamate formed β-
sheet structures. [298] Conjugated moieties allows stabilization of the conjugate 
conformation in the organism that is especially important for polypeptides with a narrow 
pH range of conformational stability such as P(L-Glu) that tends to form α-helix at 
pH=4.5. Conjugation with the hydrophilic anti-cancer agent D-penicillamine stabilized 
the helix conformation even in a completely water soluble state at pH 7.4 (normal pH of 
blood plasma). [299, 300] The secondary structure of P(L-Glu) can also be stabilized as 
a helix when functionalized with amine/guanidine as shown in Figure 20. [294] 
Remarkably, one study achieved stable helicity of up to 90%–95% following α-4-((2-
(piperidin-1-yl)ethyl) aminomethyl)benzyl incorporation into the P(L-Glu) structure. 
Interestingly, the helical structure remained even after around 40% addition of the other 
functionalized moieties. [295] Many active agents have minimal effect on conformation 
change after conjugation and nanosystem can display behavior similar to a non-modified 
polypeptide. An illustrative example of such systems is P(L-Glu)-Dox which is negatively 
charged at pH 7.6 and displays a random coil conformation. At acidic pHs, the charge is 
neutralized and the conjugate adopts an α-helical conformation, similar to that observed 
for control P(L-Glu). [301] However, upon Dox conjugation, such conformational change 
occurs at slightly less acidic environments (pH 5.7 vs. 4.5 for P(L-Glu)-Dox and P(L-
Glu), respectively). 
 




When a conjugated drug destabilizes secondary structure, additional moieties may 
be incorporated in order to achieve the necessary conformation. Methotrexate (MTX), for 
example, has a tendency to destabilize the secondary structure of P(Lys-DL-Alax) but the 
conjugate can be further stabilized with helix-stabilizing amino acids (such as Leu) or 
destabilized with Glu. [297] The study also found that the incorporation of D-amino acids 
into polypeptide polymers with L-chirality mediates the destabilization of secondary 
structure. Even small changes to a polypeptide backbone can destabilize polymer 
conjugate conformation. For example, polycysteine molecules modified with galactose 
or glucose adopt a predominantly α-helical conformation. The oxidation of the thiol group 
to sulfone destabilized the α-helix and causes a transition to a disordered conformation, 
perhaps due to the strong interaction of sulfone groups with water molecules. This results 
in the disruption of peptide hydrophobic packing and the increase of steric crowding that 
consequently results in the destabilization of the helix. Interestingly, separation of the 
thioester group by an additional methylene group led the conjugate to retain an α-helical 
conformation even after oxidation to sulfone. [302] Chain topology also influences the 
amount of secondary structure defects. For example, linear and 3-arm star P(γ-
carbobenzyloxy-L-Lys) and P(L-Glu-Bz) both displayed an α-helix conformation. 
However, smaller star-copolymers displayed smaller helix persistence length which may 
affect the binding sites. [303] Due to increased steric effects and charge repulsion, the 
helicity of star copolypeptides is usually lower than that of linear analogues. [304] 
 
I.5.3.4. Effect of Geometry 
While geometry is an important characteristic to consider during nanomedicine 
design, there have been few extensive studies on this topic until recent times. However, 
it is now evident that many nanoconjugate properties, including transport, degradation 
and release profile, are shape-dependent. [305] Conjugate diameter affects nanosystem 
velocity, diffusion, and adhesion to the blood vessels, airways, and intestine. However, 
shape has more complex effect on these characteristics because non-spherical 
nanosystems demonstrate flow-dependent alignment. Shape can also affect the targeting 
ability, as local curvature affects ligand and opsonin adsorption and the degree to which 
nanosystems fit to the contours of cellular membrane. Conjugate shape changes may lead 




internalization. However, nanodisks, as compared to nanospheres, have a tendency to 
localize within phospholipid bilayers, but not to penetrate the membrane. [306] Shape 
may even be the main driving attribute in some biological scenarios. [307] Several studies 
have demonstrated that shape, and in particular local particle shape, and not size, has a 
dominant influence on phagocytosis when alveolar macrophages where exposed to non-
spherical particles of different sizes and shapes. [305] This was due to the influence of 
local shape on macrophage actin structure [308-310] and is an important issue to take into 
account in the rational design of a given immunotherapy. 
 
Geometry of Conjugates 
It has been long understood in polymer chemistry that altering synthetic 
conditions can generate polypeptidebased polymers with multiple different 
morphologies. [311] However, there are only a few reports on polypeptide conjugates 
with a shape other than spherical. Many researchers have synthesized conjugates with 
ellipsoidal geometry based on P(L-Glu-Bz). This includes the synthesis of nanosystems 
with ellipsoidal morphology from different γ-P(L-Glu-Bz)-PEG-60 and γ-P(L-Glu-Bz)-
Bz-50 copolymers in different ratios. [312] The formation of such mixed nanosystems 
occurs without conformation change of the initial polymer molecules, as shown for γ-
P(L-Glu-Bz)-Bz-50 and P(L-Glu-Bz)-β-CD-50 (cyclodextrin). Both polymers remained 
in an α-helical conformation before and after nanosystem formation. For P(L-Glu-Bz)-
P(L-Glu) conjugates with CDDP, the polymer and the conjugate adopted ellipsoidal 
shapes (aspect ratio of 1.3, 37±7 nm x 27±6 nm) with a hydrodynamic diameter of 49–58 
nm. The authors observed no significant changes in the morphology with CDDP loading 
up to 8.3%. [313] However, terminal modifications with small targeting molecules do not 
affect the shape of polymer nanoassemblies. When comparing P(L-Glu-Bz) with benzyl, 
MeO-PEG, or PEG-biotin as a terminal groups or with benzyl and fluorescein 
isothiocyanate (FITC isomer I) as terminal groups, nanosystem morphology was 
dependent on polymer nature. Constructs containing PEG formed spherical species while 
other nanosystems displayed an ellipsoidal morphology. [312] Finally, one recent study 
found that P(L-Glu)-Dox conjugates formed fibril aggregates of approximately 40 nm in 




I.5.3.5. Effect of Composition 
Influence of Stereoisomery 
Stereoisomery of amino acids affects the conformation, biodegradability, and 
activity of conjugates on the cellular level. For branched P[L-Lys-DL-Ala-X-cAD] (cAD 
= cisaconityl daunomycin), conjugates with D- and L-Leu had similar cytotoxicity, while 
conjugates with D-Glu were seven times less toxic and conjugates with L-Glu were four 
times more toxic than Leu-containing nanosystems. Stereochemically controlled toxicity 
is thus dependent on amino acid type and is specific for each system. [314] For 
corresponding MTX conjugates, replacement of L-Leu and L-Glu with D-analogues 
produced a four to five fold decrease in activity. Polypeptides conjugated with D-amino 
acid sequences behave identically to the L-analogues due to identical physico-chemical 
properties (except conformation handedness). Poly-D-amino acids, however, are not in-
cell degradable as was shown for P(L-Glu) and P(D-Glu) conjugates with the NIR-813 
fluorescent dye. [315] Another study found no differences in P(L-Glu)-DTPA-Gd using 
D- or L-PGlu, indicating that affinity to necrotic tissues is not mediated by specific 
processes whether an enzymatic or a receptor-mediated transport mechanism is taking 
place. [283] 
 
Effect of Active Agent Characteristics 
The biodistribution of micelles is considerably more affected by size, charge, and 
surface properties than by the nature of the drug to be delivered, as the drug is usually 
concentrated in the core. [297] However, upon conjugation, the nature of the drug can 
determine chain topology leading to different biodistribution and pharmacokinetics when 
compared to the non-modified polypeptide. One interesting study constructed a series of 
conjugated radioactive metals (125I, 51Cr and 111In) and branched P(L-Lys) with short 
side chains of (DL-Ala)3, amphoteric (DL-Ala)3-Glu, polyanionic (DL-Ala)3-(Ac-Glu), 
and highly polyanionic (DL-Ala)3-(Suc-Glu). Similar elution profiles suggested structural 
similarity of the conjugates independent of the radiolabel used. Interestingly, polymers 
labeled with different metals demonstrated similar blood levels but different organ 
distribution as shown on Figure 21. [316] Unfortunately, the reason for these differences 




higher level at the clearance sites of the matrix polypeptide, the degree of retention 
depended on both the nature of the polymer and the radiometal used. [316] This study 
revealed another challenging problem for polypeptide conjugate design, namely 
understanding how the nature of the drug affects biodistribution of the whole conjugate. 
A further study assessed two other conjugates: P[LLys-Ala-Suc-Glu]-Dau with and 
without terminally conjugated 5(6)-carboxyfluorescein. Remarkably, the conjugate with 
Dau and 5(6)-carboxyfluorescein was more effective than the Dau conjugate, suggesting 
that even negligible modification (one to two molecules per conjugate) can play a crucial 
role in cellular uptake. [314] In the case of the previously discussed γ-P(L-Glu)-Prz 
conjugates, the polymer matrix did not interfere with the activity of the drug or its binding 
to the Prz target, the SGLT1 sodium-glucose linked transporter. [239, 260] 
 
Effect of Topology 
Although scarcely reported, conjugate topology can affect conjugate cellular 
uptake. In a recent study, star-shape polyglutamates St-P(L-Glu) were directly compared 
with their linear analogues P(L-Glu) with regards to cell trafficking as well as in vivo 
biodistribution and pharmacokinetics. [317] Importantly, a 3-fold cell uptake 
enhancement for the St-P(L-Glu) was demonstrated when compared to a linear 
counterpart. Both polyglutamates showed similar biodistribution profiles with renal 
excretion and no specific accumulation in any organ. However, the star-shaped polymer 
displayed longer retention times and greater distribution volume. [317] Investigations into 
the cytotoxicity of synthesized poly(γ-4-((2-(piperidin-1-yl)ethyl)aminomethyl) benzyl-
L-glutamate) (P(PA-L-Glu-Bz))-containing polymers demonstrated the highest FITC 
uptake for star copolymer 8-arm PEG113-b-P(PA-L-Glu-Bz)91 and the lowest for a graft-
copolymer. These findings correlated to the capability of the polypeptide to trigger 
membrane pore formation and suggests that the cytotoxicity of polymer/DNA complexes 
is cell-dependent and signifies that topology of the polymer affects cytotoxicity. 
I.5.3.6. Effect of the Linker 
In drug design, the scrutiny of the linker role is rarely extended above the cleavage 
mechanism and stimuli responsibility for controlled release applications. Nevertheless, in 




drug loading, and conjugate solubility. For example, incorporation of glutamyl linkers 
into the P(L-Glu)-PTX conjugate to yield poly(L-γ-glutamyl-glutamine)-paclitaxel 
nanoconjugate (PGG-PTX) drastically increased conjugate water solubility and showed 
a better therapeutic index in preclinical models. Maximum tolerated dose for PGG-PTX 
versus P(LGlu)-PTX was found to be 350 versus 160 mg PTX kg−1, respectively.  
For P(L-Lys citramide) conjugates with Norfloxacin, studies demonstrated 
spacer-dependent effects on aggregation behavior. Of the three linking strategies used 
(lysine linker, carbamate linkers, or direct linking to polymer), conjugates with the lysine 
linker tended to form aggregates. This may be due to electrostatic interactions between 
the residual primary amine group and the carboxyl groups present as pendent groups 
along the polymer chain or covalent amide bonds between amine and carboxylic acid 
groups. The carbamate space did not lead to detectable levels of aggregation. [316] 
Linkers also affect the hydrodynamic radius and zeta potential of the nanosystems. 
An increase in the number of carbons in the acid motif of the backbone results in a 
decrease in the hydrodynamic radius and an increase in zeta-potential in the following 
order Ami >Asp >Glu. [318] The structure of the linker can also affect conjugate 
cytotoxicity. When analyzed using the MCF-7 breast cancer cell line, PEG45-P(L-Lys), 
PEG45-P(L-Lys)25-CPT6, and PEG45-P(L-Lys)25-SS-CPT6 (additionally incorporated 
disulfide bond) displayed IC50 values of 500.0, 6.8, and 0.88 µg mL−1, respectively. In 
general, conjugates were more active against OVCAR-3 cell line and less active against 
MCF-7, SKOV-3, and MDA-MB-468 cells when compared with free CPT. [273] 
Additionally, a γ-P(D-Glu)-vancomycin (Van) conjugate demonstrated linker-dependent 
anti-bacterial behavior. P(D-Glu)-Van, P(D-Glu)-N-succinylethane 1.2-diamine-Van, 
and free Van displayed an anti-bacterial activity against Bacillus subtilis equal to an 8, 9, 
and 14 mm zone of inhibition at 1 mg mL−1, respectively, using a filter disk assay. Similar 
results were obtained against Van-resistant strains of Lactobacillus casei with inhibition 
area of 5 and 3 mm for conjugated and free Van, respectively. [319] 
 
I.5.3.7. Effect of Ligand Patterning 
Simultaneous binding to multiple ligands often occurs in biological systems. The 




as it allows strong binding from low surface area ligands, increased binding specificity, 
the creation of conformational contact between large biological surfaces, macroscopic 
reorganization, and redistribution of molecules. [320] Typical drug conjugate design 
includes the synthesis of constructs with random surface distribution of ligands that limit 
or completely restrict manipulations on ligand grouping, cluster size, and spacing. Even 
though many studies devoted to ligand patterning of small olygolysine with mannose and 
diglycoside clusters have been published, [321, 322] this topic remains scarcely 
investigated for polypeptide conjugates. Optimal cluster arrangement results in better 
targeting properties due to longer binding time on the cell surface and binding of more 
conjugates, all of which increase the probability of endocytosis. In cells overexpressing 
folate receptors, these receptors exist in the membrane as clusters of three or more 
molecules. Quite recently, Poon et al. prepared mixed micelles from nonfunctionalized 
and functionalized linear dendritic polymer (P(L-Asp)-Bz)12-PED (polyester Dendron)-
PEG600-FAx, where x = 1–16 with 0%–100% folate functionalization providing micelles 
with different cluster arrangement. Maximum activity corresponded to the 20%F-60% 
mix micelles (Figure 22). The binding energy increased with an increase in folate 
modification, from 10% to 40% (1.5 = 0.4 to 6.9 = 0.9 folates/Dendron) and then starts 
to decrease due to steric binding interference due to an excess of ligands clustered in a 
small binding area. [323] Another study demonstrated that P(L-Lys)-catechin conjugates 
displayed significant enhancement of concentration-dependent inhibition against 
collagenase from Clostridium histolyticum (ChC) compared to free catechin. This may 
occur due to efficient multivalent interactions between collagenase and catechin from 
P(L-Lys)-catechin. Catechin conjugates also inhibit hyaluronidase in contrast with non-






Figure 22. Effect of ligand pattern on the cellular uptake obtained by usage of polymer mixtures. Reprinted 
with permission from Ref [323].  
 
I.5.4. Stimuli-Triggered Drug Release 
Smart stimuli responsive materials have greatly evolved over the last few decades. 
The potential for molecular programming of nanomaterials to respond to small changes 
in the environment has led to the synthesis of materials in different fields including 
materials science [325] and biomedicine. [262] The human body represents a multitude 
of intrinsic microenvironments appropriate for the spatio-temporal control of drug 
release. A multitude of systems have so far been described which have the ability to 
deliver a cargo or to activate the therapeutic effect, in response to an endogenous 
environmental factor [326] (e.g., pH, redox potential, enzyme availability, or reactive 
oxygen species) or external stimuli (e.g., magnetic field, temperature, light). [262] 
Relevant examples of polypeptide conjugates described so far as drug delivery vehicles 
with inbuilt endogenously stimulated triggered release mechanisms are discussed within 
this section. [262, 326, 327] 
 
I.5.4.1. pH-Responsive Drug Release 
pH in Relevant Physiological Environments 
pH-responsive macromolecules are developed taking into account the pH 




following the route of administration and arriving to the site of action. In addition, their 
design should also consider the differential physiological pH environments comparing 
normal against pathological conditions. The design of active nanosystems responding to 
pH changes at the tissue level plays a special role for the treatment of solid tumors (and 
inflammation related pathologies) [328] where many regions are transiently or 
chronically acidic, playing an important role in tumor progression and metastasis, and 
therefore highlighting the need of non-invasive techniques for in vivo imaging and 
measurement of pH. [327, 329] At the cellular level, a mildly acidic pH gradient is 
encountered following endocytic uptake pathway. [250, 251] 
 
Polypeptide-Based pH-Responsive Drug Release Systems 
Considering that the vast majority of amino acids employed to design polypeptide 
conjugates are limited to Glu, Asp, and Lys, the chemical toolbox for pH-responsive 
systems for direct drug conjugation to polypeptide backbone employed up to date is 
reduced to compatible chemistries with amines and carboxylic acids (e.g., esters, 
carbamates). However, rationally designed linkers offer the opportunity to expand the 
toolbox to different pH-labile groups such as hydrazone, acetal, cis-acotinyl, Schiff-base 
or α-thiopropionate among others, which have all been introduced into pH-responsive 
polymer–drug conjugates to date. [330] 
Pioneering the development of amphiphilic block copolypeptide-drug conjugate 
micelles, Prof. Kataoka designed a series of PEG-P(L-Asp) block copolymer drug 
conjugates with the ability to assemble into micelles after conjugation to anthracycline 
derivatives through pH labile hydrazine bonds (Dox and Epirubicin (Epi)). [270, 332] In 
one remarkable example, Bae et al. modified the surface of PEG-P(L-Asp-hyd-Dox) 
block copolymer micelles, with an already proven outstanding pH-control on drug release 
profile (Figure 23A), [270] with piloting residues of folate for cancer cell-targeting. In 
vitro evaluation in human pharyngeal cancer cells proved the advantage of active 
targeting and an outstanding control of the release profile as a function of pH. [270] Of 
note, the NC-6300 system, which relies on a similar design, but incorporating Epi without 
active targeting residues, displayed an improved anti-tumor activity against 




cardiotoxicity. [212] Further proof-of-concept studies also validated NC-6300 against 
triple negative breast and liver tumors [332] and so granted the enrolment of this 
candidate into phase I clinical trials for advanced or metastatic tumors. Phase I trials are 
currently ongoing in Japan with NC-6300. [230] Modulation of the pH-lability, and as a 
consequence, the responsiveness to pH, depends on the bond’s chemical environment. 
   
 
Figure 23. A) Schematic representation of PEG-P(L-Asp-hyd-Dox) block copolymer micelles showing the 
chemical structure and drug release profile. Reprinted with permission from Ref [270]. B) Chemical 
structures of PEG-p(Asp-Hyd-LEV-PTX) and PEG-p(Asp-Hyd-4AB-PTX), adapted from Ref [331]; C) 
Chemical structure of P(L-Arg-CsA) conjugated through a pH-responsive self-immolative linker adapted 
from Ref [237]. 
Following this approach, different PTX prodrugs with modulated release 
characteristics have been recently published by Alani et al. (Figure 23B). [331] They 
synthesized two micelle-forming conjugates of PTX: PEG-p(Asp-Hyd-LEV-PTX) and 
PEG-p(Asp-Hyd-4AB-PTX) using two different modifications of the drug. In one, the 
hydrazone moiety is modulated through the use of alkylic (LEV), while the other uses 
aromatic (4AB) ketones. Micelles displayed a notable release rate of LEV-PTX under 
acidic pH, although they observed no 4AB-PTX release after 24 h. The authors took 
advantage of such behavior to modulate the release profile of LEV-PTX by co-assembling 




illustrating an alternative pharmacokinetictuning solution for PTX-prodrug strategies. 
Satchi-Fainaro and co-workers recently reported a polyglutamate-based combination 
conjugate bearing Dox through a hydrazone linker (EMCH) and PTX through direct 
conjugation (ester bond) as drugs in a synergistic ratio. The combination conjugate was 
highly effective in inhibiting the growth of mammary tumors compared to a combination 
of free drugs and drugs conjugated to polymers separately. [333] In an additional study, 
a comparative evaluation of linear P(L-Glu) vs. dendritic PEG-Polyglycerol bearing the 
abovementioned combination therapy revealed that activity against mammary tumors for 
the combination P(L-Glu) conjugate was superior to the dendritic polymer carrier which 
showed no differences in activity compared to the combination of drugs conjugated to the 
dendrimer separately. [333]  
Aside from hydrazone as a pH-labile linker, other chemical entities such as cis-
aconityl moiety have been incorporated into polypeptidic carriers such as P(D-Lys). Shen 
and Ryser prepared the first model of pH-sensitive linkage for Dau release from a 
lysosomotropic P(D-Lys) conjugate. [334] In spite of a lack of polypeptidic carriers 
designed for topical administration, Rothbard et al. have very elegantly conjugated the 
immunosuppressor drug cyclosporine A (CsA) to P(L-Arg) oligomers through a pH-labile 
linker for use in the topical delivery in inflammatory skin diseases. [237] In contrast with 
the typical release upon acidification, this self-immolative linker (Figure 22C) is stable 
under acidic pH (skin barrier) and takes advantage of an intramolecular nucleophilic 
attack of the secondary amine in the neighboring carbonyl group. This is enabled at 
neutral pH through the deprotonation of the amine. They proved how, in contrast to free 
CsA which cannot penetrate the skin, R7-CsA could reach dermal T lymphocytes and 
inhibit cutaneous inflammation in mouse. 
 
I.5.4.2. Redox Responsive Drug Release 
Redox Characteristics of Relevant Physiological Environments 
In general, redox microenvironments at different extracellular and intracellular 
regions are caused by the presence of reducing/oxidizing agents, as well as redox proteins, 
providing an opportunity for the controlled delivery of different active agents. At the 




in mammalian plasma (8 × 10−3 M). This is one of the main redox control nodes for 
protein signaling that, together with glutathione (GSH) marginal levels (2 × 10−6 M), 
represents the main pathways for disulfide bond reduction in a mildly oxidizing 
extracellular environment. [335, 336] Although systemic circulation of polymeric 
vehicles are thought to progress under relative oxidizing environment, the above 
mentioned conditions might promote the inactivation of disulfide-based drug delivery 
systems with prolonged blood half-life. [337] The intracellular environment, in contrast, 
provides a highly reductive environment, mediated by the action of multiple proteins 
(e.g., thioredoxin, glutaredoxin, protein disulfide isomerase) and small reductant 
molecules, mainly represented by GSH. [232] Noticeably, the redox environment in 
endosomes has been reported to be mildly oxidizing when compared to other organelles 
and cellular environments, suggesting the need for late lysosomal digestion or escape 
from endosomes in order to efficiently deliver the cargo for reductive dependent 
strategies. [335] In addition, the tumor microenvironment has been reported to be a highly 
reductive environment and so represents an attractive target for the development of redox-
responsive anti-cancer nanomedicines. [338] 
 
Polypeptide-Based Redox-Triggered Drug Release Systems 
Several examples of different redox-sensitive linkers for targeted controlled drug 
delivery are present in the literature, [339] but the field is dominated by the employment 
of disulfide bonds. The fact that disulfide-containing carriers can take advantage of the 
large intra/extracellular redox gradient, renders them very attractive for the design of drug 
and gene-delivery systems. 
In the context of polypeptidic conjugates, an interesting study based on P(D-Lys) 
structures has been developed by Shen and co-workers. They have conjugated MTX to 
P(D-Lys) using two different types of spacers and have evaluated its cytotoxic activity in 
Chinese Hamster Ovary (CHO) cells. [334] In the P(D-Lys)-SS-MTX conjugate, MTX 
was conjugated to the polymer using a disulfide spacer as a probe to study the reducing 
cytoplasmic environment. The fact that disulfide reduction did not demonstrate any 
dependence on GSH led the authors to hypothesize that the conjugate experienced an 




al, synthesized an analogue conjugate in which [125I]iodotyramine, instead of MTX, was 
again linked to P(D-Lys) through a disulfide linker.[340] The resultant P(D-Lys)-SS-
[125I]tyn conjugate was used as a probe to detect disulfide cleavage in the endocytic 
pathway. Several analyses of subcellular fractionations allowed the authors to 
hypothesize that instead of the cytosol, as would be expected, the redox environment of 
the Golgi apparatus was the most probable place of disulfide cleavage. Using a different 
approach, Zhou and collaborators recently designed a complex redox-responsive high 
drug-loaded, tumor targeted nanosystem. [273] This nanoconstruct is based on PEG-P(L-
Lys) in which the folate is covalently attached to P(L-Lys) amines through the PEG 
moiety. The system was FITC-labeled and conjugated CPT to the amine groups of block-
PLys via disulfide bonds. 
Carrying all these different moieties, the CPT-conjugate formed stable 
nanoparticulate systems in the bloodstream with uniform sizes and experienced enhanced 
accumulation and both passive and active tumor uptake. These self-assembled conjugates 
could also be loaded with a secondary active agent (Dox) physically encapsulated inside 
the core. Following FA-receptor mediated endocytosis, the conjugate was disassembled 
in the reductive environment of the cytosol via the cleavage of the disulfide linkers 
releasing CPT and Dox and leading to excellent in vitro anti-tumor activity in various 
cancer cell lines.  
Looking for efficient gene silencing, Takemoto et al. grafted siRNA to the side 
chains of a PAsp (PAsp-SS-siRNA) polymer through disulfide bonding. [341] This 
released conjugated siRNA into the cytosolic milieu due to the reductive conditions. 
Subsequent P(Asp-SS-siRNA) complexation with a poly-L-aspartamide containing 1,2-
diaminoethane side chains aimed to enhance biodegradability. Using this strategy, they 
achieved strong target-specific gene silencing in vitro employing the mouse melanoma 
B16F10-Luc cell line. Another interesting example is the polymer-protein conjugate 
based on P(L-Glu) reported by Talelli and Vicent (Figure 24A). [342, 343] In this system, 
P(L-Glu) is covalently bounded to lysozyme, used as a model protein, through disulfide 
bonds and was used for the design of a reduction sensitive PUMPT (Polymer Masked− 
Unmasked Protein Therapy) system. The P(L-Glu) cover protected and masked the 
protein efficiently, but disulfide reduction and therefore protein unmasking, restored 
lysozyme activity. Very recently, this strategy has been validated via the use of a PEG-




alanine:glyoxylate aminotransferase liver peroxisomal enzyme. [342] This can be used to 
treat primary hyperoxaluria type I, a rare genetic disease characterized by an abnormally 
high concentration of urinary oxalate that can progress to end-stage-renaldisease and to a 
potentially fatal condition called systemic oxalosis. The self-immolative disulfide 
carbonate (and carbamate) represents another interesting linker for polypeptide conjugate 
design (Figure 24B). [344] This linker has been employed for the development of a 
luciferin-releasable system based on a cell penetrating motif, octaarginine. The study 
conjugated this probe system through the selfimmolative disulfide carbonate linker 
designed for quantification of carrier uptake. Following disulfide cleavage, 
intramolecular nucleophilic attack of thiol on carbonyl atom at the intermediate specie 
yields a cyclic product releasing the native probe; a very interesting approach to consider 
for future designs. 
 
I.5.4.3. Enzyme Responsive Release 
Enzymes have long been identified as powerful biological targets for site-specific 
design of drug delivery systems. [345] Many disorders are associated with an enzyme 
imbalance, mainly overexpression of proteases, including cancer [346] or inflammatory 
diseases, amongst many notable others. For example, following polypeptide conjugates 
pathway throughout the body, extracellular proteases such as matrix metalloproteases 
(MMPs) play an important role in the degradation of extracellular matrix components and 
cell membrane proteins and are overexpressed in damaged tissues. [347, 348] 
Intracellularly, cathepsins represent the major family of proteases involved in the 
degradation and turnover of intracellular proteins. Due to their higher activity under 
acidic pH, endosomal and lysosomal locations are particularly relevant for triggering 
polypeptide conjugates degradation. [349] Therefore, proteases have constituted a 
powerful alternative for the design of specific stimuli responsive polypeptide conjugates 
and their use as a trigger for drug delivery relies on their ability to promote polypeptide 
matrix degradation and hence facilitation of drug release in a site-specific manner. 
The anti-cancer polypeptide-drug P(L-Glu)-PTX (Opaxio) in Phase III clinical 
trials represents one of the best examples in this class as, although PTX is covalently 
bound through an ester bond, its 37 wt% loading makes its release highly depending on 
cathepsin B levels. [213] A correlation between estrogen levels and cathepsin B activity 




pg mL−1 would benefit from this conjugate.[350] P(L-Glu)-CPT is another example of a 
P(L-Glu)-drug conjugate to reach Phase I clinical trials for ovarian and colorectal 
carcinomas. [351] CPT was also conjugated via an ester bond but in this case through a 
Gly linker in order to stabilize the CPT lactone ring. 
 
Figure 24. A) Schematic representation of the PUMPT strategy developed with P(L-Glu)-lysozyme 
polypeptide-protein conjugate sensitive to intracellular GSH levels. Reprinted with permission from Ref 
[343] B) Chemical structure and representation of the Luciferin releasable probe conjugated through a self-
immolative disulfide-carbonate. Reprinted with permission from Ref [344].  
 
I.5.5. Perspectives and Outlook 
The physico-chemical parameters of the conjugate, and hence the biological 




highlights the need for detailed structure-activity relationship studies to develop the 
hierarchical strategies of polypeptide conjugate design. However, structural complexity 
also represents a unique opportunity, since small changes at the structural level might 
endow nanomedicines with outstanding and unexpected biological performance. Future 
development of polypeptide-drug conjugates may proceed toward the determination of 
dependencies between physico-chemical parameters and biological activity and to the 
elaboration of careful synthetic strategies for the design of conjugates with preliminary 
designated characteristics. Extensive research in the adjacent areas of nanomedicine and 
polypeptide chemistry has allowed us to delineate possible future trends and opportunities 
to fully exploit the potential of polypeptide therapeutics: 
(1) Different polarity of amino acids and enormous possibilities of side chain 
modification allow for the synthesis of a variety of architectures. A recent study reports 
that a combination of soft and rigid helix turns in γ-P(L-Glu-Bz)-block-poly(O-benzyl-
L-hydroxyproline) results in the formation of lamellar structures with a “zig-zag” 
morphology. [352] Additionally, several interesting aggregation modes have been 
described for polypeptide-based polymers. These include helical rods and rings, [353] 
disk-like micelles with cylindrical pores, [354] bilamellar vesicles, and bicells. [355] The 
transfer of different geometries achieved for polypeptide-based polymers to the area of 
conjugates will allow the expansion of conjugate applicability and, in theory, reveal 
unknown effects of the geometry on the in vivo response in various pathological 
conditions. Many polyamino acids display tunable secondary conformation 
transformation from α-helix to β-sheet [356] and studies show that this conformation can 
be controlled via a multitude of factors as discussed in Section 4. [352] Future 
development directed toward the synthesis of stimuli-tunable conformation drug 
conjugates together with full exploitation of amino acids chemical diversity might allow 
for a step-wise adaption of the polypeptidic vehicle upon interface with biological media 
allowing for highly specific targeting site and release of the cargo within the body. For 
example, recent reports have shown the ability of short amphiphilic polyproline fragments 
to target mitochondria probably due to the specific characteristics of the polyproline helix 
conformation. [7, 357, 358] Another interesting approach toward organelle specific 
delivery relies on an adaptive response through the different stimuli gradients along the 
body of a P(L-Lys)-block–poly(L-Leu) diblock copolymer with β-carboxylic amidated 




solution. As a result, the system demonstrated step-wise hydrolysis following the 
endocytic uptake pathway resulting in an adaptive charge reversal of the nanosized 
micelles optimal for systemic circulation and endocytic uptake, followed by endosomal 
escape and nuclei internalization.  
(2) The shift to increased conjugate biodegradability is not a new paradigm in 
nanomedicine, but improvements in the in vivo degradability are not always possible. 
PEGylation remains the main strategy in the synthesis of stealth polypeptide conjugates 
even though PEG is not biodegradable and could present serious problems associated and 
hypersensitive reactions (e.g., anaphylactic reactions). [359] Several alternatives to PEG, 
such as polysarcosine, have recently been proposed, [203, 265, 360] although their use in 
the field of polymer conjugates has yet to be reported.  
(3) There is a generalized trend to explore novel nanosized delivery systems with 
increasing complexity and chemical functionality. This is rationally motivated by various 
factors: the complexity of human body, the underlying biochemical mechanisms in life 
threatening pathologies, which requires engineered nanomedicines capable of adaptation 
to a multitude of environments, and the bio-nano interface interactions which exist along 
the voyage to the site of action. However, there is now a consensus to reach a compromise 
between complexity, required to achieve highly specific and efficient activity against the 
target disease, and chemical simplicity, required for translation into real therapies. This 
necessitates that a given conjugate can be produced in a robust, reproducible, and scalable 
manner to ensure industrial feasibility and avoid premature failure at clinical trials. [361] 
(4) Incorporation of novel chemical functionalities have proven their value in 
different contexts, and beyond the increase in manufacturing complexity, potential 
opportunities to improve and complement polypeptide therapeutics toolbox are 
conceptualized in the following scientific examples with other polymeric drug delivery 
systems: 
a. Despite strong evidence for specific protease-sensitive linkers as powerful 
biological targets for drug release, this concept has not been widely exploited in 
polypeptide conjugates. However, some polymer-drug conjugates can serve as interesting 
examples to illustrate this approach and might be adapted through the proper chemistry 




specific tetrapeptide sequences, [362] in particular Gly-Phe-Leu-Gly (GFLG) and Gly-
Phe-Ala-Leu (FAL), in tumor cells. [363-366] Other studies have exploited the presence 
of enzymes in the extracellular environment, such as short peptide sequences (MMP2 
cleavable linker = H2N-GPLGIAGQ-COOH), cleavable by MMPs. [367] While these 
representative examples highlight the potential of enzyme triggered drug delivery, further 
studies are still required to obtain precise information of the target enzyme levels at the 
desired site to fine-control cell uptake and to demonstrate that in vivo drug release is 
correlated to enzymatic activity. 
b. Although poorly explored in polymer (and polypeptide) conjugate design, 
reactive oxygen species (ROS), mainly generated in the mitochondria through diverse 
endogenous sources, represent an important trigger for stimulated release. [368, 369] A 
number of existing responsive functionalities have proven the great potential for ROS-
mediated drug release via appropriate linker design (or model compounds) as well as 
ROS-mediated degradation or response of polymeric materials. 
These include phenylboronic acids and esters, [370] thioketals, [371, 372] poly-
L-methionine [373] and poly-L-proline [374, 375] among others. As an example, proline 
is the only natural-occurring amino acid capable of forming a tertiary amide bond. This 
bond is more easily oxidized as compared to secondary amide bonds and, therefore, could 
be applied for ROS triggered release of active molecules within polypeptidic conjugates. 
Although there are still no examples with conjugates, its benefits have been already 
demonstrated by Sung and co-workers who synthesized different types of ROS cleavable 
scaffolds based on poly(L-proline) and investigated their applications in tissue 
engineering. [375] They prepared porous polymeric scaffolds via crosslinking a PEG-
poly(ε-caprolactone)-poly(carboxyl-ε-caprolactone) (PEG-PCL-cPCL (4%-86%–10%)) 
block copolymer with biaminated PEG-oligo(proline)-PEG. Treatment with hydrogen 
peroxide cleaved all proline residues within 6 days and addition of the ROS generator 
SIN-1 accelerated this further. This proof of concept study suggests that it may be feasible 
to adapt synthetic strategies for the incorporation of such responsive linkers toward the 
development of ROS mediated polypeptide conjugates delivery platforms. 
c. Molecular recognition of specific molecules in biological media represents a 
highly challenging task, mainly due to the complex composition of the physiological 




intrinsic ability of phenyl boronic acids and derivatives to interact selectively with diols 
is of significant note. [376] This approach is highly attractive for the development of 
glucose sensitive systems toward an on-demand insulin release in response to changes in 
blood glucose levels. To this end, Zhao et al. have developed a polypeptidic nanogel 
based on PEG-block-γ-P(L-Glu-Bz)-co-(γ-propargyl-LGlu-graft-glucose). [377] This 
system can release physically entrapped insulin in response to specific levels of glucose 
in phosphate buffered saline. The construct displayed appropriate cytocompatibility and 
hematocompatibility allowing us to envisage the potential and feasibility of this approach 
for the chronic treatment of diabetes with on-demand insulin release systems following a 
polypeptidic conjugate design.  
As shown in this Chapter, the multivalency of the different polypeptides together 
with their biodegradability, the tunable architectural properties including size, shape, zeta 
potential, conformation, and rationally designed polymer-drug(s) linkers, have already 
been used in many different clinical applications upon conjugation of drugs or imaging 
agents as single agents or in combination therapy ranging from intravenous to topical 
administration. However, an even better understanding of polypeptide chemistry together 
with the clinical knowledge of the pathological environments to target (enzyme type and 
concentration, pH, ROS, GSH level, etc.), would allow us to improve the already 
available medicine armory and more importantly, to identify novel therapeutic 
approaches for unmet clinical needs. However, we must remember to take into account 
the robustness and industrial feasibility of polypeptide conjugate production in order to 
facilitate the transfer from bench to bedside. 
 
I.6. Physico-chemical Characterization of Polymer-drug Conjugates 
 The intrinsic molecular complexity and the multiple dynamic interactions with the 
multiple biological environments encountered following delivery to a biological system 
hamper the design of new DDS. There exists a general agreement for the need of 
characterization methodologies that, beyond quality control parameters, allow the 
identification and study of representative physicochemical descriptors [119]. These 
findings will be useful for the determination of structure-activity relationships (SARs) 




biological performance. This strategy requires a deeper and more comprehensive 
approach to the study of conformation, dimensions, dynamics, and interactions with the 
biological environment to provide robust tools towards rational design of DDS to 
overcome biological barriers.  
Following the successful achievement of nanomedicine characterization in terms 
of identity, molecular weight, composition, purity, solubility, and stability, DDS 
performance in relevant physicochemical environments must now be addressed. A 
progressive increase in media complexity would allow a more complete understanding of 
DDS performance based on the physicochemical descriptors extracted in solvated states. 
Characterization in hydrated states and relevant physiological media is accessible through 
a battery of complementary techniques entailing a multitude of different principles. Table 
6 summarizes several of the most important techniques used in physicochemical 
characterization of the different nanosystems, some of which will be explained in detail 
during the present thesis. 
 
I.7. The Importance of Faithful Preclinical Triple Negative Breast 
Cancer Models 
Development of novel nanomedicine strategies for TNBC (and most cancers) 
requires profuse preclinical studies in mouse cancer models in order to identify and 
validate novel cancer drivers and therapeutic targets, to determine in vivo drug 
pharmacokinetics and pharmacodynamics (PK/PD), and to evaluate in vivo anti-cancer 
efficacy of these novel therapeutics. Following promising preclinical results, phase I–III 
clinical trials evaluate the tolerability and anti-cancer efficacy of these drugs in human 
patients. A proportion of patients will show poor response due to intrinsic or acquired 
resistance, which may be studied mechanistically in preclinical mouse models to identify 
response biomarkers and combination therapies to prevent or overcome resistance. The 
close alignment of mouse studies and human clinical trials will lead to better patient 
stratification, identification of novel biomarkers, and development of optimal 
combination therapies, culminating in improved cancer patient care. However, the field 
currently lacks adequately described spontaneously metastatic breast cancer preclinical 





Figure 25.  Applications of preclinical murine models in basic cancer research and translational oncology.  
Adapted from Ref [378]. 
During the development of this thesis, we have established and described the 
development and characterization of two clinically relevant spontaneously metastatic 
TNBC orthotopic murine models (an immunodeficient human MDA-MB231-Luc model 
and an immunocompetent mouse 4T1 model) with a special focus on their use as in vivo 
platforms for the development of anticancer nanomedicines. Importantly, we identified 
distinctive features that may represent functional biomarkers for disease progression or 





Table 6. Summary of the most relevant techniques used to elucidate physicochemical descriptors in 
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TRIPLE-NEGATIVE BREAST CANCER PRECLINICAL 
MODELS PROVIDE FUNCTIONAL EVIDENCE OF 
















II.1. Antecedents and Background 
Triple negative breast cancer (TNBC, lacking ER, PR, and HER2 expression) 
represents around 15-20% of newly diagnosed cases [1], and the complex molecular 
landscape, low detection rate, and aggressive/highly-proliferative nature result in poor 
prognosis and heterogeneous behavior in patients. Rapid growth rates and prominent 
lymphoplasmacytic inflammatory infiltrates because of host immune responses promote 
metastasis to the lungs, liver, and brain and frequent lymphatic system involvement that 
impedes focal treatment favors recurrence, aggravates the clinical situation, and lowers 
survival rates [2]. Rapid tumor evolution also leads to the development of an inner 
hypoxic and further necrotic core [3] and the associated development of multiple drug 
resistance (MDR) and poorer prognosis [4].  
TNBC currently lacks targeted therapeutics [5], and current treatment strategies 
provide heterogeneous patient responses/outcomes [6]. Additionally, no standardized 
treatment for metastatic TNBC exists, therefore representing a critical unmet clinical need 
[7]. Studies have indicated the efficacy of certain chemotherapeutic agents, including 
anthracyclines and taxanes [8], with reduced tumor recurrence observed [9]; however, 
accurate tumor targeting and reduced side effects remain as important goals. 
Nanopharmaceuticals can enhance therapeutic outcomes by passive tumor 
targeting via the enhanced permeability and retention (EPR) effect [10], active targeting 
employing membrane receptors, optimized pharmacokinetics [11], enhanced cell 
membrane transport, and controlled drug release in the tumor microenvironment or tumor 
cell. Therefore, full characterization of preclinical models may identify functional 
descriptors and biomarkers translatable to the rational design of advanced nanomedicine-
based treatments for TNBC [12].  
Multistage animal models represent crucial translational research platforms for 
testing and validation of experimental therapies. However, the relative lack of accurately 
characterized models that faithfully mimic the pathological features of human TNBC, 
including spontaneous metastasis or multiple side alterations, frequently hampers 
research [13, 14]. Currently employed metastatic mouse models mimic advanced stage 




[13], the need to resect the primary tumor to allow metastasis, or slow metastatic 
development limits the application of this model. 
Here, we present the differential features of two clinically relevant spontaneously 
metastatic TNBC mice models, representing the murine (the well-established 4T1 model) 
[15], developed in an immunocompetent (BALB/c) background, and human (MDA-MB-
231-Luc model) disease, established, for the first time, in the immunodeficient 
(NOD/SCID) mice. Within this study, we focused on fully characterizing disease 
progression in each model and identifying functional biomarkers, key metabolites and 
differential cytokines considered crucial for prognostic potential. Furthermore, we 
analyzed the potential for these models in the development and clinical translation of 


















II.2. Results  
II.2.1. Comparison of Primary Tumor Development in TNBC Models 
Primary morphological analysis demonstrated that 4T1 tumors grew 
exponentially and homogeneously, reaching a cylindrical form after day (D)24 (Figure 
1). Subsequent analysis demonstrated slower initial growth kinetics for MDA-MB-231-
Luc tumors compared to 4T1 up to around D30, finally acquiring an amorphous 
cylindrical shape at D42 (Figure 1). Primary tumors in both models exhibited the typical 
stromal progression of most solid tumors, including inner necrotic region development 
[16], although with marked differences in growth kinetics and stromal arrangement 
(Figure 4). 
 
Figure 1: Tumor growth after cell inoculation appeared as a stiff solid mass of a similar volume after (A) 
three days (4T1) and (B) one week (MDA-MB-231-Luc). In general, 50% of 4T1 tumors invaded the 
proximal inguinal lymph node (ILN) around day 13 of tumor growth, and all ILNs became metastasized at 
day 24 (red arrows). Invasion of the proximal lymph nodes occurred to a lesser extent in the MDA-MB-
231-Luc model. 
Analysis of tumors at the experimental endpoints demonstrated that the internal 
necrotic tissue presented cellular debris with diffuse margins, pyknotic nuclei, and 
karyorrhexis in both models (See H&E sections in Figure 2A, B). While H&E tumor 




homogeneous concentric transition rings followed by a concentric proliferative region, 
MDA-MB-231-Luc tumors presented a more gelatinous necrotic core with heterogeneous 
spread of necrosis throughout the tumor stroma (Figure 2). 
 
 
Figure 2. Primary tumor development and immunohistological analysis of features. For the A) 4T1 model 
and MDA-MB-231 model B), axial tumor H-E staining, demonstrating the stromal arrangement and an 
immunohistochemical study of tumor regions. Original magnification displayed in each image. C) 
Summary table of the most relevant immunohistological markers evaluated. Qualitative scale ranging from 





Overall, the stroma surrounding MDA-MB-231-Luc tumors presented lower 
cellular density and tumors evolved as soft and flexible solid masses. Both animal models 
developed fungating lesions (round, non-bleeding skin ulcerations with firm inflamed 
borders above the mammary gland) that appeared during the first week of 4T1- and the 
second week of MDA-MB-231-Luc-tumor development, in line with human wound 
development subtypes [17] (Figure 1).  
Cytokeratin (CK)-AE1/AE3 immunostaining confirmed the epithelial nature of 
tumor cells, with expression varying between both region and model. Factor VIII 
immunostaining demonstrated similar tumor neovasculature and undamaged endogenous 
blood vessels in both models, indicating a slightly vascularized tumor stroma (Figure 2A, 
B). We subsequently evaluated region-dependent proliferative rates by Ki-67 
immunostaining and confirmed increased cell growth rates in outer regions of both 
tumors. We summarize data on immunohistochemical tumor markers in Figure 2C. 
We also morphometrically evaluated volume during tumor development in both 
models, discovering marked differences in growth kinetic profiles (Figure 3). We 
observed around 2-fold greater tumor growth rate for the 4T1 model (reaching around 1.0 
cm3 at D24) when compared to the MDA-MB-231-Luc model (reaching around 1.0 cm3 
at D42), despite notable differences in the number of inoculated cells (5 x 105 vs. 3 x 106, 
respectively).  
 





























































































































































Figure 4. H-E histological staining of primary tumors during development. A) From 3-6 days, 4T1 tumors 
appeared as a dense and compact population of viable cells in a solid, high-pressure region that pushed the 
tumor mass to grow against the abdominal wall and hypodermis. By Day 10, the first evidence of hypoxia 
and necrosis in the tumor core emerged, as result of massive blood vessel collapse. From days 10-17, the 
histological study demonstrated a central necrotic core surrounded by a concentric hypoxic, transition ring. 
B) MDA-MB-231-Luc tumors developed slower, taking seven days to acquire the same volume as the 4T1 
tumors at day 3. The first hypodense regions appeared non-concentrically at day 14 of development, with 
heterogeneously distributed small necrotic areas throughout the tumor. From day 20, several larger disperse 






Subsequent quantification of maximum tumor permeability (related to the 
enhanced permeability and retention [EPR] effect [18]) established three-fold greater 
permeability for the MDA-MB-231-Luc model when compared to the 4T1 model (33% 
injected dose (ID)/gram of tumor (g) at around D14 vs. 13% ID/g at D10, respectively, 
when analyzing tumors at around 0.1 cm3) (Figure 5).  
 
Figure 5. EPR effect quantification of primary tumors. EPRMax was around 0.1 cm3 for both tumor models, 
corresponding to day 8 and day 14 for 4T1 and MDA-MB-231-Luc, respectively. 
Tumor density analyses reflected differential stromal arrangements, as previously 
noted (Figure 6). 4T1 tumors initially displayed high density at early development time 
points (around 3 g/cm3), which then decreased progressively over two weeks to around 
1.5 g/cm3. In contrast, MDA-MB-231-Luc tumors displayed a more homogeneous 
density during tumor development, rising from 1.0 g/cm3 to 1.4 g/cm3 over the 
experimental time frame. 
 
Figure 6. Tumor density determined by simple arithmetic calculation demonstrating a lighter stroma as a 
























































































































































































































































































































Additional metabolomics analysis supported differences in tumor growth kinetics 
observed between models; 4T1 tumors displayed increased levels of guanosine and uracil 
(metabolites related to cell growth and proliferation, Figure 7C, D) and cholesterol and 
phospholipids (critical cell membrane components, Figure 7D) when compared to the 
MDA-MB-231-Luc tumors. 
 
Figure 7. Multivariate modeling resulting from the analysis of primary tumors. (A and B) OPLS-DA score 
plot representing the comparison between MDA-MB-231- Luc vs. 4T1 primary tumors (aqueous phase) 
(R2 = 0.976 / Q2 = 0.925) and organic phase (R2 = 0.982 / Q2 = 0.936), respectively. C and D) Metabolic 
changes for MDA-MB-231-Luc vs. 4T1 primary tumor (aqueous phase) and MDA-MB-231-Luc vs. 4T1 
primary tumors (organic phase) comparisons. Statistical significance determined via ANOVA t-test, (*** 
p<0.001, ** p<0.01, *p<0.05). 
Importantly, the tumor histopathological study at model endpoints also 
demonstrated a relationship between MDA-MB-231-Luc tumors, but not 4T1 tumors, and 
lipid burden (Figure 8). We observed disperse accumulation of adipocyte lobes from 
early stages of MDA-MB-231-Luc tumor development, with adipocytes distributed 




distribution pattern within the tumor stroma and further Interleukin (IL)-6 and IL-1β 
immunostaining[19] (Figure 8), we consider these adipocytes as cancer-associated 
adipocytes (CAA). Interestingly, metabolomic comparisons revealed significantly 
increased triacylglycerol (TAG) levels for MDA-MB-231-Luc tumors, a lipid whose 
synthesis/hydrolysis is controlled by adipocytes, agreeing with histopathological findings 
(Figure 7). 
 
Figure 8. CAAs from MDA-MB-231-Luc tumors exhibited extensive phenotypic changes. Subpopulations 
of tumor stroma infiltrated adipocytes expressed IL-1β and IL-6 (IL-6 to a lesser extent) (indicated with 
red arrows). Note the diminished averaged sizes, a known characteristic feature of CAA. 
 
II.2.2. Comparison of the Spontaneous Metastatic Landscape in TNBC 
Models 
4T1 tumors metastasize to liver, lungs, bones, and brain at advanced stages, and 
we employed intrinsic resistance to 6-thioguanine (6-TG) to quantify metastatic cells[20]. 
MDA-MB-231-Luc tumors produce multiple organ metastasis after intravenous cancer 
cell inoculation or after tumor resection [21]; however, to the best of our knowledge, no 
study has reported spontaneous metastatic spread from unresected MDA-MB-231-Luc 
tumors in NOD/SCID mice (e.g., see Iorns et al. [22]). In both models, we observed a 
very low incidence of brain, bone, and liver metastases, but high levels of lung and 
axillary lymph node (ALN) metastasis, a finding that correlates with the TNBC clinical 






Figure 9. A) 4T1 model lungs presented with prominent subpleural metastasis from day eight after tumor 
cell inoculation. Further analysis confirmed predominant pleural invasion, although intraparenchymal 
regions also appeared metastasized. Metastatic regions within the lungs as evidenced by CK-AE1/AE3 
immunostaining and highly proliferative nature evidenced by Ki-67 immunostaining. B) The MDA-MB- 
231-Luc model developed metastasis later (day 28) and the metastatic nodules appears disseminated 




Lungs from the 4T1 model revealed evident sub-pleural metastases from D8, 
although we discovered the first evidence of discrete micro-metastasis from D3 (Figure 
10A). Between D8 to D16, lungs presented with perivascular metastatic nodules 
following a predominantly sub-pleural pattern[23]. H&E staining identified prominent 
metastatic progression leading to disperse necrotic regions from D14 (Figure 9A). 
Additionally, macroscopic examination identified increased tissue hyperemia 
concomitant with metastasis progression; however, we did not observe this trend in 
MDA-MB-231-Luc lungs (Figure 9B).  
Metastatic burden in MDA-MB-231-Luc appeared later than in the 4T1 and 
exhibited higher variability. Macroscopic lung evaluation uncovered first signs of lung 
metastases at around D28 as homogeneously disperse nodes, with intraalveolar and 
intrabronchiolar metastatic infiltrations present throughout the lung parenchyma (Figure 
9B). Subsequently, lungs became slightly hyperemic and displayed signs of damage. We 
confirmed metastasis and enhanced proliferation in both models using CK-AE1/AE3 and 
Ki-67 immunostaining, respectively (Figure 9). Overall, we observed higher lung 
metastasis and lesser implication of the subpleural region in the MDA-MB-231-Luc 
compared to the 4T1 model. 
Comparisons of healthy and metastatic lungs at the metabolomics levels 
established significant alterations in both models. Analysis of corresponding Orthogonal 
Projections to Latent Structures Discriminant Analysis (OPLS-DA) models revealed 
similar metabolic changes for the 4T1 and MDA-MB-231-Luc models (e.g., taurine, 
glutamate, UDP-N-acetylglucosamine), while other metabolites experienced variations 
of opposite sign (e.g., lysine, tyrosine). Furthermore, comparisons between metastatic and 
healthy lungs also uncovered several unique metabolic changes (e.g., 4T1: phenylalanine, 







Figure 10: A) H-E staining of representative 4T1 lung lobes allowed the detection of initiated metastasis 
around days 3-8 after cell inoculation. CK-AE1/AE3 confirmed the presence of tumorigenic cells. Endpoint 
lung analysis revealed the presence of metastasis-derived massive hemorrhages, parenchymal karyorrhexis, 
and loss of cell morphology. In later stages, the invaded regions covered around 60% of the whole lung 
tissue and mainly appeared in subpleural location. B) First signs of metastasis appeared around day 21 in 
the MDA-MB-231-Luc model and evolved to cover most of the lung tissue at the endpoint. Metastasis 
presented with a mainly intraparenchymatous pattern with low subpleural compromise. Several adipocytic 





Figure 11: Multivariate modeling resulting from the analysis of lung metastases. (A and C) OPLS-DA 
score plot representing comparisons between healthy lung tissue vs. metastatic lung (4T1) (aqueous phase; 
R2 = 0.913 / Q2 = 0.890) and healthy lung tissue vs. metastatic lung (MDA-MB-231-Luc) (aqueous phase; 
R2 = 0.921 / Q2 = 0.806), respectively. B) and D) Metabolic changes in healthy lung tissue vs. metastatic 
lung (4T1) (aqueous phase) and healthy lung tissue vs. metastatic lung (MDA-MB-231-Luc) (aqueous 
phase) comparisons, respectively. Statistical significance determined via ANOVA t-test, (***p<0.001, ** 
p<0.01, *p<0.05). 
At the macroscopic level, inguinal lymph node (ILN) metastases appeared in most 
4T1 animals, and those with ILN metastases suffered from rapid ALN spread. Direct 
ALN metastasis without ILN involvement rarely occurred (Figure 13). However, we 
seldom found metastases on the right side of the body (side of inoculation) and so we 
focused on metastatic development from tumor to left ALN following the afferent 
lymphatic vessel. 4T1 ALNs appeared macroscopically normal until D17, after which we 




degrees of physiological activation and swelling in the absence of metastasis until D10, 
and the majority of mice displayed similar characteristics by the endpoint. However, some 
4T1 tumor-bearing mice exhibited paracortical metastatic foci within the node hilus from 
D13. Mice with similar characteristics displayed widespread metastatic invasion of the 
ALN at D20 of tumor development. By D24, mice exhibited almost complete ALN 
invasion with normal morphology loss. 
MDA-MB-231-Luc model macroscopic studies discovered lower variability in 
ALN invasion when compared to the 4T1 (Figure 13). We observed no signs of 
metastatic spread in the first three weeks of MDA-MB-231-Luc tumor development; 
however, all ALNs presented with signs of medullary sinusoidal metastasis at D21-28. 
As expected, ALN swelling directly correlated to metastasis due to the lack of lymph 
node immunoreactivity and immune-related swelling. We also discovered more 
prominent metastasis to the left ALN in the MDA-MB-231-Luc model at advanced tumor 
development stage (Figure 13). Figure 12 depicts time-frame metastatic spread in MDA-
MB-231 ALNs. 
   
Figure 12: Right ALN metastasis progressed slowly in the MDA-MB-231-Luc model without significant 
node swelling. Within 14 days, tumor cells accumulated in the subcapsular sinus, and during the following 






Figure 13: Evolution of ALN metastasis by H&E staining and CKAE1/AE3 and Ki-67 immunostaining. 
A) The 4T1 model displayed heterogeneous metastatic invasion in ALN, and the vast majority of animals 
presented metastasis in the left ALN at the experimental endpoint B) The MDA-MB-231-Luc model 




II.2.3 Non-invasive imaging of Primary Tumor and Metastasis Development 
in TNBC Models 
18F-fluorodeoxyglucose uptake by positron emission tomography (18F-FDG-PET) 
and computed tomography (CT) permitted in vivo analysis of 4T1 tumor progression[24]. 
Figure 14A depicts a three-dimensional view of 4T1 tumor development displaying 
uniform radiotracer uptake by the spheroidal tumor mass until D3. 18F-FDG-PET also 
allowed the measurement of the tumor similarly to caliper measurements (Figure 14 C). 
We observed the development of an inner tumor core from D10, growing concentrically 
within the tumor mass, confirming previous findings and coinciding with maximal EPR 
effect (Figure 5). Analysis displayed in Figure 14A confirmed tumor core necrosis via 
the lack of radiotracer uptake. At endpoint, the necrotic region constituted around 80% of 
total tumor volume, and PET analysis confirmed metastasis in the left ALN only (Figure 
14B). 
 
Figure 14: A) PET/CT combination permitted in vivo monitoring of 4T1 primary tumor progression. Note 
the increasing hypodense region developing in the tumor core corresponding to the necrotic core. B) Detail 
on metastatic spread to ALN C) Morphometric evaluation of 4T1 tumor comparing traditional caliper 




Inherent luciferase activity in MDA-MB-231-Luc cells permitted the in vivo 
tracking of tumor progression and quantification of distal metastasis by bioluminescence 
imaging (BLI) using the IVIS® system (Figure 15). Tumors grew uniformly until D28, 
after which they became amorphous, with a loss of bioluminescence, again evidencing 
the necrotic core. Figure 15 also confirmed the uniform appearance of left ALN 
metastasis at D28 as demonstrated by histopathology (Figure 13A). BLI analysis at D35 
revealed increased left ALN metastasis with extravasation to the right ALN, the 
advancement of tumor core necrosis, and metastatic spread to surrounding tissues. At 
endpoint, all mice displayed increased metastatic growth to the left ALN, invasion of the 
right ALN, and metastatic growth development in abdominal and thoracic regions. 
 
Figure 15: A) Tumor growth and metastatic landscape demonstrated by BLI in the MDA-MB-231-Luc 
tumor model. ALN metastasis noted from day 28, and necrotic tumor core noted from day 35. B) 




Dynamic PET/CT analyses demonstrated a hypodense region within MDA-MB-
231-Luc tumors at endpoint (Figure 16 - red arrow); however, we observed a thinner 18F-
FDG labeled ring in the peritumoral region indicative of lower glucose metabolism at the 
tumor site. Additionally, we observed evidence of radiotracer uptake in abdominal lymph 
nodes around the tumor site (Figure 16 inset). Figure 17 shows significantly swollen left 
ALNs by CT. By PET, we detected the expected metastatic growth with the highest 
uptake located close to the afferent region of the left ALN and metastatic spread to the 
right ALN in the absence of swelling (as shown by CT) (Figure 17 - yellow arrows). By 
CT, we also observed lung metastasis following the so-called miliary pattern[25], which 
describes innumerable small metastases of variable-size within the parenchyma (Figure 
17; consistent with Figure 9). 
      
Figure 16. Three-dimensional projections of an MDA-MB-231-Luc representative mouse at the 
experimental endpoint. CT allowed for the delimitation of the tumor region (green region). Further PET 
analysis permitted the visualization of the peritumoral region, displaying a dark hollow indicative of tumor 
necrosis (inset, red arrow). Moreover, ILN metastasis was detectable with higher prominence on the left 





Figure 17. Thoracic region in detail. Characteristic intraparenchymatous lung metastasis detected by CT 
(green arrows). In addition, the swollen left ALN detected by CT (red region), but only an active metastatic 
region was detected by PET (yellow region) within the ALN mass. 
 
Figure 18. Quantification of 18F-FDG emission in lung (A), left ALN (B) and right ALN (C) by dynamic 
PET/CT experiment over 60min. 
 
II.2.4. Comparisons of Hematological Parameters in TNBC Models 
The hematological study depicted the development of systemic pathologies during 
tumor growth in both models, including a marked tumor-derived inflammatory response 
with anemia, thrombocytosis, reticulocytosis, leukocytosis, and subsequent 




although we observed model-specific alterations related to immune system status with 
significantly higher levels of leukocytes/lymphocytes at later stages in the 4T1 model 
(Figure 20A). Both models exhibited reduced erythrocyte levels (around 8-10%) during 
tumor development, correlating to imbalanced medullary/extra-medullary hematopoiesis. 
We found more pronounced anemia in the 4T1 model with hemoglobin levels diminishing 
gradually (Figure 20A). Although more pronounced in the 4T1 model, we also 
discovered a robust increase in reticulocytes in both models; however, in contrast, we 
found significantly higher thrombocyte levels in the MDA-MB-231-Luc model (around 
800 g.L-1 vs. around  400 g.L-1) at endpoints (Figure 20A, B). 
 
Figure 19. Comparisons of blood smears from healthy and endpoint animals in the (A) 4T1 and (B) MDA-
MB-231-Luc models. Stronger acute leukocytosis stronger is appreciable in the 4T1 model. Abnormal and 
immature cells can occasionally be found (e.g., immature neutrophils or orthochromatic erythroblasts). 
Magnification: 30x 
While a severe leukemoid reaction occurred from D10 in the 4T1 model (around 
160 g.L-1), we only observed a slight effect in the MDA-MB-231-Luc model (around 27 
g.L-1) close to endpoint (Figure 20B). In both models, segmented neutrophils accounted 
for around 33% of leukocyte number before tumor cell inoculation and around 85% at the 




agreement with leukocyte counts. Wright-stained blood smears confirmed results by 
allowing comparisons with data from healthy mice with tumor model endpoint data 
(Figure 19). Although we observed a more moderate response in MDA-MB-231-Luc, 
both models exhibited extensive granulocytosis (left shift) with predominant levels of 
polynuclear-segmented leukocytes. 
Immunophoretic analysis of blood serum revealed a significant and sudden 
increase in gamma globulin and alpha 2 globulin levels and a decrease in albumin levels 
at D42 in the MDA-MB-231-Luc model (Figure 21). Moreover, we found increased beta 
globulin bands in 4T1 (D3) and MDA-MB-231-Luc (D35) models, coinciding with the 














Figure 21. Proteinograms of peripheral blood in both models during tumor progression displayed in A) 
4T1 and B) MDA-MB-231-Luc models. Beta hyperglobulinemia found in both models at the same time 
that lung metastasis evolved (D3 for the 4T1 model and D35 for the MDA-MB-231-Luc model). Data 
represent mean ± SEM. Statistical significance was determined via ANOVA t-test, (*** p<0.001, ** 
p<0.01, *p<0.05). The MDA-MB-231-Luc model displayed acute bands in the alpha immunoglobulin and 
gamma immunoglobulin, a profile compatible with ongoing inflammatory processes (increased alpha-2 





Exosomes play crucial roles in conditioning the pre-metastatic niche[26], and we 
employed NTA of peripheral blood serum to assess exosomal dynamics during tumor 
progression. We discovered peak exosome levels on the first appearance of metastasis 
(D3) in 4T1 (Figure 22), before returning to basal levels. However, we did not observe 
any fluctuations during tumor progression in the MDA-MB-231-Luc model. 
 
Figure 22: Comparisons of circulating exosome levels during tumor progression for both tumor models. 
Directly correlated with the immune system status, inflammatory response 
markers may predict clinical outcomes in cancer patients, and so, we evaluated the 
neutrophil-lymphocyte-ratio (NLR), finding a rapid increase from D6 in the 4T1 model 
(Figure 23A). As an innate immune system effector, the complement system constitutes 
the first barrier against non-self-cells and plays a decisive role in tumor growth [27]. In 
agreement, 4T1 animals displayed increasing levels of C-3 protein from D20 (Figure 
23B). 
    
Figure 23: A) Neutrophil/Lymphocyte ratio (NLR). The MDA-MB-231-Luc mouse NLR is included for 
comparative purposes, although the immunocompromised character of the NOD/SCID mice does not 




II.2.5. Dysregulated Bone Marrow Hematopoiesis in TNBC Models: A role 
for G-CSF in Extramedullary Hematopoiesis 
Initial macroscopic organ analysis indicated acute splenomegaly (0.6% to 4% total 
body weight from D6 to D24) and slight hepatomegaly (4.8% to 6% total body weight 
over 24 days) (Figure 24) in the 4T1 model, but not the MDA-MB-231-Luc model. 
 
Figure 24: A) Analysis of major organs weight in the 4T1 model revealed slight hepatomegaly and acute 
splenomegaly along tumor progression. B) No significant alterations in organ weight observed in the MDA-
MB-231- tumor model. 
 
Figure 25 A) Congestion of the spleen red pulp as consequence of the adaptive HE and megakaryocytosis 
revealed by Factor VIII immunostaining. B) Spleen in MDA-MB-231-Luc animals did not suffer from 





Histopathological studies of bone marrow uncovered reduced megakaryocytosis 
(Factor VIII), reduced myeloid cell precursors (myeloperoxidase), and enhanced 
granulocytosis (CD-15) compared to healthy tissues (Figure 26), supporting 
extramedullary hematopoiesis (EH) promoted by bone marrow myelosuppression (in 
agreement with previous hematological findings).  
    
Figure 26: G-CSF impedes the normal maturation of myeloid cell precursors in bone marrow. Factor VIII 
immunostaining demonstrates the severely reduced megakaryocyte production of the 4T1 model in 
comparison with healthy animals in contrast to the slight reduction observed in the MDA-MB-231-Luc 
model. The loss of myeloid cells in both models was observed by myeloperoxidase staining. Presence of 






Figure 27 (A). 4T1 and MDAMB-231-Luc cells secrete G-CSF, which activates extramedullary 
hematopoiesis by stimulating the release of immature myeloid precursors. The 4T1 model presented 
hepatosplenomegaly as result of erythropoiesis and megakaryopoiesis in the spleen and megakaryopoiesis 
in the liver. Multiple colonies of myeloid cell precursors found in the liver. (B). The MDA-MB-231-Luc 




Analysis of the enlarged spleen of the 4T1 model supported EH by reactive 
megakaryocytic hyperplasia, as evidenced by large numbers of Factor VIII-positive 
megakaryocytes, and ongoing erythropoiesis, as evidenced by Glycophorin A-positive 
erythroid-precursors and mature erythrocytes (Figure 27). Further studies revealed 
increased cellularity and congested red pulp with hyperplasia due to elevated reactive 
hematopoiesis (Figure 25). Studies of the MDA-MB-231-Luc model normal-sized spleen 
highlighted reactive megakaryocytic hyperplasia as the unique pathological consequence 
of EH (Figure 27).  
In the 4T1 model, we observed overt signs of EH in the liver, as evidenced by 
increased myeloid precursor cell (MPC) perivascular infiltration into the surrounding 
hepatic arteries starting from D3. At later stages, MPCs entered the liver parenchyma to 
induce reactive megakaryocytic hyperplasia (Figure 27). In contrast, MDA-MB-231-Luc 
model liver developed no significant macroscopic or histopathological abnormalities. 
 
Figure 28: G-CSF levels in the 4T1 tumor model during tumor progression 
 





To understand EH origin, we conducted immunoassays to analyze circulating 
granulocyte colony stimulating factor (G-CSF) levels[28]. We discovered increasing 
levels of total G-CSF in 4T1 model peripheral blood at early stages of tumor development 
(Figure 28), in agreement with previous studies in immunocompetent mouse models[29]. 
We also discovered increasing levels of tumor- and host-derived G-CSF during MDA-
MB-231-Luc tumor progression (Figure 29). Of note, only in vitro studies have 
previously shown G-CSF secretion from MDA-MB-231 cells[30]. High human G-CSF 
levels in MDA-MB-231-Luc started increasing from D28 (Figure 29) and correlated to 
the previously observed leukemoid/lymphoid reactions. 
 
II.3. Discussion 
The accelerated development of advanced anti-cancer therapies requires adequate 
preclinical models and the identification of functional biomarkers to facilitate clinical 
translation [31] and identification of patients that would benefit from said therapies [32]. 
In this study, we report the exhaustive characterization of relevant preclinical TNBC 
mouse models regarding systemic landscape, metastatic foci, and metabolic alterations, 
paying particular attention to functional biomarkers. Both models develop homogeneous 
primary tumors with subsequent ALN and lungs metastasis, faithfully mimicking critical 
features of the human disease. Therefore, these models offer a useful platform for 
testing/validation of advanced anticancer therapeutics, especially for the treatment of 
patients presenting with both primary tumors and metastasis. 
 
II.3.1. Modeling Capacities of the 4T1 and MDA-MB-231-Luc TNBC Models 
The rapid tumorigenic development encountered for the 4T1 model offers a rapid 
and straightforward means to assess treatment outcomes in an immunocompetent model. 
Model characteristics include aggressive primary tumor evolution as densely packed 
masses with slight anemia, thrombocytosis, and reticulocytosis in the short term, and an 
acute leukemoid reaction with lymphocytosis and complement system activation in the 
mid-to-long term. In comparison, the MDA-MB-231-Luc model displayed slower tumor 




phenotype linked to the acquisition of a pro-invasive effect of surrounding tumor cells 
[19]. Therefore, high CAA content of MDA-MB-231-Luc tumors may serve as a faithful 
model to study this phenomenon and develop treatments to avoid adipocytic pro-
tumorigenic effects. Furthermore, high lipid content and low cellular density in the tumor 
stroma generated a softer tumor mass with a three-fold higher EPR effect, thereby 
providing a model to assess EPR-related passive tumor accumulation, especially 
important for the effectiveness of nanomedicinal approaches to cancer treatment [18]. 
The flexibility and permeability of the MDA-MB-231-Luc model stroma may also 
provide a means to assess intratumoral administration strategies [33]. 
The metabolomic comparison of 4T1 and MDA-MB-231-Luc primary tumors 
suggests that specific metabolic alterations could explain the differences observed in 
growth rates, with guanosine and uracil (a pyrimidine derivative) the two most relevant 
soluble metabolites contributing to model discrimination. Interestingly, Tayyari et al. [34] 
reported that TNBC tumors displayed increased pyrimidine synthesis and elevated levels 
of myoinositol and taurine, similar to findings in our 4T1 primary tumors. Metabolomic 
analysis of organic extracts provided further evidence for lipidic reprogramming in 
TNBC development and progression; in particular, 4T1 primary tumors displayed higher 
concentrations of cholesterol and phospholipids. These alterations reflect the avidity of 
proliferative cancer cells for lipids and cholesterol [35], a characteristic now considered 
a hallmark of cancer aggressiveness [35, 36]. MDA-MB-231-Luc primary tumors also 
displayed high levels of TAGs, whose hydrolysis in adipocytes adjacent to cancer cells 
generates free fatty acids for use as an energy source by tumor cells for tumor progression 
[35].  
We observed spontaneous lung and ALN metastasis in both models; however, 
while studies suggest that the 4T1 model develops lung metastasis via the hematogenous 
route [20], we discovered earlier evidence of distal metastasis and subsequent rapid 
development predominantly through the lymphatic system, as observed in two recent 
studies [37, 38]. Therefore, the 4T1 mouse model is ideal for the development and 
validation of lymph-targeted anti-cancer therapies [39]. Additionally, alterations to the 
complement system in the 4T1 model may provide a prognostic marker of disease 
progression or even a sign of treatment efficiency when using non-immunogenic 




II.3.2. Role of G-CSF as a Critical Functional Biomarker of Metastatic 
Progression 
The colony-stimulating factor (CSF) subfamily of glycoproteins play crucial roles 
in inflammatory cell activation [40], bone marrow cell mobilization into the peripheral 
blood, and immune system activation [41]. Increasing levels of G-CSF during 4T1 tumor 
progression [29] may trigger passive compensatory EH and the concomitant leukemoid 
reaction with prominent hepatosplenomegaly [29]. The leukemoid reaction is a well-
described paraneoplastic affection, arising in around 15% of cancer patients, proposed as 
a prognostic marker for BC [42] thereby ratifying the suitability of our 4T1 model as 
preclinical BC model. 
The MDA-MB-231-Luc model presented similar hematological parameters to the 
4T1 model at early stages; however, we did not observe a leukemoid reaction 
accompanying tumor growth, and the first evidence of metastasis occurred at later time 
points through the hematological pathway. Importantly we observed that tumor- and host-
derived G-CSF release concomitant with metastasis, led to the partial restoration of the 
immune system (granulocytosis and lymphocytosis) suggesting a “metastatic switch” 
appearing from the fourth week to trigger an immunological response in the 
immunosuppressed NOD/SCID mouse model. This suggests that stromal cells and/or host 
tumor-infiltrating cells also represent a significant G-CSF source [43]. Although the 
reduced immunological competency of the host does not permit extended adaptive 
splenomegaly or hepatomegaly in this model, we observed slight passive EH in the spleen 
as a response to bone marrow myelosuppression. Surprisingly, we only observed lung 
metastasis from D28, concomitant with human G-CSF release. Studies have proposed the 
indirect role of G-CSF in pre-metastatic niche formation [44], a finding supported by our 
MDA-MB-231-Luc model discoveries. Therefore, we propose circulating G-CSF levels 
as a prognostic indicator of disease and more importantly, the inhibition of cytokines such 
as CSFs as a promising therapeutic approach alone or in combination with metastatic 
inhibitors. We do note that the possible role of either human or host G-CSF in the immune 
system reactivation of the NOD/SCID mice remains unresolved; although the leukemoid 





Our work emphasizes the active role of the immune system in metastatic spread 
in both models [45]. We suggest, after the sudden changes at week four, that a quiescent 
MDA-MB-231-Luc tumor subpopulation reactivates through a likely “metastatic switch”. 
Several tumor-derived factors could be involved in the generation of pre-metastatic niche, 
and their overexpression could be a prerequisite for metastasis development. 
 
II.3.3. Other Biomarkers and Predictive Factors 
Exosomes have emerged as regulators of inter- and intra-cellular communication 
and can “tailor” the pre-metastatic niche for engraftment of cancer cells [26]. 
Interestingly, the 4T1 model displayed significantly increased circulating blood exosomes 
at D3, simultaneous with the first evidence of lung metastasis, suggesting its active role 
in lung metastasis establishment [26]. However, we did not find any modulation in 
exosome levels in MDA-MB-231-Luc.  
The prompt hyper-β-immunoglobulinemia detected in both models coincided with 
first signs of lung metastasis. Transferrin overexpression may be connected to 
neovascularization to influence metastatic capacity in BC [46]. Transferrin-like 
lipoproteins can specifically stimulate metastatic cell growth [47]. Similarly, β-
lipoprotein (LDL) is intimately involved in angiogenic regulation, with a direct 
connection between LDL levels and metastatic progress [48]. In this context, our 
metabolomics analyses confirmed that lipid metabolism alterations closely associates 
with TNBC malignancy and metastatic progression to the lungs. 
Finally, studies have demonstrated that NLR associates with poorer prognosis in 
human cancers [49]; high NLR associates with reduced disease-free survival (DFS). 
Applying this prognostic factor in our 4T1 model, NLR values indicate worse prognosis 
from D6-10, mimicking advanced stages of the disease and providing a tool to develop 





II.3.4. Metabolomic Metastatic Signature  
Metabolomic analysis of lung tissues revealed distinct signatures for both models. 
Some metabolites exhibited the same trend when comparing metastatic and healthy lung 
tissues (taurine, glutamate, UDP-NAG, glucose), reflecting common alterations. For 
example, the metabolism of glutamate/glutamine and taurine/hypotaurine plays a 
significant role in TNBC [34], and UDP-derivatives have been linked to metastasis [50]. 
A second important group of metabolites, mostly composed of amino acids, exhibited 
changes in the opposite direction when comparing metastatic and healthy lung tissues. 
The differences in amino acids levels may relate to different growth kinetics; much faster 
for the 4T1 model, therefore, requiring more energy. Of note, several amino acids that 
exhibited lower concentrations in the MDA-MB-231-Luc model metastatic lung (i.e., 
leucine, isoleucine, and valine) are branched amino acids (BCAA), and studies have 
indicated an association between increased concentrations of BCAA and chemotherapy-
induced apoptotic processes [51]. Interestingly, the ratio of choline/GPC indicates the 
acidic nature of metastatic tumors, since lower pH (typical of tumor cells) leads to 
decreased PC and increased GPC [52]. High glutamine consumption correlates with the 
essential function of glutaminase in TNBC development [53]. Decreased creatine 
phosphate levels, perhaps related to hypoxic regions within the metastasis [54], also 
correlate with the reduced pH characteristic of tumors. 
We also found several unique metabolic changes for each model. In 4T1 
metastatic lungs, we discovered increased phenylalanine levels [55] (related with 
advanced stages of the disease), aspartate [51] (upregulated glutaminolysis) and 
ATP+ADP (fueling metastatic survival). Analysis of MDA-MB-231-Luc metastatic 
lungs revealed a specific increase in glutathione levels, a molecule that plays protective 
and pathogenic roles and promotes chemoresistance [56], and GPC levels. Overall, the 
metabolomic signature for lung metastases in each model reflects the different molecular 
and biochemical mechanisms associated with metastatic spread, which could be 
employed as a biomarker for disease monitoring during preclinical evaluation. 
Finally, we note certain limitations to our study. Our human model only represents 
one subtype (representing around 15% of all TNBC); similar analyses of additional major 
TNBC subtypes could uncover clinically relevant information. We also note the lack of 




clinical situation); however, we believe that studying metastasis in the presence of the 
primary tumor can aid the development of therapies aimed at patients presenting with 
both tumor modalities. 
 
 
Table 1. Suggested suitability for different aspects of therapy development, demonstrating evident 
complementarity of the models for TNBC drug discovery and validation. 
 
II.4. Conclusions 
Within this present study, we describe the progression of two preclinical 
spontaneously metastatic TNBC models relevant for the development of anti-cancer 
therapeutics. We concentrated on the pathological features that ultimately drive anti-
cancer treatment and, therefore, patient outcomes. Our exhaustive characterization 
demonstrated MDA-MB-231-Luc metastatic progression in the NOD/SCID model. We 
also discovered a metastatic switch in both models (MDA-MB-231-Luc and 4T1) with 
immune system activation and serum-protein profile reconfiguration, which may support 
resistance to treatment and recurrence in TNBC. The detailed characterization of relevant 
models such as these will help to foster the rational design of anti-cancer therapeutics. 
Importantly, we identified critical functional biomarkers including the EPR effect, G-
CSF, CAA infiltration, NLR, complement activation, and metabolomic signatures for 







Figure 30: Timeline of TNBC tumor progression indicating main differential features between 4T1 and 
MDA-MB231-Luc regarding primary tumor, including stroma and metastatic sites. CAA. Cancer-
Associated Adipocytes, EPR: Enhanced Permeability and Retention Effect, G-CSF: Granulocyte colony-




II.5. Materials and Methods 
II.5.1. Cell culture and Cell Characterization 
The 4T1 breast cancer cell line was obtained from ATTC ® (EU) and maintained 
in RPMI (Roswell Park Memorial Institute) Media 1640 supplemented with 10% heat-
inactivated Fetal Bovine Serum (FBS) using standard tissue culture conditions. The 
MDA-MB-231-Luc cell line was obtained and characterized at the Functional Validation 
& Preclinical Research (FVPR) of CIBBIM-Nanomedicine working as the Unit 20 of 
the ICTS “NANBIOSIS” (http://www.nanbiosis.es/portfolio/u20-in-vivo-experimental-
platform/) (Barcelona, Spain). The cells were routinely maintained in Dulbecco’s 
modified Eagle’s medium / Nutrient Mixture F-12 (DMEM/F12, Gibco) supplemented 
with 10% FBS and 500 g/mL Geneticin (Gibco) at 37 °C in a humidified atmosphere 
with 5% CO2. In both cases, media was replaced every 2 - 3 days and underwent 
passaging once cells reached 80% cell confluence. The MDA-MB-231-Luc cell line was 
fully characterized by western blotting in terms of HER2 (ErbB2, BioVision Ref 3783-
100), Estrogen Receptor (ER-alpha, Cell Signaling #8644), and Progesterone Receptor 
(PR-beta, Cell Signaling #3157) expression. Luciferase transfection efficiency and 
bioluminescence maintenance were analyzed before proceeding. 
 
II.5.2. Mouse Strains 
The 6 to 8 week-old female inbred immunocompetent BALB/c (BALB/cOlaHsd) 
mice or the immunodeficient non-obese diabetic NOD/SCID (NOD.CB17-
Prkdcscid/NCrHsd) mice used for all the experimental procedures were purchased from 
Envigo Laboratories Inc. (Spain, EU).  
 
II.5.3. Ethical Considerations 
Animal experiments were performed in accordance with the European 
Communities Council Directive (86/609/ECC) guidelines and by the Spanish Royal 




Animal Care and Use Committee and accomplished by accredited and trained staff, 
meeting the animal care rules. All mice were maintained in a specific-pathogen-free 
facility, under temperature, humidity, and using a 12h light-dark cycle. Food pellets and 
water were provided ad-libitum during the whole experiments in all cases and general 
aspect, grooming conduct, tumor size, body weight, and behavior were evaluated daily 
from the beginning of the experiment to ensure animal wellness. Tumor development did 
not lead to weight loss in the animals, nor pain-related behavior. 
 
II.5.4. Establishment of Spontaneously Metastatic Primary Tumor Models 
4T1 orthotopic tumors were induced by the subdermal inoculation of 5 x 105 4T1 
early passage cells suspended in 100 µl of Matrigel (10%) in the second left mammary 
fat pad of BALB/c females under inhalatory anesthesia (3% sevoflurane in 100% 
oxygen). Following the same experimental conditions, MDA-MB-231-Luc tumors were 
established by injecting 3 x 106 early passage cells in NOD/SCID female’s mammary fat 
pad. Tumors were morphometrically evaluated daily with an electronic caliper and tumor 
volumes were obtained by considering tumor shape as spheroidal. At progressive periods, 
representative mice were sacrificed under CO2 atmosphere and the blood, main organs, 
and tumor were extracted, weighed, and preserved for later hematological and 
histopathological analysis. The experiments were terminated when tumors reached 1.0 
cm3 (or 24 days after the inoculation in case of 4T1 tumors and 42 days after inoculation 
in case of MDA-MB-231-Luc). 
 
II.5.5. Study of Enhanced Permeability and Retention Effect 
To study vascular permeability, 200 l of Evans blue – albumin macromolecular 
complex (10mg/Kg) was administered intravenously (i.v.) (4 mice/group). After 60 
minutes, mice were sacrificed under CO2 atmosphere and tumors were resected, washed, 
and submerged in 3 ml of formamide (Sigma-Aldrich). Tissues were allowed to release 
accumulated dye preserved from light, at 60°C for 48h and the final concentration of 




II.5.6. Non-invasive Imaging Techniques to Monitor Metastasis 
Bioluminescence (BLI) by IVIS 
Luciferase-transfected MDA-MB-231-Luc cells present in the animal body were 
tracked using IVIS technology. For bioluminescence imaging (BLI), mice were 
anesthetized with 3% sevoflurane in oxygen and received a subdermal injection of 150 
mg/kg D-luciferin (Gold BioTechnology, USA). BLI was performed with the IVIS 
spectrum system 10 min after D-luciferin administration. Images were acquired using the 
automatic camera settings and BLI data were quantified with the Living Image 
(PerkinElmer, Japan) software in terms of photons per second. 
Positron Emission Tomography-Computed Tomography (PET-CT) Analysis 
PET-CT analysis employed the Albira equipment (Bruker, USA) located within 
the CIPF. Animals were kept without food for 14h prior to radiotracer administration for 
PET and housed at constant temperature of 21ºC to minimize the influence of external 
factors on glucose uptake. The average mouse weight was 19.2±0.7g, while the average 
blood glucose level was 47.2±10.1mg.dl-1. Anesthesia was induced by inhalation of 
isoflurane (4% in 100% oxygen) and maintained at (1.5% in 100% oxygen). The 
resolution of the hybrid PET/CT tomography was fixed at 1.5mm with an axial field of 9 
cm and transaxial of 8 cm. Once the parameters were fixed, animals were i.v. injected 
with 18F-FDG (IBA Molecular, Spain) with an activity of 4.5±0.1MBq through a tail vein 
catheter. The average 18F-FDG dosage was 4516.2 KBq±236.3. Dynamic PET 
experiments were performed by the acquisition of 28 frames of 60 min of total length (6 
x 10 s, 6 x 30 s, 6 x 60 s, 5 x 120 s, 4 x 300 s and 1 x 1200 s). CT scans were performed 
immediately after PET acquisitions, allowing the overlap of both images. PET images 
were reconstituted using the algorithm Maximum Likelihood Estimation Method 
(MLEM, 12 iterations) and decay, scatter, and random corrections were applied where 
required. CT scans were performed at 45 KV and 0.4 mA, with further reconstruction 
using the FBP algorithm. 
Acquired images were semi-quantitatively analyzed through the Standard Uptake 
Values (SUVs), which allowed the definition of the volumes of interests (VOIs) and 
establishment of time-activity curves (TACs) for different regions of interest. 18F-FDG 




analysis. 18F-FDG accumulation in different VOIs was measured by the same way as for 
the SUVs. To minimize the uptake fluctuations due to factors including animal weight or 
slight differences in i.v. administration, SUVs were normalized using the relationship 
between radioactivity in tissue (KBq/ml) at different acquisition time points and injected 
doses in the PET acquisition (KBq) divided by each mouse weight, obtaining a SUV 
(g/ml) as presented in the graphs.  
PET and CT data were processed using the PMOD software suite (ver3.6) (Pmod 
Technologies, Zurich, Switzerland). 18F-FDG uptake was quantified by registering 
anatomic images of CT and corresponding PET normalized to SUV. Spherical VOIs were 
established in axillar lymph nodes (diameter = 2mm) and lungs (diameter = 1mm). The 
obtained VOIs were transferred to the PET image, resulting in the TACs standardized to 
SUVs (g/ml) for each different areas of interest. 
 
II.5.7. Blood Collection and Analysis 
At defined time points, mice were sacrificed under a CO2 atmosphere. Blood was 
immediately extracted by cardiac puncture with a 1.0 ml heparinized syringe and 
transferred to a 2.0 ml Eppendorf tube. Serum was isolated and analyzed through an 
automated hematologic analyzer (Sysmex XT-2000i). Serum protein content was 
measured using an automated capillary electrophoresis system (Capillarys Sebia 2). For 
the blood smear preparation, a small drop of blood was placed near the frosted end of a 
clean glass slide. The blood was streaked in a thin film over a slide and then it was allowed 
to air-dry for 60 min. Commercial Wright’s staining procedure was performed afterward. 
 
II.5.8. Histopathological Analysis and Imaging 
Histopathological analysis were carried out in the Instituto Valenciano de 
Patología, Tumors, major organs, and areas expected to develop metastasis or 
pathological alterations, were removed from euthanized mice at relevant time points. All 
the tissues were washed in fresh PBS, carefully dried, weighed, and fixed in 4% 




marrow samples were derived from femurs decalcified by immersion in Osteodec 
(BioOptica) for 8 h. A common dehydration and paraffin-inclusion procedure was carried 
out leading to blocks that were sliced into 4-µm sections. Hematoxylin-Eosin (H-E) 
staining and immunostaining were performed as required (Dako Autostainer 48, US) and 
the slides were finally assembled with Eukitt. Tissue slides were observed under the 
microscope and those of interest were scanned with a Panoramic 250 Flash III slide 
scanner and processed with CaseViewer software (both from (3DHISTECH Ltd, 
Budapest, Hungary). A detailed list of the antibodies used can be found in the 
Supplementary Figure S11. 
 
II.5.9. Metabolomic profiling by NMR 
Samples corresponding to tumors and metastatic lungs, collected at the 
experimental endpoints, as well as healthy lungs (control samples) were removed 
following the procedures indicated above, washed in PBS, immediately frozen in liquid 
nitrogen, and stored at – 80ºC until analysis. Tissue samples were powdered and the 
metabolites were extracted and analyzed by NMR using previously described methods 
[59]. Following sample preparation, NMR spectra were recorded at 300 K (27 ºC) on a 
Bruker AVII-600 using a 5 mm TCI cryoprobe and processed using Topspin 3.5 (Bruker 
GmbH, Karlsruhe, Germany). Acquisition parameters for these experiments were 
optimized to achieve an optimal signal to noise and resolution [59]. Multivariate data 
analysis was performed with SIMCA-P 14.1 (Umetrics, Sweden). Specifically, PCA 
models were generated for the different comparisons to evaluate the intrinsic variability 
of the data and to observe clustering or separation trends. OPLS-DA models were built 
for minimizing the contribution of variability within and between the samples, and to 
further improve the separation between the groups. Identification of the most relevant 
metabolites included the analysis of the OPLS-DA loadings S-plot, that provides 
information on the relative contribution of spectral variables to the separation between 
groups. Finally, main metabolites contributing to group discrimination were integrated 




II.5.10. Statistical Analysis 
All graphs present mean ± SEM from n ≥ 3 assays. Animal assays were performed 
with 4-7 animals per group. Statistical analysis was performed using one-way ANOVA 
test and Mann–Whitney U test; comparisons with p<0.05 were considered statistically 
significant with a 95% confidence interval. 
 
II.5.11. Exosome Isolation from Mouse Blood Serum 
Fresh serum was isolated from blood through centrifugation (4000 rpm, 10 min, 
4 ºC). Serum was purified by differential centrifugation (500g, 10min; 3000g, 20min and 
10000g, 20min at 10°C). Volume was adjusted to 4ml with PBS. Then, an 
ultracentrifugation was performed (100000g, 70min, rotor MLS-50, UC Optimamax). 
The pellet was suspended in 1ml of PBS and adjusted to 4ml and the ultracentrifugation 
procedure was repeated. Finally, the pellet was suspended in 50ul and kept at 4ºC until 
analysis. 
 
II.5.12. Sizing and Quantification of Exosomes by NTA 
Purified exosomes were diluted with PBS buffer (100 – 5000 times) in order to 
reach the particle concentration (2*108 to 2*109 particles/ml) in the operational range for 
the NTA. Exosomes were then quantified and sized using the Nanosight NS300 (Malvern 
Instruments, UK). For image acquisitions, the focus was fixed to -1 and camera level set 
to 8 in all experiments. For image processing and analysis, the threshold level was 
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The experimental research presented within this Thesis Chapter has been carried 
out in tight collaboration with Dr. Coralie Deladriere, who also presented part of it in her 
thesis dissertation. As a result of this collaboration, we are both co-first authors of the 
publication [1] in the journal Advanced Functional Materials [Journal impact factor: 
12.12, scored 7 of 87 in Nanoscience and Nanotechnology (JCR, 2016), Q1], Volume 28, 
Issue 22 (DOI: 10.1002/adfm.201800931)(“Anticancer Activity Driven by Drug Linker 
Modification in a Polyglutamic Acid-based Combination-drug Conjugate”). 
---------------------------------------------------------------------------------------------------------- 
As stated in the Introduction Chapter, the polymeric carrier provides an ideal 
platform for delivery of a cocktail of drugs simultaneously [2], and so the pursuit for 
novel polymer-based combination conjugates more defined and better characterized is 
currently on first line of investigation in the polymer therapeutics field.  
In the earlies 2000, it was reported the first endocrine-chemotherapy combination 
in the form of the model compound HPMA-copolymer-aminoglutethimide-doxorubicin 
[3]. It was then hypothesized that combination of endocrine therapy and chemotherapy 
by simultaneous attachment to the same polymer would bring significant advantages. The 
combination was suitable to be administered as a single dose, leading to the benefits of 
manufacture of a single conjugate and improved patience compliance.  
After EPR-mediated targeting, arrival of both covalently conjugated drugs to the 
tumour cells at the same time can be guaranteed. This strategy also provides the 
opportunity to tailor polymer-drug linkers to impart different rates of drug release for 
each compound, allowing the incorporation of optimal drug loadings at optimal drug 
ratios to act synergistically. The conjugate was evaluated in vitro using MCF-7 cells and 
an aromatase-transfected cell line MCF-7Ca. It was found that conjugates containing both 
drugs (aminoglutethimide and doxorubicin) showed markedly enhanced cytotoxicity 
compared to PK1 (HPMA-GFLG-Dox, the conjugate that has already shown activity in 
breast cancer patients clinically), while mixtures of polymer conjugates containing only 
aminoglutethimide or only doxorubicin did not show synergistic benefit.  
These observations underlined the exciting possibility of designing polymer-drug 
combinations for improved treatment of breast and prostate cancer, including the use or 
more active anticancer drugs, more effective stimuli-responsive drug linkers and safer 




III.1. Antecedents and Background 
As stated in previous Thesis Chapters, combination anti-cancer strategies within 
nanomedicine may represent an efficient means to treat breast cancer, [4-6] a molecularly 
complex and heterogeneous disease that often metastasizes and/or becomes drug 
resistant. [7] There currently exist a wide range of strategies under investigation, 
including the liposomal entrapment of Cytarabine and Daunorubicin (FDA approved 
VyxeosTM, formerly CPX-351), which has improved all efficacy parameters, including 
overall survival, in a Phase 3 clinical trial of high-risk acute myeloid leukemia patients. 
[8] 
 Polymeric Therapeutics (PT) as single agent or as combination therapeutics offer 
numerous advantages over conventional drugs, including the possibility of an enhanced 
passive accumulation via the Enhanced Permeability and Retention (EPR) Effect on those 
tumors adequately vascularized, [9-11] or the ability to cross specific biological barriers. 
[12, 13] Moreover, drug(s) conjugation to a polymeric carrier benefits from several 
additional advantages [14, 15] as an optimized drug pharmacokinetics, multivalence that 
allows the conjugation of multiple active/imaging agents and targeting moieties, [6, 16] 
and the ability to target drug activity to tumors via bioresponsive polymer-drug linkers. 
[17] One issue limiting the widespread use of polymer conjugates is the current lack of 
understanding of the complex interplay of dynamic physicochemical factors, such as size, 
shape, surface chemistry, roughness, rigidity, and the influence of linkers and active 
agents, which characterize the interaction of nanosized PTs with the biological interface. 
[18] 
We developed the first polymer-drug combination conjugate, an N-(2-
Hydroxypropyl) methacrylamide copolymer carrying both Aminogluthetimide and 
Doxorubicin (HPMA-AGM-Dox), with the aim of combining an aromatase inhibitor with 
a chemotherapeutic agent for the treatment of chemotherapy-resistant breast cancer. [19-
21] HPMA-AGM-Dox displayed enhanced in vitro breast cancer cell toxicity compared 
to a combination of the unconjugated drugs or individual polymer-drug conjugates. [20, 
21] Recently, in vivo proof of concept for antitumor drug synergism with the combination 
conjugate has been also achieved in an aggressive metastatic 4T1 murine breast cancer 
model. [19] The mechanism of the enhanced activity appeared primarily due to the 




cell at the same time. Importantly, when protein expression of tumor tissue samples were 
analyzed, strong differences were observed in tumor-associated angiogenesis pathways, 
which could only be explained by the simultaneous estrogen inhibition induced by AGM, 
only made available at the appropriate cell and time with the combination conjugate. This 
effect was enhanced by an autophagic cell death mechanism only associated with the 
combination conjugate. [19] These results demonstrated for the first time that the rational 
design of a combination PT could significantly enhance drug therapeutic output while 
also significantly reducing the side effects and tissue damage observed when applying the 
unconjugated forms of these active agents. This concept has been further explored and 
reinforced both in vitro and in vivo through studies in our laboratory and other research 
groups. [6] 
However, despite these promising findings, preclinical evidence of detrimental 
side effects derived from the use of biopersistent polymer carriers (i.e. HPMA or 
Polyethylene glycol (PEG)) [22] have led to an exponentially growing research interest 
on biodegradable polymers, in particular, polypeptides such as poly-glutamic acid (PGA) 
[17, 23] as clinical benefits have been achieved with polypeptide based polymeric drugs, 
such as Copaxone [24] (one of the Top Ten selling drugs) [25, 26] and the lessons learnt 
with polypeptide/PGA-based anti-cancer PTs such as Opaxio. [27, 28] 
 Encouraged by the successful application of PGA to conjugate chemotherapy as 
single agents [27, 28] and in combination, [29-31] as well as our prior data combining 
endocrine and chemotherapy, [19-21] we now describe the first PGA-based combination 
conjugates bearing chemotherapy and estrogen modulator agents for the treatment of 
breast cancer. Furthermore, we took this opportunity to explore how the incorporation of 
different polymer-drug linkers influences conjugate characteristics and biological fate. 
Implementing a rational experimental design, we systematically prescreened a family of 
single and combination conjugates, provided with different drug loadings and linkers, in 
vitro in a breast cancer cell line, and then selected successfully screened conjugates for 
further assessments in an aggressive orthotopic 4T1 breast cancer murine model. We also 
studied the spatial conformation and physical structure of our conjugate family in 
biological milieu to predict and better understand intrinsic interactions with the nano-bio 
interface and therefore, therapeutic effect and mechanisms of action. Parameters assessed 




tridimensional conformation including secondary structure, size, and shape by Dynamic 
Light Scattering (DLS), Small Angle Neutron Scattering (SANS), and Circular Dichroism 
(CD). We present the selected PGA-based drug-combination conjugate as an exciting 
therapeutic candidate, underlining that the choice and/or design of drug-polymer linkers 
may allow tight spatiotemporal control of drug release and the enhanced personalized 
treatment of aggressive breast cancer. 
III.2. Results and Discussion 
III.2.1. Synthesis and Characterization of Polymer-drug Conjugates 
We employed optimized and scalable synthetic methodologies to develop a 
rationally designed family of polymer-based combination anticancer conjugates using n-
butyl poly-L-glutamic acid (PGA) (100 units, Mw ~13 kDa) as a biodegradable carrier, 
with the aim of achieving drug synergism. Aromatase inhibitors, such as 
Aminoglutethimide (AGM), induce apoptosis [32] and can act synergistically when 
combined with chemotherapeutics, [33] as previously shown in our studies with N-(2-
Hydroxypropyl) methacrylamide (HPMA)-based combination conjugates. [19-21] 
Although HPMA has demonstrated its suitability as carrier for anticancer treatments, we 
expected that replacing HPMA with PGA would improve safety issues specially in 
chronic administrations given its enhanced biodegradability. This improved characteristic 
would reduce unwanted side effects related to polymer accumulation as seen with other 
non-biodegradable carrier such as PEG. [22, 29, 34] 
 Therefore, we developed a library of well-defined PGA-conjugates via 
carbodiimide coupling (Figure 1). [21, 35] We also synthesized and fully characterized 
single-agent PGA conjugates bearing Dox or AGM for comparative purposes (Table 1 
summarizes data on all conjugates assessed). We introduced Dox directly and AGM via 
direct amide conjugation, a Gly linker (G), [36] a Gly-Gly linker (GG), [37, 38] or the 
well-known tetrapeptidic Gly-Phe-Leu-Gly linker (GFLG), which is cleaved by the 
lysosomal thiol-dependent protease Cathepsin B. [39] To explore the effect of two 
different therapeutic scenarios, we fixed Dox content within the polymer conjugate at 5% 
mol, but varied AGM from 5% mol (Low Loading [LL]) to 10% mol (High Loading [HL]) 
(Figure 1). Additionally, we also incorporated both drugs within the same PGA chain to 




employed and tight controls on drug loading permitted the scale-up of this process to 
gram-scale batches without losses in either conjugation efficiency or yield. Prior to 
characterization, we isolated and purified all conjugates by Size Exclusion 
Chromatography (SEC) to remove any excess of salts, activating agents or traces of 
unreacted drugs (See section III.4. Materials and Methods for a detailed synthetic 
methodology). 
1H-NMR characterization of the synthesized products was used to determine their 
identity and purity. As demonstrated in Figure 2, which displays spectra of representative 
conjugates, the covalent incorporation of a single drug (PGA-(G-AGM)LL, PGA-Dox) or 
the drug combination (PGA-(G-AGM)LL-Dox) into the polymer backbone resulted in the 
expected widening of characteristic drug signals (See section III.4.3 of Materials and 
Methods for details on family characterization). The signal of the Dox methylene group 
at 1.2 ppm and the signals corresponding to the aromatic ring (0.75 ppm) and ethylene 
group (7.4 ppm) of AGM permitted identity verification for both the single and 
combination nanoconjugates. As shown in Figure 3, representative conjugates displayed 
a homogeneous distribution of drug content along the polymer population (as derived 
from the SEC elution profiles in UV-Vis at 260 nm). These profiles conformed to the 
expected behavior according to size, as different conjugates exhibited slightly shorter 
retention times and broader peaks when compared with parental 
unconjugated/unmodified PGA (Figure 3), in accordance with the enhanced Mw due to 







Figure 1. Synthetic route for the preparation of single and combination PGA-drug conjugates: 1) 
Carbodiimide-based carboxylic group activation. 2) Attachment of Dox or AGM (or derivatives) for single 






Figure 2. Representative 1H-NMR spectra (D2O, 500MHz) of single and combination conjugates. 
 
Figure 3. Representative SEC chromatograms for parental PGA (RI detection, peak at 17.1 min 
corresponds to the counter-cation Na+) and PGA-Dox, PGA-(G-AGM)LL, and PGA-(G-AGM)LL-Dox 
conjugates (UV at 260nm). 
 
III.2.2. Quantitative Characterization of Total Drug Loading and Free Drug 
Content in PGA-drug Conjugates 
Despite the lower reactivity of the aromatic amine present in AGM, we found the 
synthetic carbodiimide-activation methodology to be a good and reproducible approach 
(Table 1) for both the single and combination conjugates. We noted that conjugation yield 
improved significantly when we first incorporated AGM with different peptidic linkers, 




through the primary aromatic amine of the drug. We also noted efficient conjugation of 
Dox, except for combination conjugates bearing the GFLG-AGM moiety. Lower Dox 
loading in the presence of the bulky GFLG-AGM moiety may be due to steric hindrance, 
which can limit high levels of Dox incorporation. We also found that a SEC-based 
purification procedure ensured low levels of free-drug in the final conjugates ranging 
from 0.1-0.7% w/w for Dox and 0.2-1.1% w/w for AGM (Table 1). Absolute Mw 
analysis by analytical tandem SEC-MALS-RI proved difficult due to heterogeneity in 
drug loadings and the inherent nature of the conjugates, so we calculated the theoretical 
molecular weight of PGA conjugates according to the percentage of modification (range: 
12.7 – 18.6 KDa). 
 
Table 1. Characteristics of PGA-AGM-Dox polymer-drug conjugates. (a Determined by UV-Vis (AGM) 
and HPLC (Dox). b Determined by HPLC. C Determined by aqueous SEC MALLS-RI for the sodium salt 
form of PGA. Mw of -the polymer – drug conjugates were estimated from total drug loading) 
 
III.2.3. Preliminary in vitro Evaluation and Drug Release Kinetics of PGA 
Conjugates 
To assess the biological implications of different drug linkers and drug ratios in 
the synthesized conjugates, we undertook a wide-ranging preliminary in vitro screening 




the various PGA-AGM conjugates and PGA-Dox as two separate species added 
simultaneously (i.e. drugs were not present in the same polymeric chain).  
Cell viability assays in the MCF-7ca breast cancer cell line demonstrated higher 
cytotoxicity for the combination conjugates PGA-(GG-AGM)LL-Dox (Figure 4B), PGA-
(G-AGM)LL-Dox (Figure 4C), and PGA-(G-AGM)HL-Dox (Figure 4D) when compared 
with the single PGA-Dox and PGA-AGM parent conjugates alone or in a physical 
combination (Table 2). The PGA-(AGM)LL-Dox (Figure 4A), PGA-(GFLG-AGM)LL-
Dox (Figure 4E), and PGA-(GFLG-AGM)HL-Dox (Figure 4F) did not display high 
toxicity compared to PGA-Dox at tested concentrations. We found evidence of poor Dox 
release in the conjugates bearing the tetrapeptide GFLG for AGM, which is a requisite 
for cell toxicity, probably due to restricted linker access. Of note, the physical 
combination of single drug conjugates administered at the same time (Figure 4A, E, and 
F) did mediate an enhanced cytotoxic effect when compared to the combination 
conjugates. However, the administration of two different conjugates to a patient will not 
ensure that both drugs will arrive at the target cell at the desired ratio and within the 
required period, making this treatment strategy ultimately inefficient for our selected 
molecular targets. 
  As previous studies demonstrated significant synergism between AGM and Dox 
in the different breast cancer cells when incorporated within the same non-biodegradable 
polymeric carrier, [19-21] we computed the Combination Index (CI) for our new 
biodegradable systems against MCF7-ca. [40] These calculations discovered no 
synergistic effects when we treated cells with both drugs as separate single conjugates 
(Table 2 - PGA-(AGM)LL + PGA-Dox, PGA-(GG-AGM)LL+ PGA-Dox, PGA-(G-
AGM)LL + PGA-Dox, and PGA-(G-AGM)HL + PGA-Dox), except for the PGA-(GFLG-
AGM)LL and PGA-Dox treatment, which provided the lowest CI value of 0.3. However, 
we did observe high levels of synergism (CI < 1) for the PGA-(G-AGM)LL-Dox (0.32), 
PGA-(G-AGM)HL-Dox (0.32), and PGA-(GG-AGM)LL-Dox (0.33) combination 






Figure 4. Cell toxicity study of polymer drug conjugates in MCF-7ca cells. Cell viability measured by 
MTS assay after 72 hours of treatment. PGA-(AGM)LL-Dox (A), PGA-(GG-AGM)LL-Dox (B), PGA-(G-
AGM)LL-Dox (C), PGA-(G-AGM)HL-Dox (D), PGA-(GFLG-AGM)LL-Dox (E) and PGA-(GFLG-
AGM)HL-Dox (F). Every assay is displayed with its corresponding single conjugates and Dox as free drug 







Treatment IC50* (mg/ml) CI** 
Dox 0,00024 N/A 
PGA-Dox 0,028 N/A 
PGA-(AGM)
LL
-Dox 0,53 >1 
PGA-(AGM)
LL
 N/A N/A 
PGA-(AGM)
LL 
+ PGA-Dox 0,05 >1 
PGA-(GG-AGM)
LL
-Dox 0,0011 0,32 
PGA-(GG-AGM)
LL
 N/A N/A 
PGA-(GG-AGM)
LL
+ PGA-Dox N/A >1 
PGA-(G-AGM)
LL
-Dox 0,003 0,33 
PGA-(G-AGM)
LL
 N/A N/A 
PGA-(G-AGM)
LL
 + PGA-Dox 1 1 
PGA-(G-AGM)
HL
-Dox 0,0017 0,33 
PGA-(G-AGM)
HL
 N/A N/A 
PGA-(G-AGM)
HL
 + PGA-Dox 0,055 1 
PGA-(GFLG-AGM)
LL
-Dox 0,035 >1 
PGA-(GFLG-AGM)
LL
 N/A N/A 
PGA-(GFLG-AGM)
LL
 + PGA-Dox 0,0027 0.32 
PGA-(GFLG-AGM)
HL
-Dox 0,022 0,56 
PGA-(GFLG-AGM)
HL
 N/A N/A 
PGA-(GFLG-AGM)
HL
+ PGA-Dox 0,0026 0,3 
 
Table 2. IC50 and Combination Index (CI) values for free Dox and the polymer drug conjugates in human 
MCF-7ca cells (N/A: non-applicable, *IC50 values obtained graphically, **Combination Index estimated 
by Compusyn. 
We noted that the presence of the linker drastically modified the in vitro cytotoxic 
effects; the addition of small, short, and flexible Gly or Gly-Gly linkers led to enhanced 
results when compared to direct linkage of AGM or through the more bulky GFLG linker. 
Additionally, we assessed cell toxicity of two highly synergistic conjugates found in the 
previous study in murine 4T1 breast cancer cells as a first step towards studying conjugate 
antitumor activity in an orthotopic immunocompetent mammary tumor mouse model. 
The PGA-(G-AGM)LL-Dox (IC50 = 0.0034) and PGA-(G-AGM)HL-Dox (IC50 = 0.0033) 




(IC50 = 0.0084) (Figure 5A and B. We also assessed cell toxicity of PGA-(AGM)LL-
Dox as a control for non-synergistic effect (Figure 5C) and, as expected, this combination 
conjugate displayed a higher IC50 value (0.012 mg/ml) than the combination conjugates 
bearing the Gly spacer. In general, we observed a more pronounced cytotoxic activity in 
4T1 cells than in MCF-7ca, probably due to the higher level of Cathepsin B activity in 
4T1 cells, [19] which degrades the peptidic polymer-drug linkers and the poly-L-glutamic 
acid carrier. Subsequent CI value calculations found strong synergism for the PGA-(G-





Dox 0,000085 N/A 
PGA-Dox 0,0084 N/A 
PGA-(G-AGM)
LL
-Dox 0,0034 0,388 
PGA-(G-AGM)
LL
 N/A N/A 
PGA-(G-AGM)
LL
+ PGA-Dox 0,019 >1 
PGA-(G-AGM)
HL
-Dox 0,0033 0,176 
PGA-(G-AGM)
HL
 N/A N/A 
PGA-(G-AGM)
 HL
+ PGA-Dox 0,012 >1 
PGA-(AGM)
LL
-Dox 0,012 >1 
Table 3. Determination of IC50 and Combination Index (CI) values for free Dox and the polymer-drug 
conjugates in mouse 4T1 breast cancer cell line. 
We also evaluated drug release kinetics in presence of Cathepsin B for the PGA-
(G-AGM)LL-Dox, PGA-(G-AGM)HL-Dox, and PGA-(AGM)LL-Dox conjugates (Figure 
6A-C), finding three different release profile scenarios as a consequence of drug loadings 
and linker type. The PGA-(G-AGM)LL-Dox conjugate displayed a significantly faster and 
higher release of AGM (13% after 72h) in contrast to Dox (7%) during the same time 
period. However, the PGA-(G-AGM)HL-Dox conjugate released higher amount of Dox 
(12% at 72 hours) as compared to lower levels of AGM (3%) over the same time. 
Meanwhile, the PGA-(AGM)LL-Dox conjugate displayed a simultaneous release profile 
for both drugs (~10%) over 72 hours. PGA-(G-AGM)HL-Dox and PGA-(G-AGM)LL-Dox 
differ only in their level of AGM loading, with higher loading significantly diminishing 




However, we noted a similar cytotoxic effect for both LL and HL conjugates, possibly 
mediated through different molecular mechanisms. While high Dox release from the 
PGA-(G-AGM)HL-Dox can enhance cytotoxicity, high AGM release from the PGA-(G-
AGM)LL-Dox conjugate may enhance cell sensitivity to Dox [19, 20] and provide a 
synergistic effect even given the lower levels of Dox release. Aromatase inhibitors such 
as AGM promote apoptosis [41] and this may also sensitize cancer cells to Dox treatment. 
In a direct comparison between PGA-(AGM)LL-Dox and PGA-(G-AGM)LL-Dox 
conjugates, which only differ in the addition of the small flexible Gly linker, enhanced 
AGM release seems to be related with structural alteration promoted by Gly. In terms of 
drug synergism, we found that Gly presence induced synergism while the absence of Gly 








Figure 5. Cell toxicity analysis of the polymer drug conjugates PGA-(G-AGM)LL-Dox (A), and PGA-(G-
AGM)HL-Dox (B) in 4T1 cells. C) Comparative study of cell toxicity of PGA-(G-AGM)LL-Dox, PGA-(G-
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Drug release required the strategic design of the family of polypeptide-drug 
conjugates towards lysosomotropic delivery, where the enzymatic degradation of the 
polymeric chain will release the active agents at the desired site of action. This not only 
improves therapeutic efficiency, but also reduces unwanted off-target side effects. The 
degradation process requires efficient cellular uptake and adequate access of the 
endopeptidase to the linker, [42] with accessibility directly related with the three-
dimensional spatial disposition of the polypeptide. This in turn is influenced by structural 
factors such as conjugated moieties, [43] based branched polypeptides with Ser and 
Glu/Leu in the side chains} drug loadings, [44] drug ratios, [45] linking chemistry, and 
physico-chemical descriptors mediating the nano-bio interface. [17, 46] At this point, in 
vitro behavior of the conjugates cannot be explained by taking into account drug loadings 
and linking chemistry solely, although it seems clear that under the same PGA-Dox 
linking chemistry and drug loading, incorporation of AGM at different ratios or through 












Figure 6. Drug release kinetics in presence of Cathepsin B of PGA-(G-AGM)LL-Dox (D), PGA-(G-
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III.2.4. Antitumor Evaluation and Biodistribution of Selected Conjugates in 
a 4T1 Orthotopic Breast Cancer Murine Model 
The conjugation of active agents to a biodegradable polymer provides distinct 
advantages over conventional monotherapy strategies. These include passive 
accumulation of the combination conjugate in solid tumors thanks to the EPR effect [9, 
10] as well as the simultaneous delivery of both drugs at the tumor site of action. [16] 
Given tumor complexity, modulating the activity of two pathways will often provide 
greater therapeutic effects than monotherapies. In addition, polymer conjugation permits 
enhanced blood circulation times that allows sustained bioavailability and conjugate 
accumulation in tumor vessels, so leading to enhanced therapeutic output. The orthotopic 
mouse 4T1 breast tumor model has several characteristics that make an attractive 
experimental model to mimic breast cancer [47] including the well vascularized nature of 
the tumor, [48] which is a prerequisite for the EPR effect. 
In order to explore the antitumor effect of the nanosystems under study, we 
randomly split mice inoculated with 4T1 cells into representative groups and scheduled 
three treatments every three days with selected combination conjugates and their 
corresponding single conjugates at 10 mg/kg Dox equiv. We administered Dox as a free 
agent in a control group at the maximum non-lethal dose (3 mg/kg). [19] Analysis of 
tumor growth along time (Figure 7) demonstrated high intragroup uniformity allowing 
us to effectively evaluate the antitumor effect of different treatments. Treatment with the 
single conjugates bearing AGM, Dox, the addition of either single conjugate, or free Dox 
did not significantly affect tumor growth. However, we observed a synergistic antitumor 
effect in animals treated with the PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox 
combination conjugates, as compared with the single conjugates (alone or added 






Figure 7. Antitumor activity and safety of PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox in an 
orthotopic 4T1 breast tumor mice model (A) The combination conjugates PGA-(G-AGM)HL-Dox inhibited 
tumor volume growth more than PGA-(G-AGM)LL-Dox, the simple conjugate or the combination of the 
simple conjugates (PGA-(G-AGM)HL + PGA-Dox). Data represents mean ± SEM. Statistical significance 
was determined using an ANOVA t-test, (*** p<0.005, ** p<0.01). 
We also assessed safety profiles for all tested polymer-drug conjugates via the 
study of body weight, general wellbeing, behavior, and histopathology of specific organs. 
We did not observe significant alterations in body weight of treated animals (Figure 8) 
and histological study of the kidney and liver displayed no pathological tissue alterations 
related with any conjugate-based treatment, confirming the in vivo safety of this family 
of polymer-drug conjugates (Figure 10). Subsequent analysis of survival rates (Figure 
8) demonstrated that PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox treated mice 






Figure 8. A) Kaplan–Meier survival curves by treatment demonstrating improved overall survival for PGA-
(G-AGM)HL-Dox and PGA-(G-AGM)LL-Dox. The long-rank test demonstrated significant differences (p 
<0.0001). B) Animal body weight did not significantly decrease along the experiment. 
We next studied biodistribution and pharmacokinetics for a representative 
conjugate with high antitumor activity (PGA-(G-AGM)HL-Dox) and compared the 
treatment with conventional Dox intravenous (i.v.) administration as a monotherapy in 
















Figure 9. Biodistribution study of PGA-(G-AGM)HL-Dox and Dox was studied in an orthotopic 
4T1 breast tumor mice following iv injection in a tumor (A) and in blood and in heart, spleen, kidney and 
liver at 24h (B). The conjugate remained longer than Dox in the bloodstream (C) allowing sustained state 
for better tumor accumulation D) Pharmacokinetic parameters obtained from blood sample of mice i.v. 
administered with PGA-(G-AGM)HL-Dox analyzed by a bi-compartment model (n=5). 
Passive tumor accumulation reached a maximum accumulation time at 4 hours 
after i.v. administration (59-fold in comparison with free Dox, Figure 9A). We also 
detected conjugate accumulation in the heart and spleen, although at a significantly lower 
level (Figure 9B). Given the small size of the conjugate tested, we also expected kidney 
and liver accumulation due to renal excretion, as well as clearance by the 
reticuloendothelial system (Figure 9B, which may be promoted by the altered 
conformation of the combination conjugate. [49] To perform the pharmacokinetics study, 
we analyzed plasma samples of treated animals at different times (basal, 0.5, 1, 4 and 24 
hours) and quantified Dox accumulation by HPLC (Figure 9C). We observed a similar 
blood circulation time profile for the combination polymer conjugate in comparison with 
free Dox. However, while we did not detect Dox at 30 min post administration of the free 
Dox form, we did detect Dox following combination conjugate treatment, resulting in a 
9-times higher PGA-(G-AGM)HL-Dox accumulation half-life (t½α=0.4h) when 
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‡ PGA-(G-AGM)LL-Dox vs PGA-(G-AGM)LL + PGA-Dox
Parameter Value Unit
A 72.71 % ID/mL
α 1.72 1/h
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Figure 10. H&E staining of representative histological samples showed no pathological alterations 
associated with PGA-(G-AGM)HL-Dox treatment in clearance related organs (kidney and liver) when 
compared to untreated control mice 
 
III.2.5. Physico-chemical evaluation of selected conjugates and cellular 
uptake 
The conjugation of single drugs and combinations of drugs influences conjugate 
size and conformation, and these effects modify the biophysical properties and thus the 
pharmacokinetic and biodistribution profile of the resultant conjugate. Conjugated 
moieties introduce new spatial and charged elements that change the electrostatic 
equilibrium of the whole anionic polypeptide. [17] While the behavior of our conjugates 
in the animal model can be explained by the drug release kinetics, drug synergism 
profiles, and the in vitro analyses, any correlation between drug loadings, linking 
chemistry, and in vivo fate remains unsolved. Such correlations are driven by an intricate 
and complex interplay of interconnected factors. The lack of descriptive elements to 
predict biological output within this family of polymer-drug conjugates motivated us to 
carry out a more detailed physico-chemical characterization of the conjugates, looking at 
conformational and structural/morphological features that might allow us to rationalize 





      
Figure 11. Physico-chemical characterization of selected combination conjugates PGA-(AGM)LL-Dox, 
PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox. A) Circular Dichroism data on selected conjugates in 
phosphate buffer 10mM, pH=7.4 at 0,6mg/ml; B) Size distribution graphs in Number obtained by DLS in 
PBS at 2mg/ml. 
At the molecular level, secondary structure analysis by Circular Dichroism (CD) 
(Figure 11A) demonstrated that PGA-(G-AGM)LL-Dox clearly deviated from the 
expected random coil conformation of the polyanionic PGA towards a partial alpha-helix 
conformation. [50] We performed measurements in 10 mM phosphate buffer (pH=7.4) in 
order to avoid the influence of pH on PGA secondary structure. Therefore, we attributed 
the observed changes in conformation exclusively to the modifications performed. [51] 
PGA-(AGM)LL-Dox, demonstrated a trend towards an alpha-helix conformation. The 
native secondary structure expected for PGA backbone seems to govern the overall 
conformation with increasing hydrophilic Gly linker length. Interestingly, the percentage 




PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox demonstrated that the significant 
trend to partial alpha-helix structure can only be attributable to the increase of G-AGM 
moiety loading. G-AGM appears to partially shift the secondary structure to alpha-helix 
again, even more markedly than in the parent conjugate with direct attachment of drugs.  
In order to ascertain how these observations at molecular level correlate with the 
polymer-drug conjugate conformations adopted in solution, we studied selected samples 
by SANS. The scattering data obtained for PGA-(AGM)LL-Dox, PGA-(G-AGM)LL-Dox, 
PGA-(G-AGM)HL-Dox and PGA-(GG-AGM)LL-Dox are shown on a log-log plot in 
Figure 12. We fitted the data according to a broad peak model [52] (See section 
Materials and Methods III.4.6 for fitting details and complete analysis).  
 
Figure 12. SANS profiles and fitting. 
The predominant conformation of PGA in its protonated state in solution at low 
concentration is a helical structure at the molecular scale, giving rise to rod-like molecules 
at acidic pH, while random coil is the preferred conformation in the carboxylate form 
(pH>pKa). [51] These helixes associate in solution to form larger clusters that have an 
internal structure arising from alignment of the individual rod-like PGA molecules. Apart 
from the conjugate PGA-(G-AGM)HL-Dox (68 nm), the total size of the clusters is outside 
of the accessible Q range for SANS, in agreement with the Volume and/or Intensity data 
obtained by DLS where the large-sized aggregates population has a much pronounced 




However, detailed information can be provided on the alignment and spacing of 
molecules within the clusters. Due to the low drug loading and the single contrast (H-
conjugate in D2O), the PGA polymer backbone dominated the observed scattering. 
Hence, the SANS data provides information on how the drug and linker conjugation affect 
the PGA solution structure. The higher slope of the low Q scattering data (n) for the PGA-
(GG-AGM)LL-Dox, PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox conjugates, 
compared to PGA-(AGM)LL-Dox suggests a fundamental difference in structure of the 
aggregates formed by these conjugates. Fitting parameters for PGA-(GG-AGM)LL-Dox, 
PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox are indicative of more collapsed 
clusters (i.e. in the globular state with less free space within the scattering body). For the 
PGA-(AGM)LL-Dox conjugate, fitting data suggested a more open Gaussian-like 
structure at this length scale (i.e. that the clusters are likely to be less densely internally 
packed). This would be in agreement with the measured size distributions by number 
shown in Figure 11B, where the large aggregates are outweighed, and hence the 
predominant clusters sizing follow the trend PGA-(GG-AGM)LL-Dox < PGA-(G-
AGM)HL-Dox < PGA-(G-AGM)LL-Dox < PGA-(AGM)LL-Dox with the latter showing 
Rh size distributions of 100 nm in both number or intensity plots, in agreement with cryo-
transmission electron microscopy (TEM) (Figure 13A).. The Gly linker introduces a 
hydrophilic character in the AGM construct, and computed LogP values (a measure of 
hydrophobicity or hydrophilicity) for AGM (1.46), G-AGM (0.09) and GG-AGM (-1.06) 
demonstrated a significant reduction of hydrophobicity of AGM upon Gly incorporation. 
Hence, PGA-(AGM)LL-Dox had the highest hydrophobic character, displayed the highest 
propensity to aggregate (section III.4.8 of Materials and Methods), and also had the 
largest cluster size.  
In the high Q region of the SANS data, the experiment probes the arrangement of 
chains within the cluster. Conjugates with low loading of AGM attached by a Gly-Gly 
and Gly linker both gave a small, broad peak (centered at Q0 = 0.062 and 0.043 Å
-1, 
respectively) in the scattering data (Inset in Figure 12). This peak corresponds to a length 
scale of around 100-140 Å (2π/Q0) within the structure, which is attributed to regular 
spacing of adjacent rigid molecules within the cluster. The absence of a peak for PGA-
(AGM)LL-Dox and PGA-(G-AGM)HL-Dox indicated a loss of short range order within 
the aggregate, presumably as the effect of chain-chain charge interactions is outweighed 




smaller Q0 value for PGA-(G-AGM)LL-Dox agrees with the lower flexibility of the 
linking group (compared to PGA-(GG-AGM)LL-Dox) causing a greater perturbation of 
the PGA conformation. The peak observed in PGA-(G-AGM)LL-Dox is lost when 
increasing the AGM loading to form PGA-(G-AGM)HL-Dox. This further highlights 
drug-caused perturbation of PGA clusters.  
 
Figure 13. A) Representative Cryo-TEM image of PGA-(AGM)LL-Dox in H2O at 2mg/ml, scale bar is 100 
nm. B) Cellular uptake study of the selected conjugates by flow cytometry. Results are represented as the 
average of Cell associated fluorescence (CAF) ± SEM. (n=3). 
Taken together, these data indicate that direct conjugation of the AGM molecules 
(in addition to the Dox present in all conjugates) disrupts the ability of the PGA to adopt 
its preferred solution conformation. [37, 38] The flexibility introduced by the Gly-Gly 
linker allows the character of the polymer backbone to dominate the structures formed, 
with the conjugate containing Gly-Gly linker (most flexible) showing the scattering most 
similar to that of pure PGA (peak is present). [37, 38] With the Gly linker, at low G-AGM 
loading the Gly affords sufficient flexibility for the PGA to retain its internal ordering 
(peak), and the overall aggregated morphology (n-3). These data are consistent with CD 
spectroscopy that reports a range of helical content of the conjugates as discussed above 
(Figure 11A). Comparing the SANS data for these two conjugates, we start to see the 
influence of the additional G-AGM on the secondary structure. At low G-AGM loading 
the overall structure remains broadly similar to that expected for pure PGA, as described 
above. At high loading PGA-(G-AGM)HL-Dox, packing of the individual molecules in 
the clusters is less ordered, (loss of peak). This is presumably due to a reduction in PGA-




indicated by the peak at high Q. This lessened repulsion allows for closer association of 
the conjugate molecules, and the clusters become smaller and more globular (turnover at 
low Q). This smaller globular structure is a favorable result, as it is apparent that 
conjugates with such morphologies, as shown by SANS, give lowest IC50 values (Tables 
2 and 3).  
For the PGA-(AGM)LL-Dox, PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-
Dox the CD, DLS and SANS data can help to correlate structure, conformation and drug 
release studies with the biological output (Table 4). Results from in vitro and in vivo 
experiments suggest that the drug release profile is the main factor in the antitumor 
activity of this family of conjugates. However, for PGA-(AGM)LL-Dox exists evidence 
of a higher helical conformation and propensity to aggregate with the biggest cluster sizes 
and degradation of the PGA-(±G)-drug links is not (or certainly is less) inhibited. 
However, although this conjugate also displays by far the most efficient cellular uptake 
along the family, the simultaneous drug release and subsequent drug antagonism 
translates into low cytotoxicity. Combined with the identical polymer-drug linkages this 
accounts for the similar release profiles for both drugs. For the PGA-(G-AGM)LL-Dox, 
AGM was released preferentially to Dox. The more strongly helical structure of the 
individual PGA-(G-AGM)LL-Dox conjugate molecules indicated by CD supports the 
lower accessibility of Dox, and ordered spacing structures within the clusters suggests 
structure with greater accessibility for the cathepsin B cleaving group. It is more difficult 
to reconcile the release data for the PGA-(G-AGM)HL-Dox conjugate: lower release of 
AGM and high release of Dox. CD reports a helical structure at the molecular level, SANS 
reports disordered clusters of molecules that are smaller and more densely packed than 
PGA-(G-AGM)LL-Dox. Neither technique probes the detailed packing of the AGM 
around the PGA helix, but SANS assessments indicate that, at high G-AGM content, 
inter-molecular interactions are AGM, rather than PGA, dominated. Intra-molecular or 
indeed inter-molecular AGM-AGM interactions may somehow be screening the linkers. 
This might also be indicative of non-random distribution of the drug along the PGA chain 
at the higher loading either at outset, or induced as the drug loading changes at very low 
release levels. More detailed structural studies at key time-points would be required to 










We have designed a wide family of single and combination polymer-drug 
conjugates aiming for efficient antitumor treatment for breast cancer. Within the present 
family of PGA-AGM-Dox conjugates, we ratify the importance of the presence of both 
drugs in the same polymeric carrier that secures their co-delivery to the same cell. Of 
note, we paid special attention to the interplay between biological behavior and 
determinant physico-chemical properties. As expected drug ratio is a key feature ruling 
conjugate activity as seen for PGA-(G-AGM)HL-Dox vs. PGA-(G-AGM)LL-Dox in this 
case. More importantly, we discovered that the presence of the small and flexible Gly 
linker (the smallest amino acid, involving less than 1% of the total molecular weight of 
the conjugate) plays a decisive role in the structure of the whole macromolecule and hence 
significantly influences biological activity. The introduction of Gly induces a significant 
shift in drug release kinetics, size, secondary structure, and internal arrangement of the 
polypeptidic backbone as derived from the intensive CD, DLS, and SANS studies. The 
different configuration for Gly linker introduction (G or GG) between the polymer and 
AGM seems to modify the spatial disposition of the conjugate in such a way as to modify 
the disposition of the conjugate for the protease cleavage allowing a differential release 




that the kinetics of drug release is one of the major physicochemical descriptors to take 
into account when designing combination therapeutics.  
As seen within this work, the choice of linkers employed in the conjugation of 
active agents in a combination-polymer-drug conjugate can endow the complex 
macromolecular system with enhanced properties. In our family of conjugates the best 
performance was seen with PGA-(G-AGM)HL-Dox, conjugate bearing a 2:1 (AGM:Dox) 
drug ratio and Gly as AGM linker. This combination conjugate showed significantly 
greater antitumor effects than PGA-(G-AGM)LL-Dox (1:1 AGM:Dox ratio) and even 
more remark performance if compared with those with a direct AGM conjugation. 
 Our results lay the groundwork to move towards the efficient design of newer 
conjugates with more adequate linkers allowing enhanced spatio-temporal control on 
release profiles, seeking for synergistic effects and, therefore, improved antitumor effects. 
Our results also highlight the importance of an exhaustive supramolecular 
characterization to adequately compare in vitro and in vivo assessments. 
 
III.4. Materials and Methods 
III.4.1. Materials 
 
All organic solvents were of analytical grade purchased from Scharlab and used 
without further purification. All chemicals were of reagent grade and used without further 
purification and were purchased from Sigma-Aldrich otherwise stated. Poly-(alpha-L-
glutamic acid) (Mw: 12900Da, PDI: 1.2, 100 subunits per polymer, PGA100u) was 
obtained from Polypeptide Therapeutic Solutions SL (Valencia, Spain). Doxorubicin 
hydrochloride salt was purchased from Xingcheng Chempharm Co. Ltd (Zhejiang, 
China). Aminoglutethimide was purchased from Sigma-Aldrich. Anhydrous N,N-
Dimethylformamide (DMF, ≥99.8% anhydrous) was purchased from Scharlab SL 
(Sentmenat, Spain). 1-Hydroxibenzotriazol monohydrate (HOBt) was purchased from 
Iris Biotech GmbH (Marktredwitz, Germany). Deuterated dimethyl sulfoxide (d6-
DMSO) and deuterium oxide were purchased from Deutero GmbH. Ultrapure water with 




Preparative SEC was performed using either Sephadex® G-25 or Sephadex® LH-20 and 
were purchased from GE Healthcare Bio-Sciences AB (Uppsala, Sweden). 
Phenazinemethosulfate (PMS) was supplied by Sigma (Sp). Dulbecco’s Modified Eagle’s 
Medium (DMEM), Leibovitz, Phosphate buffer saline (PBS), Fetal bovine serum (FBS) 
Medium 200, Low Serum Growth Supplement (LSGS) and Trypsin, were provided from 
Gibco. (3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) was supplied by Promega (Sp). Oregon Green was purchased 
from Invitrogen. 
 
III.4.2. Physico-chemical characterization methods 
III.4.2.1. Ultraviolet-Visible Spectroscopy (UV-VIS) 
UV-VIS measurements were performed using JASCO V-630 spectrophotometer 
at 25 °C with 1.0 cm matched quartz cells and with spectral bandwidth of 0.5 nm. 
Determination of total AGM content by UV Spectroscopy.  
AGM or the corresponding amino acid-AGM derivative, X-AGM, were first 
prepared for use as calibration standards. A stock solution of AGM derivative in HPLC 
grade MeOH was prepared (1 mg/mL). To obtain a calibration curve samples were diluted 
using MeOH to give a concentration range of 0-50 μg/mL for AGM or 0-130 μg/mL for 
X-AGM. The total drug loading of the conjugates was determined by measuring the 
optical density at 254 nm in milliQ H2O. PGA in the same concentration range as the 
conjugates analyzed (0-5 mg/mL) was used as blank.  
III.4.2.2. High Performance Liquid Chromatography (HPLC) 
Analytical determination of total drug loadings and free drugs was performed on 
a Waters HPLC system provided with 2x515 binary pumps, autosampler 717 Plus, FLD 
2475 and PDA 2996. RP C-18 Lichrospher analytical column was employed (Scharlab). 
Chromatograms were treated with Empower 2.0 software (Waters).  
Determination of total Dox loading by HPLC.  
Aqueous solutions of PGA-X-AGM-Dox conjugates (1 mg/mL) were prepared, 




water. Then 1 mL of 2 M HCl was added and the tubes were heated at 80°C for 30 min 
in order to get Dox aglycone. After cooling down to RT. 1 mL 2 M NaOH and the pH of 
the samples was adjusted to 8,5 with ammonium formate buffer (100 μL, 1.0 M, pH 8,5). 
In parallel the same procedure was carried out for the parent compound Dox (using 100 
mL of a 1 mg/mL stock aqueous solution). Daunorubicin (Dau) was used here as internal 
standard; 100 mL of a 1 mg/mL stock aqueous solution was added to each sample. 
Samples were then thoroughly extracted by vortexing (3x10 sec). The upper aqueous 
layer was carefully removed and the solvent was evaporated under reducer pressure 
(speedvac). The dry residue was dissolved in 100 mL of HPLC grade methanol. Addition 
of 100 mL of methanol to redissolve the product gave a 100 mg/mL stock from which a 
range of concentrations were prepared (2-60 mg/mL). The amount of total drug was 
determined by HPLC using RP18 column (125x4 mm), with a flow rate of 1 mL/min and 
using a gradient elution [solvent A: 2-propanol/H2O 12:88 (v/v), solvent B: 2-
propanol/H2O 29:71 (v/v)] adjusted to pH=3,2 with orthophosphoric acid. The total run 
time was 25 min and the gradient profile was: t = 0 A 0%, t = 1 A 60%, t = 3 A 60%, t = 
8 A 0%, t = 18 A 0%, t = 20 A 100%, t = 20 A 100%. To monitor Dox and Dau standard 
a fluorescence detection at λ= 485 nm for excitation and λ= 560 nm for emission was 
used. Retention time (tr) was 15 min for Dox aglycone and 20 min for Dau aglycone. 
Determination of free Dox content by HPLC.  
100 μL of a known concentration of PGA-X-AGM-Dox conjugate was added with 
100 μL of NaHCO3 and 100 μL of Dau (1 mg/mL) as internal standard. Free Dox and 
Dau were thoroughly extracted with CHCl3:Isopropyl alcohol 4:1 (3x30 sec). The upper 
aqueous layer was carefully removed and the organic phase dried through N2 flow. The 
dry residue was dissolved in 100 μL of HPLC grade MeOH. In parallel the same process 
was also carried out with a mixture of Dox and Dau to construct a standard curve. The 
standards were dissolved in 1 mL of HPLC grade MeOH to give a 100 mg/mL stock 
solution from which a range of concentration were prepared (5-100 mg/mL). The amount 
of free drug was determined by HPLC using RP18 column (125x4 mm), with a flow rate 
of 1 mL/min and using a gradient elution [A: 2-propanol/H2O 12:88 (v/v), solvent B: 2-
propanol/H2O 29:71 (v/v)] adjusted to pH 3,2 with o-phosphoric acid. Total run time was 
42 min and the gradient profile was: t = 0 A 0%, t = 1 A 0%, t = 26 A 100%, t = 27 A 




fluorescence detection at λex = 485 nm for excitation and λem = 560 nm for emission was 
used. The tr was 20 min for Dox and 30 min for Dau. 
Determination of total AGM loading by HPLC, indirect analysis.  
The dried residue obtained from the conjugation reactions was dissolved in 
CH2Cl2 and all remaining precipitate was filtered off. AGM is completely soluble in 
CH2Cl2. The solvent was evaporated under reduced pressure and MeOH (10 mL) was 
added to make the stock solution. 3 different concentrations were injected to the HPLC 
(after filtered through 0,45 μm). The free amount of drug in the conjugate residues was 
determined by HPLC using a RP18 column (125x4 mm), with a flow rate of 1 mL/min 
and using a gradient elution [A: H2O milliQ+0,1%TFA, solvent B: ACN+0,1%TFA]. 
Total run time 25 min and the gradient profile was: t=0 A 90%, t=4 A 90%, t=19 A 10%, 
t=21 A=90%, t=25 A=90%, t=40 A 0%, t=42 A 0%. Oestradiol (1 μg/mL) was used as 
internal standard. A UV-Vis diode array (DAD) was used as detector. The retention time 
was 2 min for GGAGM, 6 min for G-AGM and 5 min for AGM. 
Determination of free AGM content by HPLC 
To evaluate the free drug, 100 μL of a known concentration of polymer conjugate 
was added with 100 μL of sodium bicarbonate and 100 μL of oestradiol (1 μg/mL) as 
internal standard. Free X-AGM and oestradiol were thoroughly extracted with a mixture 
(5 mL) of AcOEt : Isopropyl alcohol 4:1 (3x10 s). The upper organic layer was carefully 
removed and dried through N2 flow. The dried residue was dissolved in 100 μL of HPLC 
grade ACN. In parallel to construct a standard curve, the same concentrations used for 
the determination of the total drug loading were used to obtain an HPLC standard curve. 
100 μL of each concentration was added to a mixture of 100 μL of bicarbonate, 100 μL 
of oestradiol and 700 μL of milliQ H2O and thoroughly extracted as described above. 
The amount of free drug was determined by HPLC using the same HPLC protocol 
described for the determination of the total drug loading by HPLC (indirect measurement, 
see below). Retention time was 2 min for GG-AGM, 6 min for G-AGM, 5 min for AGM 





III.4.2.3. Matrix Assisted Laser Desorption/Ionization–Time Of Flight (MALDI-
TOF) 
1 μL of sample was spotted into the MALDI target plate. After droplets were air-
dried at room temperature, 0.5 μL of matrix (5 mg/mL CHCA (Sigma) in 0.1% TFA-
ACN/H2O (1:1, v/v)) was added and allowed to air-dry at room temperature. The samples 
were analyzed in a 4700 Proteomics Analyzer (ABSciex) in positive reflection mode 
(3000 shots every position) in a suitable range of mass. The samples were also analyzed 
in a 4700 Proteomics Analyzer (ABSciex) in linear mode (3000 shots every position) in 
a suitable range of mass. A matrix sample was analyzed under the same experimental 
conditions. 
 
III.4.2.4. Nuclear Magnetic Resonance (NMR) Spectroscopy  
NMR spectra were recorded at 27 °C (300 K) on an Avance III 500 MHz Bruker 
spectrometer equipped with a 5 mm TBI broadband probe or a 300 UltrashieldTM from 
Bruker (Billerica MA, USA). Data were processed with the software Mestrenova (Bruker 
GmbH, Karlsruhe, Germany). Samples were prepared tipically at 5mg/ml in deuterated 
solvents.  
 
III.4.2.5. Size Exclusion Chromatography (SEC) in aqueous media. 
SEC measurements in aqueous media containing 0.5 M of NaNO3 and 
0.005%(w/w) azide as an additive were performed in a AF2000 system from Postnova 
Analytics (Landsberg, Germany). The system was configured to work on SEC mode with 
an isocratic pump (PN1130) an autosampler (PN5300), a refractive index (RI, PN3150), 
21 angle-multi angle light scattering (MALS, PN3621) and a UV-Visible (PN3211) 
detectors. A working flow rate of 0.7 mL∙min-1 at 30 °C was employed with one TSKgel 
G3000PWXL column.  
 
III.4.2.6. Circular Dichroism (CD).  
CD Spectroscopy was performed with a J-815 CD Spectrometer (JASCO 
Corporation) using a Peltier thermostated cell holder (PTC-423, JASCO Corporation) 




L∙min-1) was lead through the spectrometer and controlled with a nitrogen flow monitor 
(Afriso Euro-Index). The samples were dissolved under different conditions (ddH2O or 
PB, and different concentrations ranging from 0.6mg∙mL-1). Samples were measured 
repeatedly (n= 3) in a quartz cuvette with d= 0.1 cm.  
III.4.2.7. Dynamic Light Scattering (DLS). 
DLS measurements were performed using a Malvern ZetasizerNanoZS instrument, 
equipped with a 532 nm laser at a fixed scattering angle of 173°. Solutions were sonicated 
for 10 min and allowed to age for the required time, filtered through a 0.45 μm cellulose 
membrane filter and measured. Size distribution was measured (radius, nm) for each 
polymer per triplicate with n> 3 measurements.  
- Size measurements, polymer solutions were prepared under different conditions 
(ddH2O, phosphate buffers or salt containing solutions, at different 
concentrations and temperatures), automatic optimization of beam focusing and 
attenuation was applied for each sample.  
- Critical aggregation concentration was evaluated through an already described 
method[53] using DLS by plotting the scattered intensity (mean count rate 
(kcps)) vs. the concentration.  
 
III.4.2.8. Cryo-TEM.  
Samples were vitrified in an FEI's vitrobot: A 60 μL drop of an aqueous 
suspension of the material was placed on a TEM holey carbon copper grid, excess of 
water was blotted away at the vitrobot with filter paper and the grid were freeze-plunged 
in liquid ethane. Samples were then transferred under liquid nitrogen atmosphere to a 
Gatan TEM cryo-holder equipped with a liquid nitrogen reservoir. After that, samples 
were transferred to a Tecnai T20 (FEI company) operated at 200 KV. All observations 
were done at low temperature (100 K). 
 
III.4.2.9. Small Angle Neutron Scattering (SANS)  
Small-angle neutron scattering (SANS) experiments were performed on the D11 
instrument at the Institute Laue-Langevin (ILL) in Grenoble, France. Sample solutions 
were prepared at a conjugate concentration of 10 mg mL-1 on a 1ml scale in D2O (pH=5.5, 




changer thermostatted at 37°C (± 0.2). Scattering data were corrected for the scattering 
and transmission of the solvent and quartz cell, and placed on an absolute intensity scale 
by reference to H2O. Three sample detector distances were used to cover a Q range of 
0.002 – 0.43 Å-1. Data were analyzed by a model fit using SASview. [54] 



























Figure 14. General synthetic scheme for the preparation of AGM-peptidyl derivatives 
 
Synthesis of Cbz-Gly-AGM 
 
Figure 15. Synthetic scheme for the preparation of Cbz-Gly-AGM. 
 
A solution of EDC (1.97 mmol, 377.8 mg) in dry DMF(1mL) was added dropwise 
to a solution of Cbz-Gly-OH (1.72 mmol, 361.12 mg) in dry DMF (10.0 ml). Activation 
was allowed to stand over an ice bath, under stirring and N2 atmosphere. 10 minutes later, 
Aminoglutethimide (1.64 mmol, 582,3 mg) was added and once dissolved, pH of the 
solution was adjusted to 8.0 by addition of some drops of DIEA. Reaction proceeded 
during 24 hours at room temperature under N2 atmosphere and then solvent was 
evaporated under reduced pressure. Viscose residue was partitioned between CHCl3 and 
water. The organic phase was washed with dilute HCl solution, water and dilute sodium 
bicarbonate to be finally dried over sodium sulfate. Solvent was evaporated and final 
white/yellow powder was obtained (yield = 80,8%) 1H NMR (300 MHz, DMSO) δ 10.83 
(s, 1H), 10.00 (s, 1H), 7.55 (dd, J = 17.1, 7.3 Hz, 5H), 7.25 (t, J = 10.7 Hz, 4H), 5.05 (s, 
2H), 3.80 (s, J = 6.1 Hz, 2H), 2.49 – 2.25 (m, 2H), 2.24 – 2.01 (m, 2H), 1.97 – 1.63 (m, 
2H), 0.75 (t, J = 7.3 Hz, 3H).13C NMR (75 MHz, DMSO) δ 177.62 – 174.91 (s), 173.19 
(d, J = 5.9 Hz), 168.76 (d, J = 48.6 Hz), 159.22 – 155.39 (m), 138.15 (t, J = 45.9 Hz), 
136.46 – 133.53 (s), 121.07 – 117.54 (m), 68.34 – 63.76 (m), 51.90 – 48.89 (s), 44.34 (d, 
J = 23.7 Hz), 34.25 – 31.32 (s), 29.47 (d, J = 13.6 Hz), 27.49 – 25.09 (s), 11.04 – 7.81 (s). 





Figure 16. 1H-NMR assignment for Cbz-Gly-AGM. 
 







Synthesis of Gly-AGM 
 
Figure 18. Synthetic scheme for the preparation of Gly-AGM. 
 
200 mg of 1a were dissolved in dry MeOH (20 mL) and a spoon of Pearlman’s 
catalyst, Pd(OH)2 over charcoal, was added. Reductive H2 atmosphere was established by 
careful purging and priming the flask. Methanolic suspension was stirred in H2 
atmosphere overnight. Carbon was filtered off with celite and solvent was evaporated 
under reduced pressure to yield brownish fine powder (yield = 91%) was characterized 
by 1H-NMR in d6-DMSO. 1H NMR (300 MHz, DMSO) δ 10.84 (s, 1H), 10.72 (s, 1H), 
8.42 – 8.06 (s, 2H), 7.71 – 7.50 (d, 2H), 7.28 (d, J = 9.0, 2.2 Hz, 2H), 3.76 (s, J = 10.5 
Hz, 2H), 2.36 (m, 2H), 2.21 – 2.01 (m, 2H), 1.94 – 1.65 (m, 2H), 0.75 (t, J = 7.3 Hz, 
3H).13C NMR (75 MHz, DMSO) δ 178.14 – 174.91 (s), 174.61 – 171.61 (s), 167.03 – 
162.97 (s), 137.43 (s), 136.24 – 133.76 (s), 129.18 – 125.65 (s), 121.37 – 117.84 (s), 52.65 











Figure 20. MALDI-TOF spectrum of Gly-AGM. 
 
Synthesis of Cbz-Gly-Gly-AGM 
 
Figure 21. Synthetic scheme for the preparation of Cbz-Gly-Gly-AGM. 
Synthesis of Cbz-Gly-Gly-AGM was carried out following the same procedure 
described for compound Cbz-Gly-AGM using Cbz-Gly-Gly-OH instead (1.72 mmol, 
361.12 mg). (yield = 80,8%) 1H NMR (300 MHz, DMSO) δ 10.82 (s, 1H), 9.90 (s, 1H), 




3.90 (d, J = 5.7 Hz, 2H), 3.69 (d, J = 6.1 Hz, 2H), 2.44 – 2.23 (m, 2H), 2.24 – 2.01 (m, 
2H), 1.96 – 1.63 (m, 2H), 0.75 (t, J = 7.3 Hz, 3H).13C NMR (75 MHz, DMSO) δ 175.61 
(s), 174.61 – 172.21 (s), 169.73 (s), 168.01 (s), 159.22 (s), 137.48 (d, J = 47.7 Hz), 134.80 
(s), 128.79 (s), 128.19 (s), 126.95 (d, J = 26.8 Hz), 121.37 (s), 67.82 (s), 52.65 (s), 45.06 









Figure 23. MALDI-TOF spectrum of Cbz-Gly-Gly-AGM. 
  
Synthesis of Gly-Gly-AGM 
 
Figure 24. Synthetic scheme for the preparation of Gly-Gly-AGM. 
 
Deprotection of Cbz-Gly-Gly-AGM was performed following the same procedure 
described for the deprotection of Cbz-Gly-AGM. Yield (76%) 1H NMR (300 MHz, 
DMSO) δ 10.76 (s, 1H), 10.21 (s, 1H), 8.72 (s, 1H), 7.66 – 7.48 (d, 2H), 7.31 – 7.10 (d, 
2H), 3.99 (d, J = 2.9 Hz, 2H), 3.56 (d, J = 22.4 Hz, 2H), 2.34 (t, J = 24.8 Hz, 2H), 2.24 – 
1.98 (m, 2H), 1.97 – 1.67 (m, 2H), 0.75 (t, J = 6.0 Hz, 3H). 13C NMR (75 MHz, DMSO) 
δ 176.24 (s), 173.01 (s), 168.90 (s), 138.01 (s), 135.56 (d, J = 90.9 Hz), 128.12 (s), 121.89 










Figure 25. 1H-NMR assignment for Gly-Gly-AGM. 
 
 




Synthesis of Cbz-Leu-Gly-AGM 
 
Figure 27. Synthetic scheme for the preparation of Cbz-Leu-Gly-AGM. 
 
The general coupling procedure described for compound Cbz-Gly-AGM was used 
to synthesize compound Cbz-Leu-Gly-AGM using Cbz-Leu-Gly-OH instead (1.72 
mmol, 361.12 mg). Yield=82%. 1H NMR (300 MHz, DMSO) δ 10.82 (s, 1H), 9.80 (s, 
1H), 8.46 (m, 1H), 7.62(d, 3H), 7.34 (d, 2H), 7.25 (d, 4H), 5.16 (s, 2H), 4.06 (dd, J = 14.7, 
8.1 Hz, 1H), 3.87 (d, J = 5.7 Hz, 2H), 2.38 (dd, J = 22.2, 4.9 Hz, 2H), 2.34 – 2.23 (m, 
2H), 2.22 – 1.98 (m, 2H), 1.95 – 1.74 (m, 1H), 1.65 (dt, J = 13.1, 6.5 Hz, 2H), 1.57 – 1.36 
(m, 1H), 0.88 (t, J = 6.8 Hz, 6H), 0.80 – 0.57 (m, 3H).13C NMR (75 MHz, DMSO) δ 
176.23 (s), 174.19 (s), 167.53 (s), 139.18 – 136.70 (m), 136.23 – 133.79 (m), 128.22 (dd, 
J = 42.8, 31.5 Hz), 127.75 – 126.37 (m), 120.81 (s), 80.58 (s), 65.71 (s), 54.79 (s), 50.04 






















Synthesis of Leu-Gly-AGM 
 
Figure 30. Synthetic scheme for the preparation of Leu-Gly-AGM. 
 
Deprotection of Cbz-Leu-Gly-AGM was carried out following the same 
procedure described for deprotection of Cbz-Gly-AGM to yield Leu-Gly-AGM. Yield 
(79%). 1H NMR (300 MHz, DMSO) δ 10.83 (s, 1H), 10.24 (s, 1H), 8.94 (t, J = 5.7 Hz, 
1H), 8.28 (s, 1H), 7.61 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H), 4.11 – 3.88 (m, 2H), 
3.85 (s, 2H), 3.63 (dq, J = 13.1, 6.5 Hz, 1H), 2.45 – 2.27 (m, 2H), 2.25 – 1.97 (m, 2H), 
1.93 – 1.79 (m, 1H), 1.76 – 1.62 (m, 2H), 1.57 (dt, J = 20.7, 7.0 Hz, 2H), 0.98 (t, J = 9.6 
Hz, 2H), 0.92 (t, J = 6.1 Hz, 4H), 0.75 (t, J = 7.3 Hz, 3H).13C NMR (75 MHz, DMSO) δ 
177.53 (s), 172.90 (d, J = 47.0 Hz), 170.92 (s), 168.44 (s), 138.85 (s), 135.84 (s), 127.51 
(d, J = 58.4 Hz), 121.58 (s), 51.15 (d, J = 24.0 Hz), 49.88 (d, J = 54.6 Hz), 44.07 (s), 32.57 
(s), 30.70 (s), 23.98 (s), 23.76 (s), 23.05 (s), 22.54 (s), 9.38 (s). MALDI-TOF: [M]+ + 
[H+]= 403.19; [M]+ + [Na+]= 425.18. 
 





Figure 32. MALDI-TOF spectrum of Leu-Gly-AGM. 
 
Synthesis of Cbz-Gly-Phe-Leu-Gly-AGM 
 
Figure 33. Synthetic scheme for the preparation of Cbz-Gly-Phe-Leu-Gly-AGM. 
 
Cbz-Gly-Phe-Leu-Gly-AGM was synthesized following the general coupling 
procedure previously described using Cbz-Gly-Phe-OH (1.72 mmol, 361.12 mg) and 
compound Leu-Gly-AGM(1.64 mmol, 582,3 mg). Final purification by silica gel 
chromatography was performed with CHCl2/MeOH 95/5 (v/v) as a mobile phase to yield 
the product as a fine brown oil (69% yield). 1H NMR (300 MHz, DMSO) δ 10.95(s), 
10.04 (s, 1H), 8.27 (m, 2H), 8.09 – 7.90 (m, 1H), 7.75 – 7.52 (m, 4H), 7.49 – 7.05 (m, 
10H), 5.24 (s, 1H), 4.71 (m, 1H), 4.41 – 4.19 (m, 1H), 3.98 – 3.73 (m, 2H), 3.73 – 3.46 
(m, 2H), 3.13 – 2.66 (m, 2H), 2.42 – 2.27 (m, 2H), 2.24 – 2.01 (m, 2H), 1.95 – 1.72 (m, 
2H), 1.69 – 1.57 (m, 1H), 1.55 – 1.44 (m, 2H), 0.99 – 0.81 (m, 6H), 0.80 – 0.62 (m, 




(s), 167.70 (d, J = 46.5 Hz), 138.84 – 136.95 (m), 134.86 (s), 129.66 (s), 129.36 – 127.54 
(m), 127.54 – 126.28 (m), 120.34 – 118.29 (m), 80.44 – 78.22 (m), 65.37 (d, J = 84.2 Hz), 
54.34 (d, J = 29.1 Hz), 51.28 – 49.39 (m), 32.59 (s), 29.55 (s), 26.51 (s), 24.55 (s), 23.44 
(s), 22.06 (d, J = 11.5 Hz), 9.45 (d, J = 13.2 Hz). MALDI-TOF: [M]+ + [K+]= 779.35; 
[M]+ + [Na+]= 763.18. 
 












Figure 35. 1H-1H COSY NMR spectrum of for Cbz-Gly-Phe-Leu-Gly-AGM. 
 
 






Synthesis of Gly-Phe-Leu-Gly-AGM 
 
Figure 37. Synthetic scheme for the preparation of Gly-Phe-Leu-Gly-AGM. 
 
Deprotection of Cbz-Gly-Phe-Leu-Gly was performed following the same 
procedure described for previous deprotection. No further purifications were required 
Yield=65%. 1H NMR (300 MHz, DMSO) δ 10.81 (S, 1H), 10.12 – 9.93 (d, 2H), 8.23 (m, 
2H), 8.03 (s, 1H), 7.61 (dd, J = 8.7, 2.3 Hz, 4H), 7.42 – 7.02 (m, 10H), 4.83 – 4.52 (m, 
1H), 4.32 (td, J = 14.4, 7.9 Hz, 1H), 4.05 – 3.74 (m, 2H), 3.60 – 3.42 (m, 2H), 3.25 – 2.67 
(m, 2H), 2.46 – 2.23 (m, 2H), 2.23 – 2.01 (m, 2H), 1.70 – 1.59 (m, 2H), 1.55 (dd, J = 15.1, 
7.7 Hz, 1H), 1.48 – 1.30 (m, 2H), 1.00 – 0.80 (m, 6H), 0.80 – 0.67 (m, 3H).13C NMR (75 
MHz, DMSO) δ 177.08 – 174.82 (m), 174.07 – 172.12 (m), 139.07 – 137.35 (m), 134.83 
(s), 130.44 – 129.16 (m), 128.53 (s), 126.96 (d, J = 24.7 Hz), 120.82 – 118.80 (m), 63.30 
– 61.79 (m), 55.19 – 53.68 (m), 52.71 – 51.21 (m), 50.98 – 49.25 (m), 34.16 – 31.75 (m), 
30.03 – 28.30 (m), 27.02 – 25.29 (m), 25.07 – 22.82 (m), 22.59 – 21.39 (m), 9.97 – 8.55 





Figure 38. 1H-NMR assignment for Gly-Phe-Leu-Gly-AGM. 
 




III.4.4. Synthesis of PGA conjugates as single and combination agents 
 
Figure 40. General synthetic scheme for the preparation of AGM-peptidyl derivatives 
 
Synthesis of single PGA-X-AGM conjugates 
Poly-L-glutamic acid (PGA) (0,51 mmol of glutamic acid units (GAU), 80,3 mg) 
was dissolved in anhydrous DMF (5 mL). Carboxylic groups were activated by adding 
DIC (0,808 mmol, 126,2 μL) and HOBt (0,808 mmol, 109 mg). After 15 min of 
activation, the required amount of compound 2 (0,0269 mmol eq. to GAU to reach 5 
mol% modification, 0,0538 for 10% modification) was added. The pH was controlled and 
adjusted with DIEA to pH8. The reaction was monitored by TLC and was left to react for 
36 h at RT, under stirring and dry N2 atmosphere. Then, DMF was evaporated under 
reduced pressure and the conjugate was precipitated over cold Diethylether/Acetone 4/1. 
Precipitate was stirred and isolated by centrifugation and dried under vacuum. PGA-X-
AGM sodium salt was obtained by dissolving in milliQ water with the addition of some 
drops of NaHCO3 1M until complete dissolution. Two purification steps (dialysis against 
water (membrane MWCO 3,5 KDa) and SEC in water (Sephadex G-25) were carried out 
in order to remove the excess of salt and any remaining impurities including free drug. 





Figure 41. 1H-NMR spectra of compounds 3 (PGA-X-AGM single conjugates. From top to bottom: 3e, 3f, 
3b, 3c, 3g).  
Synthesis of single PGA-Dox conjugates 
PGA (0,51 mmol of glutamic acid units (GAU), 80,3 mg) was dissolved in 
anhydrous DMF (5 mL). Carboxylic groups were activated by adding DIC (0,808 mmol, 
126,2 μL) and HOBt (0,808 mmol, 109 mg). After 15 min of activation, DOX.HCl 0,0269 
mmol, 14 mg) was incorporated to the reaction mixture and the pH was adjusted carefully 
with DIEA to 7.5-8. The reaction was monitored by TLC and left to stand for 36h at R.T. 
under stirring, dry N2 atmosphere and protected from light. DMF was evaporated under 
los pressure and the conjugate was precipitated over cold Diethylether/Acetone 4/1. 
Precipitate was stirred and isolated by centrifugation and dried under vacuum. PGA-X-
AGM sodium salt was obtained by dissolving in milliQ water with the addition of some 
drops of NaHCO3 1M until complete dissolution. Purification by SEC (Sephadex G-25, 
milliQ water as mobile phase) was carried out in order to remove the excess of salt and 
any remaining impurities including traces of activating agents or free drug. After 




Conjugation and purity was confirmed by 1H NMR (spectra of compounds 3a-f 
can be found in supporting figures section, Figure SI9) and SEC-UV also provided 
evidences of homogeneous drug conjugation along the Mw population.  
Synthesis of PGA-X-AGM-Dox combination conjugates 
PGA (0,51 mmol of glutamic acid units (GAU), 80,3 mg) was dissolved in dry 
DMF (5 mL). Carboxylic groups were activated by adding DIC (0,808 mmol, 126,2 μL) 
and HOBt (0,808 mmol, 109 mg). After 15 min of activation, X-AGM (0,0269 mmol,) 
was added. The pH was controlled and adjusted with DIEA to pH8. The reaction was 
monitored by TLC and was left to react for 36 h at Rt, under stirring and dry N2 
atmosphere. Small fraction was isolated and purified apart for further determination of 
drug loading. Carboxylic groups were reactivated again by a new addition of DIC and 
HOBt following the same procedure described before and DOX.HCl was added. pH was 
adjusted again to 7.5 - 8 with DIEA and the reaction was left to react for 36h more at 
room temperature protected from light and keeping N2 atmosphere and continuous 
stirring. The solvent was evaporated by high vacuum and polymer conjugate precipitated 
following the same protocol as for the single conjugates. Carboxylate salt form of the 
conjugate was obtained as described previously. Purification by SEC (Sephadex G25, 
milliQ water as mobile phase) was carried out in order to remove the excess of salt and 
any remaining impurities including traces of activating agents or free drug. After 
lyophilization, the reaction yield was around 75%. Conjugation and purity was confirmed 
by 1H NMR (spectra of compounds 4a-f can be found in supporting figures section, Figure 







Figure 42. 1H-NMR spectra of compounds 4 (PGA-X-AGM-DOX combination conjugates). From top to 
bottom: 4f, 4e, 4d, 4c, 4b. 
 
III.4.5. Histopathological analysis 
Organs expected to develop metastasis or pathological alterations, were removed 
from just euthanized mice at desired relevant time points. All the organs were washed in 
fresh PBS, carefully dried, weighed and fixed in paraformaldehyde (PFA) at room 
temperature for 24h. PFA was eliminated by successive washing with PBS, replacing 
completely the wash every time (5 times of 20 min, fast agitation), Once washed, organs 
were stored in a cold solution of PBS with 0.05% of sodium azide and preserved at 4ºC 
and darkness. Further inclusion in paraffin was preceded by several dehydration steps of 
2 min immersion in successive alcoholic solutions with increased degree (30%, 50% 70%, 
96% and 99.9%) and two final washes of 100% xylol. Afterwards, paraffin blocks were 
cut in 3um slides and placed in SuperFrost-plus glass slides for the hematoxylin-eosin 
(HE) staining. For this staining, the remaining paraffin from tissue slides was previously 
removed with xylene and then slides were rehydrated with a successive ethanol solutions 




samples were washed with DEM water (1.5min), blueing buffer (1min), and water 
(1.5min). Tissue slides were next incubated for 2 min in lithium carbonate and 
hydrochloric acid 0.25% in ethanol 70% to remove the possible excess of hematoxylin 
staining. Following, tissue slides were incubated with Dako Eosin for 2 min and the final 
dehydration was performed by washing with 96% ethanol (0.5min) and 99.9% ethanol 
(2.5min). The slide was finally assembled with Eukitt. For the image capturing, tissue 
slides were observed under the microscope and the ones of interest were scanned with a 
Panoramic 250 Flash III (3DHISTECH Ltd, Budapest, Hungary) and processed with 
CaseViewer software, from the same company. 
 
III.4.6. SANS Analysis 
The data for all samples clearly consists of two regions. At low Q values (<0.01 
Å-1), data presents as a straight line. This is indicative of Porod scattering where the slope 
(n) is given by scattering from either a mass fractal (n=1-3) or surface fractal (n=3–4). At 
high Q, the scattering data has a different pattern, with the data showing a steady deviation 
from linearity or, in some cases, exhibiting a small peak at Q ~ 0.06. Peaks such as these 
have been observed previously in scattering from unmodified polyglutamic acid at similar 
solution concentrations,[37, 55] with the exact Q value being dependent upon polymer 
concentration and degree of polymerization. Data were fitted according to a broad peak 
model,[52] described in equation 1, where the first term accounts for scattering at low Q 
(arising from larger polymer clusters). Ip(0) is the scattering intensity at q = 0 and n the 
fractal dimension. For long rigid structures n=1, increasing to 2 for Gaussian chains and 
tending towards 3 for collapsed polymer systems. The second term describes scattering 
from the solvated polymer chains. IL(0) is the scattering intensity at q = 0, ξ the correlation 
length, m the fractal dimension and Q0 the peak position. When no peak is present Q0 = 0 
and the model is reduced to that of the typical correlation length model.[56] 
For the PGA-(G-AGM)LL-DOX data, it can be seen on the figure that the 
scattering profile starts to curve at low Q values (< 0.0043 Å-1) with the intensity 
plateauing. This is indicative of the particle size approaching the Guinier regime and the 
overall polymer size being on the length scale accessible on the SANS Q range. In this 
instance, more information can be extracted and therefore, in place of the Porod 




equation 2. V is the excluded volume parameters, a the statistical length of the polymer 
chain and n the degree of polymerization.[57] 
The fitting parameters obtained from this model are the Porod exponent, n, which 
is related to the excluded volume parameter as m = 1/v and has the same meaning as in 
equation 1, and the radius of gyration though the equation 3. Fits to these models are 
presented in the figure and fit parameters given in the table above. 
 
Figure 43: Sans Analysis: top) fitting parameters for selected conjugates; bottom left) equations employed 
for the fitting; bottom right) The scattering data obtained for PGA-(AGM)LL-(Dox), PGA-(G-AGM)LL-
(Dox), PGA-(G-AGM)HL-(Dox) and PGA-(GG-AGM)LL-(Dox) are shown on a log-log plot in.  
PGA-(GG-AGM)LL-Dox n/a 3.2 1.4 16 0.062 0.0168 4.30E-08 0.042
PGA-(G-AGM)LL-Dox n/a 2.8 1.8 15.6 0.043 0.0257 1.66E-06 0.042
PGA-(G-AGM)HL-Dox 680 3 1.8 25.942 n/a 0.11 30.1* 0.04
PGA-(AGM)LL-Dox n/a 2.2 2.2 34 n/a 0.23712 5.80E-06 0.049
IP(0) Binc /cm
-1 
Rg (±10 Å) n m ξ ± 2 Å Q0 / Å
-1
IL(0)







+ 𝑏𝑘𝑔  …eq. (1) 






















III.4.7. DLS analysis in terms of intensity and volume 
Figure 44: Size by DLS of selected conjugates in terms of Intensity and Volume 
 
III.4.8. Critical Aggregation Concentration of selected polymer-drug 
conjugates 
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IV.1. Antecedents and Background 
The hypoxic and acidic environment of the tumor microenvironment (TME) 
promotes the survival of cancer cells in comparison to normal cells [1] and represents a 
crucial target for the newest generation of anticancer drug delivery systems (DDS). The 
higher glycolytic rate of tumor cells generates and sustains the acidic character of the 
TME [2] and provides a rationale for the specific design of targeted DDS. If properly 
engineered, nanoscale DDS passively accumulate within the TME of adequately 
vascularize tumors [3-5] by the enhanced permeability and retention (EPR) effect and the 
presence of pH-labile linkers within the DDS can then trigger conjugated drug release. 
Other than TME-targeting of pH-labile DDS, endocytic internalization promotes 
lysosomal degradation [6] of polymers such as poly-L-glutamatic acid (PGA), thanks to 
the presence of hydrolytic enzymes such as Cathepsin B [7]. 
 Our laboratory recently reported the development of PGA-based combination 
conjugates bearing a synergistic ratio of the anthracycline drug doxorubicin (Dox) and 
the aromatase inhibitor Aminoglutethimide (AGM) [8]. Specific engineering of the three-
dimensional (3D) conformation permitted similar optimal release rates for Dox and 
AGM, with release rate representing the parameter controlling drug-drug synergism [8, 
9]. This synergism translated to an enhanced antitumor efficacy in the orthotopic 4T1 
triple negative breast cancer (TNBC) preclinical model [10]. The release of both drugs 
via protease-cleavable drug linkers relied on the heterogeneous expression of various 
hydrolytic enzymes within the TME activity (at both the patient [11] and tumor level 
[12]). This fact highlights the need for patient stratification in DDS treatment cohorts, a 
requirement exemplified by clinical data obtained for Opaxio®, which displayed optimal 
activity in phase III clinical trials in premenopausal women with optimally high levels of 
estrogen to promote cathepsin B activity [13]. 
 We aimed to potentiate the therapeutic capacity of our previously described PGA-
combination conjugates by also promoting metastasis inhibition through the 
incorporation of a pH-labile linker for Dox (simple hydrazone moiety or complex EMCH 
[N-ε-maleimidocaproic acid hydrazide] moiety), while retaining the optimized glycine-
based linking chemistry for AGM [8], using our metastatic TNBC mice as preclinical 




metastasis in TNBC, a particularly aggressive breast cancer subtype that features a unique 
microenvironment distinct from that of other subtypes, especially when compared to 
Luminal A [14, 15]. Furthermore, due to molecular complexity and heterogeneity, TNBC 
lacks the targeted treatments available for other breast cancer subtypes. 
During this study, we discovered that low Dox loading and shorter hydrazone 
linkers yielded optimal antitumor and antimetastatic effects in our TNBC model. RNA 
sequencing (RNA-seq) analysis employed to explore the mechanism of action of TME-
targeted conjugates revealed the inhibition of metastatic pathways and the importance of 
immunomodulation. This powerful genomics tool allowed us to elucidate the functional 
aspects of gene expression driving cell death at the genome-wide level and the 
establishment of relationships with the physico-chemical descriptors. To the best of our 
knowledge, this study represents one of the few studies of this type within polymer 
therapeutics and demonstrates the enormous potential of polymer genomics [16] to 
















IV.2. Results and Discussion 
IV.2.1. Synthesis and Characterization of Polymer-drug Conjugates 
We previously demonstrated optimal therapeutic benefit with PGA-AGM-Dox 
combination conjugates presenting a differential (faster) Dox release rate when compared 
to AGM in an orthotopic TNBC model [10]. To enhance this effect, we incorporated 
hydrazone-based pH-sensitive linkers for Dox conjugation while retaining the original 
optimized linking chemistry for AGM (Gly-AGM). 
As demonstrated in Figure 1 and 2, we employed two different pH-sensitive 
hydrazone linkers: we used the direct conjugation through the C-13 Dox ketone [17] or 
conjugation employing a flexible, hydrophobic, and longer maleimido linker (EMCH) 
that we hypothesized would provide even faster Dox release. Direct conjugation required 
the previous modification of the PGA backbone with tert-butylcarbazate (Figures 3 and 
4). The EMCH spacer required the previous modification of Dox to obtain EMCH-Dox 
as well as previous modification of the PGA backbone with a PD moiety. The last stage 
involved the reduction of the disulfide bond to yield the conjugate through the thioether 
derivative (Figure 1). This Dox-linker strategy (Figure 5 and 6) has its origin in the 
development of Aldoxorubicin (formerly, INNO-206, EMCH-Dox) as a bovine serum 
albumin (BSA)-binding-Dox prodrug [18] and has been reported previously for a PGA-
based combination conjugate [19]. 
Additionally, to explore the effect of different Dox loadings and encouraged by 
preliminary results demonstrating enhanced cytotoxicity in the lower Dox loading range 
[8], we fixed G-AGM content in all combination conjugates at 10% mol, but varied Dox 
loading from 1% mol (Low Loading [LL]) to 3% mol (High Loading [HL]) (Table 1). 
Unfortunately, we could not generate the single conjugate incorporating a high loading 
of the bulky EMCH moiety (PGA-EMCHHL), most probably due to steric impediments. 
We performed the direct attachment of G-AGM and the precursor moieties (tert-
buthylcarbazate and PD) by carbodiimide coupling to achieve our combination (Figure 






Figure 1. Synthetic Scheme followed to achieve for Polyglutamate (PGA)-based single conjugates. i) 
DMTMM.BF
4
, DIEA, ahn-DMF, 15min, R.T. ii) t-butylcarbazate, 24h, pH=8, R.T.; iii) TFA, 30min, R.T.; 
iv) DOX.HCL, CH
3
COOH (cat.), 36h. and NaHCO
3 
(dil) v) Piridildithiol, 24h, pH=8, R.T.; vi.a) EMCH-
Dox, TCEP (cat.) and NaHCO
3 







Figure 2. Synthetic scheme followed to generate poly-L-glutamate (PGA)-based combination conjugates. 
i. a) DMTMM.BF4, DIEA, ahn-DMF, 15min, R.T. i. b) t-butyl carbazate, G-AGM, 24h, pH=8, R.T.; ii) 
TFA, 30min, R.T.; iii. a) DOX.HCL, CH3COOH (cat.), 36h. iii. b) NaHCO3 (dil) iv. a) DMTMM.BF4, 
DIEA, ahn-DMF, 15min, R.T. iv. b) Piridildithiol, G-AGM, 24h, pH=8, R.T.; v. a) EMCH-Dox, TCEP 







H-NMR characterization of intermediate products: A) PGA-NH-Boc, B) PGA-NH-NH
2
, and C) 
PGA-PD 
        
Figure 4. 
1
H-NMR characterization of intermediate products: A) PGA-(G-AGM)-NH-Boc, B) PGA-(G-
AGM)-NH-NH
2





Figure 5. EMCH-Dox synthetic scheme. 
 
 
Figure 6. EMCH-Dox and corresponding precursors. 
1
H-NMR characterization: A) 6-maleimidocaproic 
acid (300 MHz, CDCl
3
). B) Tert-butyl 6-maleimidocaprohydrazinecarboxylate (300 MHz, CDCl
3
). C) 6-









Figure 7. MALDI-TOF characterization of EMCH-Dox and corresponding precursors: A) 6-
maleimidocaproic acid, B) Tert-butyl 6-maleimidocaprohydrazinecarboxylate, C) 6-
maleimidocaprohydrazide, and D) 6-maleimidocaprohydrazone-Dox. 
 
We then carried out the physico-chemical characterization of all synthesized 
conjugates. Figure 8 depicts the spectra of representative conjugates with chemical shifts 
attributed to the incorporation of one or both drugs. The signal corresponding to the 
ethylene group ( 0.75ppm) and those at the aromatic region ( 7.5 ppm) indicated the 
presence of G-AGM. Dox aromatic rings signals appeared in the region of  7.0-8.0 ppm 
and the methylene group of the amino-sugar moiety at  1.25ppm. The conjugates bearing 
EMCH-Dox presented a characteristic ethylene signal of the EMCH spacer ( 3.3ppm) 
also present in the combination conjugate; however, the aromatic signals of the drug 
practically disappeared. Additionally, the broadening of polymer signals also represented 





Table 1. Physico-chemical characteristics of PGA-drug conjugates. ACalculated spectrophotometrically by 
UV-VIS, BAveraged form 1H-NMR and UV measurements, CSize by Number, and DCalculated according 
to the drug loading. 
We also employed 1H-NMR to evaluate single conjugates precursors, PGA-PD, 
PGA-NH-NHBoc, PGA-NH-NH2 (Figure 3), and the combination conjugates precursors 
PGA-(G-AGM)-PD, PGA-(G-AGM)-NH-NHBoc, and PGA-(G-AGM)-NH-NH2 
(Figure 4). Additional 1H-NMR assignments of final conjugates (Figures 8 and 12) can 
be compared with the corresponding spectra of the free parent drugs, demonstrating the 
presence of the drug within the nanoconjugate structure (Figure 9). 
 





Figure 9. : Dox (A) and AGM (B) 1H-NMR signal assignments. 
 
Size-exclusion chromatography (SEC) elugrams demonstrated single 
homogeneous Mw distribution by refractive index (RI), and no evidence of free drug 
presence (Figure 10). We note that the conjugation of one or both drugs did not 
significantly modify the Dh in solution by DLS (number), and most of the conjugates 
exhibited a monomodal averaged Dh of ~3-6 nm, except in the case of the single conjugate 
PGA-(Hyd-Dox)LL (Dh ~290nm) and the combination conjugate PGA-(G-AGM)-
(EMCH-Dox)LL (Dh ~18nm).  
Interestingly, DLS measurements regarding intensity (Figure 12), revealed a 
bimodal population distribution indicating the coexistence of unimers and aggregates. 
Although we expected the higher Dox-loaded conjugates and those bearing the 
hydrophobic EMCH linker to aggregate given the overall increased hydrophobicity, we 






Figure 10. SEC elugrams for parental PGA compared with single conjugates and combination conjugates, 
respecttively (RI detection, peak at 17.1 min corresponds to the counter-cation Na+). 
 
This counterintuitive finding may indicate that the overall aqueous solution 
conformation is driven by a complex interplay of dynamic factors (including the 
polyelectrolyte effect [20, 21]) and not only imposed by the hydrophobicity of the loaded 
drugs as a single factor [8]. We aim to undertake additional studies involving 
complementary techniques, such as in-flow fractionation techniques [20, 22] to reveal the 
contribution of both, hydrophobicity and polyelectrolyte effect to the global spatial 
arrangement of conjugated macromolecules. 
 




                
                  




     
Figure 13. 
1
H-NMR assignments of representative drug signals for the single (2. to 4.) and combination (5. 




IV.2.2. Dox Release Kinetics as a Crucial Feature Driving in vitro Output 
To understand the biological implications of different drug-linker use and drug 
loading/ratio in our conjugates, we performed cell toxicity assays in 4T1 murine breast 
cancer cells. Figure 14 depicts the in vitro effect of the PGA-(G-AGM)-(Hyd-Dox)HL, 
PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(EMCH-Dox)HL, and PGA-(G-AGM)-
(EMCH-Dox)LL combination conjugates. Cell viability assays demonstrated higher 
cytotoxicity for the PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-Dox)HL, and 
PGA-(G-AGM)-(EMCH-Dox)LL combination conjugates when compared with PGA-(G-
AGM)-(EMCH-Dox)HL, which displayed very low cytotoxicity.   
 
     Figure 14. Cell viability and drug release kinetic analyses for combination conjugates. Cell viability 
measured by MTS assay after 72 hours of treatment with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-
(Hyd-Dox)HL, PGA-(G-AGM)-(EMCH-Dox)L, PGA-(G-AGM)-(Hyd-Dox)HL or free Dox. Data 
expressed as mean ± SEM, at least n = 3 experiments per treatment. 
Although cytotoxicity assays provided non-statistically-significant differences at 
the range of concentrations tested, both combination conjugates incorporating low Dox 
loadings presented with trends towards higher cytotoxicity (IC50 = 0.13 g/mL and 0.45 
g/mL for PGA-(G-AGM)-(EMCH-Dox)LL and PGA-(G-AGM)-(Hyd-Dox)LL, 
respectively, vs. IC50=0.79 g/mL for PGA-(G-AGM)-(Hyd-Dox)HL) (Figure 15). In 
contrast with our previously reported PGA-(G-AGM)-Dox family [8], we did not observe 
any significant differences in cell toxicity between the single and the combination 
conjugates (Figure 16), indicating a lack of AGM:Dox synergism at the drug ratios 




            
Figure 15. IC50 values for free Dox and polymer-drug conjugates in the mouse 4T1 breast cancer cell line. 
 
Figure 16. Comparative cell viability study for the single and combination conjugates in mouse 
4T1 breast cancer cell line demonstrating lack of drug synergism. A) PGA-(Hyd-Dox)LL vs. PGA-(G-
AGM)-(Hyd-Dox)LL, B) PGA-(Hyd-Dox)HL vs. PGA-(G-AGM)-(Hyd-Dox)HL, C) PGA-(EMCH-Dox)LL 
vs. PGA-(G-AGM)-(EMCH-Dox)LL, and D) IC50 values of the single conjugates. 
 
To explain this biological/therapeutic output, we evaluated Dox release from the 
combination conjugates at physiological and acidic pH, as well as in the presence of 
Cathepsin B (Figure 17). As expected, we found differential release profiles depending 




(EMCH-Dox)LL combination conjugate displayed rapid Dox release at pH 5.0 during the 
first 8 h, reaching a maximum of 16%, and a slower Dox release (~2%) at physiological 
pH (7.4). Remarkably, the corresponding combination conjugate with higher Dox 
loading, PGA-(G-AGM)-(EMCH-Dox)HL, displayed almost no Dox release at pH 5 or 
7.4 (<1%) during the same time period (Figure 19). These results, together with DLS 
measurements (by number) (Figure 11), suggest a distinct conjugate solution 
conformation due to a different spatial arrangement of Dox molecules as a function of 
loading. We hypothesize that high loading of EMCH-Dox promotes a more condensed 
structure (lower Dh), with the hydrazone bond hidden from the acidic environment and 
thereby hindering Dox release. This may also explain the difficulty we faced when 
attempting to increase Dox loading. Therefore, we also hypothesize that low loadings of 
EMCH-Dox correlate with a more swollen structure (higher Dh), promoting a higher level 
of hydrazone exposure and Dox release. 
          
Figure 17. Kinetics of drug(s) release from PGA-(G-AGM)-(Hyd-Dox)LL under hydrolytic and 





Conjugates obtained by direct conjugation displayed similar Dox loading-related 
release behavior (Figure 18). The PGA-(G-AGM)-(Hyd-Dox)LL combination conjugate 
exhibited up to 10% Dox released at pH 5.0 within 8 h and less than 1% at pH 7.4. In 
contrast, the PGA-(G-AGM)-(Hyd-Dox)HL combination conjugate displayed only 2% 
Dox release at pH 5.0 within the same time frame. Independently of the Dox linking 
chemistry employed, lower loading correlated higher release rates, thereby explaining the 
differential cytotoxicity observed. For hydrazone-derivative conjugates, we did not find 
any differences by DLS regarding number. However, measurement by intensity suggested 
a higher aggregation tendency (larger Dh) for the combination conjugate bearing the lower 
Dox loading (PGA-(G-AGM)-(Hyd-Dox)LL when compared to the corresponding 
conjugate with higher Dox loading (PGA-(G-AGM)-(Hyd-Dox)HL.  
 
Figure 18. pH-dependent and Cathepsin B-dependent Dox and AGM releases of PGA-(G-AGM)-(Hyd-
Dox)
HL
; n = 3 experiments per assay. 
 
As we conjugated AGM through a pH-stable chemical bond, we expect AGM 
release from the PGA mainchain by cathepsin B-driven degradation [8]. Therefore, we 
expected much faster overall Dox release rates from Dox-hydrazone-bearing conjugates 
than AGM release (only influenced by protease presence). However, cathepsin B 
degradation studies with (PGA-(G-AGM)-(Hyd-Dox)HL (Figure 17) clearly 
demonstrated that this assumption was wrong and that the final conjugate solution 




this conjugate could be responsible for the lack of activity as well as drug synergism 
discovered. In the case of the most active conjugate, (PGA-(G-AGM)-(Hyd-Dox)LL, we 
observed similar results, however in this particular case, and we believe is the reason for 
the enhanced activity, Dox release profile was faster at very early time-points (at pH 5 as 
well as in the presence of cathepsin B, showing the preferential hydrolytic mechanism 
triggering Dox release) most probably due to a greater accessibility of the hydrazine 
triggered by a less compact structure. The final relative release profile comparing Dox vs. 
AGM could also explain the absence of drug synergism as we obtained an inverse relative 
bioavailable AGM:Dox ratio from that previously identified as synergistic [8]. 
 
Figure 19. A) pH-dependent Dox release of PGA-(G-AGM)-(EMCH-Dox)
LL
. B) pH-dependent Dox 
release of PGA-(G-AGM)-(EMCH-Dox)
HL.
n = 3 experiments per assay. 
In summary, the release kinetics findings correlate with in vitro results: the 
combination conjugate displaying the highest IC50 (PGA-(G-AGM)-(EMCH-Dox)HL) 
demonstrated almost no Dox release, while the conjugate showing the highest Dox release 
(PGA-(G-AGM)-(EMCH-Dox)LL) corresponded to the highest cytotoxicity. As 
demonstrated previously [8, 23], the selection of drug linkers, drug ratios, and drug 




macromolecular configuration, varying key parameters, including hydrodynamic size and 
drug release kinetics, which directly influence biological readout. 
IV.2.3. Study of Combination Conjugates Antitumor Activity and Safety in a 
Spontaneously Metastatic TNBC Murine Model 
The antitumor/antimetastatic effect of polymer-drug combination conjugates 
requires accumulation within the tumor site by passive (EPR effect) accumulation and/or 
active targeting. We and others have previously described the spontaneously metastatic 
4T1 TNBC murine model developed in immunocompetent BALB/c mice [10, 24, 25], 
which included the study of EPR effect [4]. This preclinical model faithfully mimics the 
human clinical scenario, offering an opportunity for reliable DDS in vivo testing [10]. 
To examine combination conjugate antitumor efficacy, we randomly distributed 
tumor-bearing mice whose volumes had reached ~0.1cm3 (maximal EPR effect [10]) into 
representative groups and scheduled four treatments every three days with the conjugates 
showing the best cytotoxic activity (at 10 mg/kg Dox equivalents) (Figure 20A). In 
addition, we administered Dox to a control group at 5 mg/kg and unconjugated PGA as a 
vehicle control at 25 mg/kg (maximum concentration used for the conjugates as a carrier). 
Both PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL combination 
conjugates exhibited substantial antitumor activity (50% tumor reduction compared with 
PBS-treated mice). Furthermore, we noted a similar decrease in tumor volume in the free 
Dox-treated animals. However, treatment with unconjugated PGA and PGA-(G-AGM)-
(Hyd-Dox)HL did not significantly diminish tumor growth when compared with PBS-
treated mice. In good agreement with our in vitro findings, we did not find improvements 
in efficacy when we administered the physical mixture of single conjugates (PGA-(G-
AGM) + PGA-(Hyd-Dox)LL) or the combination conjugate PGA-(G-AGM)-(Hyd-Dox)LL 
in comparison to the administration of the PGA-(Hyd-Dox)LL single conjugate, 
suggesting, in this case, that the presence of AGM plays a relatively minor role. As stated 
above, this result could be explained by the differential bioavailable drug ratio employed 
when compared to previous protease labile PGA-AGM-Dox conjugates [8] (Figure 17).  
To further understand the effect of our combination conjugates on tumor growth, 
we studied tumor density (Figure 20A) and the relationship between proliferation (via 




experimental endpoint. We did not observe significant tumor necrosis within the free 
Dox-treated animals, perhaps due to lower levels of drug persistence within the tumor 
stroma. However, treatment with the two combination conjugates displaying the most 
promising therapeutic effects (PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-
(EMCH-Dox)LL) led to the appearance of large necrotic tumor cores (Figure 21A) and 
optimal tumor growth inhibition (Figure 20A). Furthermore, these two combination 
conjugates inhibited the proliferation of viable outer cells (Figure 21A), indicating 
possible cell-cycle arrest induced by prolonged Dox exposure driven by both passive 
conjugate accumulation and sustained stromal release [26, 27]. Although necrosis is 
typically related with hypodense tissue regions, our analyses demonstrated higher 
necrosis in the denser tumors (~1.9g/cm3 vs. placebo ~1.4g/cm3). PGA-(G-AGM)-(Hyd-
Dox)HL treated tumors presented the lowest density, similar to the PBS control group 
(~1.3g/cm3) (Figure 20B). Of note, 4T1 tumors develop coagulative necrosis [28, 29] 
characterized by the preservation of the basic structural outline of the affected cells in a 
compact network and the accumulation of inflammatory cells [30]. Dox-related hypoxia 
[31] may lead to tumor tissue ischemia and thus to more hypoxic tumors resulting in 
increased coagulative necrosis and therefore, denser tumors. 
   
Figure 20. A) Tumor growth inhibition of previously selected polymer-drug conjugates. Data represent 
mean ± SEM. Statistical significance was determined using an ANOVA t-test, (* p<0.05, ** p<0.01, *** 
p<0.001). B) Evaluation of tumor density after different treatments. 
To assess safety, we systematically evaluated, body weight, general aspect, 
behavior, and post-mortem major organ weights of all animals employed. We observed 




Dox)LL, PGA-(G-AGM)-(Hyd-Dox)HL, or Dox, which displayed a 100% survival rate 
(Figure 21B). However, PGA-(G-AGM)-(EMCH-Dox)LL treated presented with 
lethargy, weakness, and slight dyspnea immediately following the third and fourth iv. 
administration, with only 50% of animals surviving (Figure 22A). Post-mortem organ 
analysis revealed increased relative liver weight in all animals compared to healthy (non-
tumor bearing animals) noting the largest relative liver weight increase in animals treated 
with PGA-(G-AGM)-(EMCH-Dox)LL. However, we note that animals treated with PGA-
(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(Hyd-Dox)HL, and Dox exhibited smaller 
increases in relative liver weight when compared to the PBS-treated (tumor-bearing) 
control animals, suggesting better overall anti-tumor activity. 
 
Figure 21.) A) Comparisons of H&E and Ki-67 axial sections of tumors with different treatments at the 
experimental endpoint. B) Relative mice body weight during treatments. 
Of the organs studied, histopathological analyses revealed treatment-related 
adverse effects in the liver, as noted, and the heart, one of the key organs that present 
anthracycline-related pathologies [32, 33]. The liver presented significant hydropic 
degeneration, suggesting possible treatment-associated toxicity (Figure 23) and hearts of 
animals treated with Dox presented with myocardial fiber tortuosity, interfibrillar edema, 
and abundant fibrosis as major cardiomyopathies (Figure 22C). Although we discovered 
some disperse regions presenting minor levels of fibrosis, we observed no other major 
Dox-related cardiomyopathies in animals treated with two most effective antitumor 
treatments (PGA-(G-AGM)-(EMCH-Dox)LL or PGA-(G-AGM)-(Hyd-Dox)LL). 
All combination conjugates demonstrated safer in vivo therapeutic characteristics 




Nevertheless, the PGA-(G-AGM)-(EMCH-Dox)LL combination conjugate-treated 
animals demonstrated low overall survival and some degree of hepatotoxicity. Of note, 
the PGA-(G-AGM)-(EMCH-Dox)LL combination conjugate exhibited the lowest Dox 
loading, and so, we required highly concentrated doses of the conjugate to reach desired 
Dox equivalents, which increased the final solution viscosity; a parameter with the 
potential to affect proper blood distribution. Second, the larger size and heightened ability 
of this combination conjugate to aggregate in solution might promote accumulation in 
other organs, as well as in the tumor. 
 
Figure 22. A) Kaplan-Meyer survival curves demonstrating the safety of the combination conjugates 
with the exception of PGA-(G-AGM)-(EMCH-Dox)LL, that shows only 50% of mice survival. B) Relative 
liver weight by treatments demonstrating tumor-related hepatomegaly in the PBS group, which was 
partially improved with Dox, PGA-(G-AGM)-(Hyd-Dox)HL, PGA-(G-AGM)-(Hyd-Dox)LL. Greater organ 
weight was related to the treatment PGA-(G-AGM)-(EMCH-Dox)LL. Statistical significance was 
determined using an ANOVA t-test (* p<0.05, ** p<0.01, *** p<0.001). C) Mice-treated heart sections 
showing Dox-induced cardiotoxicity using H&E and Masson’s immunostaining compared with the 
cardio-safety displayed by the combination conjugates.  
Livers from animals receiving PGA-(G-AGM)-(EMCH-Dox)LL, developed even 
higher hydropic degeneration (vacuolar degeneration), coinciding with organ swelling 
(Figure 23) when compared with free Dox treatment [32]. Chemotherapeutic drug-
induced hydropic degeneration occurs by direct and indirect toxicity mechanisms. The 
direct action causes increased cell membrane injury [34] leading to cellular injury (e.g., 
cisplatin and Dox). The indirect action includes the release of highly toxic and reactive 




increased influx of sodium and water causing cellular swelling. Therefore, enhanced liver 
toxicity and reduced overall survival might be the result of a sum of factors, such as the 
possible accumulation of this conjugate and corresponding Dox-associated toxicity in the 
liver.  
 
Figure 23. H&E staining of liver sections after the most relevant treatments.  
Overall, the PGA-(G-AGM)-(Hyd-Dox)LL combination conjugate displayed the 
greatest antitumor activity and the most significant inhibition of tumor cell proliferation 
without impairing safety, thereby demonstrating the benefits of the rationally designed 
polymer conjugation-based strategies. 
 
IV.2.4. Study of Antimetastatic Activity of Combination Conjugates and 
Effects on Extramedullary Hematopoiesis and Leukemoid Reaction 
Lung metastasis is the most common complication of breast cancer patients and 
is identified in 60-70% of all cancer patients [37]. During primary tumor progression, 
cancer cells escape from the tumor stroma and travel through the bloodstream or 
lymphatic system to generate metastatic foci within the lung parenchyma or in the 
subpleural region. The 4T1 orthotopic TNBC BALB/c murine model is suitable for 
antimetastatic nanomedicines validation as it faithfully mimics the human clinical 
scenario, including spontaneously metastatic to the lung [10, 24]. This model develops 
the first signs of lung metastasis around day three after cell implantation, although our 
scheduled treatment began on day eight (max EPR). As depicted in Figure 24A, the PGA-
(G-AGM)-(Hyd-Dox)LL combination conjugate displayed optimal antimetastatic activity: 
a 90% reduction in lung metastasis when compared with non-treated mice. The EMCH-




displayed the same antimetastatic potential as free Dox. Further histopathological 
analysis confirmed these results (Figure 24B); animal receiving PGA-(G-AGM)-(Hyd-
Dox)LL treatment (optimal antitumor combination conjugate) also displayed reduced 
subpleural and intraparenchymatous metastatic foci when compared with other 
treatments. 
 
Figure 24. A) Quantification of lung metastasis in response to treatment - metastasis was significantly 
decreased after the treatment with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(EMCH-Dox)LL and free 
Dox. Statistical significance was determined using an ANOVA t-test (* p<0.05, ** p<0.01, *** p<0.001). 
B) H&E histological analysis of representative lung lobes receiving different treatments. Red arrowheads 
indicate metastatic nodules identified under the microscope.  
Figure 25. A) Tumor-induced splenomegaly, demonstrating the maximum weight of spleen in control 




PGA-(G-AGM)-(Hyd-Dox)HL or PGA-(G-AGM)-(Hyd-Dox)LL, demonstrated significant spleen weight 
reduction. B) Histopathological examination of spleens of mice treated with different conjugates. 
Splenomegaly correlates with congested red pulp as demonstrated by H&E and CD23. 
4T1 tumor development blocks medullar erythropoiesis and, as a consequence, 
causes splenic and hepatic erythropoiesis which promotes acute splenomegaly in mice 
[10, 38, 39]. We evaluated the capacity of combination conjugates to reduce this 
secondary effect of tumor progression by examining spleen weights and histopathological 
features. As depicted in Figure 25A, we observed significant decreases in spleen weight 
in mice treated with PGA-(G-AGM)-(Hyd-Dox)LL, PGA-(G-AGM)-(EMCH-Dox)LL, or 
free Dox (the most effective antitumor treatments), with spleen weight in the PGA-(G-
AGM)-(Hyd-Dox)HL treated animals similar to PBS (tumor-bearing) animals. Further 
histopathological analyses confirmed previous findings (Figure 25B).  
We discovered severe congestion of the red pulp and hyperplasia due to elevated 
reactive hematopoiesis in the spleens of PBS control mice and the combination conjugate 
PGA-(G-AGM)-(EMCH-Dox)HL treated mice. Spleens from mice treated with Dox, 
PGA-(G-AGM)-(Hyd-Dox)LL, or PGA-(G-AGM)-(EMCH-Dox)LL displayed a partially 
restored splenic parenchyma. However, the severe leukemoid (leukocytosis) reaction 
observed in the PBS treated mice developed to a lesser extent in animals treated with Dox 






Figure 26. 4T1 tumor development produced acute lymphocytosis and leukocytosis (with major proportion 
of segmented neutrophils) as seen in the PBS-treated mice (A, B, C). Animals treated with Dox and PGA-
(G-AGM)-(Hyd-Dox)LL demonstrated a recovery to the normal levels of lymphocytes, leukocytes and 
segmented neutrophils. Statistical significance was determined using an ANOVA t-test (* p<0.05, ** 
p<0.01, *** p<0.001 and ****p<0.0001). 
The reduction in metastasis at the experimental endpoint might imply two 
different antimetastatic mechanisms induced by our combination conjugates. Greater 
anti-tumor activity (primary tumor), a reduction of tumor growth and tumor cell 
proliferation, may inhibit metastatic-related processes, including angiogenesis, migration, 
and/or epithelial-mesenchymal transition of tumor cells. Additionally, given the enhanced 
size in solution of the conjugates, the higher ability to aggregate and the accelerated Dox 
release kinetics of the low loading combination conjugates could promote accumulation 
in the lungs [40], leading to a direct effect on metastatic tumor cells. We hope that 
additional experiments focused on lung accumulation will corroborate these hypotheses. 
In summary, the combination conjugates with lower Dox loading exhibit higher 
antitumor and antimetastatic activity, coinciding with higher Dox release influenced by 
the conjugate solution conformation and tumor stromal features.  
 
IV.2.5. Transcriptomic study of Combination Conjugates 
IV.2.5.1. Gene Ontology Analysis 
To understand the molecular basis of the responses to the different combination 
conjugates, we performed RNA-seq analysis of tumors derived from treated animals and 
compared genes differentially expressed between each possible pair-wise comparison 
(Figure 27). In agreement with the above-described physiological characterization 
assays, we found that the highest number of differentially expressed genes, compared to 
the PBS control group, corresponded to the PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-
AGM)-(EMCH-Dox)LL combination conjugates. Of note, the PGA-(G-AGM)-(Hyd-
Dox)HL combination conjugate, which demonstrated no differences in tumor growth 
inhibition with respect to PBS control, displayed significantly lower numbers of 
differentially expressed genes when compared to other treatments. Therefore, we 




PGA-(G-AGM)-(EMCH-Dox)LL treatments to understand similarities and differences in 
molecular responses. 
 
Figure 27. A) Differentially expressed genes in different comparisons between conjugate-based treatments 
and PBS. B) Heat map of selected differentially regulated genes between P-(EMCH)LL vs. PBS, P-(Hyd)LL 
vs. PBS and P-(EMCH)LLvs. P-(Hyd)LL. P-(EMCH)LL = PGA-(G-AGM)-(EMCH-Dox)LL; P-(Hyd)LL = 
PGA-(G-AGM)-(Hyd-Dox)LL. 
GO enrichment analysis revealed the enrichment of 62 and five terms in genes 
that were up- or down-regulated, respectively, when comparing (PGA-(G-AGM)-(Hyd-




while 11 and 10 GO terms were enriched in up- or down-regulated genes between the two 
conjugates. 
 
Figure 28. Network visualization of the statistically significant GO terms grouped by hyper-categories. A) 
Venn diagram comparing the GO terms up or downregulated between PGA-(G-AGM)-(Hyd-Dox)LL- PBS; 
PGA-(G-AGM)-(EMCH-Dox)LL – PBS and PGA-(G-AGM)-(Hyd-Dox)LL- PGA-(G-AGM)-(EMCH-
Dox)LL paired comparisons. Red numbers: upregulated GO terms; blue numbers: downregulated genes. 
Networks were constructed from these results, and the more relevant are demonstrating similarities (C,E) 
and differences (B,D) between the two drug conjugates. Networks constructed through REVIGO web 




level. Nodes size indicates the frequency of the GO term in the EBI-GOA database. Edges indicates highly 
similar GO terms regarding the number of genes shared. (PGA-(G-AGM)-(Hyd-Dox)LL : P-(Hyd)LL ,PGA-
(G-AGM)-(EMCH-Dox)LL: P-(EMCH)LL). 
Upregulated processes common for PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-
AGM)-(EMCH-Dox)LL include chemotaxis, positive regulation of interferon-gamma-
mediated (IFN-γ) signaling pathway, response to interferon alpha (IFN-α), granzyme 
(GZMB)-mediated apoptotic signaling pathway, and autophagy of host cells, amongst 
others (Fig. 28D), indicating that treatment induced a shared activation signature related 
to inflammation, apoptosis induction and autophagy activation. 
Interferon signaling pathways (IFN-α and IFN-γ) are involved in immune 
response, inhibition of cell proliferation, inflammation, immune surveillance and tumor 
suppression by inducing the transcription of a number of IFN-stimulated genes [41]. 
Binding of IFN-γ and IFN-α to their respective receptors promotes the activation of 
PI3K/AKT and JAK/STAT pathways [41, 42], resulting in the synthesis of several pro-
apoptotic factors, but also inhibiting the synthesis of anti-apoptotic genes [43]. We also 
detected the upregulation of the GZMB-mediated pathway, a process that involves T-cell 
mediated cytotoxicity and perforin (PRF1)-GZMB-dependent killing of the cell through 
the induction of apoptosis [44], found in our enrichment results. Additionally, we 
identified the upregulation of autophagy, which is a different type of active programmed 
cell death [45]. Interestingly, both treatments caused a marked upregulation of T-cell 
chemotaxis; T-cell trafficking to and increasing the T-cell frequency at the TME is one 
of the major challenges for adoptive immunotherapy as a new strategy against tumor 
development and metastasis [46]. 
Taken together, these upregulated pathways indicate the contribution of different 
cell death mechanisms, including processes leading to apoptosis and others mediating 
autophagy, in both PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL 
treatments. 
Both treatments also provoked the downregulation of processes related to cell 
proliferation, intercellular signaling and metastasis, blood vessel development 
(angiogenesis), epithelial-mesenchymal transition (EMT), epithelial cell proliferation 






The link between angiogenesis and EMT is widely accepted, as the same factors 
that drive endothelial cells toward a pro-angiogenic phenotype may also drive epithelial 
cells toward a mesenchymal stem cell (MSC) phenotype. Thus, angiogenesis can be 
accomplished through endothelial sprouting or non-sprouting microvascular growth, 
similarly to how endothelial cells gain invasive and migratory properties to become MSCs 
[47 ]. In this context, EMT and angiogenesis have emerged as integral processes in the 
promotion of carcinogenesis [48, 49]. 
Genes related to “epithelial cell proliferation” involved in mammary gland duct 
elongation also displayed downregulated expression. This GO term includes may genes 
playing an important role in mammary gland organogenesis and development [50]. The 
mammary gland epithelium passes through several cycles of proliferation and cell death 
during pregnancy, lactation, and involution. However, many of the signaling mechanisms 
that control the initial invasion of the fat pad by the epithelium and regulate its continuing 
plasticity can be harnessed or corrupted by tumor cells to support their aberrant growth 
and progression towards invasion [51]. Accordingly, we hypothesize that at least part of 
the anti-cancer activity of our conjugates might be mediated by the inhibition in the 
proliferation of mammary gland cells. Additionally, the PGA-(G-AGM)-(Hyd-Dox)LL 
and PGA-(G-AGM)-(EMCH-Dox)LL combination conjugates downregulate the protein 
kinase C (PKC) pathway, which could imply deactivation of NF-κB signaling [52]. 
Overexpression of the factor NF-κB is frequently found in cancer and other inflammatory 
diseases, and a potential inhibition of NF-κB here could be an additional anticancer effect 
of our combinatorial therapy.  
As mentioned, we discovered a total of 67 GO terms (5 downregulated terms and 
62 upregulated terms) enriched in a comparison between PGA-(G-AGM)-(Hyd-Dox)LL 
and PGA-(G-AGM)-(EMCH-Dox)LL treated tumors. This indicates a stronger and more 
general effect of PGA-(G-AGM)-(Hyd-Dox)LL when treating tumor cells compared to 
PGA-(G-AGM)-(EMCH-Dox)LL. PGA-(G-AGM)-(EMCH-Dox)LL involves fewer 
targeted processes, such as stem cell proliferation and epidermal cell differentiation, 
indicating a role of this combination conjugate in reducing cancer cell growth (Figure 
28D). PGA-(G-AGM)-(Hyd-Dox)LL specifically activates general processes such as 




(Figure 28E), suggesting that the PGA-(G-AGM)-(Hyd-Dox)LL is more effective in 
provoking a general immune response that might contribute to fight tumor progression, 
improve health status of the individual and increase survival rates. In this sense, we 
observed higher survival rates of mice treated with PGA-(G-AGM)-(Hyd-Dox)LL, which 
corroborates this assumption. 
 
IV.2.5.2. Pathway Analysis Highlights Mechanistic Differences between PGA-(G-
AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL 
We used the PaintOmics 3 tool to create a mechanistic representation of some of 
the processes involved in the PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-
(EMCH-Dox)LL modes of action. PaintOmics 3 analysis confirmed and expanded GO 
enrichment results in relation to cell survival/apoptosis (Figure 29A) and inflammation, 
angiogenesis, and metastasis (Figure 29B), revealing additional similarities and 
differences between the two conjugates. 
We uncovered evidence of both conjugates inducing apoptosis through the 
activation of the GZMB) signaling pathway. Indeed, we found strong upregulation of 
GZMB and PRF1 for both treatments (Figure 29A, see first two columns of gene 
heatmaps); however, we also detected activation of the apoptosis extrinsic pathway, 
which involves the activation of cell surface death receptors (FAS, TNFR) by 
extracellular ligands such as FAS-L or TNF, resulting in the cleavage or activation of 
caspase-8 and a signaling cascade that culminates in cell death [53]. We note the strong 
upregulating of all these markers for both conjugates (Figure 29A). Additionally we 
demonstrated the differences between the two conjugates in the third column of the gene 
heatmaps (Figure 29A). PGA-(G-AGM)-(Hyd-Dox)LL exhibits consistent activation of 
typical pro-apoptotic markers such as tubulin alpha 1b (TUBA1B), poly(ADP-Ribose) 
polymerase 1 (PARP1), beta-actin (ACTB), and myeloid cell leukemia sequence 1 
(MCL1) (red in gene heatmaps).  
However, PGA-(G-AGM)-(EMCH-Dox)LL more frequently triggers the 
overexpression of cell survival and anti-apoptotic genes, including as B-cell lymphoma 2 




repeat containing 2 (BIRC2), mouse double minute 2 homolog (MDM2), and TNF 
receptor-associated factor 1 (TRAF1) (blue in gene heatmaps). 
 
Figure 29. Simplified representation of genes involved in processes affected for the PGA-(G-AGM)-(Hyd-
Dox)LL and PGA-(G-AGM)-(EMCH-Dox)LL conjugates. A) Processes related to cell survival and apoptosis 
and B) Inflammation, angiogenesis, and metastasis. Genes represented as heat maps: from left to right, 
log2-fold change values between PGA-(G-AGM)-(Hyd-Dox)LL- PBS; PGA-(G-AGM)-(EMCH-Dox)LL – 




Blue: downregulation in the first treatment of the pair; red: upregulation in the first treatment of the pair; 
blunt ends: negative relationship; arrowheads: positive relationship; green-background stars: Statistically 
significant differences between that pair in that gene (p < 0.01). 
From these observations, we hypothesize that PGA-(G-AGM)-(Hyd-Dox)LL 
treatment is not only stronger in provoking apoptosis through upregulation of 
proapoptotic processes, but also reduces the expression of genes related to cell survival 
and anti-apoptosis, jointly contributing to a robust apoptotic response. 
Pathway enrichment analysis also revealed stronger angiogenesis and 
inflammation activities for PGA-(G-AGM)-(Hyd-Dox)LL treatment than for PGA-(G-
AGM)-(EMCH-Dox)LL (Figure 28D). Prostaglandin-endoperoxide synthase 2 (PTGS2), 
a marker of pro-angiogenesis processes [54] that, although overexpressed for both 
conjugates, exhibited higher levels for PGA-(G-AGM)-(Hyd-Dox)LL treatment (Figure 
29B). Similarly, although inflammation was a hallmark of both treatments (Figure 28B), 
selected inflammatory biomarkers such as Interleukin (IL)1B, IL6, Interferon- and TNF-
 were upregulated following PGA-(G-AGM)-(Hyd-Dox)LL treatment compared to 
PGA-(G-AGM)-(EMCH-Dox)LL (Figure 29B), which might mediate the differential 
inflammatory response between the two conjugates. 
Protein tyrosine kinase 2 (PTK2) and the matrix metallopeptidases 1 and 9 
(MMP1 and MMP9) displayed higher levels in PGA-(G-AGM)-(EMCH-Dox)LL 
treatment (Figure 29B), suggesting that these genes might mediate the increased trend 
for heightened metastatic activity observed in PGA-(G-AGM)-(EMCH-Dox)LL treated 
tumors when compared to PGA-(G-AGM)-(Hyd-Dox)LL. 
 
IV.3. Conclusions 
Both experimental results and transcriptional analysis indicate that the two most 
effective conjugates, PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-(EMCH-
Dox)LL, target the TME to trigger a cascade of molecular events that promote tumor cell 
death (apoptosis and autophagy) and inhibit tumor-related activities, including metastasis 




However, we also highlight significant differences between the two combination 
conjugates: PGA-(G-AGM)-(Hyd-Dox)LL triggers a more intense immune response that 
might explain why recipient mice display a higher survival rate. Also, PGA-(G-AGM)-
(Hyd-Dox)LL leads to higher pro-apoptotic activity, lower anti-apoptotic signals, and 
inhibition of metastasis, which support the overall response to this treatment.  
We have also demonstrated the relative importance of targeting the TME for 
drug release and optimizing the bioavailable drug ratio in a combination therapy, 
highlighting the importance of a chemical rationale for polymer-drug(s) linker 
design. Adequate drug release kinetics represents a crucial parameter towards 
achieving an adequate safety:efficacy ratio and may secure an adequate therapeutic 
window for future treatments. 
Finally, this study also demonstrates the utility of side-by-side 
transcriptional analysis that serves to understand our results and promote the 
future design of advanced polymer-based DDS for the treatment of metastatic TNBC 
among others. 
 
IV.4. Materials and Methods 
IV.4.1. Materials 
All reagent grade chemicals purchased from Sigma-Aldrich were used without 
any purification. Poly-(alpha-L-glutamic acid) (Mw: 12900Da, PDI: 1.2, 100 subunits per 
polymer, PGA100u) was obtained from Polypeptide Therapeutic Solutions SL (Valencia, 
Spain). Doxorubicin hydrochloride salt was purchased from Xingcheng Chempharm Co. 
Ltd (Zhejiang, China). Aminoglutethimide was purchased from Sigma-Aldrich. 
Anhydrous N,N-dimethylformamide (DMF, ≥99.8% anhydrous) was purchased from 
Scharlab SL (Sentmenat, Spain). MTS reagent was supplied by Promega (Spain). 
Ultrapure Milli-Q water with a resistance of 18 MΩ.cm was used in all aqueous 
preparations (Millipore). Preparative size-exclusion chromatography (SEC) was 
performed using Sephadex® G-25 or Sephadex® LH-20 purchased from GE Healthcare 
Bio-Sciences AB (Uppsala, Sweden). Tert-butyl-carbazate and N,N-




Eagle’s Medium (DMEM), phosphate buffer saline (PBS), fetal bovine serum (FBS) 
medium 200, low serum growth supplement (LSGS), and trypsin were provided from 
Gibco. 
IV.4.2. Synthesis of Single Conjugates 
Synthesis of PGA-Hyd-Dox 
We employed an optimized protocol derived from a previously described strategy 
by Van Heeswijk in order to generate PGA-Hyd-Dox conjugates [17]. 
Synthesis of PGA-NH-NHBoc 
PGA (300mg, 2.32 mmol, 1.0 equivalents (eq.), 100 units, Mw~13 KDa) was 
dissolved in 10 ml of anhydrous DMF in an inert atmosphere with gently stirring. Then, 
the eq. for the required modification of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-
morpholinium tetrafluoroborate salt (DMTMM.BF4) was added (i.e. 15.34 mg, 0.116 
mmol, 0.05 eq. for 5% modification) to activate the carboxylic acid of the polymer. After 
15 minutes (min), tert-butyl-carbazate (NH2-NHBoc) (18.38 mg, 0.139 mmol, 0.06 eq. 
for 5% modification) was added and the pH of the reaction fixed to 8 by dropwise addition 
of N,N-diisopropylethylamine (DIEA) as a non-nucleophilic base. After 24 hours (h), the 
solvent was concentrated under reduced pressure and the oily product was isolated by 
three precipitations over cold diethyl ether. The resulting solid was washed with acidified 
water (pH~3) to remove traces of DMTMM activated ester. After freeze-drying, 5 mg of 
the resulting PGA-NH-NHBoc were dissolved in 500 l of 1.0 M deuterated sodium 
hydrogen carbonate (NaDCO3) and analyzed by NMR to ensure purity and to calculate 
the % of modification by 1H-NMR (Figure 3). 
Synthesis of PGA-NH-NH2 
Deprotection of the primary amine from PGA-NH-NHBoc was carried out by 
dissolving the resulting solid in trifluoroacetic acid (TFA) and stirring in a round bottom 
flask at room temperature (RT) for 30 min. The solution was precipitated twice over 
diethyl ether, washed twice with water, and then freeze-dried. The final % of hydrazine 
of PGA-HN-NH2 was determined by TNBSA (trinitrobenzene sulfonic acid) assay 




Synthesis of PGA-hyd-Dox 
Conjugation of Dox through an N-acyl-hydrazone bond was performed by 
dissolving 200 mg (1.55 mmol, 1.0 eq.) of PGA-NH-NH2 in 8 ml of anhydrous 
dimethylsulfoxide (DMSO) in an inert atmosphere with gently stirring. Dox (543.52 
g/mol, 1.5 eq. with respect to free –NH2 groups) was dissolved and 20 l of glacial acetic 
acid added dropwise to act as a catalyst. The reaction was allowed to proceed in darkness 
for 48 h at RT. The solution was then concentrated under reduced pressure and the viscose 
product precipitated twice over acetone/chloroform (4:1). The removal of unreacted Dox 
was performed twice by SEC with DMF as the mobile phase using a LH-20 gel. The first 
eluting fraction, corresponding to the acid form of the final conjugate, was collected and 
dried under vacuum and the water-soluble sodium salt form of the final product was 
obtained by dissolving the resulting solid in 0.25M NaHCO3. The last purification step 
was performed by SEC in Milli-Q water with G-25 resin. The first fraction containing the 
salt form of the final conjugate was collected and freeze-dried obtaining a red fine 
powder. 
 





Synthesis of PGA-(G-AGM) 
G-AGM and PGA-(G-AGM) were synthesized and characterized following a 
previously described protocol [8]. 
Synthesis of PGA-EMCH-Dox 
EMCH-Dox was prepared following a procedure developed by Willner and co-
workers [55] including some improvements to increase yield [56]. Final characterization 
(including 1H-NMR spectrum and matrix-assisted laser desorption/ionization time-of 
flight (MALDI-TOF) analysis) of all the intermediate products (as well as EMCH-Dox), 
matched previously described data (Figures 5-7). 
Synthesis of PGA-Pyridyl disulfide (PD) 
PGA (300mg, 2.32 mmol, 1.0 eq., 100 units, Mw~13 KDa) was dissolved in 10 
ml of anhydrous DMF in an inert atmosphere with gently stirring. Then, the eq. for the 
aimed modification of DMTMM.BF4 was added (i.e. 15.34 mg, 0.116 mmol, 0.05 eq. for 
5% modification) to activate the carboxylic acid of the polymer. After 15 min, pyridyl 
disulfide cysteamine HCl Salt (PD) (30.9 mg, 0.139 mmol, 0.06 eq. for 5% modification) 
was dissolved and the pH of the reaction was fixed to 8 by the dropwise addition of DIEA. 
24h later, the solvent was concentrated under high vacuum and the resultant product was 
purified by three precipitations over cold diethyl ether. The excess of activated DMTMM 
ester was removed by two washings with acidic water (pH~3). Once dried, 5 mg of 
resulting PGA-PD was dissolved in 1M NaDCO3 to ensure purity and to determine the % 
of modification by 1H-NMR. Additional measurement of PD modification was performed 
by full reduction of the disulfide and direct spectrophotometric measurement of the 





Figure 33. Representative example of indirect measurement of PD content of pyridyl disulfide by 
complete reduction to pyridine-2-thione 
Synthesis of PGA-EMCH-Dox 
PGA-PD (1.55 mmol, 1.0 eq) was dissolved in 10 ml of anhydrous DMF in an 
inert atmosphere. EMCH-Dox (750.76 g/mol, 1.5 eq. with respect to PD modification) 
was added to the solution and the reaction was initiated by the addition of tris(2-
carboxyethyl)phosphine (TCEP) (0.15 eq. with respect to the PD modification) as a 
reducing agent. The reaction was allowed to proceed for 48 h in the dark at RT. After this 
step, the solvent was evaporated under reduced pressure and the resulting viscose product 
was purified and analyzed by the same procedure previously described for the conjugate 
PGA-hyd-Dox.   
 
IV.4.3. Synthesis of Combination Conjugates 
Synthesis of PGA-(G-AGM)-Hyd-Dox 
We employed an optimized protocol derived from a previously described strategy 
by Van Heeswijk in order to generate PGA-Hyd-Dox conjugates [17]. Hydrazone-based 




tert-butyl-carbazate. Further Boc deprotection of the amino-group allowed final Dox 
coupling. PGA (300 mg, 2.32 mmol, 1.0 eq., 100 units, Mw ~13 KDa) was dissolved in 
10 ml of anhydrous DMF in an inert atmosphere. DMTMM.BF4 (0.3 eq.) was added to 
the solution and 15 min later G-AGM (0.164 mmol, 58.2 mg) and tert-butyl-carbazate 
(18.38 mg, 0.139 mmol, 0.06 eq. for 5% modification) were added. The reaction 
proceeded for 48 h and the workup was performed as already described procedure for the 
workup of PGA-NH-NHBoc. Once the stability of G-AGM in TFA was ensured (Figure 
34), Boc release was performed as for the synthesis of PGA-NH-NH2 (see section 2.3.1.2) 
and Dox was coupled through a hydrazone bond following the same procedure as for the 
synthesis of PGA-hyd-Dox. 
 
Synthesis of PGA-(G-AGM)-EMCH-Dox 
EMCH-Dox-based combination conjugates were synthesized by one-pot direct 
attachment of G-AGM and PD and further EMCH-Dox coupling through the reduction 
of PD. PGA (300mg, 2.32 mmol, 1.0 eq., 100 units, Mw~13 KDa) was dissolved in 10 
ml of anhydrous DMF in an inert atmosphere. DMTMM.BF4 (i.e. 15.34 mg, 0.116 mmol, 
0.05 eq. for 5% modification) was added to the solution and 15 min later G-AGM (0.164 
mmol, 58.2 mg) and PD (30.9 mg, 0.139 mmol, 0.06 eq. for 5% modification) were added. 
The reaction proceeded for 48 h and the workup was performed as for the PGA-NH-
NHBoc. An aliquot was isolated for G-AGM and PD loading determination. For EMCH-
Dox attachment, PGA-(G-AGM)-PD was dissolved in anhydrous DMF and EMCH-Dox 
(750.76 g/mol, 1.5 eq. with respect to PD modification) was dissolved and TCEP (0.15 
eq. with respect to the PD modification) was finally added as reducing agent. Boc release 
was performed as for the synthesis of PGA-NH-NH2 and Dox was coupled through a 






Figure 34. 1H-NMR proof of stability of G-AGM under TFA conditions for 4h. 
 
IV.4.4. Physico-chemical Characterization 
Quantification of Drug Loading 
AGM loading in single conjugates was determined by UV and 1H-NMR analyses. 
In the case of combination conjugates, AGM was quantified prior to the incorporation of 
Dox by the same procedure. A small aliquot of the final PGA-(G-AGM) or the precursors 
PGA-(G-AGM)-NH-NHBoc / PGA-(G-AGM)-PD were isolated, converted into salt 
form as described before, and purified. Samples were split and AGM loading was 
determined either by 1H-NMR or UV-VIS spectrophotometry. For NMR quantification, 
2O of each conjugate were prepared and protons from 
aromatic signals and from the methylene group allowed quantification. For UV 
quantification, a calibration curve of G-AGM in DMSO 50% (v/v) was performed with 
dilutions ranging from 0.05 to 0.065 mg/ml, measuring the absorbance at 246 nm using a 




conjugate were prepared and the AGM loading was calculated from the absorbance and 
the calibration curve. 
Dox loading in both single and combination conjugates was determined by 
measuring the absorbance of three aliquots of the conjugate (0.1, 0.25, and 0.5 mg/ml) in 
DMSO 50% (v/v) (λ = 480 nm) and by the use of molar absorbance of Dox in this solvent 
(20.280 L mol-1cm-1). 
Identity and purity confirmation by 1H-NMR  
NMR spectra were recorded at 27°C (300K) on an Advance III 500MHz Bruker 
spectrometer equipped with a 5mm TBI broadband probe or a 300 UltrashieldTM from 
Bruker (Billerica MA, USA). Data were processed with the software Mestrenova (Bruker 
GmbH, Karlsruhe, Germany). Samples were prepared at the desired concentration in 
D2O. 
Uniformity and Mw distribution by Analytical Size Exclusion Chromatography 
(SEC)  
SEC measurements were performed using PBS as mobile phase in an AF2000 
system from Postnova Analytics. The system was configured to work on SEC mode with 
an isocratic pump (PN1130) an autosampler (PN5300), and a refractive index (RI, 
PN3150) detector. A flow rate of 0.7 mL/min at 30°C was employed with one TSKgel 
G3000PWXL (Tosoh) column.  
Size measurements by Dynamic Light Scattering (DLS) 
DLS measurements were performed using a Malvern ZetaSizer NanoZS 
instrument with a 633 nm laser at a fixed emission angle of 173°. Conjugate solutions in 
PBS were sonicated until complete dissolution, filtered through a 0.45 µm cellulose 
membrane filter, and allowed to stabilize for 10-15 min prior to measurement. Size 
distribution was determined for each conjugate in triplicate. Automatic optimization of 
beam focusing and attenuation was applied for each sample. Each solution was analyzed 
6-8 times depending on the correlogram quality. Unless stated, the term size refers to 




IV.4.5. Cell Culture and In vitro Cytotoxicity Analysis of Conjugate 
The 4T1 cell line was maintained in RPMI supplemented with 10% heat 
inactivated FBS at 37ºC in a controlled atmosphere of air / CO2 (95/5 vol./vol.). Media 
was replaced every 48 - 72 hours and underwent passaging when 80% cell confluence 
was reached. Cytotoxic assays were performed according to a previously described 
protocol [8]. In brief, cells were seeded in sterile 96-well microtiter plates at concentration 
of 6,250 cells/cm2. Plates were incubated for 24 h and then solutions of free drugs and 
conjugates were tested at final concentrations ranging from 0 to 0.1 mg/ml of drug 
equivalents. After 72 h of treatment, cell viability was determined suing a Cell Titer 96 
Aqueous non-radioactive cell proliferation assay accordingly to manufacturer’s guidance. 
The optical density of each well was measured at 490 nm in a Wallac 1420 
spectrophotometer. Cell viability was expressed as a percentage of the viability of 
untreated cells established as control. 
 
IV.4.5.1. pH-dependent Drug Release 
Specific Dox release under mild acidic conditions was demonstrated in vitro by 
liquid-liquid extraction and further quantification by reversed-phase high-performance 
liquid chromatography (RP-HPLC). The conjugates were incubated in 50 mM PBS at pH 
7.4 and pH 5.0, mimicking the blood and tumor (and/or lysosomal) environment 
respectively. At determined time points, 100 l aliquots were made up to 1 ml with 
phosphate buffer pH 7.4 in a 15 ml tube. Then, 5 ml of CHCl3 was added and the mixture 
was vortexed for 60 seconds (s). The aqueous phase was removed and the organic phase 
was evaporated using a Speedvac concentrator. The resulting pellet was dissolved in 200 
µl MeOH HPLC-grade and 20µl aliquots were analyzed by RP-HPLC (Mobile phase: 
formate buffer pH 3.5 / Acetonitrile, 69:31 v/v, flow rate: 1.0 ml/min, diode array 
detector: 480nm, fluorescence detector: λex = 480nm, λem = 565 nm). A calibration curve 
was performed by successive analysis of samples ranging from 0.005 to 0.065 mg/ml of 
pure Dox in MeOH under the same experimental conditions. Retention time of Dox was 




IV.4.5.2. Cathepsin B-dependent Drug Release Kinetics 
Cathepsin B (5 U) was added to a solution of 2 mg of each conjugate, in 1 mL of 
a pH 6 buffer composed of 20 mM sodium acetate, 2 mM ethylenediaminetetraacetic acid 
(EDTA), and 5 mM dithiothreitol (DTT). The incubation was carried out at 37°C. 
Aliquots (100 l) were taken at times up to 48 h, immediately frozen in liquid nitrogen, 
and stored in the dark until assayed by HPLC as described above for pH-dependent drug 
release assay. The free drug (0.75 mg/mL) was also incubated under same conditions and 
later used as the reference control. 
 
IV.4.6. Establishment of Highly Metastatic 4T1 murine Breast Cancer Model and 
in vivo Validation of Conjugates 
6-8 week old female BALB/c mice used for all experimental procedures were 
purchased from Envigo Laboratories Inc. (Spain, EU). 4T1 orthotopic tumors were 
induced by the subdermal inoculation of 5 x 105 4T1 early passage cells suspended in 100 
µl of sterile MatrigelTM in the second left mammary fat pad of females under inhalatory 
anesthesia (3% sevoflurane in 100% oxygen). Tumors were morphometrically evaluated 
daily with an electronic caliper and tumor volumes were obtained by considering tumor 
shape as spheroids [8, 10]. 
 
IV.4.6.1. In vivo study at 10 mg/Kg Dox-equivalent dose 
Eight days before induction, tumor sizes reached 0.1 cm3 and mice were split into 
representative groups. Conjugate-based treatments were dissolved in sterile PBS and 
immediately injected intravenously (i.v.) in four doses of 10 mg/Kg of Dox equivalents 
every three days. Free Dox was dissolved in saline and administered at 5 mg/Kg as 
control, following the same schedule. Tumors were measured daily with a digital caliper 
before every treatment and daily after the last dose with tumor volumes calculated 
considering spherical growth by applying the formula: 4/3 x Π x (height /2 x length / 2 x 




implantation, mice were sacrificed using a CO2 atmosphere and major organs, tumors, 
and blood were extracted for further analysis. 
 
IV.4.6.2. Hematological Study 
Blood was extracted immediately after sacrificing mice by cardiac puncture with 
a 1.0 ml heparinized syringe and transferred to a 2 ml Eppendorf tube. Blood was gently 
homogenized and left to reach RT and then kept at 4 ºC until analysis (within the first 30 
min after extraction). Serum was isolated by centrifugation (4000 rpm, 10 min, 4 ºC) and 
analyzed using an automated hematologic analyzer (Sysmex XT-2000i).  
 
IV.4.6.3. Histopathological Study 
All tissues were washed in fresh PBS, carefully dried, weighed, and fixed in 
paraformaldehyde (PFA) at room temperature for 24 h. PFA was eliminated by successive 
washing with PBS (5 times x 20 min, rapid agitation). Once washed, tissues were stored 
in a solution of PBS with 0.05% of sodium azide as preservant at 4 ºC protected from 
light. Bone marrow samples were derived from femurs decalcified by immersion in 
Osteodec (BioOptica) for 8 h. A common dehydration and paraffin-inclusion procedure 
was carried out [10] leading to blocks that were sliced into 3-µm sections. Hematoxylin-
Eosin staining [10] and immunostaining were performed as required and the slides were 
assembled with Eukitt. Tissue slides were observed under the microscope and those of 
interest were scanned with a Panoramic 250 Flash III slide scanner and processed with 
CaseViewer software (both from 3DHISTECH Ltd, Budapest, Hungary). 
 
IV.4.6.4. Safety Evaluation of Treatments 
Treatments safety was evaluated by tracking body weight and comparisons with 
control and healthy animals, as well as further histopathological studies of key organs. 




conduct modification. Postmortem, major organs were also analyzed histopathologically 
for any treatment-derived damage.  
 
IV.4.6.5. Tumor Density 
Tumor density was obtained by simple arithmetic calculation and allowed us to 
elucidate differential stromal arrangement due to the different treatments. 
 
IV.4.7. Evaluation of the Antimetastatic Effect of Conjugates in the Lung 
Lung metastasis was evaluated following a previously described protocol [57] 
with several improvements. Lungs were removed immediately after animal sacrifice and 
washed in PBS. Tissues were then transferred to a P-6 plate previously filled with 3 ml 
of cold Hank's Balanced Salt Solution 1X (HBSS - Gibco) and washed twice. Over a new 
empty P-6 plate, organs were mixed with surgical scissors for 2 min and 2.5 ml of cold 
collagenase Type IV (Gibco 17104-019) was added to each well. The tissue mixture was 
transferred into a 15 ml falcon tube and incubated at 4°C for 90 min in a rotatory shaker 
at maximum speed. Once the digestion was finished, the largest tissue pieces were broken 
 nylon filter (Fisher). 
The filtered suspension was collected by adding 5 ml of HBSS 1X in the falcon and then 
centrifuged at 1,500 rpm (10°C, 5 min). Supernatant was removed and the pellet was 
washed twice with 10 ml of HBSS and the pellet was then suspended in 10 mL of medium 
(RPMI1640 + 10% FBS + penicillin/streptomycin + fungizone) and seeded in P-6 plates 
(1.4 ml each). The cells were incubated at 37ºC under 5% CO2 allowing uniform growth. 
After 5 days, every well was washed 3 times with PBS. 6-thioguanine resistant-
cells adhered to the plate and other cells could be easily removed. 2 mL of fresh medium 
and 2 l 6-thioguanine were added back and incubation was allowed to continue. 
Eleven days after seeding, cells were washed twice with PBS, trypsinized (700 l 
of trypsin), and resuspended in 800 l of medium. Finally, cells were counted with trypan 




IV.4.7.1. Extraction of RNA from Frozen Tumors and Sequencing 
Total RNA isolation was performed from 50 mg of previously pulverized frozen 
tumor employing the PureLink RNA Mini kit (Ambion-Life Technologies) following 
manufacturer’s recommendations. The On-column PureLink DNase Kit (Invitrogen) was 
used to purify the DNA-free RNA. The qualification and integrity of total RNA was 
performed with an Agilent Technologies 2100 Bioanalyzer (or 4200 Tape Station). 
TruSeq Stranded mRNA libraries were constructed and sequenced at Macrogen (Seoul, 
Korea) using an Illumina HiSeq4000 platform (paired-end with a length of 100 bp). 
 
IV.4.7.2. Mapping and Quantification 
Raw paired-end sequences were mapped against the mouse reference genome with 
STAR aligner software [58]. There was no need to trim or filter due to the high quality of 
the samples, checked with FastQC tool (URL: 
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The mapping step was 
completed with a mean of an 88% of uniquely mapped reads. The quantification of the 
transcripts was performed with RSEM software [59]. 
 
IV.4.7.3. RNA-seq Data Analysis 
Low count genes in RNA-seq count data were filtered with NOISeq package [60] 
and kept for the statistical analysis the 14,323 genes having an average of more than one 
read count per million reads in any of the four experimental groups. The resulting count 
matrix was normalized by the sequencing depth to make samples comparable. Data were 
transformed with the Voom approach [61] to get a normal distribution. The limma R 
package [62], which is based on linear models, was used to obtain the differentially 
expressed genes among experimental groups. We performed 5 different comparisons: 
PGA-(G-AGM)-(EMCH-Dox)LL, PGA-(G-AGM)-(Hyd-Dox)LL and PGA-(G-AGM)-
(Hyd-Dox)HL versus PBS (control), PGA-(G-AGM)-(Hyd-Dox)LL versus PGA-(G-
AGM)-(Hyd-Dox)HL, and PGA-(G-AGM)-(Hyd-Dox)LL versus PGA-(G-AGM)-




p-value [63] lower than 0.05 and an absolute log fold-change value higher than 0.5 were 
declared as differentially expressed. 
 
IV.4.7.4. Functional Analysis 
Gene Ontology functional enrichment analysis using the Fisher’s exact test was 
performed for genes selected (nominal p-value <0.01) at each of the above comparisons. 
Additionally, the log2-fold change at each pair wise comparison was calculated and 
exported to PaintOmics 3 [64] for KEGG pathway analysis. KEGG pathways were 
manually edited to improve interpretation of functional analysis results. 
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The experimental basis and research presented in this Thesis chapter correspond 
to a project nearing full development in the laboratory. Given the novelty, patentability, 
and robust antitumor and antimetastatic activities of one of the developed combination 
conjugates, we have protected some of the proceeding data.  
To this end, we have purposely omitted certain parts of the materials and methods, 
citations, chemical entities, drug structures and NMR assignations. Furthermore, some 
parts of the physicochemical characterization of the drug precursors and the final 
conjugates have been purposely removed to protect the identity of both drugs and the 
chemical modifications employed for the combination conjugates. 
We have purposely omitted the names of the two drugs involved in this study; 
these drugs are a Tyrosine-Kinase Inhibitor and a Topoisomerase Inhibitor. Therefore, 
we used the acronyms “TKI” and “TI” to refer both drugs, respectively, throughout. 
Despite this fact, we hope that the information provided will suffice for a complete 
understanding of the research rationale. Even given the relative incompleteness of our 













































V.1. Antecedents and Background 
As already stated in previous Chapters, the primary complication in the treatment 
of TNBC results from a lack of expression of the ER, PR, and HER2 hormonal receptors 
that impedes the administration of targeted therapies [1]. Owing to intrinsic 
characteristics such as extensive clinical heterogeneity, high metastatic capacity, rapid 
growth rates, and high risk of early relapse, monotherapies based on chemotherapy 
(topoisomerase inhibitors or TIs, in particular) represent the first line treatment for this 
aggressive breast cancer subtype [2]. 
Importantly, several studies have revealed low antitumor responses with single 
agents-based treatments, including chemotherapeutics, epigenetic treatments, or 
immunotherapies in most of TNBC subtypes. However, the co-administration of 
chemotherapeutic agents in a synergistic ratio can substantially improve clinical 
outcomes [3]. 
Among the therapeutic approaches for TNBC, the family of SRC (Proto-oncogene 
Tyrosine-protein Kinase) Inhibitors, a specific type of tyrosine kinase inhibitor (TKIs) 
deserves particular interest. SRC plays critical roles in cell adhesion and motility [4], 
which both represent important mechanisms for cancer progression and invasiveness. 
Accordingly, TNBC cell lines display high sensitivity to certain TKIs in preclinical 
studies [5]. Additional studies have indicated a heightened sensitivity of the 
mesenchymal-like TNBC subtype to TKIs [6], which may be explained by the 
overexpression of genes related to cell motility in this particular TNBC subtypes and the 
crucial role of SRC-family kinases in cell migration. 
Studies have reported robust drug synergism between TIs and TKIs [7]; however, 
only a few examples in the literature discuss combinations conjugated to drug delivery 
systems (DDS) for the treatment of breast cancer. These studies include non-
biodegradable polyethylene glycol (PEG)-ylated peptidic nanocarriers [8] or micelles [9] 
where the DDS physically entraps one or both drugs. 
 The conjugation of active agents to a biodegradable polymer provides distinct 




kinetics through the rational design of stimuli-responsive linking chemistry and the co-
delivery of both drugs at a desired synergistic ratio. 
We previously discussed both the advantages of combination therapies based on 
polymer-drug conjugates for breast cancer (Chapters 1, 3, and 4) and the importance of 
the rational design of newer biodegradable conjugates with enhanced drug linkers that 
permit improved spatiotemporal control on release profiles (a prerequisite for the 
maximization of synergistic effects) and, therefore, improved antitumorigenic capacity. 
Herein, we present the rational design of poly-L-glutamic acid-(PGA) based 
combination conjugates bearing a synergistic combination of a TI and a TKI, engineered 
with optimized drug linkers to maximize drug synergism. Additionally, we demonstrate 
cytotoxic effects in vitro and the antitumor and antimetastatic properties in vivo of 
selected combination conjugates. 
We focused on the mesenchymal-like TNBC subtype, which represents around 
20% of total TNBC cases. This particularly aggressive subtype is characterized by the 
expression of factors involved in cell motility, extracellular receptor interaction, cell 
differentiation pathways, and growth factor signaling pathways [10]. To reproduce the 
mesenchymal-like TNBC-subtype clinical scenario, we employed the human MDA-MB-
231-Luc cell line to test the cytotoxicity of our combination conjugates and to develop a 
spontaneously metastatic immunocompromised orthotopic murine model in NOD/SCID 











V.2. Results and Discussion 
V.2.1. Synthesis and Characterization of Combination Conjugates 
The conjugation of anticancer drugs to a biodegradable polymeric DDS through 
stimuli-responsive drug linkers that allow modulable release kinetics represents a proven 
approach for the effective synergistic co-delivery of drugs. We took advantage of the 
expertise acquired during this Thesis with regards to the development of different drug 
linkers (pH-stable amide, acid-sensitive hydrazone, and pH-sensitive ester linkers) to 
develop a new combination conjugate incorporating two synergistic anticancer drugs with 
optimal release kinetics to achieve drug synergism both in vitro and in vivo. 
The first synthetic approach (See Section V.2.3.) involved the direct attachment 
of both drugs to the polymeric backbone; the TI through an amide bond, employing the 
same procedure previously described (based on carbodiimide coupling) (See Chapter 
III), and the TKI through an ester bond. After the evaluation of the first approach, we 
decided to incorporate two different drug linkers to fine-tune combination conjugate 
pharmacokinetics; we attached the TI through the previously described hydrazone bond 
(see Chapter IV) while we modified the TKI with different alpha amino acids (α-aa) to 
achieve an ester bond of different stability (see section 2.4 and Materials and Methods). 
Figure 1 exhibits the synthetic scheme for the development of single and combination 
conjugates. 
As the UV spectra of the drugs employed presented overlapping profiles (Figure 
2) and so the peaks cannot be exclusively attributable to a single drug, we could not 
determine the drug loadings of the combination conjugates by direct measurement. 
Therefore, we implemented an elaborated procedure that allows this determination: we 
measured calibration curves of the TKI (λmax = 324nm) and the TI (λmax = 480nm) in 
DMSO 50% as shown in Figure 2A, B. These curves allowed for the determination of 
the molar extinction coefficient of both drugs at their respective absorption maximum. 
Then, we measured the absorption of the combination conjugate at 324 nm (λmax of the 
TKI) and we calculated the contribution of the TI at the same wavelength. Finally, by 
applying the Lambert-Beer equation, we calculated the concentration and, therefore, the 





Figure 1: Synthetic Scheme used to obtain single polyglutamate (PGA)-based conjugates (A and B) 
and combination PGA-based conjugates (C). A) i) t-butyl carbazate, anh. DMF, 24 h, pH=8, R.T. ii) 
TFA, 30 min, R.T. iii) TI, CH3COOH (cat.), 36h. and NaHCO3 (dil) B) i) TKI / aa-TKI, EDC, DMAP, C) 
i) t-butyl carbazate, anh. DMF. ii) TKI derivative, 24h, pH=8, R.T. iii) TFA, 30min, R.T. iv) TI, CH3COOH 






Figure 2. UV-VIS spectra of the TKI (A), the TI (B) and the overlapping of both spectra (C), demonstrating 
the overlapping signals of both species. D) Representative UV-VIS spectra of the combination conjugate 
PGA-TKI-TI at 0.1 and 0.25 mg.mL-1. 
 We carried out the identification and characterization of all synthesized 
conjugates by 1H-NMR and studied the size in solution and z-potential via dynamic light 
scattering (DLS). As shown in Table 1, we aimed for highly efficient conjugation as 
demonstrated by achieving 5 mol% drug loadings in all conjugates both for the TKI and 
the TI with great conjugation efficiencies. However, the direct conjugation of the TKI 
resulted in a reduced yield reaction in both the single and the combination conjugates 
after several improvement trials most probably due to steric hindrance. Interestingly, the 
yield improved significantly after the attachment of an amino acid linker.  
We also evaluated the hydrodynamic radius (Rh) in phosphate buffer (PB) and 
Milli-Q water (see Table 1). We observed an average Rh of 33-88 nm for conjugates in 
water. All the conjugates demonstrated smaller Rh in PB (around 3-10nm), as expected 




conjugates, probably due to intramolecular interactions. The analysis of z-potential 
revealed an overall negative charge for the polypeptide, with values ranging from -11 to 
-43 mV without a distinct relationship with the nature of the incorporated moieties. 
 
Table 1. Characteristics of PGA-TKI-TI polymer-drug conjugates. DLS determined by Number. C.E.= 
conjugation efficiency  
 
V.2.2. Establishment of an Optimized TI:TKI Ratio to Achieve Synergism 
On the basis of previous studies demonstrating drug synergism between TKIs and 
TIs in different breast cancer cell lines [7], we in vitro corroborated the results in two 
representative TNBC cell models: the murine 4T1 and the human MDA-MB-231-Luc 
models. The first columns in Figure 3 depict the cytotoxicity of both drugs administered 
simultaneously in both cell lines. 
Thanks to the versatility of polymer-drug combination conjugates and the rational 
design of drug linkers, we can optimize the entire system to promote the release of drugs 
at an adjusted ratio and relative controlled release kinetics always seeking for drug 
synergism.  
From our previous experience in this area, polymer-drug combination conjugates 
bearing certain TIs demonstrated enhanced antitumor effect following a high TI release 




with both drugs vs. the treatment of the TKI following an initial treatment with the TI 
alone. To determine the optimal synergistic ratio, we computed the combination index 
(CI) for each separate treatment schedule (CI >1 antagonism, CI <1 synergism). 
     
 
Figure 3. Assessment of the TKI and the TI combination in vitro cytotoxicity in 4T1 (A) and MDA-MB-
231-Luc (B) tested at different TKI/TI ratios. Data represents the cell toxicity when both drugs were 
administered simultaneously (“Simult. Admin.”) and with 24 h delay for the TKI administration (“TKI 
delay”). 
As depicted in Figure 3A, MDA-MB-231-Luc cells displayed higher sensitivity 
to the TI than to the TKI in vitro (as single agents). Co-treatment enhanced cytotoxicity 
at all ratios employed, thereby demonstrating drug synergism; however, TI treatment 
combined with delayed (24 hours) TKI treatment resulted in even higher percentage of 




(lowest CI) for a TI:TKI ratio of 1:5 and with delayed administration of TKI (Figure 3A). 
Following a similar assessment in 4T1 cells, we discovered that the TKI demonstrated 
higher cytotoxicity than the TI, while co-treatment led to higher cytotoxicity (and 
therefore better drug synergism) than that observed in MDA-MB-231-Luc cells. We also 
found in this case that the drug synergism at a 1:1 ratio was similar to that for TI:TKI 1:5 
and not significantly different were found with a delay in the TKI administration (Figure 
3B).  
Considering these results, we sought to improve synergistic effects by means of 
polymer conjugation under the hypothesis that anticancer activity will benefit from a 1:1 
TI:TKI ratio and ideally a non-simultaneous release preferentially being TI release 
required first.  
 
V.2.3. Synthesis and in vitro Evaluation of a TKI-TI Combination Conjugate 
via Direct Conjugation 
Trying to proof our hypothesis, and once we established a drug ratio that provided 
optimal synergism (1:1 TKI:TI), we directly attached (absence of drug linkers) both drugs 
to the PGA backbone. This procedure represented the most straightforward approach for 
chemical conjugation and allowed the assessment of possible drug synergism. We 
synthesized (see Figure 1) and characterized (see Table 1) a combination conjugate 
employing an ester bond for the TKI conjugation and a pH-stable amide bond for the TI  
conjugation. 
When studying the in vitro toxicity of our combination conjugate in MDA-MB-
321-Luc cells, we found similar cytotoxicity to treatments with a PGA-TKI single 
conjugate, the sum of single PGA-TKI and PGA-TI conjugates, and co-treatment with 
free drugs (Figure 4). While we found similar results in the 4T1 cell line, we did observe 
higher sensitivity to the combination of free drugs (Figure 5), in agreement with previous 
data. The lack of significant differences between conjugates and free drugs suggested the 
rapid release of the TKI and the absence of TI release from single or combination 





Figure 4. In vitro cytotoxicity of PGA-TKI-TI combination conjugate, the corresponding single conjugates, 
and the free drugs in the MDA-MB-231-Luc cell line.      
 
Figure 5. In vitro cytotoxicity of a PGA-TKI-TI combination conjugate, the corresponding single 
conjugates, and the free drugs in the 4T1 cell line.      
To explain our in vitro data and to mimic the degradative environment of the 
endocytic pathway, we performed in vitro drug release assays in the presence of the 




release from the directly coupled combination conjugate (Figure 6) in support of previous 
in vitro data. 
 
Figure 6. Drug release kinetics from PGA-TKI-TI in the presence of cathepsin B. Data expressed as mean 
± SEM, with at least n = 3 experiments per treatment. 
Taken together, these data establish several design implications for an advanced 
combination conjugate. First, a combination conjugate would benefit from a higher and 
more rapid TI release, as demonstrated by the in vitro assays (See Figure 3). Second, as 
previous studies demonstrated, a greater drug synergism would be achieved by a drug-
linker that could slow down TKI release. 
 In Chapter III, we implemented two different length hydrazone-based Dox 
linkers for its specific release in an acidic environment. The shorter hydrazone linker 
demonstrated not only more straightforward chemistry but also a safer in vivo profile and 
better in vivo performance. Consequently, we decided to incorporate a short hydrazone 
linker to enhance the TI release in this case; however, the incorporation of a drug-linker 
that delays the TKI release represented a more challenging task. 
 
V.2.4. Optimization of Polyglutamate-TKI Linker Looking For a Slow TKI 
Release 
In the hope of a modulated TKI release, we considered the incorporation of simple 
α-aa between TKI and the PGA backbone, in such way that stabilizes the ester bond, 




Acid-catalyzed hydrolysis of esters takes place via an AAC2 (acidic, acyl, 
bimolecular) mechanism as depicted in Figure 7. Although the hydrolysis rate is a 
complicated process dependent on factors such as the electrostatic effects of the 
surrounding substituents, the resonant effect, or the hydrogen bonding effect [12], it is 
assumed that the presence of bulky groups in the alpha position of the ester bond (R1 in 
Figure 7) decreases the decomposition rate [13, 14]. 
 
Figure 7: General scheme of the most common mechanism for acid-catalyzed ester hydrolysis, proceeding 
through a tetrahedral intermediate and acyl cleavage. 
    
Figure 8. A) General scheme for preparation of α-aa-TKI derivative. i) anh. DMF, ii) EDAC, DMAP iii) 
TKI, 8h, pH=8, R.T.; iv) TFA, 30 min, R.T. Gly-TKI, R= 0; Ala-TKI, R= CH3; Abu-TKI, R= CH2-CH3; 
Leu-TKI, R= CH2-CH-(CH3)2; Val-TKI, R= CH-(CH3)2; Phe-TKI, R= CH2-C6H5; B) Schematic 
representation of incorporation of α-aa with crescent bulkiness as TKI drug linker and the expected decrease 




Therefore, we hypothesized that the modification of the TKI through an ester 
bond, with α-aa of different bulkiness could yield a range of α-aa-TKI with different 
hydrolysis rates. Subsequent conjugation of prodrugs to PGA through a stable amide bond 
would then generate pH-sensitive single conjugates of the TKI derivatives.  
To this end, we selected six α-aa’s substituents with increasing volume in the 
alpha position and we expected decreasing hydrolysis rate of the ester as displayed in 
Figure 8 as the aa volume increased from Glycine (R = 0), Alanine (R = methyl), alpha-
aminobutyric acid (R = methyl), Valine (R = isopropyl), Leucine (R = isobutyl), and 
finally Phenylalanine (R = benzyl). 
 
Figure 9. pH-dependent release profiles of PGA-α-aa-TKI single conjugates. 
Once synthesized and adequately characterized (See Subsequent Section and 
Characterization table), we screened hydrolytic drug release at physiological pH (7.4) 
and at a pH characteristic of the tumor microenvironment (pH ~5). As seen in Figure 9 a 
non-linear relationship between bulkiness of the α-substituent and drug release kinetics 
at acidic pH was encountered. This highlights the multiple factors driving the overall 
conjugate solution conformation and how a simple amino acid incorporation can alter the 
conjugate tridimensional conformation, thereby varying the exposure of the drug linker 
modifying, therefore, the pH sensitivity (see chapter III). Among the observed pH-




aa-TKI single conjugates, the bulky amino acid valine promoted the slowest TKI release 
under the mildly acidic conditions compared to the other single conjugates. Furthermore, 
the PGA-Val-TKI single conjugate demonstrated the highest stability at physiological 
pH, a crucial requirement for any DDS to protect the cargo during blood circulation. For 
all these reasons, we proposed that the Val approach could meet the requirements for the 
new combination conjugates. 
We also studied the in vitro cytotoxicity of this family of PGA-α-aa-TKI single 
conjugates, to determine how the differences observed in the release kinetics could affect 
the in vitro activity. Even though we expected greater differences given the wide range 
of -aa-modified-TKI conjugates, we found similar toxicity profiles (Figure 10). 
However, a closer look when we examined the IC50 values allow to discuss several 
rational correlations with TKI release rates. PGA-Gly-TKI showed the lowest IC50, 
similar to free TKI (IC50=0.026 and IC50=0.025, respectively), in agreement with the 
fastest TKI release rate that correlates with the least hidden ester. PGA-Ala-TKI 
(IC50=0.035), PGA-Abu-TKI (IC50=0.039), PGA-Leu-TKI (IC50=0.041), PGA-Phe-
TKI (IC50=0.039) and PGA-TKI (IC50=0.033) showed slightly greater IC50 values 
corresponding to bulkier aa volumes and therefore greater ester protection. Finally, 
whereas PGA-Val-TKI is not the bulkiest aa, it showed the highest IC50 value 
(IC50=0.103) nicely correlating with the slowest TKI release. Therefore, it is clear that 
apart from alpha substitution there are other design features that drives ester stability [13, 
14], as for example the degree of substitution in the beta position of the aa (Val is the 
most substituted in such position (R = isopropyl) (Figures 7, 8)). 
 




On the basis of these findings, we decided to synthesize a combination conjugate 
with a pH-sensitive hydrazone for the TI and the Val-linker for the TKI. 
 
V.2.5. In Vitro Activity of TI-TKI Combination Conjugate with optimally 
designed linkers. Study of Drug Release Kinetics 
 
Initial in vitro cytotoxicity assays of the PGA-(Val-TKI)-(Hyd-TI) combination 
conjugate and the corresponding single conjugates in the MDA-MB-231-Luc cell line 
demonstrated enhanced biological performance for the combination conjugate as shown 
in Figure 11 (drug concentrations expressed in TI equivalents) and Figure 12 (drug 
concentrations expressed in TKI equivalents). Overall, the combination conjugate 
displayed slightly higher cytotoxicity than the physical mixture of the single conjugates. 
However, when computing the CI (See Tables in Figures 11 and 12), we noted a higher 
drug synergism for the combination conjugate, demonstrating the advantages of polymer-
based combination strategies. 
 






Figure 12. Cytotoxicity in TKI equivalents and combination index. n/a: not-applicable 
 
Drug release in the biological medium is driven by a complex interplay of 
physicochemical factors, including tridimensional conformation of the conjugate, 
interaction with blood proteins, or blood shear stress. [15-17] However, the study of drug 
release kinetics in vitro in the presence of the proteolytic enzyme cathepsin B 
(overexpressed in most solid tumors) provides a suitable model system to study 
pharmacokinetics for a lysosomotropic delivery mechanism. 
 
Figure 13. Drug release kinetics of the combination conjugate PGA-(Val-TKI)-(Hyd-TI) in the presence 





In vitro drug release kinetics of the PGA-(Val-TKI)-(Hyd-TI) combination 
conjugate demonstrated a sudden and rapid TI release over the first 8 h of incubation and 
a sustained release up to 72 h (6%). In contrast, the release profile of the TKI 
demonstrated a delayed and progressive release with respect to the TI, reaching 9% of 
drug release over 72 h. These results support the rational linker design approach followed, 
as the hydrazone linker incorporated for the TI promoted the required early faster release 
than the TKI, which presented an impaired release rate by the valine linker. 
Overall, we developed a combination conjugate bearing two anticancer drugs via 
rationally designed bioresponsive linkers that allow to deliver them at the appropriate 
relative bioavailable ratio to promote an enhanced synergistic effect.  
 
V.2.6. In Vivo Antitumor Activity of PGA-(Val-TKI)-(Hyd-TI) combination 
conjugate. 
To explore the antitumor effect of the developed conjugates, we employed 
previously established murine model (See Chapter II). We randomly split mice 
inoculated with the luciferase-transfected MDA-MB-231-Luc cells into representative 
groups and scheduled six treatments every four days with selected combination 
conjugates and their corresponding single conjugates at the optimized drug equivalents. 
We administered the TI and the TKI as free agents in a control group at the maximum 
non-lethal doses. Analysis of tumor growth vs. time (Figure 14) revealed high intragroup 
uniformity allowing us to evaluate the antitumor effect of the different treatments 
effectively. Treatment with the single conjugates bearing the TI, the TKI, the addition of 
either single conjugate, or free TI or TKI did not significantly affect tumor growth. 
However, we observed a significant reduction in primary tumor growth in animals treated 





Figure 14. In vivo evaluation of the combination conjugate PGA-(Val-TKI)-(Hyd-TI) and related single 
conjugates in an orthotopic MDA-MB-231-Luc murine model.  
 
We also assessed safety profiles for all tested drugs and polymer-drug conjugates 
by means of body weight monitoring and general wellbeing. We did not observe 
significant alterations in body weight in any of the animals treated with single or 
combination conjugates except a slight weight loss in the group of animals treated with 
PGA-(Val-TKI)-(Hyd-TI) (Figure 15A). However, the administration of free TI or the 
sum of the TI + the TKI at the same doses as the conjugates (in drug equivalents) led to 
an abrupt weight loss following the first dose that enhanced with the second dose (> 10% 
weigth loss) that resulted in some animals dead and obliged us to sacrifice the rest of the 
animals of those groups before day 10. Subsequent analysis of survival rates (Figure 15B) 
demonstrated a low survival rate for animals treated with free TI (both groups, TI and TI 





Taken altogether, these data demonstrated the therapeutic improvements 
obtained first upon polypeptide conjugation (safety), and more importantly following the 
incorporation of two synergistic bioactive agents in the same biodegradable polymeric 
carrier (therapeutic activity).  
 
Figure 15. Proof of safety of the polymer-drug conjugates: A) Body weight loss (relative to the initial 
body weight) during the experiment. B) Kaplan-Meyer survival rates of different treatments. 
 
V.2.7. In Vivo Antimetastatic Activity of PGA-(Val-TKI)-(Hyd-TI) 
combination conjugate. 
 
The MDA-MB-231-Luc orthotopic TNBC NOD/SCID murine model is suitable 
for antimetastatic nanomedicine validation as it faithfully mimics the human clinical 
scenario, including spontaneous metastasis to the lung (see Chapter II). This model 
develops profuse lung metastasis with concomitant axillary lymph node (ANL) invasion. 
Thanks to the luciferase transfection of MDA-MB-231 cell line, metastatic cells can be 
monitored by bioluminescence (BLI)-based imaging. As depicted in Figure 16, the PGA-
(Val-TKI)-(Hyd-TI) combination conjugate displayed optimal antimetastatic activity: a 




conjugates, the sum of single conjugates, and control (non-treated) mice. Additionally, 
the conjugate demonstrated better antimetastatic efficiency in ALN (Figure 16B). 
Interestingly, the single conjugates administered alone or in a physical mixture, produced 
an increase in either lung metastasis or ALN metastasis. Additional experiments are 
currently underway in order to understand this undesired effect. 
          
Figure 16. Study of metastasis inhibition. A) Lung metastasis; B) Ex-vivo lung metastasis by means of 
BLI C) ALN metastasis  
 
V.3. Conclusions 
Effective systemic treatments for TNBC require multiple targeted approaches, 
given its heterogeneity and molecular complexity. Encouraged from promising studies in 
the laboratory, we incorporated two synergistic drugs: a TI (having the ability to kill cells 
undergoing DNA replication, stopping the reading of the DNA for protein production, 
and blocking repair of DNA damage) and a TKI, (that compete with the ATP binding site 
of the catalytic domain of several oncogenic tyrosine kinases, impairing key processes in 




communication) to a biodegradable polymeric carrier, polyglutamate,  that accumulates 
specifically in the tumor after i.v. administration, once the EPR takes place.  
The polymer-drug conjugate arose from the direct drug attachment to the polymer 
lacked for drug synergism due to an inappropriate pharmacokinetics. Taking advantage 
of the multivalency of the PGA as carrier, we followed a rational design to promote and 
improve drug synergism by the incorporation of a hydrazone linker for the TI (that 
promoted a fast TI release as seen in Chapter IV) and a Val linker for the TKI (that delayed 
TKI release), meeting, therefore, the design requirements previously observed in our in 
vitro studies with free drugs. This optimized combination conjugate demonstrated an 
enhanced anticancer effectiveness in a human TNBC immunodeficient mice model, 
leading to a 50% of primary tumor growth reduction with almost total remission of lung 
metastasis. 
In order to complement this research, additional histopathological studies are 
currently being conducted, looking for cancer cell proliferation in primary tumors and 
metastasized lungs and the possible damage/improvement on major organs.   
Interestingly, after treatments with both of our single conjugates PGA-Val-TKI 
and PGA-Hyd-TI separately or in physical mixture, we observed an apparently pro-
metastatic behavior in lungs, while we do not found antitumor benefit for those 
conjugates. Because metastatic disease is the major cause of cancer-related mortality and 
is currently incurable, it is critical that we develop strategies to prevent progression of 
cancer to the metastatic stage and to prevent further spread from already existing 
metastatic foci. Our combination conjugate succeeds in metastasis inhibition, but the fact 
that our single conjugates positively modulates metastatic spread, suggest the possible 
activation of any prometastatic mechanism related to the physicochemical properties of 
the conjugates, their pharmacokinetics or combination of both, and this must be 
elucidated. 
Several studies with anticancer treatments such as paclitaxel and other 
chemotherapies modulate the tumor microenvironment and promote breast cancer cell 
intravasation and dissemination to distant sites [18-20]. To explain this, is generally 
proposed a mechanism through which tumor cells from primary breast lesions may 




microenvironment of metastases (TMEM). The particular physico-chemical 
characteristics or drug-release kinetics of our single conjugates could modulate the tumor 
microenvironment in this way. Other possible explanation could involve the activity of 
tumor macrophages.[21] As response to the presence of the tumor, classically activated 
(M1) macrophages are activated by IFN-γ, LPS or TLR ligands, secrete pro-inflammatory 
cytokines and play tumouricidal roles. Alternatively activated (M2) macrophages are 
activated by IL-4 and IL-13, secrete anti-inflammatory cytokines IL-10 and TGF-β and 
play tumourigenic roles. However, the so called tumor-associated macrophages (TAMs) 
display M2-like phenotype and exhibit pro-tumourigenic features. It has also been 
described how certain chemotherapies could reprogram these TAMs and how TAMs are 
able to facilitate metastasis progression. [22] 
In order to explain this behavior, additional deeper in vivo validation of our 
treatments in an immunocompetent TNBC mice model is currently being accomplished, 
with the aim of evaluate the effects of the treatment at immune system level and reveal 
its possible relationship with cancer cell dissemination.  
 
V.4. Materials and Methods 
 
V.4.1. Materials. 
All chemicals were reagent grade and used without further purification, unless 
otherwise indicated. All solvents were of analytical grade. Preparative SEC was 
performed using Sephadex G-25 medium from GE as well as PD MiniTrap G-10 ™ 
columns containing 2.1 mL of Sephadex™ G-10. 
 
V.4.2. Characterization Techniques. 
NMR spectroscopy, DLS, 1H-NMR and UV were performed using the equipments 







V.4.3. Synthetic Protocols. 
V.4.3.1. General Procedure for The Synthesis of TKI-Derivatives 
 
This section has been hidden purposely 
Workup 
Reaction mixture was transferred to a 50 ml falcon tube and remaining traces were 
washed out with some new DMF. Then, milliQ water was added until reaction mixture 
precipitate is observed. The heterogeneous mixture was transferred to a 500ml separation 
funnel and remaining traces were washed out with a mixture of DMF and water. Aqueous 
part was extracted 3 times with 100ml AcOEt and the organic part was kept apart. Then, 
all organic fractions were mixed and washed with 100 ml of diluted NaHCO3. Next, a 
new wash with 100 ml of milli-Q water was carried out. Organic phase was finally 
separated into a 1000ml Erlenmeyer flask and allow to dry by adding anhydrous MgSO4. 
Then, a final white fine powder was obtained by evaporating the solvent under rotatory 
evaporator (yield: 90-95% depending on the amino acid). 
Flash-Column 
Mobile phase was prepared by mixing CH2Cl2, MeOH and NH4(OH) (100/7/1) 
(v/v).  Some of the TKI-derivatives were directly soluble in the mobile phase, but others 
were seeded as a suspension. Column progression could be followed under UV light (λ = 
366nm). All fractions were analysed by TLC and selected ones are placed together and 
evaporated using rotatory evaporator. 1H-NMR will confirm the identity and purity of the 
compound. 
Boc-Deprotection 
Boc-aa-TKI derivative was placed in a 25 ml round bottomed flask and a 
deprotection solution is prepared before, to avoid local decrease of pH that could degrade 
the ester bond. 1,2 ml of HCl in dioxane solution (4M) was diluted in 5 ml of EtOAc and 
the mixture was added in the flask containing the Boc-aa-TKI provided with a magnetic 
stirrer. Deprotection was allowed to proceed for 90-120 min and the solid adhered in the 
flask walls was scratched to put all the solid in suspension. After this time, reaction was 
transferred into a 50 ml falcon tube and washed with more EtOAc. To improve 
precipitation, 5ml of hexane was also added and the mixture was centrifuged. The 




a new centrifugation was carried out. The supernatant was discarded and the solid was 
dried under vacuum for 1 hour. After that a solution of 30ml Milli-Q water and dil. 
NaHCO3 was added in order to neutralize the remaining HCl and once well mixed, some 
drops of NaHCO3 1,0M solution were also added up to pH = 7-8.  After 24h of freeze 
drying the solid, its identity can be ensured by 1H NMR and COSY experiments. 
 
V.4.3.2. General Procedure for Conjugates Synthesis  
 
TKI-derivatives are provided with terminal amines. Therefore, the conjugation 
was performed according to the previously described conjugation protocols (Chapter III 




V.4.4. Biological Evaluation of the Polymer-Drug Conjugates  
V.4.4.1. Cathepsin B-Mediated Drug Release Kinetics 
Drug release kinetics in presence of cathepsin B was accomplished as explained 
in Chapters III and IV. 
 
V.4.4.2. In vitro evaluation   
Cell culture experiments to determine cytotoxicity and combination index in the 
4T1 cell line were performed as described in previous chapters. Alternatively, MDA-MB-
231-Luc cells were seeded in sterile 96-well microtiter plates at concentration of 7,500 
cells/cm2 under standard culture conditions. Plates were incubated for 24 h and then 
solutions of free drugs and conjugates were tested at final concentrations ranging from 
0.0001  to 1000 µg/ml of drug equivalents. 
V.4.4.3. In vivo evaluation 
Animal experiments to determine antitumor and antimetastatic activities of the 
conjugates have been accomplished following the same ethical regulations and 







[1] Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: 
challenges and opportunities of a heterogeneous disease. Nature reviews Clinical oncology. 
2016;13:674-90. 
[2] Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. 
Cancer biology & medicine. 2015;12:106-16. 
[3] Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and 
novel combination therapies. Cancer Treatment Reviews. 2018;62:110-22. 
[4] Gelman IH. Src-family tyrosine kinases as therapeutic targets in advanced cancer. Frontiers 
in bioscience (Elite edition). 2011;3:801-7. 
[5] This reference has been ommited purposely 
[6] Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of 
human triple-negative breast cancer subtypes and preclinical models for selection of targeted 
therapies. The Journal of clinical investigation. 2011;121:2750-67. 
[7] This reference has been ommited purposely 
[8] This reference has been ommited purposely 
[9] This reference has been ommited purposely 
[10] Ahn SG, Kim SJ, Kim C, Jeong J. Molecular Classification of Triple-Negative Breast Cancer. 
Journal of Breast Cancer. 2016;19:223-30. 
[11] Cameron GG. Polyelectrolytes: formation, characterization and application. H. 
Dautzenberg, W. Jaeger, J. Kötz, B. Philipp, Ch. Seidel and D. Stscherbina. Carl Hanser Verlag, 
Munich, 1994. pp. xiv + 343, price DM168.00. ISBN 1-56990-127-9. ISBN 3-446-17127-4. Polymer 
International. 1995;38:106-. 
[12] Norcross BE. Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed. 
(March, Jerry). Journal of Chemical Education. 1993;70:A51. 
[13] Wolfe NL, Steen WC, Burns LA. Phthalate ester hydrolysis: Linear free energy relationships. 
Chemosphere. 1980;9:403-8. 
[14] Carboxylic Acids and Esters (1969). John Wiley & Sons, Ltd.; 1969. 
[15] Zagorodko O, Arroyo-Crespo JJ, Nebot VJ, Vicent MJ. Polypeptide-Based Conjugates as 
Therapeutics: Opportunities and Challenges. Macromolecular bioscience. 2016;17:1600316. 
[16] Duro-Castano A, Nebot VJ, Nino-Pariente A, Arminan A, Arroyo-Crespo JJ, Paul A, et al. 
Capturing "Extraordinary" Soft-Assembled Charge-Like Polypeptides as a Strategy for 
Nanocarrier Design. Advanced materials (Deerfield Beach, Fla). 2017;29. 
[17] Arroyo-Crespo Juan J, Deladriere C, Nebot Vicent J, Charbonnier D, Masiá E, Paul A, et al. 
Anticancer Activity Driven by Drug Linker Modification in a Polyglutamic Acid-Based 
Combination-Drug Conjugate. Advanced Functional Materials. 2018;28:1800931. 
[18] Karagiannis GS, Pastoriza JM, Wang Y, Harney AS, Entenberg D, Pignatelli J, et al. 
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated 
mechanism. Science translational medicine. 2017;9:eaan0026. 
[19] Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms 
and translational opportunities. Clinical & experimental metastasis. 2018. 
[20] DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy 
in Breast Cancer. The New England journal of medicine. 2017;377:2287-9. 
[21] Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. 
British journal of cancer. 2017;117:1583. 
[22] Genard G, Lucas S, Michiels C. Reprogramming of Tumor-Associated Macrophages with 




























































































Current statistics show that around one in eight women will suffer from breast 
cancer. Growing incidence, increasing clinical costs derived from breast cancer care, and 
a general lack of effective therapeutics highlight the urgent need for novel treatment 
approaches [1]. Although postmenopausal age and hereditary predisposition remain 
critical risk factors, weight, alcohol consumption, diet, and lifestyle represent controllable 
risk factors [2]. Breast cancer is a systemic disease encompassing a very large group of 
illnesses characterized by abnormal cell growth. However, the existence of multiple 
subtypes, presenting differential signatures (e.g., hormone receptor expression, 
proliferative rate, invasiveness) requires effective and adaptive therapies for such a 
complex disease. The treatment approaches employed for breast cancer treatment 
currently depend on the stage and molecular subtype. Local treatment at early stages 
includes surgery and radiation therapy, while advanced stages of the disease may require 
systemic treatments based on chemotherapy, hormone therapy, and targeted therapy [3]. 
 
Around 15% of diagnosed breast cancers are considered triple negative (TNBC), 
a subtype associated with high metastasis incidence (and decreased overall survival) and 
affects mainly young women (<40) [4]. Among breast cancer subtypes, TNBC (lacking 
expression of hormone receptors) displays the most heterogeneous molecular features, 
which translates into a complex clinical presentation and differential response to 
standardized treatments. The lack of hormone receptors makes targeted or hormone 
therapy ultimately inadequate, and although some reports suggest that TNBC responds to 
chemotherapy better than other types of breast cancer, prognosis remains poor in most 
cases [5]. Therefore, research efforts into the design of effective treatments usually 
require a drug-combination strategy, rather than a monotherapy approach, to affect 
different cancer cell pathways. 
 
During the preparation of this Thesis, we aimed to understand the complex 
pathology of TNBC through the establishment of two relevant preclinical TNBC murine 
models. Additionally, we also took on the challenging task of developing effective 




Research using animal models has been instrumental in delivering improved 
therapies for breast cancer and generating new insights into the mechanisms that underpin 
the disease development [6]. However, the lack of accurately characterized multistage 
animal models (those capable of mimicking progressive stages of the human disease) that 
faithfully simulate the pathological features of human TNBC, including spontaneous 
metastasis or multiple side alterations, frequently hampers research [7]. Currently 
employed metastatic mouse models mimic advanced stages of the disease, but the 
requirement for infusions of high concentrations of aggressive breast cancer cells [7], the 
need to resect the primary tumor to allow metastasis, or slow metastatic development 
limits the application of these models. 
 
Herein, we have described two preclinical spontaneously metastatic TNBC 
orthotopic murine models for the evaluation of advanced therapeutics: an 
immunodeficient human MDA-MB-231-Luc model and an immunocompetent mouse 
4T1 model. These models offer a useful platform for testing/validation of advanced 
anticancer therapeutics, especially for the treatment of patients presenting with both 
primary tumors and metastasis. We took advantage of these preclinical models to evaluate 
the therapeutic potential of polymer-drug conjugate families, including the study of 
primary tumor growth inhibition, tumor characterization after treatment, and their 
evaluation of antimetastatic activity in lungs and axillary lymph nodes (ALN). 
 
 The immunocompetent model (BALB/c - 4T1) exhibited aggressive primary 
tumor evolution as densely packed masses with slight anemia, thrombocytosis, and 
reticulocytosis in the short term, and an acute leukemoid reaction that led to bone marrow 
failure and subsequent extramedullary hematopoiesis in the spleen and liver 
(splenomegaly and liver). Immunological disorders included lymphocytosis and 
complement system activation in the mid-to-long term. Additional tumor-related 
hematological disorders included β- and γ-immunoglobulinemia, increased neutrophil-to-
lymphocytes (NLR) ratio, and increased levels of G-CSF correlating with a metastatic 
switch. After systemic administration of our polymer-drug conjugates, such cancer-
derived pathologies represent biomarkers for tumor progression and as “therapeutic 
checkpoints” to evaluate the effectiveness of our preclinical treatments. As observed 
throughout the preparation of this Thesis, the knowledge and understanding of both 




conjugates, and new therapeutic checkpoints have arisen and then subsequently 
incorporated into our analyses. Accordingly, we employed the immunocompetent model 
for conjugate evaluations in Chapter III and Chapter IV. This model was used to 
demonstrate not only antitumor efficacy (primary tumor and metastasis progression) but 
also safety of selected treatments, including as drugs aminogluthethimide (endocrine) and 
doxorubicin (chemotherapy) and poly-L-glutamic acid (PGA) as carrier. A 
comprehensive analyses, concerning the antimetastatic activity of the conjugates both in 
lungs and ALN, modulation of tumor density and necrosis between treatments, and the 
decrease in tumor cell proliferation rate was performed. We also observed improvements 
at the immunological level following the most effective treatment, observing a reduction 
in leukocytosis and confirming a significant reduction in extramedullary hematopoiesis.  
 
We later incorporated the immunosuppressed model (NOD/SCID MDA-MB-231-
Luc) to evaluate conjugates in human-derived orthotopic breast cancer tumors. This 
model offers a new testing perspective, as it allowed us to explore TNBC therapies in the 
absence of an immune system, even if mice display a natural weakness and tolerate lower 
doses of chemotherapeutics [8]. We used this model to evaluate the efficacy of the 
combination conjugates based on a tyrosine kinase inhibitor (TKI) and a topoisomerase 
inhibitor (TI) (Chapter V) and tracked antimetastatic effect in lungs and ALN by non-
invasive imaging techniques (BLI) thanks to the luciferin transfection of the MDA-MB-
231 cell line. Interestingly, we found cancer associated adipocytes (CAA) in primary 
tumors of this model (Chapter II) and a partial restoration of the immune system at late 
stages of the disease. We hope that further experiments will explore the effect of our 
anticancer combination in the presence of cancer-associated adipocytes (CAA) and its 
role on immune restoration. Additional experiments will encompass the full histological 
characterization of critical organs and the analysis of cytokine levels from frozen serum.  
 
As a functional tool for the characterization of disease progression, we employed 
NMR-metabolomics analysis of metastatic lungs and tumors. Metabolomic analysis can 
help us to understand the biochemical alterations sustaining the onset and progression of 
pathological processes, and the molecular mechanisms involved in response to new 
therapies. We previously reported a metabolomic study concerning functional 
comparisons of tumor tissue following treatments with the free form of Dox and HPMA-




metabolomics, we discovered that polymer conjugation leads to increased apoptosis, 
reduced glycolysis, and reduced levels of phospholipids when compared to the free Dox 
which all represent indicators of enhanced antitumor activity.  
 
The metabolomic comparison of 4T1 and MDA-MB-231-Luc primary tumors 
suggested that specific metabolic alterations could explain the differences observed in 
growth rates, being much faster and aggressive the 4T1 model. We also confirmed that 
lipid metabolism alterations closely associate with TNBC malignancy and metastatic 
progression to lungs. Moreover, the metabolomic signature for lung metastases in each 
model reflected the different molecular and biochemical mechanisms associated with 
metastatic spread and, therefore, could be employed as a biomarker for disease 
monitoring during preclinical evaluation. Given the robust nature of NMR-metabolomics 
and the description of a metabolic signature of primary tumors and metastasis in our 
preclinical models, we now plan to extend the analysis to different organs and biofluids 
in mice treated with the most effective combination conjugates to correlate therapeutic 
benefit with metabolic alterations. 
 
Our combination conjugates are part of one of the most successful classes of 
nanomedicine, polymer therapeutics (PT), which have been proposed as a valid 
therapeutic platform towards the development of viable breast cancer treatments. PT are 
considered new chemical entities with 24 products currently on the market, including 
PEGylated proteins, polymeric drugs, and one polymer-drug conjugate, and a growing 
pipeline in clinical development [10-13]. 
 
The intrinsic features of PT offer strategic advantages to overcome the main 
limitations of low molecular weight drugs. These features include (i) improved 
pharmacokinetic (PK) profiles and enhanced plasma half-life, (ii) the incorporation of 
targeting moieties for active targeting, (iii) carrier multivalency for tunable drug(s) 
loading capacity and drug combinations,  (iv) controlled and sustained release of 
conjugated drugs via bioresponsive linkers; and (v) chemical stability, reduced 






Towards the development of a new generation PT, we followed the following 
guidelines: (i) the employment of biodegradable polymeric carriers, such as 
polyglutamates, which allow chronic treatments and avoids biopersistence and polymer-
derived side effects, (ii) the use of sophisticated physico-chemical characterization 
methodologies in relevant biological media, allowing a better control of the final product 
and a broader and more reliable understanding of the developed systems. This 
characterization also allows for constant PT improvement via feedback to the original 
design from the observed physico-chemical behaviors, and (iii) the use of combination 
therapy as a primary tool to enhance therapeutic potential via drug synergism.  
 
A growing number of polymeric conjugates are already implemented in 
preclinical and clinical trials in combination with free drugs or radiotherapy [14]. The 
importance of anticancer combination therapies has been corroborated via the 
development of VYEOXS™ (already in post-marketing observational study) by Celator 
Pharmaceuticals (now in Jazz Pharmaceuticals). VYXEOS™ (formerly CPX-351) 
employs a liposomal strategy (Combiplex®) that physically entraps a combination of 
cytarabine and daunorubicin in a synergistic ratio for the successful treatment of acute 
myeloid leukemia [15] and represents a clear example in which rational design provides 
benefits to the patient. Combination therapy may provide further benefit when compared 
to physical entrapment, as the presence of bio-responsive polymer-drug linker(s) allows 
better control of drug PK and improved therapeutic output. Of note, the incorporation of 
drug combinations into the same polymeric carrier represents the only strategy that 
ensures the transport of both drugs to the same target cell within the same timeframe [16]. 
 
The Polymer Therapeutics Laboratory at CIPF, Valencia, currently works in the 
development of polymer-based combination conjugates for the treatment of hormone-
dependent advanced (metastatic) breast cancer. The first attempt to develop a 
combination conjugate employed the copolymer 2-(hydroxypropyl) methacrylamide 
(HPMA), bearing a combination of endocrine (aromatase inhibitor, aminogluthethimide 
(AGM)) and chemotherapy (Dox) for the treatment of breast cancer in postmenopausal 
patients [17, 18]. 
 
We based the design of HPMA-AGM-Dox on two main pillars: (i) the 




chemoresistant breast cancer patients [19], and (ii) aromatase inhibitors act 
synergistically with chemotherapy [20]. HPMA-AGM-Dox displayed enhanced in vitro 
breast cancer cell toxicity compared to a combination of the unconjugated drugs or 
individual polymer-drug conjugates [17, 18]. Recently, in vivo proof of concept for 
antitumor drug synergism with the combination conjugate has been achieved in an 
aggressive metastatic 4T1 murine breast cancer model [21]. Enhanced activity appeared 
primarily due to improved drug release kinetics and the bioavailability of both drugs in 
the same cell at the same time. Importantly, tumor sample protein expression analysis 
demonstrated robust differences in tumor-associated angiogenesis pathways, which could 
be explained by the estrogen inhibition induced by AGM. This effect was enhanced by 
an autophagic cell death mechanism only associated with the combination conjugate [9, 
18]. These results demonstrated for the first time that the rational design of a combination 
PT could significantly enhance safety as well as therapeutic drug output. This concept 
has been further explored and reinforced both in vitro and in vivo through studies in our 
laboratory and other research groups [22]. 
 
However, limitations with existing polymeric systems, such as a lack of 
biodegradability, biocompatibility, and multifunctionality, inevitably lead to side effects 
and poor patient compliance. A new generation of biodegradable polymers are excellent 
candidates for drug delivery, as they can overcome the previously mentioned limitations. 
Particularly polypeptides, since clinical benefits have been achieved with polymeric 
drugs, such as Copaxone [23] (one of the top ten selling drugs) [10, 24] and PGA-based 
anticancer therapeutics such as Opaxio™ [25], designated as orphan drug in combination 
with radiotherapy and temozolomide for the treatment of glioblastoma multiforme. 
 
Encouraged by the successful application of PGA in the conjugation of single 
chemotherapeutic drugs [25] and their combination [22, 26], as well as our prior studies 
combining endocrine and chemotherapy [17, 18], we directed the first efforts of this 
Thesis towards the development of the first PGA-based combination conjugates bearing 
chemotherapeutic and estrogen modulating agents for the treatment of breast cancer 
(Chapter III). Furthermore, we took this opportunity to explore how the incorporation 





AGM is a commercially available first-generation aromatase inhibitor, and its 
chemical structure permits simple derivatization and easy conjugation to PGA. For these 
reasons, we considered the application of AGM as a means to achieve proof of concept. 
AGM has been superseded by more potent inhibitors, including the triazoles class 
(anastrozole and letrozole), although these lack the functional groups required for 
conjugation, and the steroid exemestane (currently being explored in the lab).  
 
Keeping invariable the direct attachment of Dox through an amide bond, we 
studied the influence of the incorporation of two drug ratios (5:5 (LL) and 10:5 (HL) 
AGM: Dox) for AGM via small drug linkers. At the in vitro level, we found that the 
addition of small, short, and flexible Gly or Gly–Gly linker led to enhanced cytotoxicity 
when compared to a more bulky GFLG linker or the direct linkage of AGM. We also 
observed a synergistic in vivo antitumor effect in animals treated with the PGA-(G-
AGM)LL-Dox and PGA-(G-AGM)HL-Dox combination conjugates, as compared with the 
single conjugates (alone or added simultaneously). 
 
The study of in vitro drug release represented a vital point of this research. When 
we compared the release profiles of both drugs under the same experimental conditions 
(i.e. in the presence of cathepsin B mimicking lysosomotropic delivery), we noted a 
strong influence of the linking chemistry and drug ratio on drug release kinetics. 
Interestingly, when we compared the two most relevant combination conjugates which 
differed only in their level of AGM loading, the PGA-(G-AGM)HL-Dox combination 
conjugate with high loading displayed diminished drug release kinetics when compared 
to the PGA-(G-AGM)LL-Dox combination conjugate with lower loading, perhaps due to 
structural modifications in the polymer chain. However, we noted a similar cytotoxic 
effect for both LL and HL conjugates, suggesting that they mediate their effect through 
different molecular mechanisms. While attempting to understand this behavior, we 
realized that the degradation process requires efficient cellular uptake and access of the 
proteolytic trigger (mainly cathepsin B) to cleave the polymer-drug linker [27].  
Molecular access is directly correlated with the 3D spatial disposition of the polypeptide, 
which, in turn, may be influenced by structural factors such as the conjugated moieties 
[27], drug loadings [28], drug ratios [29], linking chemistry, and physicochemical 





To establish direct structure-activity relationships (SAR), we looked for critical 
physico-chemical descriptors driving in vitro and in vivo output of PGA-AGM-Dox 
conjugates. Circular dichroism (CD) and Small Angle Neutron Scattering (SANS) 
analysis of the most effective AGM-Dox combination conjugate (PGA-(G-AGM)LL-Dox) 
revealed the impact of the Gly linker on the structure of the whole macromolecule. The 
Gly linker partially shifts the secondary structure to alpha helix, when compared to the 
parent conjugate with direct attachment of both drugs. Also, this conjugate presented with 
smaller and more compact aggregates with no evidence of internal ordering. Overall, the 
data provided by CD, DLS, and SANS, can correlate structure and conformation with 
drug release and biological output. Results from in vitro and in vivo experiments suggest 
that the drug release that drives the antitumor activity of AGM-Dox conjugates can be 
modulated by the rational design and of polymer-drug linking chemistry.  
 
 After the development of this first family of conjugates, we next aimed to further 
enhance its antitumor activity. We discovered that faster release of Dox, the more active 
agent, when compared to AGM boosted drug synergism. Also, we noted that the release 
of both drugs relied exclusively on the heterogeneous expression (at both the patient [31] 
and tumor level [32]) of various proteolytic enzymes within the tumor microenvironment 
(TME). This highlights the need for patient stratification in PT treatment cohorts, a 
requirement exemplified by clinical data obtained for Opaxio®, which displayed optimal 
activity in phase III clinical trials in premenopausal women with levels of estrogen high 
enough to promote cathepsin B activity [33]. 
 
 With these considerations, alongside the acidic nature of the TME [34], we 
decided to implement pH-sensitive hydrazone Dox linkers to the PGA carrier and 
maintained the linking chemistry for AGM. We employed two different pH-sensitive 
hydrazone linkers: the direct conjugation through the C-13 Dox ketone [35-37] or 
conjugation employing a flexible, hydrophobic, and longer maleimido linker (EMCH). 
This Dox-linker strategy has its origin on the development of Aldoxorubicin (formerly, 
INNO-206, EMCH-Dox) as a bovine serum albumin (BSA)-binding-Dox prodrug [38] 
and has been reported previously for a PGA-based combination conjugate [22]. 
 
To understand the biological implications of different drug linkers and drug 




contrast with our previously reported PGA-(G-AGM)-Dox family [39], we did not 
observe significant differences in cell toxicity between the single and the combination 
conjugates (for the most relevant combination conjugate, PGA-(G-AGM)-(Hyd-Dox)LL), 
indicating a lack of AGM:Dox synergism at the drug ratios employed achieved 
hydrazone-mediated conjugation. While we considered that drug synergism required the 
balanced co-delivery of the drug combination and rapid Dox release via a hydrazone 
linker, the cathepsin B degradation studies instead indicated the critical nature of the final 
conjugate solution conformation. In the case of the most active conjugate, (PGA-(G-
AGM)-(Hyd-Dox)LL), the more rapid Dox release at very early time-points at pH 5 and 
in the presence of cathepsin B demonstrated the preferential hydrolytic mechanism 
triggering Dox release offering the greatest antitumor effect. However, the final relative 
release profile comparing Dox vs. AGM (with greater overall AGM bioavailability) could 
explain the absence of drug synergism as we obtained an inverse relative bioavailable 
AGM: Dox ratio from that previously identified as synergistic [8]. 
 
Concerning the in vivo evaluation, the combination conjugate (PGA-(G-AGM)-
(Hyd-Dox)LL presented similar antitumor activity as the combination conjugate (PGA-
(G-AGM)-(EMCH-Dox)LL. Additionally, we demonstrated improved antitumor and 
antimetastatic activity with hydrazone-based combination conjugates when compared 
with the direct conjugation. [39] However, the observed reduction of the overall survival 
(OS) in mice motivated us to discard the EMCH-based subfamily of conjugates. We 
proposed two different explanations for the observed associated toxicity of the 
combination conjugate. The first relates to the increased final solution viscosity (due to 
the high conjugate concentration needed to reach the desired Dox equivalents), a 
parameter with the potential to affect proper blood distribution. The second relates to the 
larger size and heightened ability of this combination conjugate to aggregate in solution, 
which might promote accumulation in other organs, as well as in the tumor. Additionally, 
this increased in size may also promote certain protein corona aggregation upon arrival 
to the bloodstream, while this effect could also enhance the size and promote undesired 
side effects, leading to systemic toxicity. The higher hydropic degeneration supports both 
explanations (vacuolar degeneration) observed in livers from animals treated with this 
conjugate. Although none of our experiments demonstrated any apparent AGM effect, 




these conjugates in other models (towards chronic application) could display additional 
benefits from AGM. 
 
To understand the molecular basis of the responses to the different combination 
conjugates, we implemented a battery of RNA-seq analysis of tumor tissues derived from 
treated animals and compared genes differentially regulated between each possible pair-
wise comparison. Through this experiments, we observed a more general effect of PGA-
(G-AGM)-(Hyd-Dox)LL when treating tumor cells compared to PGA-(G-AGM)-(EMCH-
Dox)LL. PGA-(G-AGM)-(EMCH-Dox)LL involves fewer targeted processes, such as stem 
cell proliferation and epidermal cell differentiation, indicating a role of this combination 
conjugate in reducing cancer cell growth. Additionally, PGA-(G-AGM)-(Hyd-Dox)LL 
specifically activates general processes such as defense/immune responses, 
inflammation, phagocytosis, cell signaling and metastasis, suggesting that this 
combination conjugate is more effective in triggering a general immune response that 
might contribute to stall tumor progression, improve health status of the individual, and 
increase survival rates.  
 
Finally, we decided to exploit all the expertise acquired and techniques 
implemented to develop a more challenging PGA-based combination conjugate. Among 
the therapeutic approaches devised for TNBC treatment, inhibition of SRC (proto-
oncogene tyrosine-protein kinase) deserves particular interest due to critical roles in cell 
adhesion and motility [40], which both represent essential mechanisms for cancer 
progression and invasiveness. Accordingly, TNBC cell lines display high sensitivity to 
tyrosine kinase inhibitors (TKIs) in preclinical studies [41]. Additional data have 
indicated a heightened sensitivity of the mesenchymal-like TNBC subtype to TKIs [42, 
43], which may be explained by the overexpression of genes related to cell motility in 
this particular TNBC subtypes and the crucial role of SRC-family kinases in cell 
migration. Recent research have demonstrated robust drug synergism between TIs and 
TKIs. However, only a few examples in the literature discuss combinations of such drugs 
within polymer backbones for the treatment of breast cancer. These studies include non-
biodegradable polyethylene glycol (PEG)-ylated peptidic nanocarriers [44] or micelles 
[45] where the polymer physically entraps one or both drugs. On this basis, we believed 
that we could enhance the already reported drug synergism by the rational design of 




conjugate for a TKI and a TI. A first conjugate employing direct conjugation of both 
drugs (amide linker for the TI and ester linker for the TKI) lacked drug synergism due to 
an inappropriate pharmacokinetics. As a consequence, we took advantage of the 
multivalency of PGA as carrier, and rationally designed drug linkers to promote and 
improve drug synergism by the incorporation of two modifications: a hydrazone linker 
for the TI (to achieve fast TI release) and a simple amino acid (Val) [46] linker for TKI 
(to diminish TKI release).  
 
This optimized combination conjugate demonstrated elevated in vitro drug 
synergism in two TNBC cell lines (4T1 and MDA-MB-231-Luc).  Importantly, we 
observed enhanced in vivo safety as at 1.5mg/Kg drug equivalents, the TI resulted lethal 
at the second dose, while animals treated with the PGA-(Val-TKI)-(Hyd-TI) did not 
suffer any visible treatment-related toxicity even after six doses. As well as anticancer 
effects in vivo, leading to 50% of primary tumor growth reduction and almost total 
remission of lung metastasis. Although this research currently remains unfinished, we 
demonstrate a significantly improved in vivo output, and we hope the additional ongoing 
histopathological studies to analyze cancer cell proliferation in primary tumors, 
metastasized lungs and major organs, will allow a better understanding of the therapeutic 
value of such conjugates.   
 
Undesirably, after treatments with our non-active single conjugates PGA-Val-TKI 
and PGA-Hyd-TI separately or as physical sum, we observed pro-metastatic behavior in 
the lungs. Several studies of anticancer treatments have demonstrated that some 
chemotherapeutics modulate the tumor microenvironment and promote breast cancer cell 
intravasation and dissemination to distant sites [47-49]. Following treatment, tumor cells 
from primary breast lesions may intravasate and disseminate at sites of microanatomical 
structures called tumor microenvironment of metastases (TMEM). The particular 
physico-chemical characteristics or drug-release kinetics of our single conjugates could 
modulate the tumor microenvironment in this way. Other possible explanation could 
involve the activity of tumor macrophages [50]. In response to tumor presence, classically 
activated (M1) macrophages activate, secrete pro-inflammatory cytokines, and play 
tumouricidal roles. Alternatively activated (M2) macrophages secrete anti-inflammatory 
cytokines IL-10 and TGF-β and play tumourigenic roles. However, so-called tumor-




tumourigenic features. Studies have described how chemotherapies could reprogram 
these TAMs to facilitate metastasis progression [51]. A series of further experiments are 
ongoing to investigate the possibilities with the hope of controlling undesired effects. 
 
In conclusion, we suggest that the results presented indicate that the development 
of these PGA-based combination conjugates paves the way for the construction of more 
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The objectives achieved during the development of this Thesis have significant 
relevance for the treatment of triple-negative breast cancer (TNBC) with biodegradable 
polymer-based combination conjugates. We highlight the main conclusions below: 
 
1. We have characterized two spontaneously metastatic and preclinically relevant 
murine models of TNBC for testing and validation of nanomedicine. In summary, 
we have studied metastasis progression via hematological analysis, identified 
specific biomarkers of metastasis via nuclear magnetic resonance (NMR) 
metabolomics, histopathologically characterized relevant organs presenting 
pathologies as a consequence of tumor development, and finally detected the 
modulation of tumor cytokines in plasma and identified descriptors that allow 
advanced antitumor treatment evaluation. 
 
2. We have developed three families of polymer-drug combination conjugates, based 
on the biodegradable carrier poly-L-glutamic acid incorporating two drugs in a 
synergistic ratio for treatment of TNBC. 
 
3. To improve and optimize drug release and potentiate synergism, we have 
developed and fully characterized polymer-drug linkers that are sensitive to 
different biological stimuli. These included peptide bonds (degraded by 
proteolytic enzymes overexpressed in most solid tumors and tumor cell 
lysosomes), ester bonds, (sensitive to pH and esterases), and pH-sensitive bonds, 
(for drug release drugs at the required ratio and quantity in the slightly acidic 
conditions of the tumor microenvironment and/or endosome/lysosome). 
 
4. We employed advanced characterization techniques in biologically relevant 
solutions to physicochemically characterize our developed conjugates, thereby 






5. We have evaluated in vitro the developed conjugates in clinically relevant breast 
cancer cell lines. Studies of cytotoxicity, synergism, cellular internalization, and 
drug release (in biologically relevant conditions in the presence of degrading 
enzymes) have provided crucial information permitting advances in conjugate 
design.  
 
6. We then in vivo evaluated promising conjugates in our established preclinical 
murine models, demonstrating antitumor/antimetastatic efficacy and safety. 
Furthermore, we monitored previously identified disease descriptors that 
permitted assessment of the therapeutic potential of polymer-drug combination 
conjugates. 
 
7. Finally, we studied primary tumor at transcriptomic and metastasized lungs at 
transcriptomic and metabolomic level. The transcriptomic analysis clarified cell 
death mechanisms following conjugate treatments and allowed us to establish 
direct relationships between cell death mechanisms and physicochemical 
descriptors of the polymer-drug combination conjugates. The metabolomic results 
identified significant differences in the production/consumption of critical 
metabolites during metastatic development, allowing us a complete understanding 
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1. INTRODUCCIÓN, ANTECEDENTES Y MARCO TEMÁTICO DE 
LA TESIS 
El cáncer de mama es el cáncer más frecuente en mujeres y la segunda causa de 
muerte después de las enfermedades cardiovasculares. La supervivencia a esta 
enfermedad ha mejorado sustancialmente en la última década gracias a la incorporación 
de nuevas terapias y desarrollo de nuevas herramientas para el diagnóstico precoz [1]. Sin 
embargo, este porcentaje no ha mejorado en tumores metastásicos (estadío avanzado de 
la enfermedad). Se trata de una patología altamente heterogénea que presenta gran 
diversidad genética que se traduce en diferencias en cuanto al comportamiento biológico 
y, por lo tanto, grandes diferencias en las respuestas terapéuticas entre los pacientes ante 
un mismo tratamiento [2-4]. Ante este escenario, se hacen necesaria la aplicación de 
diferentes abordajes terapéuticos que actúen sobre diferentes vías de desarrollo de la 
enfermedad. 
 
Entre los diferentes subtipos de cáncer de mama se encuentra el cáncer de mama 
triple negativo (CMTN) que representa entre un 15-20% de todos los carcinomas de 
mama [5]. El CMTN se caracteriza, molecularmente, por la falta de expresión del receptor 
de estrógeno (ER), el receptor de progesterona (PR) y el receptor-2 del factor de 
crecimiento epidérmico humano (HER2) y presenta un mal pronóstico clínico debido a la 
agresividad clínica del tumor primario, a la alta tasa de metástasis y a la deficiente 
detección temprana de la enfermedad. La mayoría de los pacientes con CMTN mantiene 
la enfermedad residual después del tratamiento, por lo que existe un alto riesgo de 
reincidencia y por lo tanto, hay una disminución en la supervivencia después de los 3-5 
años del tratamiento. Los pacientes de CMTN presentan una esperanza de vida menor a 
5 años desde el diagnóstico [2].  
 
Actualmente, existe poca información en la que basarse para la selección del 
tratamiento adecuado para CMTN. Éste subtipo de cáncer es insensible a algunos de los 
tratamientos más eficaces disponibles para el cáncer de mama, incluyendo la terapia 
dirigida al HER2 (trastuzumab), los tratamientos endocrinos (tamoxifeno), o los 
inhibidores de la aromatasa. Los tratamientos convencionales quimioterapéuticos suelen 
ser el tratamiento de elección ya que se ha aceptado que los CMTN muestran alta 




Entre los fármacos más frecuentemente utilizados se emplean principalmente las 
antraciclinas y los taxanos, que han demostrado en estudios clínicos fase I ser efectivos 
en los estadios tempranos de la enfermedad [6]. Sin embargo, los pacientes en estadíos 
avanzados de la enfermedad han mostrado una baja respuesta a este tipo de terapia debido 
a resistencias a múltiples fármacos (MDR). Estos motivos justifican la necesidad del 
desarrollo de nuevos fármacos dirigidos a nuevas dianas terapéuticas [5]. 
 
En la última década los avances en nanotecnología y ciencia de materiales han 
permitido el desarrollo de sistemas innovadores de liberación controlada de fármacos y 
técnicas de imagen que han aportado importantes beneficios para la salud humana y han 
abierto nuevos mercados a la industria farmacéutica [7, 8]. Los Polímeros Terapéuticos 
han sido considerados una de las nanomedicinas más ventajosas. Estas nuevas entidades 
químicas engloban una variedad de sistemas macromoleculares complejos cuya 
característica común es la presencia de un enlace químico (covalente) entre el agente(s) 
bioactivo y el transportador polimérico soluble en medio acuoso.  
 
Como principales beneficios, la conjugación de fármacos a transportadores 
poliméricos, (i) aumenta su solubilidad acuosa y (ii) cambia la farmacocinética del 
fármaco tanto a nivel sistémico como a nivel celular, con la posibilidad de mejorar 
claramente el valor terapéutico de los fármacos. Además, (iii) el uso de nanoconjugados 
ofrece un alta especificidad tumoral debido al efecto de permeabilidad y retención 
aumentada (EPR,‘enhanced permeability and retention effect’) [9, 10] y por tanto (iv) una 
menor toxicidad sistémica. Asimismo, (v) permiten la superación de mecanismos 
quimioresistentes, al emplear la endocitosis como principal mecanismo de internalización 
celular. Gracias a sus características intrínsecas a nanoescala (controlada 
multifuncionalidad, arquitectura, y presencia de elementos biosensibles), esta clase de 
nanofármacos pueden ser diseñados para que expongan características únicas. (vi) Son 
capaces de alcanzar lugares a los que otros 'nanotransportadores’ más grandes (i.e. 
liposomas) no se pueden llegar. (vii) Son capaces de cruzar barreras biológicas naturales 
y muestran un tráfico celular específico dependiente de las arquitecturas químicas que 
posean. Por último y no menos importante, (viii) permiten un mayor control de la 
farmacocinética de el/los fármaco/s conjugado/s gracias a la incorporación de enlaces 





A día de hoy, fruto de la investigación translacional en el ámbito de Polímeros 
Terapéuticos, se han transferido exitosamente 24 productos al mercado. Dos de ellos, -
Glatiramer (Sanofi Aventis-Teva) y Neulasta (Amgen)- para el tratamiento de esclerosis 
múltiple y para tratamientos anticancerígenos respectivamente, se hallan dentro de los 10 
fármacos más vendidos en EEUU [12]; demostrando así su beneficio clínico. Entre los 
productos comercializados se encuentran fármacos poliméricos [13], conjugados 
polímero-proteína [14] (37) y conjugados polímero-aptamero [15] que actualmente se 
encuentran en uso clínico, y un conjugado polímero-fármaco (Movantik) para uso oral. 
[16] 
 
Debido a la complejidad molecular de las patologías humanas a menudo se 
emplean múltiples fármacos en combinación que son administrados simultáneamente 
para atacar diferentes dianas farmacológicas y de este modo mejorar la eficacia a la vez 
que disminuye la resistencia. Por este motivo surge la llamada terapia de combinación 
polimérica [17]. Los conjugados polímero-fármaco son excelentes herramientas para el 
desarrollo de este interesante concepto [18]. 
 
Un creciente número de conjugados poliméricos ya han sido probados 
clínicamente en combinación con fármacos libres o radioterapia [18, 19]. Sin embargo, 
el empleo de polímeros que contienen múltiples fármacos conjugados a través de enlaces 
biodegradables, permite tener un mayor control en la liberación de los fármacos, siendo 
además la única estrategia que asegura el transporte efectivo de ambos fármacos a la 
misma célula tumoral con adecuada farmacocinética [19, 20] haciendo esta estrategia más 
eficiente con respecto al resto. El laboratorio de Polímeros Terapéuticos es pionero en el 
desarrollo de conjugados de combinación para el tratamiento de cáncer de mama 
hormono‐dependiente avanzado (metastásico). Este concepto fue demostrado con el 
conjugado modelo basado en el transportador no biodegradable (copolimero 2‐
(Hidroxipropil) metacrilamida (HPMA)-(AGM)‐Dox, que transporta una combinación 
de terapia endocrina (el inhibidor de aromatasa aminoglutetimida, AGM) indicado para 
pacientes postmenopáusicas) y quimioterapia (Dox) para el tratamiento de cáncer de 
mama [17]. Su diseño se basó en dos observaciones principalmente: (i) el copolímero 
HPMA‐Dox (PK1) es un conjugado en fase clínica II con demostrada actividad en 




pueden actuar de forma sinérgica con quimioterapia [22] especialmente en mujeres 
postmenopáusicas (77% incidencia). A pesar de que AGM es un inhibidor de aromatasa 
de primera generación, presentaba una funcionalización química muy adecuada para ser 
conjugado al polímero y estaba disponible comercialmente. Por tanto era un fármaco 
adecuado en esta primera fase de prueba de concepto [23]. Actualmente, AGM ha sido 
reemplazado por inhibidores más potentes pertenecientes a la clase de los triazoles 
(anatrozol y letrozol) (no adecuados para conjugación) y, recientemente, por el 
inactivador esteroidal exemestano (explorado actualmente en el laboratorio). Estos 
fármacos presentan un mejor perfil de toxicidad y una mayor actividad antitumoral 
cuando se compara con la terapia convencional.  
 
El conjugado de combinación (HPMA-AGM-Dox) demostró un aumento muy 
marcado de citotoxicidad en modelos celulares de cáncer de mama positivos en receptores 
de estrógenos (ER+) (MCF-7 y MCF-7ca (transfectada de forma estable con el gen 
humano aromatasa)) y también in vivo en un modelo de cáncer de mama metastásico 
(4T1), cuando dicha citotoxicidad se comparó con los conjugados individuales por 
separado (HPMA-Dox) o una mezcla física de ambos (HPMA-Dox + HPMA-AGM). 
Diferentes estudios mecanísticos comparativos entre HPMA-Dox y HPMA-AGM-Dox 
demostraron que esta sinergia es únicamente observable cuando los dos fármacos se 
hallan covalentemente unidos al mismo portador polimérico. Además de ello, se observó 
una biodistribución diferente entre los dos conjugados, una cinética de liberación distinta 
cuando los dos fármacos están en el mismo portador polimérico, e incluso un cambio en 
su mecanismo molecular (autofagia vs. apoptosis e inhibición de procesos angiogénicos 
(VEGF, iNOS)) [24]. 
 
Cabe destacar que, la importancia de este tipo de terapia de combinación 
anticancerígena ha sido corroborada en clínica (Combiplex® aprobada por la FDA en 
2017 para leucemia mieloide aguda) con los estudios realizados por Celator 
Pharmaceuticals Inc. (ahora Jazz Pharmaceuticals) en los cuales se ha empleado un 
liposoma de combinación ofreciendo ventajas significativas frente a tratamientos 
individuales [25]. 
A lo largo de esta Tesis hemos tomado como base de partida el conocimiento 
aportado a lo largo del desarrollo conjugado de combinación HPMA-AGM-Dox para 




poliglutámico (PGA) de posible mayor relevancia clínica debido a su biodegradabilidad. 
Adicionalmente, hemos hecho especial hincapié en la caracterización fisicoquímica de 
los conjugados, investigado la influencia de la incorporación de diferentes enlaces 
polímero-fármaco en la biofísica de la macromolécula y cómo esos cambios promueven 
diferentes efectos conformacionales y consecuentemente biológicos in vitro e in vivo. 
 
Finalmente, se ha mejorado el conocimiento y la caracterización de un modelo 
murino inmunocompetente previamente descrito (4T1) y se ha desarrollado un modelo 
nuevo inmunodeprimido (MDA-MB-231-Luc), clínicamente más relevante. Los modelos 
animales capaces de reproducir varias etapas del desarrollo de cáncer de mama 
representan plataformas de investigación translacional cruciales para evaluar y validar 
terapias experimentales. Sin embargo, la falta de modelos caracterizados con precisión 
que imiten fielmente las características patológicas del CMTN humano, incluyendo la 
metástasis espontánea o las alteraciones colaterales múltiples, con frecuencia dificultan 
la investigación [26, 27]. Los modelos de ratones metastásicos actualmente empleados 
imitan la enfermedad en estadío avanzado, pero el requisito de infusiones de altas 
concentraciones de células de cáncer de mama agresivas [26], la necesidad de extirpar el 
tumor primario para permitir la metástasis o el desarrollo metastásico lento limita la 
aplicación de estos modelos. 
 
2. OBJETIVOS DE LA INVESTIGACIÓN 
 
Los objetivos del presente trabajo de Tesis se centran en el diseño y desarrollo de 
varias familias de conjugados de combinación polímero-fármaco basado en el uso de 
polímeros biocompatibles y biodegradables para su aplicación en el tratamiento de cáncer 
de mama triple negativo (CMTN) en estadío avanzado o metastásico. Este objetivo global 
enmarca los siguientes objetivos específicos: 
 
 
1. El desarrollo y la caracterización exahustiva de dos modelos animales 
ortotópicos de cáncer de mama, espontáneamente metastásicos y preclínicamente 




2. Síntesis, caracterización fisicoquímica completa y evaluación biológica de 
conjugados de combinación de fármacos basados en ácido poli-L-glutámico (PGA) que 
incorporan fármacos en una relación adecuada, así como enlaces polímero-fármaco 
biosensibles de para lograr la sinergia en modelos de TNBC. 
 
El diseño racional de los conjugados de combinación implicará: 
 
i) Investigación de enlaces polímero-fármaco de diferente naturaleza bioreactiva 
(proteasa frente a respuesta al pH). 
ii) Estudios de relación estructura-actividad (SAR) en medios biológicamente 
relevantes. 
iii) Estudios in vitro e in vivo (seguridad, farmacocinética y actividad 
anticancerígena) en modelos preclínicamente relevantes (Objetivo 1). 
 
 3. Implementación de técnicas -ómicas (metabolómica y transcriptómica) en el 
desarrollo de conjugados poliméricos de combinación para comprender, no solo el 
mecanismo de acción molecular sino también identificar biomarcadores relevantes y 




3.1. Materiales e instrumentación. 
3.1.1. Materiales. 
Todos los reactivos usados durante el desarrollo de la presente Tesis fueron de 
grado analítico, superior, y se usaron sin purificación adicional, a no ser que se indique 
en el correspondiente apartado. Los disolventes usados también eran de grado analítico, 
superior, o HPLC, cuando fue necesario y se secaron previamente a su uso. De manera 
general, las reacciones llevadas a cabo en disolventes orgánicos se realizaron bajo 





Los métodos más frecuentemente empleados para el aislamiento y purificación de 
los conjugados poliméricos fueron la diálisis (con membranas de 1, 3, 5 o 10 kDa), 
ultrafiltración (usando Vivaspin®) o cromatografías por exclusión de tamaño, usando 
resina Sephadex® LH-20 medium para disolventes orgánicos o Sephadex® G-25 
medium en el caso de purificaciones en fase acuosa. 
 
Los animales de experimentación empleados a lo largo de la Tesis, se adquirieron 
en Envigo Laboratories Inc. (España). Se utilizaron ratones hembras de 6 a 8 semanas de 
las cepas BALB/c OlaHsd  y NOD.CB17-Prkdcscid / NCrHsd. 
 
3.1.2. Instrumentación. 
Espectroscopía de Resonancia Magnética Nuclear (NMR). Los espectros 1H NMR y 
DOSY NMR se llevaron a cabo en un sistema Bruker Advance AC 300 (300 MHz) o  
V500 (500 MHz) utilizando para ello al menos 5 mg de compuesto, temperatura ambiente 
y disolventes deuterados. Los datos obtenidos se analizaron mediante el software 
MestreNova 6.2. 
 
Espectroscopia por Dicroísmo circular. Se realizó en un espectrómetro J-815 CD 
Spectrometer (JASCO Corporation) equipado con un soporte de celda termostatizado 
(PTC-423, JASCO Corporation), un refrigerante (JULABO F250, JASCO Corporation) 
y flujo controlado de nitrógeno (~2.7 L.min-1) (Afriso Euro-Index). Las muestras se 
midieron en agua desionizada o PB 7.4 para polímeros en la forma sal sódica. Las medidas 
se realizaron en cubetas de cuarzo, de d= 0.1 cm y por triplicado. 
 
Dispersión de Luz Dinámica (DLS). Las medidas tanto de tamaño de partícula como de 
potencial ζ se realizaron a 25˚C en un dispositivo Malvern Zetasizer Nano ZS equipado 
con un láser (532 nm) a un ángulo de dispersión fijo de 90˚. La celda utilizada fue DTS 
1070. Para las medidas de tamaño, el tiempo de equilibrado fue de 0 min con atenuación 
automática. El índice de refracción del disolvente, en este caso agua, fue 1,330 y, por lo 
tanto, la viscosidad fue 0,8872. Para el análisis de los diferentes polímeros se utilizó el 
índice de refracción del látex de poliestireno (1,590). Cada muestra se midió tres veces 
con 10 submedidas. El potencial ζ se calculó a través del modelo Smoluchowski. Se 





Espectroscopía Ultravioleta-Visible (UV-Vis). Los espectros se adquirieron en un 
espectrofotómetro Jasco V-630 UV/Vis a 25˚C con celdas de plástico o cuarzo (en su 
caso) de 1 cm y ancho de banda de 0.5 nm. 
 
Microscopía Electrónica de Transmisión (TEM). Las imágenes se adquirieron en un 
microscopio de transmisión electrónica FEI Tecnai G2 Spirit (FEI Europe, Eindhoven, 
Netherlands) usando una cámara digital Morada (Olympus Soft Image Solutions GmbH, 
Münster, Germany). Para su preparación, las muestras se adsorbieron en rejillas de cobre 
recubiertas por una película de carbón de 200 mallas. Tras ello, se realizó una tinción de 
contraste negativo con una disolución de acetato de uranilo al 2%. 
 
Victor2 WallaceTM para medidas de absorbancia o fluorescencia. Para determinar 
absorbancias o fluorescencias en fracciones de purificación o ensayos celulares se usó un 
equipo Victor2 Wallac 1420 Multilabel HTS Counter Perkin Elmer (Northwolk, CT, 
EEUU) utilizando placas de 96 pocillos y las correspondientes longitudes de onda 
(emisión/excitación) propias de cada compuesto. 
 
Dispersión de Neutrones de Ángulo Pequeño (SANS).  
Los experimentos de SANS se llevaron a cabo utilizando el difractómetro D11 del 
Instituto Laue-Langevin (ILL, Grenoble) y los difractómetros SANS2d y LOQ en ISIS 
pallation Neutron Source (Didcot, UK). Todas las disoluciones fueron preparadas en 
disolventes deuterados a la concentración máxima de 1 wt% y se colocaron en celdas de 
cuarzo de 2 mm de camino óptico. Los volúmenes de muestra fueron aproximadamente 
de 0,6 cm3. Los datos fueron recogidos y corregidos de la transmisión y dispersión de la 
celda y del disolvente y se pusieron en una escala de intensidad absoluta. Los datos de 
dispersión fueron expresados en función del vector de dispersión Q, el cual viene dado 
por Q = 4nπ/λ sin (θ/2) en el que n es el índice de refracción para los neutrones (n≈1), λ 
es la longitud de onda, y θ es el ángulo de dispersión. 
 
3.2. Consideraciones éticas 
Los experimentos con animales se realizaron en conformidad con las directrices 




1201/2005. Todos los procedimientos experimentales fueron aprobados por el comité 
institucional sobre el cuidado y uso de animales y realizados por personal acreditado y 
capacitado, que cumplen con las normas de cuidado de los animales. Todos los ratones 
se mantuvieron en una instalación libre de patógenos específicos (SPF), a temperatura y 
humedad controlada y utilizando un ciclo de luz y oscuridad de 12 horas. Se proporcionó 
pienso estandarizado libre de alfalfa como alimento y agua ad-libitum durante todos los 
experimentos. En todos los casos se evaluó el aspecto general, la conducta de 
acicalamiento, el tamaño del tumor, el peso corporal y el comportamiento general desde 
el comienzo del experimento para garantizar el bienestar de los animales. El desarrollo 
del tumor no produjo pérdida de peso en los animales, ni se observó ningún 
comportamiento relacionado con el dolor. 
 
3.3. Métodos más relevantes. 
3.3.1. Acoplamientos peptídicos. 
Protocolo 1. En un matraz de fondo redondo equipado con un agitador magnético y 
entrada y salida de nitrógeno seco se disuelven 200 mg de PGA forma ácida (1.55 mmol, 
1 eq.) en 10 mL de DMF anhidro. Seguidamente se añade la correspondiente cantidad de 
DMTMM∙BF4 como activante de ácidos carboxílicos, para el porcentaje de modificación 
deseado (para un 10% de modificación, 0.1 equivalentes). Tras 10 minutos, se añade el 
doble de eq. que de DMTMM∙BF4 de la correspondiente amina a conjugar (para un 10 % 
de modificación 0.3 eq.). Se ajusta el pH a 8, y la mezcla se deja reaccionar durante 16 
horas a temperatura ambiente. Tras ello, se realizan las purificaciones estándar usando 
diálisis, o exclusión molecular, o precipitación ácido-base. El producto se caracteriza por 
RMN y por las técnicas espectrofotométricas correspondientes. 
 
Protocolo 2. En un matraz provisto de un agitador magnético y una entrada y salida de 
nitrógeno, se pesa PGA forma ácida (0.225 mmol UAG, 1 eq.) y se disuelve en DMF 
anhidro bajo atmósfera de nitrógeno. A continuación, se añade DIC (i.e. 0.15 eq. para una 
modificación de un 10 %) y se deja reaccionar durante 5 minutos a temperatura ambiente. 
Tras ello, se añade HOBt (0.15 eq. para una modificación del 10 %). La reacción se deja 
transcurrir durante 10 minutos más y se añade a continuación 0.10 eq. de la amina 




reaccionar durante 48 horas. Finalmente, el disolvente se elimina a vacío, y el producto 
se convirtió en la forma sal mediante la adición de bicarbonato sódico. Tras ello, se 
procede a su purificación mediante los métodos estándar de diálisis, G25 o precipitación 
ácido-base.  
 
3.3.2. Determinación de la concentración de agregación crítica (CAC) de los 
conjugados poliméricos mediante DLS.  
Se disolvieron los polímeros basados en PGA en PBS 7.4 a diferentes concentraciones 
dentro de un rango de 0.004-2 mg∙mL-1. Se usó PGA lineal como control negativo. Cada 
solución se preparó fresca para las medidas, se sonicó durante 5 minutos y se dejó 24 
horas para su estabilización. Las medidas de DLS se hicieron por triplicado con 
parámetros fijados para todas las muestras. Los datos se expresaron en Kcps vs 
concentración, donde la intersección entre las curvas nos da el valor de CAC. Los estudios 
de co-ensamblaje de diferentes polímeros se llevaron a cabo de igual forma, pero 
añadiendo a cada serie de concentraciones, una cantidad por debajo de su CAC del 
polímero con quien se quiere averiguar el co-ensamblaje. 
 
3.3.3. Ensayos In vitro. 
Degradaciones con Catepsina B. La biodegradabilidad de varios poliglutamatos en 
presencia de la enzima lisosomal catepsina B se evaluó in vitro. Brevemente, se 
prepararon disoluciones de 2 mg∙mL-1 de polímero en tampón acetato (para 3 mg de 
polímero, 700 μL de tampón acetato 20 mM, pH 6, 100 μL de EDTA 2 mM, 100 μL de 
DTT 5 mM). Finalmente, se añadieron 6.25 unidades de Catepsina B disueltas en 100 μL 
de tampón acetato pH 6 20 mM). Las mezclas se mantuvieron a 37 °C bajo agitación, y 
se tomaron alícuotas a diferentes tiempos (0, 0.5, 1, 2, 4, 8, 24, 48 y 72 h). La 
concentración de fármaco liberada en cada caso se analiza mediante técnicas 




Cultivos celulares. La línea celular de cáncer de mama humano dependiente de 
estrógenos MCF-7ca (transfectada con aromatasa humana) se mantuvo en DMEM 
complementado con Suero Bovino Fetal (SFBS) inactivado al 10% (SFBS) con estradiol 
y 0,75 mg / mL de geneticina G418 sobre condiciones de cultivo celular estándar (37ºC 
y 5% de CO2). Las células 4T1 se mantuvieron en RPMI suplementado con 10% de Suero 
Bovino Fetal (FBS) inactivado por calor sobre condiciones estándar de cultivo de tejidos. 
Las células humanas de cáncer de mama MDA-MB-231-Luc se mantuvieron de forma 
rutinaria en el medio de Eagle modificado por Dulbecco / Mezcla de nutrientes F-12, 
DMEM/F12, (Gibco) suplementado con 10% FBS y 500ug/mL de Geneticina a 37 ° C en 
una atmósfera humidificada con 5% de CO2. En todos los casos, los medios se 
reemplazaron cada 2 - 3 días y se sometieron a pases una vez que las células alcanzaron 
el 80% de confluencia. 
 
Ensayos MTS de viabilidad celular. Las líneas celulares se sembraron en placas de 96 
pocillos estériles a la concentración de 12500 células / cm2 para MCF-7ca, 6250 células 
/ cm2 para 4T1 y 7.500 células / cm2 para MDA-MB-231-Luc. Las placas se incubaron 
durante 24 h y posteriormente se analizaron los fármacos libres y los conjugados se 
analizaron en las concentraciones finales que varían de 0 a 0,1 mg / ml de equivalentes 
del fármaco. Después de 72 h de tratamiento, se midió la viabilidad celular usando el 
ensayo de proliferación celular no radiactiva Acuático Cell Titer 96 (Promega, 
Corporation, España, UE) de acuerdo con las instrucciones del fabricante. La densidad 
óptica de cada pocillo se midió a 490 nm usando una estación de trabajo Wallac 1420 
(PerkinElmer, MA, EE. UU.). La viabilidad celular se expresó como un porcentaje de la 
viabilidad de las células de control no tratadas. 
 
3.3.4. Ensayos in vivo. 
Desarrollo de modelos ortotópicos de cáncer de mama triple negativo. Para la inducción de 
los tumores en el modelo 4T1 se inocularon subdérmicamente d 5 x 105 células de pase 
temprano suspendidas en 100 μl de Matrigel (20%) en la segunda mama izquierda inferior 
de hembras BALB/c (BALB/cOlaHsd)  bajo anestesia inhalatoria (sevoflurano al 3% en 
oxígeno al 100%). Siguiendo las mismas condiciones experimentales, se establecieron 




NOD/SCID (NOD.CB17-Prkdcscid/NCrHsd). Los tumores se evaluaron 
morfométricamente diariamente con un calibre electrónico y se obtuvieron volúmenes 
tumorales considerando la forma del tumor esferoidal. Las metástasis en órganos de 
interés en el modelo 4T1 se aislaron y evaluaron siguiendo un protocolo previamente 
descrito. 
 
Estudio de la actividad antitumoral y antimetastásica de los conjugados poliméricos en 
ambos modelos murinos previamente implementados. Después de 8 días tras la inoculación 
celular, cuando el tamaño del tumor alcanzó 0,1 cm3, los ratones se dividieron en grupos 
representativos y los conjugados se inyectaron por vía intravenosa (iv) en tres/cuatro dosis 
(según el caso) en los correspondientes equivalentes de fármaco cada tres días. Los 
fármacos libres libre se disolvieron en solución salina y se usaron como un control de 
fármaco libre, administrados siguiendo el mismo esquema. Los tumores se midieron cada 
3 días con un calibre digital y se obtuvieron volúmenes considerando el crecimiento de 
esferoides, aplicando la fórmula (altura / 2 x longitud / 2 x ancho / 2)3 x (4/3 Pi). Una vez 
que los tumores alcanzaron 1,0 cm3 (16 días después del primer tratamiento), los ratones 
se sacrificaron en atmósfera de CO2 y se recogieron la sangre, los órganos principales y 
los tumores para su posterior análisis histopatológico. 
 
Tomografía de Emisión de Positrones (PET). El análisis PET-CT empleó el equipo 
Albira (Bruker, EE. UU.) Ubicado dentro del CIPF.  Para el análisis PET-CT, los animales 
se mantuvieron en ayunas durante 14 h antes de la administración del radiotrazador para 
PET y se alojaron a 21ºC constantes. El peso promedio del ratón fue de 19.2 ± 0.7 g, 
mientras que el nivel promedio de glucosa en sangre fue de 47.2 ± 10.1 mg.dl-1. La 
anestesia se indujo por inhalación de isoflurano (4% en oxígeno al 100%) y se mantuvo 
en (1,5% en oxígeno al 100%). La resolución de la tomografía híbrida PET / CT se fijó 
en 1,5 mm con un campo axial de 9 cm y transaxial de 8 cm. Una vez que los parámetros 
fueron arreglados, los animales fueron inyectados de manera i.v. con 18F-FDG con una 
actividad de 4.5 ± 0.1MBq a través de un catéter en la vena de la cola. La dosis promedio 
de 18F-FDG fue 4516.2 KBq ± 236.3. Los experimentos dinámicos de PET se realizaron 
mediante la adquisición de 28 cuadros de 60 minutos de longitud total (6 x 10 s, 6 x 30 s, 
6 x 60 s, 5 x 120 s, 4 x 300 s y 1 x 1200 s). Las imágenes de PET se reconstituyeron 




iteraciones) y se aplicaron correcciones de desintegración, dispersión y aleatorias cuando 
fue necesario.  
 
Estudio de bioluminscencia (BLI) mediante IVIS. Las células MDA-MB-231-Luc 
transfectadas con luciferasa presentes en el cuerpo del animal se trazaron utilizando la 
tecnología IVIS Spectrum. Para la obtención de imágenes de bioluminiscencia (BLI), los 
ratones se anestesiaron con sevoflurano al 3% en oxígeno y recibieron una inyección 
subdérmica de 150 mg / kg de D-luciferina. La adquisición se realizó con el sistema de 
espectrometría IVIS 10 min después de la administración de D-luciferina. Las imágenes 
se adquirieron usando la configuración automática de la cámara y los datos BLI se 
cuantificaron con el software Living Image en términos de fotones por segundo. 
 
Biodistribución de los conjugados poliméricos. Se usaron ratones con 0,1 cm3 de tumor 
(desarrollados como se detalla anteriormente) para el estudio de biodistribución. Los 
conjugados de interés fueron iv. administrados a la adecuada concentración y los grupos 
de animales (n = 6) fueron sacrificados en diferentes tiempos (0, 8, 24, 48 y 72 horas). Se 
recogieron la sangre, los principales órganos y el tumor y se congelaron y almacenaron a 
-80 °C hasta su posterior análisis. Posteriormente, Los órganos y el tumor se suspendieron 
en 2 ml de PBS frío y se mezclaron enérgicamente mediante el uso de un mezclador 
Ultraturrax. El pH de la mezcla homogénea resultante se ajustó a 8,5 añadiendo algunas 
gotas de tampón de formiato de amonio 1 M y seguidamente se extrajo tres veces con 5,0 
ml de una mezcla de CH3Cl/iPrOH 4:1 (v/v). Las fases acuosas se descartaron y los 
sobrenadantes se concentraron hasta sequedad bajo corriente de N2. Los residuos finales 
se disolvieron en 100 μl de MeOH de grado HPLC y las muestras se analizaron mediante 
RP-HPLC siguiendo el mismo método para la determinación de fármaco libre ya descrito. 
Las mediciones fluorescentes finales relacionadas con el fármaco de interés se 












4.1. Modelos preclínicos de cáncer de mama triple negativo que proporcionan 
evidencias funcionales de progresión metastásica y su adecuación para la evaluación 
de nanomedicinas (Capítulo II, manuscrito en  revisión (Int. J. Cancer)). 
 
El desarrollo acelerado de terapias avanzadas anticancerígenas requiere modelos 
preclínicos que permitan la identificación de biomarcadores funcionales para facilitar la 
traslación clínica [28]  y la estratificación de pacientes [29]. A lo largo del presente trabajo 
de Tesis, se presenta una caracterización amplia y detallada de dos modelos murinos de 
cáncer de mama triple negativo (CMTN) espontáneamente metastásicos y 
preclínicamente relevantes (un modelo de células humanas MDA-MB-231-Luc  
desarrollado en un ratón inmunodeficiente y un modelo 4T1 murino desarrollado en ratón 
inmunocompetente) con un enfoque especial en su uso como plataformas vivas para el 
desarrollo de nanomedicinas anticancerígenas. Ambos modelos desarrollan homogéneos 
tumores primarios con posterior metástasis en nódulo linfático axilar (ALN) y pulmones, 
reproduciendo fielmente las características más determinantes de la patología humana. 
Nuestras comparaciones han revelado descriptores importantes con respecto a los 
procesos tisulares / moleculares interconectados que conducen el avance de la 
enfermedad hacia la metástasis. Los descriptores incluyen diseminación metastásica por 
vía linfática, remodelación del sistema inmune, adipocitos asociados al cáncer y 
alteraciones metabólicas relevantes. Asimismo, hemos identificado características 
distintivas que pueden representar biomarcadores funcionales para la progresión de la 
enfermedad o incluso como herramientas de diagnóstico molecular. Por lo tanto, estos 
modelos ofrecen una plataforma útil para la prueba / validación de terapias contra el 
cáncer, especialmente para el tratamiento de pacientes que se presentan con ambos 
tumores primarios y metástasis. 
 
 
4.2. Actividad anticancerígena promovida por modificaciones en el enlace polímero-
fármaco en un conjugado de combinación basado en ácido poliglutámico (PGA) 





Tal y como se ha comentado y discutido anteriormente a lo largo de este trabajo 
de Tesis, las nanoterapias de combinación para el tratamiento de cáncer de mama se 
benefician del efecto sinérgico de los fármacos incorporados en el nanosistema [30]. Sin 
embargo, la mayoría de los transportadores poliméricos poseen baja biodegradabilidad, 
limitada sinergia de los fármacos combinados, ineficaz regulación de la liberación de 
dichos fármacos, y una falta de control en la conformación en solución de la 
macromolécula final (que define el potencial biológico) lo que limita la aplicación de esta 
estrategia de forma más amplia.  
 
A lo largo de este Capítulo de Tesis, hemos diseñado una amplia familia de 
conjugados polímero-fármaco con buenos resultados en actividad anticancerígena, 
incorporando la antraciclina doxorrubicina (Dox) y el inhibidor de aromatasa 
aminoglutetimda (AGM). Con esta nueva familia de conjugados PGA-AGM-Dox, se ha 
ratificado la importancia de la presencia de ambos fármacos en el mismo portador 
polimérico para asegurar su liberación simultánea en la misma célula.  
 
Hemos prestado especial atención a la interacción entre el comportamiento 
biológico y las propiedades fisicoquímicas de los conjugados en solución acuosa. Como 
esperábamos, la proporción de los fármacos conjugados es una característica clave a la 
hora de controlar la actividad biológica tal y como hemos podido observar en las 
comparativas PGA-(G-AGM)HL-Dox frente a PGA-(G-AGM)LL-Dox. Quizá más 
importante es el hecho de descubrir que la presencia de un pequeño y flexible espaciador 
de Glicina (Gly) entre AGM y el polímero (el aminoácido más pequeño, que supone 
menos del 1% del peso molecular total del conjugado) juega un papel decisivo en la 
estructura de toda la macromolécula y por lo tanto, influye significativamente en la 
actividad biológica. Igualmente, la introducción de Gly induce un cambio significativo 
en la cinética de liberación del fármaco, tamaño hidrodinámico, estructura secundaria y 
disposición interna del esqueleto polipeptídico, tal y como hemos podido observar tras 
los análisis de dicroísmo circular (CD), dispersión dinámica de luz (DLS), y estudios de 
Dispersión de Neutrones de Ángulo Pequeño (SANS). La distinta configuración 
molecular proporcionada por el espaciador de Gly (Gly o Gly-Gly) parece modificar la 
disposición espacial del conjugado de tal manera que se ve favorecido el acceso de la 
enzima proteolítica catepsina B, lo que se traduce en una liberación diferencial de AGM 




idea de que la cinética de la liberación del fármaco es uno de los principales descriptores 
fisicoquímicos a tener en cuenta al diseñar terapias combinadas basadas en polipéptidos. 
 
Como hemos podido demostrar en este trabajo, la elección de los enlaces 
empleados en la conjugación de agentes activos en un conjugado de combinación 
polimérico puede dotar al complejo sistema macromolecular con propiedades mejoradas 
con respecto a la conjugación directa. En esta familia de conjugados los mejores 
resultados biológicos se obtuvieron con PGA-(G-AGM)HL-Dox, en el cual la relación 
molar de fármacos es 2:1 (AGM:Dox) y empleando Gly como enlace para AGM. Este 
conjugado ha demostrado significativamente mayor efecto antitumoral que PGA-(G-
AGM)LL-Dox (1:1 AGM:Dox en mol) e incluso mayor, comparado con los conjugados 
derivados de unión de AGM directa. Nuestros resultados sientan las bases para avanzar 
hacia el diseño eficiente de nuevos enlaces polímero-fármaco que permitan un control 
espaciotemporal mejorado en los perfiles de liberación, mejorando los efectos sinérgicos 
y, por lo tanto, mejorando la actividad antitumoral. Nuestros resultados también resaltan 
la importancia de caracterización supramolecular exhaustiva para comparar 
adecuadamente evaluaciones in vitro e in vivo. 
 
 
4.3. Conjugado de combinación basado en PGA dirigido al microambiente tumoral 
para el tratamiento del cáncer de mama triple negativo (Capítulo IV, manuscrito en 
revisión (Biomaterials)). 
 
Tras los resultados positivos obtenidos con la conjugación de AGM y Dox, 
empleando para ambos fármacos enlaces peptídicos, se observó una mejoría terapéutica 
cuando la presencia de los enlaces polímero-fármaco promovían la liberación más rápida 
de Dox frente a la de AGM. Sobre esta base se desarrolló una nueva familia de conjugados 
poliméricos similares, incorporando un enlace hidrazona sensible al pH con el objetivo 
de promover una mayor liberación de este fármaco en el microentorno tumoral.  
 
Tanto los resultados experimentales como el análisis transcripcional de tejido 
tumoral realizado a posteriori, indicaron que los dos conjugados más efectivos, PGA-(G-




tumoral (TME) para desencadenar un cascada de eventos moleculares que promueven la 
muerte de las células tumorales (principalmente mediante apoptosis y autofagia) e inhiben 
las actividades relacionadas con progresión del tumor, incluyendo metástasis y la 
proliferación celular. Sin embargo, también descubrimos diferencias significativas entre 
los dos conjugados de combinación: PGA-(G-AGM)-(Hyd-Dox)LL desencadena una 
respuesta inmune más intensa que podría explicar por qué los ratones receptores muestran 
una mayor tasa de supervivencia. Además, PGA-(G-AGM)-(Hyd-Dox)LL conduce a una 
mayor actividad proapoptótica, señales antiapoptóticas más bajas e inhibición de la 
metástasis, que respaldan la respuesta global a este tratamiento. 
 
También hemos demostrado la importancia de dirigir el tratamiento al TME para 
la liberación del fármaco in situ y optimizar la proporción del fármaco biodisponible en 
una terapia de combinación, destacando la importancia del diseño racional de enlaces 
biosensibles efectivos. La cinética adecuada de liberación del fármaco representa un 
parámetro crucial para lograr una adecuada relación seguridad / eficacia y puede asegurar 
una ventana terapéutica adecuada para tratamientos futuros. Finalmente, este estudio 
también demuestra la utilidad del análisis transcripcional de tejido tumoral sometido a 
tratamiento sistémico, que sirve para mejorar la comprensión de nuestros resultados y 
promover el diseño futuro de sistemas de liberación de fármacos avanzados basados en 
polímeros para el tratamiento de CMTN metastásico, entre otros. 
 
4.4. Diseño racional de conjugados de combinación basados en poliglutamato, 
incorporando inhibidores de la tirosina-quinasa e inhibidores de la topoisomerasa 
para el tratamiento de CMTN metastásico (Capítulo V, manuscrito en preparación). 
 
Finalmente, se han aplicado los conocimientos adquiridos a lo largo del desarrollo 
de esta Tesis para el diseño de un nuevo conjugado de combinación (PGA-TKI-TI), que 
tiene como objetivo la liberación controlada de dos fármacos anticancerígenos sinérgicos 
(un inhibidor de la tirosina-quinasa (TKI) y un inhibidor de la topoisomerasa (TI)). Para 
desarrollar este conjugado, se ha empleado la química previamente optimizada, dotando 
al conjugado de un enlace sensible al pH (hidrazona) para la liberación de TI en el 
microentorno tumoral. Adicionalmente, se ha comprobado que la conjugación directa del 
TKI al polímero no resultaba en una adecuada cinética de liberación y como consecuencia 




de conjugados PGA-aa-TKI simples, incorporando aminoácidos de distinta naturaleza 
(hidrofobicidad cadena lateral) entre el polímero y el fármaco, con el fin de obtener una 
modulación en la liberación del fármaco. Una vez evaluada la familia de conjugados 
simples en términos de liberación de fármaco in vitro y actividad citotóxica, se ha elegido 
el aminoácido valina como el mejor enlace para intercalar entre el TKI y el polímero. El 
conjugado de combinación obtenido, PGA-(Val-TKI)-(hyd-TI) fue evaluado in vitro, en 
dos líneas celulares de CMTN y demostró una mayor citotoxicidad que los conjugados 
simples administrados por separado y la suma física de ambos, y una mayor sinergia entre 
ambos fármacos  demostrándose la ventaja de la conjugación de dos fármacos al mismo 
portador polimérico. Seguidamente, se evaluó su capacidad antitumoral y antimetastásica 
en un modelo murino inmunodeprimido de CMTN, cuyo desarrollo se expone en el 
Capítulo II. El conjugado de combinación PGA-(Val-TKI)-(hyd-TI) demostró una 
mayor capacidad antitumoral (un ~50% de reducción de crecimiento de tumor primario 
con respecto al control sin tratar) y una mayor capacidad de reducción de metástasis en 
pulmón y ALN un ~90% de reducción en pulmón y un 60% en ALN) con respecto al 
control sin tratar. Se demostró nuevamente, una mayor sinergia entre fármacos en el 
conjugado de combinación y un mayor efecto terapéutico que al administrar los 
conjugados simples por separado o la suma física de ambos, demostrándose la ventaja de 
la conjugación de dos fármacos al mismo portador polimérico. Finalmente, se validó el 
conjugado en un modelo murino (también definido en el Capítulo II) inmunocompetente, 
con resultados similares. Además, en éste modelo hemos podido observar otras mejorías 
con respecto a los animales sin tratar, como una reducción de la esplenomegalia asociada 
al tumor, y una inhibición de la secreción de algunas citoquinas tumorales. 
 
5. CONCLUSIONES. 
Durante el desarrollo de la presente Tesis, se han logrado una serie de objetivos, 
haciendo de éste trabajo innovador y con relevancia en el ámbito de la terapia de 
combinación basada en polímeros biodegradables para el tratamiento de CMTN. Las 
principales conclusiones se destacan a continuación: 
 
1. Se han caracterizado en detalle dos modelos murinos de cáncer de mama 




para ser empleados como plataformas de testeo y validación de conjugados 
polimérico-fármaco. Se han estudiado las repercusiones del avance de la 
metástasis, mediante análisis hematológicos. Se han identificado 
biomarcadores específicos de metástasis para cada modelo mediante 
metabolómica por resonancia magnética nuclear (RMN). También se han 
caracterizado histopatológicamente los órganos más relevantes que 
presentaban patologías como consecuencia del desarrollo del tumor. 
Finalmente, se ha detectado una modulación de citoquinas tumorales en 
plasma y, se han podido identificar diferentes descriptores que permiten 
evaluar la eficacia de los tratamientos antitumorales en el ámbito de la 
nanomedicina y en particular, de los Polímeros Terapéuticos. 
 
2. Se han desarrollado tres familias de conjugados de combinación polímero-
fármaco, basados en ácido poliglutámico, incorporando dos fármacos en 
proporciones sinérgicas para tratamiento de CMTN. 
 
3. Con el fin de mejorar y optimizar las cinéticas de liberación de los fármacos 
y mejorar su sinergia, se han desarrollado y caracterizado enlaces polímero-
fármaco sensibles a distintos estímulos biológicos, incluyendo enlaces 
peptídicos (degradables bajo la actividad proteolítica de enzimas 
sobreexpresadas en los lisosomas de las células tumorales), enlaces éster, 
(sensibles a variaciones del pH y a la presencia de esterasas), y enlaces 
sensibles al pH, (destinados a liberar específicamente los fármacos en la 
proporción y cantidad adecuada en el microentorno tumoral y/o a lo largo del 
proceso endosomolítico, ambos ambientes ligeramente ácidos). 
 
4. Se han caracterizado fisicoquímicamente las familias de conjugados 
desarrollados, mediante técnicas avanzadas de caracterización en soluciones 
biológicamente relevantes, que han permitido establecer relaciones 
estructura-actividad de los diferentes conjugados en la mayoría de los casos. 
 
5. Se han evaluado in vitro los conjugados previamente desarrollados, en 
varias líneas celulares de cáncer de mama clínicamente relevantes. Estos 




internalización celular y han proporcionado información decisiva para 
avanzar en el diseño de los conjugados. Asimismo, se han estudiado in vitro 
las cinéticas de liberación de fármaco en diferentes ambientes biológicamente 
relevantes y en presencia de enzimas degradantes. 
 
6. Los conjugados poliméricos previamente desarrollados que han 
demostrado los mejores resultados preliminares in vitro, se han evaluado in 
vivo (en los modelos murinos preclínicos establecidos). Esta evaluación ha 
demostrado su actividad antitumoral y antimetastásica, así como su 
seguridad, y se han podido monitorizar diversos descriptores de la 
enfermedad, identificados previamente, que han permitido valorar el 
potencial terapéutico de nuestros conjugados de combinación. 
 
7.  Finalmente, se han estudiado diversas muestras biológicas (tumor primario 
y pulmones metastatizados) mediante transcriptómica y proteómica. Estas 
dos potentes herramientas analíticas han permitido esclarecer algunos 
aspectos funcionales de la expresión génica responsables de la muerte celular 
a nivel genómico tras los tratamientos, y ha permitido establecer relaciones 
directas entre los mecanismos de muerte celular y algunos descriptores físico-
químicos de los conjugados poliméricos. Por su parte, los resultados 
metabolómicos han permitido identificar diferencias significativas en la 
producción/consumo de metabolitos clave en el desarrollo de la metástasis, 
con diferencias claras entre los dos modelos murinos empleados y ha 
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